Compounds and  medicaments using same

ABSTRACT

The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB:wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.

TECHNICAL FIELD

The present disclosure relates to a novel fused tricyclic compound that is useful as a medicament, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. More specifically, the present disclosure relates to a pharmaceutical composition comprising the fused tricyclic compound or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. The present disclosure also relates to a therapeutic agent comprising the fused tricyclic compound or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

BACKGROUND ART

Rabies is an infection induced by a rabies virus. The mortality after the onset in humans is almost 100%. While over 15 million people worldwide are vaccinated postexposure for the prophylaxis of rabies every year, the worldwide number of fatalities due to rabies is about 55000 annually. An effective therapeutic method for rabies still has not been established. There is still a demand for the establishment thereof.

SUMMARY OF INVENTION Solution to Problem

The present disclosure provides a compound and a method for the treatment of rabies and other diseases.

The present disclosure was completed by the inventors from finding that compounds represented by the following formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB and the structural formulas related thereto, or a pharmaceutically acceptable salt thereof (hereinafter, also referred to as “the compound(s) of the present disclosure” or “the present compound(s)”) can achieve the objects as a result of diligent study.

The present disclosure provides the following items.

[Item 1]

A compound represented by formula XXIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₃, and R₄ are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group, and

R_(2A) and R_(2B) are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a heterocycle, wherein the heterocycles are each independently and optionally substituted.

[Item 1B]

The compound represented by formula XXIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof according to item 1, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl,

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 2]

A compound represented by formula XXIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₃, and R₄ are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group,

R_(2A) and R_(2B) are each independently hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocycle, optionally substituted carbonyl, or an optionally substituted functional group, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a heterocycle, wherein the heterocycles are each independently and optionally substituted.

[Item 2B]

The compound represented by formula XXIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof according to item 2, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl,

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 3]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R₁, R₃, and R₄ are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and

the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, and the non-aryl heterocycle and the heteroaryl ring of R_(2A) and R_(2B) are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.

[Item 4]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 4B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 5]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁, R₃, and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.

[Item 5B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁, R₃, and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group V.

[Item 6]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 6B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 7]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, carbamoyl, or optionally substituted alkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 7B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, carbamoyl, or optionally substituted C₁₋₁₂ alkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 8]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro; formyl; substituted carbonyl; or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₁ and R₄ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 8B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen; C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, C₃₋₁₀ cycloalkyl, and substituted C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro; formyl; substituted carbonyl; or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₁ and R₄ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 9]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; alkylcarbonyl; arylalkylcarbonyl; arylalkyloxycarbonyl; alkoxycarbonyl; arylcarbonyl; aryloxycarbonyl; carbamoyl; alkylcarbamoyl; or arylalkylcarbamoyl, wherein the substituted amino each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 9B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₄ are each independently hydrogen; C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; C₁₋₁₂ alkylcarbonyl; C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl; C₆₋₁₀ aryl C₁₋₆ alkyloxycarbonyl; C₁₋₁₂ alkoxycarbonyl; C₆₋₁₀ arylcarbonyl; C₆₋₁₀ aryloxycarbonyl; carbamoyl; C₁₋₁₂ alkylcarbamoyl; or C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl, wherein the substituted amino have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 10]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy, wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₃ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 11]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy.

[Item 11B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is hydrogen; C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, amino, C₁₋₆ alkoxycarbonylamino, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl, and hydroxy.

[Item 12]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy; heteroarylalkyl; substituted heteroarylalkyl; cycloalkyl; or substituted cycloalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group VI.

[Item 13]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; heteroarylalkyl; alkoxycarbonyl-substituted heteroarylalkyl; or cycloalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

[Item 13B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, and 5- to 10-membered heterocycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and hydroxy; 5- to 10-membered heteroaryl C₁₋₆ alkyl; C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl; or C₃₋₁₀ cycloalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

[Item 14]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 14B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 15]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) is hydrogen, and R_(2B) is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; or cycloalkyl.

[Item 15B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) is hydrogen, and R_(2B) is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and hydroxy; or C₃₋₁₀ cycloalkyl.

[Item 16]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.

[Item 16B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of C₁₋₆ alkyl and hydroxy.

[Item 17]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, alkyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, carbamoyl, or arylalkylcarbamoyl.

[Item 17B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkyloxycarbonyl, C₁₋₁₂ alkoxycarbonyl, carbamoyl, or C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl.

[Item 17C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is hydrogen, methyl, ethyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, tert-butylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, ethoxybenzyl, tert-butoxybenzyl, aminobenzyl, (cyclopentylcarbonylamino)benzyl, (cyclopentylmethylamino)benzyl, (dimethylamino)benzyl, (carbamoylethylcarbonylamino)benzyl, (carboxyethylcarbonylamino)benzyl, nitrobenzyl, hydroxybenzyl, 3-methylbutanoyl, isobutylcarbonyl, 2-phenylacetyl, isopropyloxycarbonyl, benzoyl, or phenyloxycarbonyl.

[Item 17D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) is hydrogen, R_(2B) is methyl, isopropyl, isobutyl, n-pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, carbamoylmethyl, carbamoylethyl, carboxyethyl, hydroxyethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, (tetrahydro-2H-pyran-2-yl)methyl, benzyl, phenylethyl, naphthalenylmethyl, naphthalenylethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, tert-butoxybenzyl, hydroxybenzyl, α-hydroxymethylphenethyl, β-hydroxyphenethyl, pyridinylmethyl, (1H-indol-3-yl)ethyl, (1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, cyclopentyl, or cyclohexyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.

[Item 17E]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxymethyl, hydroxyethyl, (tert-butyldimethylsilyloxy)ethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, or hydroxybenzyl.

[Item 17F]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, methyl, ethyl, isobutyl, formyl, acetyl, 3-methylbutanoyl, 2-phenylacetyl, methoxycarbonyl, ethoxycarbonyl, 2-methylpropyloxycarbonyl, tert-butoxycarbonyl, benzoyl, benzyl, benzyloxycarbonyl, aminocarbonyl, N-benzylaminocarbonyl, propylcarbamoyl, N-isobutylaminocarbonyl, or N-benzylaminocarbonyl.

[Item 17G]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the compound is a compound selected from the group consisting of compound numbers IB-1 to IB-995 and IF-1 to IF-931.

[Item 18]

A compound represented by formula XXIIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 19]

A compound represented by formula XXIIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 20]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R₁ and R₃ are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and

the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, and the non-aryl heterocycle and the heteroaryl ring of R_(2A) and R_(2B) are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.

[Item 21]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

[Item 22]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₃ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.

[Item 23]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₃ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, and R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 24]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₃ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 25B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₃ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

[Item 25]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is hydrogen; alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, hydroxy, substituted oxy, formyl, substituted carbonyl, cycloalkyl, and substituted cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro; formyl; or substituted carbonyl, wherein the substituted amino, substituted oxy, substituted carbonyl, substituted cycloalkyl, and substituted alkyl in R₁ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 26]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is hydrogen; alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl-substituted amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; alkylcarbonyl; arylalkylcarbonyl; alkoxycarbonyl; arylcarbonyl; aryloxycarbonyl; carbamoyl; alkylcarbamoyl; or arylalkylcarbamoyl, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 27B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is hydrogen; C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, amino, substituted amino, nitro, and hydroxy; formyl; C₁₋₁₂ alkylcarbonyl; C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl; C₁₋₁₂ alkoxycarbonyl; C₆₋₁₀ arylcarbonyl; C₆₋₁₀ aryloxycarbonyl; carbamoyl; C₁₋₁₂ alkylcarbamoyl; or C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 27C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, amino, substituted amino, nitro, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 28]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is hydrogen; alkyl; formyl; substituted carbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl; heteroarylalkyl; or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R₃ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 29B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is hydrogen; alkyl; formyl; alkylcarbonyl; arylalkylcarbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino; heteroarylalkyl; or alkoxycarbonyl-substituted heteroarylalkyl.

[Item 29C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is hydrogen; C₁₋₁₂ alkyl; formyl; C₁₋₆ alkylcarbonyl; C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₆ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino; 5- to 10-membered heteroaryl C₁₋₆ alkyl; or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl.

[Item 29D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₆ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

[Item 29]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; alkyl; formyl; substituted carbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl; heteroarylalkyl; or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

[Item 30B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; alkyl; formyl; alkylcarbonyl; arylalkylcarbonyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino; heteroarylalkyl; or alkoxycarbonyl-substituted heteroarylalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

[Item 30C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; C₁₋₁₂ alkyl; formyl; C₁₋₆ alkylcarbonyl; C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C₆₋₁₀ aryl C₁₋₁₂ alkyl; C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino; 5- to 10-membered heteroaryl C₁₋₁₂ alkyl; or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₁₂ alkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

[Item 30D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently hydrogen; C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl; C₆₋₁₀ aryl C₁₋₁₂ alkyl; C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino; 5- to 10-membered heteroaryl C₁₋₁₂ alkyl; or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₁₂ alkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

[Item 30]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 31B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

[Item 31]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) is hydrogen, and R_(2B) is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen and alkyl.

[Item 32B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) is hydrogen, and R_(2B) is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen and C₁₋₆ alkyl.

[Item 32]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; or arylalkyl.

[Item 32B]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is C₁₋₁₂ alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.

[Item 32C]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is methyl, n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, aminopropyl, 2-(tert-butyl-dimethylsilyloxy)ethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, (tert-butyl)benzyl, methoxybenzyl, ethoxybenzyl, (tert-butoxy)benzyl, (trifluoromethoxy)benzyl, (dimethylamino)benzyl, nitrobenzyl, or hydroxybenzyl.

[Item 32D]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R_(2A) and R_(2B) are each independently isopropyl, isobutyl, sec-butyl, pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, (tert-butoxycarbonyl)ethyl, carbamoylethyl, carboxyethyl, hydroxyethyl, aminopropyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, (1,2,3,4-tetrahydronaphthalenyl)methyl, (tetrahydro-2H-pyranyl)methyl, benzyl, phenylethyl, naphthalenylmethyl, (naphthalenyl)ethyl, β,-hydroxyphenethyl, α-(hydroxymethyl)phenethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, (tert-butoxy)benzyl, hydroxybenzyl, pyridinylmethyl, quinolinylethyl, (1-(tert-butoxycarbonyl)-1H-indolyl)ethyl, cyclopentyl, or cyclohexyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.

[Item 32E]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, aminopropyl, (tert-butyldimethylsilyloxy)ethyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, (tert-butoxy)benzyl, or hydroxybenzyl.

[Item 32F]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the compound is a compound selected from the group consisting of compound numbers IIB-1 to IIB-1129 and IIF-1 to IIF-1047.

[Item 33]

An antiviral agent for a virus in the Lyssavirus genus, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.

[Item 34]

The antiviral agent according to any one of the preceding items, wherein the virus in the Lyssavirus genus comprises a rabies virus.

[Item 35]

A medicament comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.

[Item 36]

The medicament according to any one of the preceding items, which is a prophylactic agent or a therapeutic agent for rabies.

[Item 37]

A pharmaceutical composition comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[Item 38]

A pharmaceutical composition for the prophylaxis or treatment of rabies, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[Item 39]

An anticancer agent comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.

[Item 40]

The medicament according to any one of the preceding items, which is a prophylactic agent or a therapeutic agent for cancer.

[Item 41]

A pharmaceutical composition for the prophylaxis or treatment of cancer, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[Item 42]

A method for the prophylaxis or treatment of rabies, characterized by administering a prophylactically or therapeutically effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, the antiviral agent according to any one of the preceding items, the medicament according to any one of the preceding items, or the pharmaceutical composition according to any one of the preceding items to a patient in need thereof.

[Item 43]

Use of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, for the manufacture of a medicament for the prophylaxis or treatment of rabies.

[Item 44]

A method for the prophylaxis or treatment of cancer, characterized by administering a prophylactically or therapeutically effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, the anticancer agent according to any one of the preceding items, the medicament according to any one of the preceding items, or the pharmaceutical composition according to any one of the preceding items to a patient in need thereof.

[Item 45]

Use of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the anticancer agent according to any one of the preceding items, for the manufacture of a medicament for the prophylaxis or treatment of cancer.

[Item 46]

A method for the prophylaxis or treatment of rabies, comprising administering an effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[Item 47]

A method for the prophylaxis or treatment of cancer, comprising administering an effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof to a subject in need thereof.

The present disclosure also provides the following items.

[Item A1]

A compound represented by formula IF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl, and

R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, or optionally substituted carbamoyl.

[Item A2]

A compound represented by formula IB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl, and

R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, or optionally substituted carbamoyl.

[Item A3]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and

R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted alkoxycarbonyl, or optionally substituted carbamoyl.

[Item A3a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and

R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, or optionally substituted alkoxycarbonyl.

[Item A4]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, or optionally substituted C₃₋₆ cycloalkyl C₁₋₆ alkyl, and

R₄ is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkylcarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₁₋₆ alkoxycarbonyl, or optionally substituted C₁₋₆ alkylcarbamoyl.

[Item A4b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, or optionally substituted C₃₋₆ cycloalkyl C₁₋₆ alkyl, and

R₄ is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkylcarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, or optionally substituted C₁₋₆ alkoxycarbonyl.

[Item A5]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently C₁₋₆ alkyl, hydroxy-substituted C₁₋₆ alkyl, carbamoyl-substituted C₁₋₆ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₆ alkyl, carboxy-substituted C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₆ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₆ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₆ alkyl, or C₃₋₆ cycloalkyl C₁₋₆ alkyl.

[Item A5a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently C₁₋₆ alkyl, hydroxy-substituted C₁₋₆ alkyl, carbamoyl-substituted C₁₋₆ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₆ alkyl, carboxy-substituted C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₆ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₆ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₆ alkyl, or C₃₋₆ cycloalkyl C₁₋₆ alkyl.

[Item A5b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkylcarbonyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₁₋₆ alkoxycarbonyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkoxycarbonyl, carbamoyl, optionally substituted C₁₋₆ alkylcarbamoyl, or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl.

[Item A5c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl or optionally substituted arylalkyl.

[Item A5d]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A5e]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, or (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A5f]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is naphthalen-1-ylmethyl or optionally substituted benzyl.

[Item A5g]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently alkyl or optionally substituted benzyl, and R₂ is optionally substituted benzyl.

[Item A5h]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently C₁₋₆ alkyl, benzyl, C₁₋₄ alkyl-substituted benzyl, chloro-substituted benzyl, C₁₋₄ alkoxy-substituted benzyl, or amino-substituted benzyl, and R₂ is benzyl or chloro-substituted benzyl.

[Item A5i]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ and R₃ are each independently isobutyl, isopentyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R₂ is benzyl, 3-chlorobenzyl, or 3,4-dichlorobenzyl.

[Item A6]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C_(6-lo) arylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl, C₆₋₁₀ aryl C₁₋₆ alkoxycarbonyl, carbamoyl, C₁₋₆ alkylcarbamoyl, or C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl.

[Item A6b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₆₋₁₀ arylcarbonyl, or C₁₋₆ alkoxycarbonyl.

[Item A7]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylcarbonyl, C₆ arylcarbonyl, C₆ aryl C₁₋₄ alkylcarbonyl, C₁₋₄ alkoxycarbonyl, C₆ aryl C₁₋₄ alkoxycarbonyl, carbamoyl, C₁₋₄ alkylcarbamoyl, or C₆ aryl C₁₋₄ alkylcarbamoyl.

[Item A7b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylcarbonyl, C₆ arylcarbonyl, or C₁₋₄ alkoxycarbonyl.

[Item A8]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, tert-butoxycarbonyl, or propylcarbamoyl.

[Item A8b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, or tert-butoxycarbonyl.

[Item A9]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is C₁₋₄ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₄ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₄ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₄ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

[Item A9b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.

[Item A10]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.

[Item A10b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is 1-methylpropyl, isopropyl, isobutyl, isopentyl, n-hexyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or cyclohexylmethyl.

[Item A11]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.

[Item A11b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is 1-methylpropyl, isopropyl, isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.

[Item A12]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₆ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁-4 alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, halo-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

[Item A12b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, or cyclohexylmethyl.

[Item A13]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.

[Item A14]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.

[Item A14b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, or hydroxyethyl.

[Item A14c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.

[Item A15]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is C₁₋₄ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₄ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

[Item A15b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, which is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 3-methoxy-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.

[Item A16]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl. [Item A17] The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.

[Item A17b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, hydroxymethyl, or naphthalen-1-ylmethyl.

[Item A17c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.

[Item A18]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen or alkyl.

[Item A18a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen or C₁₋₆ alkyl.

[Item A18b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen or ethyl.

[Item A19]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₄ is hydrogen.

[Item A20]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein R₁ is C₁₋₆ alkyl or C₆₋₁₀ aryl C₁₋₆ alkyl, and R₂ and R₃ are each independently C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A21]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, isopentyl, or benzyl, R₂ is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl, and R₃ is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.

[Item A22]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the compound is a compound of formula IF, R₁ is isobutyl, R₂ is benzyl, and R₃ is benzyl.

[Item A23]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the compound is compound of formula IF, R₁ is benzyl, R₂ is benzyl, and R₃ is isobutyl.

[Item A24]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the compound is a compound of formula IF, R₁ is isobutyl, R₂ is benzyl, and R₃ is 3-methylbenzyl.

[Item A25]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

the compound is a compound of formula IF, R₁ is benzyl, R₂ is 3,4-dichlorobenzyl, and R₃ is isobutyl.

[Item A26]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IF is a compound selected from the group consisting of IF-1, IF-2, IF-3, IF-4, IF-5, IF-6, IF-7, IF-8, IF-9, IF-10, IF-11, IF-12, IF-13, IF-14, IF-15, IF-16, IF-17, IF-18, IF-19, IF-20, IF-22, IF-23, IF-24, IF-25, IF-26, IF-27, IF-28, IF-29, IF-30, IF-31, IF-32, IF-33, IF-34, IF-35, IF-36, IF-38, IF-39, IF-40, IF-41, IF-42, IF-43, IF-44, IF-45, IF-46, IF-47, IF-49, IF-50, IF-54, IF-57, IF-58, IF-68, IF-69, IF-70, IF-71, IF-72, IF-73, IF-74, IF-76, IF-77, IF-80, and IF-81 to IF-884.

[Item A26b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IF is (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)-1,7-dibenzyl-N-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N,1-dibenzyl-7-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isopentyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(3-methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(4-methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3-methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, (3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N-(3,4-dichlorobenzyl)-7-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide, or (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-4-ethyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-caboxamide.

[Item A27]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IB is a compound selected from the group consisting of IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, IB-8, IB-9, IB-10, IB-11, IB-12, IB-13, IB-14, IB-15, IB-16, IB-17, IB-18, IB-19, IB-20, IB-21, IB-22, IB-23, IB-24, IB-25, IB-26, IB-27, IB-28, IB-29, IB-30, IB-31, IB-32, IB-33, IB-34, IB-35, IB-36, IB-37, IB-38, IB-39, IB-40, IB-41, IB-42, IB-43, IB-44, IB-45, IB-46, IB-47, IB-49, IB-50, IB-54, IB-57, IB-58, IB-64, IB-68, IB-69, IB-70, IB-71, IB-72, IB-73, IB-74, IB-75, IB-76, IB-77, IB-78, IB-79, IB-80, and IB-81 to IB-923.

[Item A27b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound of formula IB is (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N,1-diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7-diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)—N-benzyl-1,7-diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isopentyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-7-isobutyl-N-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, (3S*,3aS*,6R*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(3-methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide, or (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3-methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-caboxamide.

[Item A28]

A compound represented by formula IIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl.

[Item A29]

A compound represented by formula IIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl.

[Item A30]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.

[Item A31]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, or optionally substituted C₃₋₆ cycloalkyl C₁₋₆ alkyl.

[Item A32]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently C₁₋₆ alkyl, hydroxy-substituted C₁₋₆ alkyl, carbamoyl-substituted C₁₋₆ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₆ alkyl, carboxy-substituted C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₆ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₆ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₆ alkyl, or C₃₋₆ cycloalkyl C₁₋₆ alkyl.

[Item A32a]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently C₁₋₆ alkyl, hydroxy-substituted C₁₋₆ alkyl, carbamoyl-substituted C₁₋₆ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₆ alkyl, carboxy-substituted C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₂₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₆ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₆ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₆ alkyl, or C₃₋₆ cycloalkylC₁₋₆alkyl.

[Item A32b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted alkyl or optionally substituted arylalkyl.

[Item A32c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂ and R₃ are each independently optionally substituted C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A33]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is C₁₋₄ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₄ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₄ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₄ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

[Item A33b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, cyclohexylmethyl, or

[Item A34]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.

[Item A35]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.

[Item A35b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₂ is isopropyl, 1-methylpropyl, isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or

[Item A36]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₆ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, halo-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

[Item A36b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, hydroxymethyl, cyclohexylmethyl, or

[Item A37]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.

[Item A38]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, or hydroxyethyl.

[Item A38b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or

[Item A39]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is C₁₋₄ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₄ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

[Item A39b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 4-(tert-butoxy)benzyl, 3-methoxy-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, or

[Item A40]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.

[Item A41]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino) propyl, hydroxymethyl, or naphthalen-1-ylmethyl.

[Item A41b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₃ is isobutyl, 2-carboxyethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or

[Item A42]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₆ alkyl or C₆₋₁₀ aryl C₁₋₆ alkyl, R₂ and R₃ are each independently C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A42b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂, and R₃ are each independently C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A42c]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁, R₂, and R₃ are each independently C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₂₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, or (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl.

[Item A42d]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is C₁₋₆ alkyl or C₆ aryl C₁₋₄ alkyl, R₂ is C₁₋₆ alkyl or C₁₋₄ alkyl-substituted benzyl, and R₃ is C₁₋₆ alkyl or C₆ aryl C₁₋₄ alkyl.

[Item A43]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, benzyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, R₂ is isobutyl, benzyl, naphthalen-1-ylmethyl, 4-methylbenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R₃ is isobutyl, isopentyl, or benzyl.

[Item A43b]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein

R₁ is isobutyl, isopentyl, or benzyl, R₂ is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl, and R₃ is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.

[Item A44]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound is a compound of formula IIF, R₁ is isobutyl, R₂ is 4-methylbenzyl, and R₃ is benzyl.

[Item A45]

The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, wherein the compound is a compound of formula IIB, R₁ is benzyl, R₂ is isobutyl, and R₃ is isobutyl.

[Item A46]

An antiviral agent for a virus in the Lyssavirus genus, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.

[Item A47]

The antiviral agent according to any one of the preceding items, wherein the virus in the Lyssavirus genus comprises a rabies virus.

[Item A48]

A medicament comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items.

[Item A49]

The medicament according to any one of the preceding items, which is a prophylactic agent or a therapeutic agent for rabies.

[Item A50]

A pharmaceutical composition comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, and a pharmaceutically acceptable carrier.

[Item A51]

A pharmaceutical composition for the prophylaxis or treatment of rabies, comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, and a pharmaceutically acceptable carrier.

[Item A52]

The compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof for use as an antiviral agent for a virus in the Lyssavirus genus, preferably a rabies virus, or for the prophylaxis or treatment of rabies.

[Item A53]

A method for the prophylaxis or treatment of rabies, characterized by administering a prophylactically or therapeutically effective amount of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, the antiviral agent according to any one of the preceding items, the medicament according to any one of the preceding items, or the pharmaceutical composition according to any one of the preceding items to a patient in need thereof

[Item A54]

Use of the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, for the manufacture of a medicament for the prophylaxis or treatment of rabies.

The present disclosure is intended so that one or more of the features described above can be provided not only as the explicitly disclosed combinations, but also as other combinations thereof. Additional embodiments and advantages of the present disclosure are recognized by those skilled in the art by reading and understanding the following detailed description as needed.

Advantageous Effects of Invention

The compounds of the present disclosure exhibit an excellent antiviral action on viruses in the Lyssavirus genus including the rabies virus. Therefore, the compounds of the present disclosure are useful as a therapeutic agent and/or prophylactic agent for rabies.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows an ORTEP diagram for the results of X-ray crystallography in Synthesis Example: IF-1.

FIG. 2 shows a chromatogram upon separation of the racemate in Synthesis Example: IF-1 using a chiral column, CHIRALPAK IG (5 μm, 4.6×150 mm), mobile phase: methanol:diethylamine (100:0.1).

FIG. 3 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 4 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 5 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 6 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 7 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 8 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 9 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 10 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 11 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 12 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 13 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 14 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 15 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 16 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 17 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 18 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 19 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 20 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 21 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 22 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 23 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 24 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 25 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 26 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 27 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 28 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 29 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 30 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 31 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 32 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 33 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 34 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 35 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 36 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 37 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 38 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 39 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 40 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 41 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 42 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 43 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 44 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 45 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 46 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 47 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 48 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 49 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 50 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 51 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 52 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 53 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 54 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 55 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 56 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 57 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 58 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 59 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 60 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 61 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 62 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 63 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 64 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 65 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 66 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 67 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 68 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 69 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 70 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 71 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 72 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 73 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 74 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 75 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 76 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 77 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 78 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 79 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 80 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

FIG. 81 shows the ¹H-NMR chart for an exemplary compound of the present disclosure (formula in the figure).

DESCRIPTION OF EMBODIMENTS

Hereinafter, the present disclosure is described in more detail.

Throughout the entire specification, a singular expression should be understood as encompassing the concept thereof in the plural form, unless specifically noted otherwise. Thus, singular articles (e.g., “a”, “an”, “the”, and the like in the case of English) should also be understood as encompassing the concept thereof in the plural form, unless specifically noted otherwise. The terms used herein should also be understood as being used in the meaning that is commonly used in the art, unless specifically noted otherwise. Thus, unless defined otherwise, all terminologies and scientific technical terms that are used herein have the same meaning as the general understanding of those skilled in the art to which the present disclosure pertains. In case of a contradiction, the present specification (including the definitions) takes precedence.

Definitions

The terms and the general technology used in the present disclosure are first described.

As used herein, the term “group” refers to a monovalent group, unless especially noted otherwise. Examples of a group that is not a monovalent group include alkylene group (divalent) and the like. The term “group” may also be abbreviated in the following description of substituents or the like.

As used herein, the number of substituents when a group is defined as “optionally substituted” or “substituted” is not particularly limited as long as it is substitutable and is one or more. The description for each group is also applicable when the substituent is a part of or a substituent on another substituent, unless specifically noted otherwise.

As used herein, “maximum substitutable number” is the maximum number of substituents that a group can have. The number can vary for each group. For example, the number is 3 for a methyl group, 5 for an ethyl group, 7 for a benzyl group, and 10 for a naphthalenyl ethyl group.

For a group that is modified by “optionally substituted” or “substituted” herein, any portion of the group can be substituted. For example, “optionally substituted arylalkyl” and “substituted arylalkyl” can have the aryl moiety substituted, the alkyl moiety substituted, or both the aryl moiety and the alkyl moiety substituted.

As used herein, the substituent used when “optionally substituted” can be one or more of the same or different substituents selected from any one of the following substituent groups I to VI. While the types of atoms within a substituent associated with attachment are not particularly limited by the type of substituent, if the atom to which a substituent attaches is an oxygen atom, a nitrogen atom, or a sulfur atom, the atom is limited to and selected from those with an attachment point in the following substituents that is a carbon atom.

Substituent group I consists of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted alkyloxy, unsubstituted or substituted alkenyloxy, unsubstituted or substituted alkynyloxy, unsubstituted or substituted aryl-L_(X)-oxy, unsubstituted or substituted cycloalkyl-L_(X)-oxy, unsubstituted or substituted heteroaryl-L_(X)-oxy, unsubstituted or substituted heterocycloalkyl-L_(X)-oxy, unsubstituted or substituted alkyloxyalkyl, unsubstituted or substituted alkenyloxyalkyl, unsubstituted or substituted alkynyloxyalkyl, unsubstituted or substituted aryloxyalkyl, unsubstituted or substituted cycloalkyloxyalkyl, unsubstituted or substituted heteroaryloxyalkyl, unsubstituted or substituted heterocycloalkyloxyalkyl, unsubstituted or substituted alkyloxyalkyloxy, unsubstituted or substituted alkenyloxyalkyloxy, unsubstituted or substituted alkynyloxyalkyloxy, unsubstituted or substituted aryloxyalkyloxy, unsubstituted or substituted cycloalkyloxyalkyloxy, unsubstituted or substituted heteroaryloxyalkyloxy, unsubstituted or substituted heterocycloalkyloxyalkyloxy, unsubstituted or substituted alkylcarbonyl, unsubstituted or substituted alkenylcarbonyl, unsubstituted or substituted alkynylcarbonyl, unsubstituted or substituted aryl-L_(X)-carbonyl, unsubstituted or substituted cycloalkyl-L_(X)-carbonyl, unsubstituted or substituted heteroaryl-L_(X)-carbonyl, unsubstituted or substituted heterocycloalkyl-L_(X)-carbonyl, unsubstituted or substituted alkylcarbonyloxy, unsubstituted or substituted alkenylcarbonyloxy, unsubstituted or substituted alkynylcarbonyloxy, unsubstituted or substituted aryl-L_(X)-carbonyloxy, unsubstituted or substituted cycloalkyl-L_(X)-carbonyloxy, unsubstituted or substituted heteroaryl-L_(X)-carbonyloxy, unsubstituted or substituted heterocycloalkyl-L_(X)-carbonyloxy, unsubstituted or substituted alkylcarbonylamino, unsubstituted or substituted alkenylcarbonylamino, unsubstituted or substituted alkynylcarbonylamino, unsubstituted or substituted aryl-L_(X)-carbonylamino, unsubstituted or substituted cycloalkyl-L_(X)-carbonylamino, unsubstituted or substituted heteroaryl-L_(X)-carbonylamino, unsubstituted or substituted heterocycloalkyl-L_(X)-carbonylamino, unsubstituted or substituted alkylcarbonylthio, unsubstituted or substituted alkenylcarbonylthio, unsubstituted or substituted alkynylcarbonylthio, unsubstituted or substituted aryl-L_(X)-carbonylthio, unsubstituted or substituted cycloalkyl-L_(X)-carbonylthio, unsubstituted or substituted heteroaryl-L_(X)-carbonylthio, unsubstituted or substituted heterocycloalkyl-L_(X)-carbonylthio, unsubstituted or substituted alkylcarbonylimino, unsubstituted or substituted alkenylcarbonylimino, unsubstituted or substituted alkynylcarbonylimino, unsubstituted or substituted aryl-L_(X)-carbonylimino, unsubstituted or substituted cycloalkyl-L_(X)-carbonylimino, unsubstituted or substituted heteroaryl-L_(X)-carbonylimino, unsubstituted or substituted heterocycloalkyl-L_(X)-carbonylimino, unsubstituted or substituted alkylthio, unsubstituted or substituted alkenylthio, unsubstituted or substituted alkynylthio, unsubstituted or substituted aryl-L_(X)-thio, unsubstituted or substituted cycloalkyl-L_(X)-thio, unsubstituted or substituted heteroaryl-L_(X)-thio, unsubstituted or substituted heterocycloalkyl-L_(X)-thio, unsubstituted or substituted alkylamino, unsubstituted or substituted alkenylamino, unsubstituted or substituted alkynylamino, unsubstituted or substituted alkynylamino, unsubstituted or substituted aryl-L_(X)-amino, unsubstituted or substituted cycloalkyl-L_(X)-amino, unsubstituted or substituted heteroaryl-L_(X)-amino, unsubstituted or substituted heterocycloalkyl-L_(X)-amino, unsubstituted or substituted alkylsulfonyl, unsubstituted or substituted alkenylsulfonyl, unsubstituted or substituted alkynylsulfonyl, unsubstituted or substituted aryl-L_(X)-sulfonyl, unsubstituted or substituted cycloalkyl-L_(X)-sulfonyl, unsubstituted or substituted heteroaryl-L_(X)-sulfonyl, unsubstituted or substituted heterocycloalkyl-L_(X)-sulfonyl, unsubstituted or substituted alkylsulfonylamino, unsubstituted or substituted alkenylsulfonylamino, unsubstituted or substituted alkynylsulfonylamino, unsubstituted or substituted aryl-L_(X)-sulfonylamino, unsubstituted or substituted cycloalkyl-L_(X)-sulfonylamino, unsubstituted or substituted heteroaryl-L_(X)-sulfonylamino, unsubstituted or substituted heterocycloalkyl-L_(X)-sulfonylamino, unsubstituted or substituted alkylimino, unsubstituted or substituted alkenylimino, unsubstituted or substituted alkynylimino, unsubstituted or substituted aryl-L_(X)-imino, unsubstituted or substituted cycloalkyl-L_(X)-imino, unsubstituted or substituted heteroaryl-L_(X)-imino, unsubstituted or substituted heterocycloalkyl-L_(X)-imino, unsubstituted or substituted alkyloxyimino, unsubstituted or substituted alkenyloxyimino, unsubstituted or substituted alkynyloxyimino, unsubstituted or substituted aryl-L_(X)-oxyimino, unsubstituted or substituted cycloalkyl-L_(X)-oxyimino, unsubstituted or substituted heteroaryl-L_(X)-oxyimino, unsubstituted or substituted heterocycloalkyl-L_(X)-oxyimino, unsubstituted or substituted alkyloxycarbonyl, unsubstituted or substituted alkenyloxycarbonyl, unsubstituted or substituted alkynyloxycarbonyl, unsubstituted or substituted aryl-L_(X)-oxycarbonyl, unsubstituted or substituted cycloalkyl-L_(X)-oxycarbonyl, unsubstituted or substituted heteroaryl-L_(X)-oxycarbonyl, unsubstituted or substituted heterocycloalkyl-L_(X)-oxycarbonyl, unsubstituted or substituted alkyloxycarbonylamino, unsubstituted or substituted alkenyloxycarbonylamino, unsubstituted or substituted alkynyloxycarbonylamino, unsubstituted or substituted aryl-L_(X)-oxycarbonylamino, unsubstituted or substituted cycloalkyl-L_(X)-oxycarbonylamino, unsubstituted or substituted heteroaryl-L_(X)-oxycarbonylamino, unsubstituted or substituted heterocycloalkyl-L_(X)-oxycarbonylamino, unsubstituted or substituted alkylsulfanyl, unsubstituted or substituted alkenylsulfanyl, unsubstituted or substituted alkynylsulfanyl, unsubstituted or substituted aryl-L_(X)-sulfanyl, unsubstituted or substituted cycloalkyl-L_(X)-sulfanyl, unsubstituted or substituted heteroaryl-L_(X)-sulfanyl, unsubstituted or substituted heterocycloalkyl-L_(X)-sulfanyl, unsubstituted or substituted alkylsulfinyl, unsubstituted or substituted alkenylsulfinyl, unsubstituted or substituted alkynylsulfinyl, unsubstituted or substituted aryl-L_(X)-sulfinyl, unsubstituted or substituted cycloalkyl-L_(X)-sulfinyl, unsubstituted or substituted heteroaryl-L_(X)-sulfinyl, unsubstituted or substituted heterocycloalkyl-L_(X)-sulfinyl, unsubstituted or substituted alkylcarbamoyl, unsubstituted or substituted alkenylcarbamoyl, unsubstituted or substituted alkynylcarbamoyl, unsubstituted or substituted aryl-L_(X)-carbamoyl, unsubstituted or substituted cycloalkyl-L_(X)-carbamoyl, unsubstituted or substituted heteroaryl-L_(X)-carbamoyl, unsubstituted or substituted heterocycloalkyl-L_(X)-carbamoyl, unsubstituted or substituted alkylsulfamoyl, unsubstituted or substituted alkenylsulfamoyl, unsubstituted or substituted alkynylsulfamoyl, unsubstituted or substituted aryl-L_(X)-sulfamoyl, unsubstituted or substituted cycloalkyl-L_(X)-sulfamoyl, unsubstituted or substituted heteroaryl-L_(X)-sulfamoyl, and unsubstituted or substituted heterocycloalkyl-L_(X)-sulfamoyl, wherein L_(X) is a single bond or unsubstituted or substituted alkylene,

wherein the substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted cycloalkyl, substituted heteroaryl, substituted heterocycloalkyl, and substituted alkylene moieties (fully or partially) in the substituent group each independently have one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfa, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, alkyloxy, alkenyloxy, alkynyloxy, aryl-L_(X)-oxy, cycloalkyl-L_(X)-oxy, heteroaryl-L_(X)-oxy, heterocycloalkyl-L_(X)-oxy, alkyloxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl, aryloxyalkyl, cycloalkyloxyalkyl, heteroaryloxyalkyl, heterocycloalkyloxyalkyl, alkyloxyalkyloxy, alkenyloxyalkyloxy, alkynyloxyalkyloxy, aryloxyalkyloxy, cycloalkyloxyalkyloxy, heteroaryloxyalkyloxy, heterocycloalkyloxyalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aryl-L_(X)-carbonyl, cycloalkyl-L_(X)-carbonyl, heteroaryl-L_(X)-carbonyl, heterocycloalkyl-L_(X)-carbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, aryl-L_(X)-carbonyloxy, cycloalkyl-L_(X)-carbonyloxy, heteroaryl-L_(X)-carbonyloxy, heterocycloalkyl-L_(X)-carbonyloxy, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, aryl-L_(X)-carbonylamino, cycloalkyl-L_(X)-carbonylamino, heteroaryl-L_(X)-carbonylamino, heterocycloalkyl-L_(X)-carbonylamino, alkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, aryl-L_(X)-carbonylthio, cycloalkyl-L_(X)-carbonylthio, heteroaryl-L_(X)-carbonylthio, heterocycloalkyl-L_(X)-carbonylthio, alkylcarbonylimino, alkenylcarbonylimino, alkynylcarbonylimino, aryl-L_(X)-carbonylimino, cycloalkyl-L_(X)-carbonylimino, heteroaryl-L_(X)-carbonylimino, heterocycloalkyl-L_(X)-carbonylimino, alkylthio, alkenylthio, alkynylthio, aryl-L_(X)-thio, cycloalkyl-L_(X)-thio, heteroaryl-L_(X)-thio, heterocycloalkyl-L_(X)-thio, alkylamino, alkenylamino, alkynylamino, alkynylamino, aryl-L_(X)-amino, cycloalkyl-L_(X)-amino, heteroaryl-L_(X)-amino, heterocycloalkyl-L_(X)-amino, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, aryl-L_(X)-sulfonyl, cycloalkyl-L_(X)-sulfonyl, heteroaryl-L_(X)-sulfonyl, heterocycloalkyl-L_(X)-sulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, aryl-L_(X)-sulfonylamino, cycloalkyl-L_(X)-sulfonylamino, heteroaryl-L_(X)-sulfonylamino, heterocycloalkyl-L_(X)-sulfonylamino, alkylimino, alkenylimino, alkynylimino, aryl-L_(X)-imino, cycloalkyl-L_(X)-imino, heteroaryl-L_(X)-imino, heterocycloalkyl-L_(X)-imino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, aryl-L_(X)-oxyimino, cycloalkyl-L_(X)-oxyimino, heteroaryl-L_(X)-oxyimino, heterocycloalkyl-L_(X)-oxyimino, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryl-L_(X)-oxycarbonyl, cycloalkyl-L_(X)-oxycarbonyl, heteroaryl-L_(X)-oxycarbonyl, heterocycloalkyl-L_(X)-oxycarbonyl, alkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryl-L_(X)-oxycarbonylamino, cycloalkyl-L_(X)-oxycarbonylamino, heteroaryl-L_(X)-oxycarbonylamino, heterocycloalkyl-L_(X)-oxycarbonylamino, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, aryl-L_(X)-sulfanyl, cycloalkyl-L_(X)-sulfanyl, heteroaryl-L_(X)-sulfanyl, heterocycloalkyl-L_(X)-sulfanyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, aryl-L_(X)-sulfinyl, cycloalkyl-L_(X)-sulfinyl, heteroaryl-L_(X)-sulfinyl, heterocycloalkyl-L_(X)-sulfinyl, alkylcarbamoyl, alkenylcarbamoyl, alkynylcarbamoyl, aryl-L_(X)-carbamoyl, cycloalkyl-L_(X)-carbamoyl, heteroaryl-L_(X)-carbamoyl, heterocycloalkyl-L_(X)-carbamoyl, alkylsulfamoyl, alkenylsulfamoyl, alkynylsulfamoyl, aryl-L_(X)-sulfamoyl, cycloalkyl-L_(X)-sulfamoyl, heteroaryl-L_(X)-sulfamoyl, and heterocycloalkyl-L_(X)-sulfamoyl.

Substituent group II consists of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, unsubstituted or substituted C₁₋₁₂ alkyl, unsubstituted or substituted C₂₋₁₂ alkenyl, unsubstituted or substituted C₂₋₁₂ alkynyl, unsubstituted or substituted C₀₋₁₀ aryl, unsubstituted or substituted C₃₋₁₀ cycloalkyl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl, unsubstituted or substituted C₁₋₁₂ alkyloxy, unsubstituted or substituted C₂₋₁₂ alkenyloxy, unsubstituted or substituted C₂₋₁₂ alkynyloxy, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-oxy, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-oxy, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-oxy, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-oxy, unsubstituted or substituted C₁₋₁₂ alkyloxy C₁₋₁₂ alkyl, unsubstituted or substituted C₂₋₁₂ alkenyloxy C₁₋₁₂ alkyl, unsubstituted or substituted C₂₋₁₂ alkynyloxy C₁₋₁₂ alkyl, unsubstituted or substituted C₀₋₁₀ aryloxy C₁₋₁₂ alkyl, unsubstituted or substituted C₃₋₁₀ cycloalkyloxy C₁₋₁₂ alkyl, unsubstituted or substituted 5- to 10-membered heteroaryloxy C₁₋₁₂ alkyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyloxy C₁₋₁₂ alkyl, unsubstituted or substituted C₁₋₁₂ alkyloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted C₂₋₁₂ alkenyloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted C₂₋₁₂ alkynyloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted C₆₋₁₀ aryloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted C₃₋₁₀ cycloalkyloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted 5- to 10-membered heteroaryloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted 5- to 10-membered heterocycloalkyloxy C₁₋₁₂ alkyloxy, unsubstituted or substituted C₁₋₁₂ alkylcarbonyl, unsubstituted or substituted C₂₋₁₂ alkenylcarbonyl, unsubstituted or substituted C₂₋₁₂ alkynylcarbonyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-carbonyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-carbonyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-carbonyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-carbonyl, unsubstituted or substituted C₁₋₁₂ alkylcarbonyloxy, unsubstituted or substituted C₂₋₁₂ alkenylcarbonyloxy, unsubstituted or substituted C₂₋₁₂ alkynylcarbonyloxy, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-carbonyloxy, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-carbonyloxy, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-carbonyloxy, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-carbonyloxy, unsubstituted or substituted C₁₋₁₂ alkylcarbonylamino, unsubstituted or substituted C₂₋₁₂ alkenylcarbonylamino, unsubstituted or substituted C₂₋₁₂ alkynylcarbonylamino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-carbonylamino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-carbonylamino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-carbonylamino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-carbonylamino, unsubstituted or substituted C₁₋₁₂ alkylcarbonylthio, unsubstituted or substituted C₂₋₁₂ alkenylcarbonylthio, unsubstituted or substituted C₂₋₁₂ alkynylcarbonylthio, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-carbonylthio, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-carbonylthio, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-carbonylthio, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-carbonylthio, unsubstituted or substituted C₁₋₁₂ alkylcarbonylimino, unsubstituted or substituted C₂₋₁₂ alkenylcarbonylimino, unsubstituted or substituted C₂₋₁₂ alkynylcarbonylimino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-carbonylimino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-carbonylimino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-carbonylimino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-carbonylimino, unsubstituted or substituted C₁₋₁₂ alkylthio, unsubstituted or substituted C₂₋₁₂ alkenylthio, unsubstituted or substituted C₂₋₁₂ alkynylthio, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-thio, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-thio, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-thio, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-thio, unsubstituted or substituted C₁₋₁₂ alkylamino, unsubstituted or substituted C₂₋₁₂ alkenylamino, unsubstituted or substituted C₂₋₁₂ alkynylamino, unsubstituted or substituted C₂₋₁₂ alkynylamino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-amino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-amino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-amino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-amino, unsubstituted or substituted C₁₋₁₂ alkylsulfonyl, unsubstituted or substituted C₂₋₁₂ alkenylsulfonyl, unsubstituted or substituted C₂₋₁₂ alkynylsulfonyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-sulfonyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-sulfonyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-sulfonyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-sulfonyl, unsubstituted or substituted C₁₋₁₂ alkylsulfonylamino, unsubstituted or substituted C₂₋₁₂ alkenylsulfonylamino, unsubstituted or substituted C₂₋₁₂ alkynylsulfonylamino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-sulfonylamino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-sulfonylamino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-sulfonylamino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-sulfonylamino, unsubstituted or substituted C₁₋₁₂ alkylimino, unsubstituted or substituted C₂₋₁₂ alkenylimino, unsubstituted or substituted C₂₋₁₂ alkynylimino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-imino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-imino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-imino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-imino, unsubstituted or substituted C₁₋₁₂ alkyloxyimino, unsubstituted or substituted C₂₋₁₂ alkenyloxyimino, unsubstituted or substituted C₂₋₁₂ alkynyloxyimino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-oxyimino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-oxyimino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-oxyimino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-oxyimino, unsubstituted or substituted C₁₋₁₂ alkyloxycarbonyl, unsubstituted or substituted C₂₋₁₂ alkenyloxycarbonyl, unsubstituted or substituted C₂₋₁₂ alkynyloxycarbonyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-oxycarbonyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-oxycarbonyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-oxycarbonyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-oxycarbonyl, unsubstituted or substituted C₁₋₁₂ alkyloxycarbonylamino, unsubstituted or substituted C₂₋₁₂ alkenyloxycarbonylamino, unsubstituted or substituted C₂₋₁₂ alkynyloxycarbonylamino, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-oxycarbonylamino, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-oxycarbonylamino, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-oxycarbonylamino, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-oxycarbonylamino, unsubstituted or substituted C₁₋₁₂ alkylsulfanyl, unsubstituted or substituted C₂₋₁₂ alkenylsulfanyl, unsubstituted or substituted C₂₋₁₂ alkynylsulfanyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-sulfanyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-sulfanyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-sulfanyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-sulfanyl, unsubstituted or substituted C₁₋₁₂ alkylsulfinyl, unsubstituted or substituted C₂₋₁₂ alkenylsulfinyl, unsubstituted or substituted C₂₋₁₂ alkynylsulfinyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-sulfinyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-sulfinyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-sulfinyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-sulfinyl, unsubstituted or substituted C₁₋₁₂ alkylcarbamoyl, unsubstituted or substituted C₂₋₁₂ alkenylcarbamoyl, unsubstituted or substituted C₂₋₁₂ alkynylcarbamoyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-carbamoyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-carbamoyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-carbamoyl, unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-carbamoyl, unsubstituted or substituted C₁₋₁₂ alkylsulfamoyl, unsubstituted or substituted C₂₋₁₂ alkenylsulfamoyl, unsubstituted or substituted C₂₋₁₂ alkynylsulfamoyl, unsubstituted or substituted C₆₋₁₀ aryl-L_(X)-sulfamoyl, unsubstituted or substituted C₃₋₁₀ cycloalkyl-L_(X)-sulfamoyl, unsubstituted or substituted 5- to 10-membered heteroaryl-L_(X)-sulfamoyl, and unsubstituted or substituted 5- to 10-membered heterocycloalkyl-L_(X)-sulfamoyl, wherein L_(X) is a single bond or unsubstituted or substituted C₁₋₁₂ alkylene,

wherein the substituted C₁₋₁₂ alkyl, substituted C₂₋₁₂ alkenyl, substituted C₂₋₁₂ alkynyl, substituted C₆₋₁₀ aryl, substituted C₃₋₁₀ cycloalkyl, substituted 5- to 10-membered heteroaryl, substituted 5- to 10-membered heterocycloalkyl, and substituted alkylene moieties (fully or partially) in the substituent group each independently have one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, oxo, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfa, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureide, amidino, amidinoamino, C₁₋₁₂ alkyl, C₁₋₁₂ haloalkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, C₁₋₁₂ alkyloxy, C₁₋₁₂ haloalkyloxy, C₂₋₁₂ alkenyloxy, C₂₋₁₂ alkynyloxy, C₆₋₁₀ aryl-L_(X)-oxy, C₃₋₁₀ cycloalkyl-L_(X)-oxy, 5- to 10-membered heteroaryl-L_(X)-oxy, 5- to 10-membered heterocycloalkyl-L_(X)-oxy, C₁₋₁₂ alkyloxyalkyl, C₂₋₁₂ alkenyloxyalkyl, C₂₋₁₂ alkynyloxyalkyl, C₆₋₁₀ aryloxyalkyl, C₃₋₁₀ cycloalkyloxyalkyl, 5- to 10-membered heteroaryloxyalkyl, 5- to 10-membered heterocycloalkyloxyalkyl, C₁₋₁₂ alkyloxyalkyloxy, C₂₋₁₂ alkenyloxyalkyloxy, C₂₋₁₂ alkynyloxyalkyloxy, C₆₋₁₀ aryloxyalkyloxy, C₃₋₁₀ cycloalkyloxyalkyloxy, 5- to 10-membered heteroaryloxyalkyloxy, 5- to 10-membered heterocycloalkyloxyalkyloxy, C₁₋₁₂ alkylcarbonyl, C₂₋₁₂ alkenylcarbonyl, C₂₋₁₂ alkynylcarbonyl, C₆₋₁₀ aryl-L_(X)-carbonyl, C₃₋₁₀ cycloalkyl-L_(X)-carbonyl, 5- to 10-membered heteroaryl-L_(X)-carbonyl, 5- to 10-membered heterocycloalkyl-L_(X)-carbonyl, C₁₋₁₂ alkylcarbonyloxy, C₂₋₁₂ alkenylcarbonyloxy, C₂₋₁₂ alkynylcarbonyloxy, C₆₋₁₀ aryl-L_(X)-carbonyloxy, C₃₋₁₀ cycloalkyl-L_(X)-carbonyloxy, 5- to 10-membered heteroaryl-L_(X)-carbonyloxy, 5- to 10-membered heterocycloalkyl-L_(X)-carbonyloxy, C₁₋₁₂ alkylcarbonylamino, C₂₋₁₂ alkenylcarbonylamino, C₂₋₁₂ alkynylcarbonylamino, C₆₋₁₀ aryl-L_(X)-carbonylamino, C₃₋₁₀ cycloalkyl-L_(X)-carbonylamino, 5- to 10-membered heteroaryl-L_(X)-carbonylamino, 5- to 10-membered heterocycloalkyl-L_(X)-carbonylamino, C₁₋₁₂ alkylcarbonylthio, C₂₋₁₂ alkenylcarbonylthio, C₂₋₁₂ alkynylcarbonylthio, C₆₋₁₀ aryl-L_(X)-carbonylthio, C₃₋₁₀ cycloalkyl-L_(X)-carbonylthio, 5- to 10-membered heteroaryl-L_(X)-carbonylthio, 5- to 10-membered heterocycloalkyl-L_(X)-carbonylthio, C₁₋₁₂ alkylcarbonylimino, C₂₋₁₂ alkenylcarbonylimino, C₂₋₁₂ alkynylcarbonylimino, C₆₋₁₀ aryl-L_(X)-carbonylimino, C₃₋₁₀ cycloalkyl-L_(X)-carbonylimino, 5- to 10-membered heteroaryl-L_(X)-carbonylimino, 5- to 10-membered heterocycloalkyl-L_(X)-carbonylimino, C₁₋₁₂ alkylthio, C₂₋₁₂ alkenylthio, C₂₋₁₂ alkynylthio, C₆₋₁₀ aryl-L_(X)-thio, C₃₋₁₀ cycloalkyl-L_(X)-thio, 5- to 10-membered heteroaryl-L_(X)-thio, 5- to 10-membered heterocycloalkyl-L_(X)-thio, C₁₋₁₂ alkylamino, C₂₋₁₂ alkenylamino, C₂₋₁₂ alkynylamino, C₂₋₁₂ alkynylamino, C₆₋₁₀ aryl-L_(X)-amino, C₃₋₁₀ cycloalkyl-L_(X)-amino, 5- to 10-membered heteroaryl-L_(X)-amino, 5- to 10-membered heterocycloalkyl-L_(X)-amino, C₁₋₁₂ alkylsulfonyl, C₂₋₁₂ alkenylsulfonyl, C₂₋₁₂ alkynylsulfonyl, C₆₋₁₀ aryl-L_(X)-sulfonyl, C₃₋₁₀ cycloalkyl-L_(X)-sulfonyl, 5- to 10-membered heteroaryl-L_(X)-sulfonyl, 5- to 10-membered heterocycloalkyl-L_(X)-sulfonyl, C₁₋₁₂ alkylsulfonylamino, C₂₋₁₂ alkenylsulfonylamino, C₂₋₁₂ alkynylsulfonylamino, C₆₋₁₀ aryl-L_(X)-sulfonylamino, C₃₋₁₀ cycloalkyl-L_(X)-sulfonylamino, 5- to 10-membered heteroaryl-L_(X)-sulfonylamino, 5- to 10-membered heterocycloalkyl-L_(X)-sulfonylamino, C₁₋₁₂ alkylimino, C₂₋₁₂ alkenylimino, C₂₋₁₂ alkynylimino, C₆₋₁₀ aryl-L_(X)-imino, C₃₋₁₀ cycloalkyl-L_(X)-imino, 5- to 10-membered heteroaryl-L_(X)-imino, 5- to 10-membered heterocycloalkyl-L_(X)-imino, C₁₋₁₂ alkyloxyimino, C₂₋₁₂ alkenyloxyimino, C₂₋₁₂ alkynyloxyimino, C₆₋₁₀ aryl-L_(X)-oxyimino, C₃₋₁₀ cycloalkyl-L_(X)-oxyimino, 5- to 10-membered heteroaryl-L_(X)-oxyimino, 5- to 10-membered heterocycloalkyl-L_(X)-oxyimino, C₁₋₁₂ alkyloxycarbonyl, C₂₋₁₂ alkenyloxycarbonyl, C₂₋₁₂ alkynyloxycarbonyl, C₆₋₁₀ aryl-L_(X)-oxycarbonyl, C₃₋₁₀ cycloalkyl-L_(X)-oxycarbonyl, 5- to 10-membered heteroaryl-L_(X)-oxycarbonyl, 5- to 10-membered heterocycloalkyl-L_(X)-oxycarbonyl, C₁₋₁₂ alkyloxycarbonylamino, C₂₋₁₂ alkenyloxycarbonylamino, C₂₋₁₂ alkynyloxycarbonylamino, C₆₋₁₀ aryl-L_(X)-oxycarbonylamino, C₃₋₁₀ cycloalkyl-L_(X)-oxycarbonylamino, 5- to 10-membered heteroaryl-L_(X)-oxycarbonylamino, 5- to 10-membered heterocycloalkyl-L_(X)-oxycarbonylamino, C₁₋₁₂ alkylsulfanyl, C₂₋₁₂ alkenylsulfanyl, C₂₋₁₂ alkynylsulfanyl, C₆₋₁₀ aryl-L_(X)-sulfanyl, C₃₋₁₀ cycloalkyl-L_(X)-sulfanyl, 5- to 10-membered heteroaryl-L_(X)-sulfanyl, 5- to 10-membered heterocycloalkyl-L_(X)-sulfanyl, C₁₋₁₂ alkylsulfinyl, C₂₋₁₂ alkenylsulfinyl, C₂₋₁₂ alkynylsulfinyl, C₆₋₁₀ aryl-L_(X)-sulfinyl, C₃₋₁₀ cycloalkyl-L_(X)-sulfinyl, 5- to 10-membered heteroaryl-L_(X)-sulfinyl, 5- to 10-membered heterocycloalkyl-L_(X)-sulfinyl, C₁₋₁₂ alkylcarbamoyl, C₂₋₁₂ alkenylcarbamoyl, C₂₋₁₂ alkynylcarbamoyl, C₆₋₁₀ aryl-L_(X)-carbamoyl, C₃₋₁₀ cycloalkyl-L_(X)-carbamoyl, 5- to 10-membered heteroaryl-L_(X)-carbamoyl, 5- to 10-membered heterocycloalkyl-L_(X)-carbamoyl, C₁₋₁₂ alkylsulfamoyl, C₂₋₁₂ alkenylsulfamoyl, C₂₋₁₂ alkynylsulfamoyl, C₆₋₁₀ aryl-L_(X)-sulfamoyl, C₃₋₁₀ cycloalkyl-L_(X)-sulfamoyl, 5- to 10-membered heteroaryl-L_(X)-sulfamoyl, and 5- to 10-membered heterocycloalkyl-L_(X)-sulfamoyl.

Substituent group III consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidinoamino, alkyl, aryl, cycloalkyl, heteroaryl, alkyloxy, alkylcarbonyl, cycloalkylcarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, alkylamino, cycloalkylalkylamino, alkyloxycarbonyl, and trialkylsilyloxy, and these groups of the substituent group are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, alkyl, haloalkyl, alkyloxy, haloalkyloxy, and alkyloxycarbonyl.

Substituent group III is preferably substituent group III′, which consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidinoamino, C₁₋₁₂ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5- to 10-membered heteroaryl, C₁₋₁₂ alkyloxy, C₁-alkylcarbonyl, C₃₋₁₀ cycloalkylcarbonyl, C₁₋₁₂ alkylcarbonylamino, C₃₋₁₀ cycloalkylcarbonylamino, C₁₋₁₂ alkylamino, C₃₋₁₀ cycloalkyl C₁₋₆ alkylamino, C₁₋₁₂ alkyloxycarbonyl, and tri-C₁₋₆ alkylsilyloxy, wherein these groups of the substituent group are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, C₁₋₁₂ alkyl, C₁₋₁₂ haloalkyl, C₁₋₁₂ alkyloxy, C₁₋₁₂ haloalkyloxy, and C₁₋₁₂ alkyloxycarbonyl.

Substituent group IV consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidino, alkyl, aryl, cycloalkyl, heteroarylheterocycloalkyl, arylalkyl, cycloalkylalkyl, alkyloxy, aryloxy, alkylcarbonyl, cycloalkylcarbonyl, alkyloxycarbonyl, and trialkylsilyloxy, and these groups of the substituent group are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, alkyl, haloalkyl, alkyloxy, haloalkyloxy, and alkyloxycarbonyl.

Substituent group IV is preferably substituent group IV′, which consists of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, amidino, C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl C₁₋₆ alkyl, C₁₋₆ alkyloxy, C₆₋₁₀ aryloxy, C₁₋₆ alkylcarbonyl, C₃₋₁₀ cycloalkylcarbonyl, C₁₋₆ alkyloxycarbonyl, and tri-C₁₋₆ alkylsilyloxy, and these groups of the substituent group are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, carbamoyl, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyloxy, C₁₋₆ haloalkyloxy, and C₁₋₆ alkyloxycarbonyl.

Substituent group V consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, alkyloxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, alkyloxyoxy, alkylamino, arylamino, cycloalkylamino, heteroarylamino, heterocycloalkylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heteroarylcarbonyl, heterocycloalkylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkyloxycarbonyl, alkylcarbamoyl, arylcarbamoyl, cycloalkylcarbamoyl, heteroarylcarbamoyl, and heterocycloalkylcarbamoyl, wherein these groups of the substituent group are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, alkyl, alkyloxy, haloalkyl, haloalkyloxy, alkylamino, formyl, alkylcarbonyl, alkyloxycarbonyl, and alkylcarbamoyl.

Substituent group V is preferably substituent group V′, which consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, C₁₋₁₂ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, C₁₋₁₂ alkyloxy, C₆₋₁₀ aryloxy, C₃₋₁₀ cycloalkyloxy, 5- to 10-membered heteroaryloxy, 5- to 10-membered heterocycloalkyloxy, C₁₋₁₂ alkylamino, C₆₋₁₀ arylamino, C₃₋₁₀ cycloalkylamino, 5- to 10-membered heteroarylamino, 5- to 10-membered heterocycloalkylamino, formyl, C₁₋₁₂ alkylcarbonyl, C₆₋₁₀ arylcarbonyl, C₃₋₁₀ cycloalkylcarbonyl, 5- to 10-membered heteroarylcarbonyl, 5- to 10-membered heterocycloalkylcarbonyl, C₁₋₁₂ alkyloxycarbonyl, C₆₋₁₀ aryloxycarbonyl, C₃₋₁₀ cycloalkyloxycarbonyl, 5- to 10-membered heteroaryloxycarbonyl, 5- to 10-membered heterocycloalkyloxycarbonyl, C₁₋₁₂ alkylcarbamoyl, C₆₋₁₀ arylcarbamoyl, C₃₋₁₀ cycloalkylcarbamoyl, 5- to 10-membered heteroarylcarbamoyl, and 5- to 10-membered heterocycloalkylcarbamoyl, wherein these groups of the substituent group are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, C₁₋₆ alkyl, C₁₋₆ alkyloxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkyloxy, C₁₋₆ alkylamino, formyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkyloxycarbonyl, and C₁₋₆ alkylcarbamoyl.

Substituent group VI consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, alkyl, alkyloxy, haloalkyl, haloalkyloxy, alkylamino, formyl, alkylcarbonyl, alkyloxycarbonyl, and alkylcarbamoyl.

Substituent group VI is preferably substituent group VI′, which consists of halogen, hydroxy, carboxy, amino, formyl, carbamoyl, cyano, nitro, amidino, amidinoamino, C₁₋₆ alkyl, C₁₋₆ alkyloxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkyloxy, C₁₋₆ alkylamino, formyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkyloxycarbonyl, and C₁₋₆ alkylcarbamoyl.

As used herein, examples of substituents used when “optionally substituted” include substituent group α and substituent group β. Substituent group a can be substituent group α1, substituent group α2, or substituent group α3. Substituent group β can be substituent group β1, substituent group β2, or substituent group β3. Substituents used when “optionally substituted” can be selected from substituent group α1, and substitution can be performed with 1 to 5 of the same or different substituents. While the types of atoms within a substituent associated with attachment are not particularly limited by the type of substituent, if the atom to which a substituent attaches is an oxygen atom, a nitrogen atom, or a sulfur atom, the substituent is limited to those with an attaching atom that is a carbon atom from the following substituents.

Substituent group α1 includes

1) halogen atom 2) hydroxyl group 3) carboxyl group 4) cyano group 5) C₁₋₆ alkyl 6) C₂₋₆ alkenyl 7) C₂₋₆ alkynyl 8) C₁₋₆ alkoxy 9) C₁₋₆ alkylthio 10) C₁₋₆ alkylcarbonyl 11) C₁₋₆ alkylsulfonyl (however, each substituent from 5) to 11) is optionally substituted with 1 to 5 of the same or different substituents selected from substituent group (1) 12) C₃₋₁₀ alicyclic group 13) C₃₋₁₀ alicyclic oxy 14) C₆₋₁₀ aryloxy 15) 5- to 6-membered heteroaryloxy 16) 4- to 10-membered non-aryl heterocyclyloxy 17) C₃₋₁₀ alicyclic thio 18) C₆₋₁₀ arylthio 19) 5- to 6-membered heteroarylthio 20) 4- to 10-membered non-aryl heterocyclylthio 21) C₆₋₁₀ aryl 22) 5- to 6-membered heteroaryl 23) 4- to 10-membered non-aryl heterocycle 24) C₃₋₁₀ alicyclic carbonyl 25) C₆₋₁₀ arylcarbonyl 26) 5- to 6-membered heteroarylcarbonyl 27) 4- to 10-membered non-aryl heterocyclylcarbonyl 28) C₃₋₁₀ alicyclic sulfonyl 29) C₆₋₁₀ aryl sulfonyl 30) 5- to 6-membered heteroarylsulfonyl 31) 4- to 10-membered non-aryl heterocyclylsulfonyl (however, each substituent from 12) to 31) is optionally substituted with 1 to 5 substituents in substituent group β1 or 5) C₁₋₆ alkyl) 32) —NR^(10a)R^(11a) 33) —SO₂—NR^(10b)R^(11b) 34) —NR^(10c)—C(═O) R^(11c) 35) —NR^(10d)—C(═O) OR^(11d) 36) —NR^(12a)—C(═P) NR^(10e)R^(11e) 37) —NR^(10i)—SO₂—R^(11i) 38) —NR^(12c)—SO₂—NR^(10j)R^(11j)

39) —C(═O) OR^(10k)

40) —C(═O) NR^(10l)R^(11k) 41) —C(═O) NR^(10m)OR^(11l) 42) —C(═O)NR^(12d)—NR^(10n)R^(11m) 43) —C(═NR^(13a))R^(10s) 44) —C(═NR^(13c))NR^(10t)R^(11q) 45) —C(═NR^(13d)) NR^(12f)—NR^(10u)R^(11r) 46) —NR^(17c)—C(═NR^(13k))R^(17d) 47) —NR^(12g)—C(═NR^(13e))—NR^(10v)R^(11s) 48) —NR¹⁴—C(═NR^(13f))—NR^(12h)—NR^(10w)R^(11t)

49) —OC(═O)R^(10x) 50) —OC(═O)OR^(10y)

51) —OC(═O)—NR^(10z1)R^(11u) 52) —NR^(12i)—NR^(10z2)R^(11v) 53) —NR^(10z3)OR^(11w), and 54) protecting group, and

substituent group β1 is a group consisting of

1) halogen atom, 2) hydroxyl group, 3) carboxyl group, 4) cyano group, 5) C₃₋₁₀ alicyclic group, 6) C₁₋₆ alkoxy, 7) C₃₋₁₀ alicyclic oxy, 8) C₁₋₆ alkylthio, 9) 5- to 6-membered heteroarylthio, 10) C₆₋₁₀ aryl, 11) 5- to 6-membered heteroaryl, 12) 4- to 10-membered non-aryl heterocycle, 13) C₁₋₆ alkylcarbonyl, 14) C₃₋₁₀ alicyclic carbonyl, 15) C₆₋₁₀ arylcarbonyl, 16) 5- to 6-membered heteroarylcarbonyl, 17) 4- to 10-membered non-aryl heterocyclylcarbonyl, 18) —NR^(15a)R^(16a), 19) —SO₂—NR^(15b)R^(16b), 20) —NR^(15c)—C(═O)R^(16c) 21) —NR^(17a)—C(═O)NR^(15d)R^(16d) 22) —C(═O)NR^(15e)R^(15e), 23) —C(═NR^(13g))R^(15f), 24) —C(═NR^(13h)) NR^(15g)R^(16f) 25) —NR^(16g)—C(═NR^(13i))R^(15h) 26) —NR^(17b)—C(═NR^(13j))—NR^(15i)R^(16h), and 27) protecting group (however, each substituent from 5) to 17) in substituent group β1 is optionally substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, carboxyl group, and —NR^(18a)R^(18b)), wherein

R^(13a), R^(13a2), R^(13c), R^(13c2), R^(13d), R^(13d2), R^(13e), R^(13f), R^(13g), R^(13g2), R^(13h), R^(13h2), R^(13i), R^(13j), and R^(13k) are each independently the same or different hydrogen atom, hydroxyl group, C₁₋₆ alkyl, C₁₋₆ alkoxy, or C₁₋₆ alkoxycarbonyl,

R^(10a), R^(10b), R^(10c), R^(10d), R^(10e), R^(10i), R^(10j), R^(10k), R^(10l), R^(10m), R^(10n), R^(10s), R^(10s2), R^(10t), R^(10t2), R^(10u), R^(10u2), R^(10v), R^(10w), R^(10x), R^(10y), R^(10z1), R^(10z2), R^(10z3), R^(11a), R^(11b), R^(11c), R^(11d), R^(11e), R^(11i), R^(11j), R^(11k), R^(11l), R^(11m), R^(11q), R^(11q2), R^(11r), R^(11r2), R^(11s), R^(11t), R^(11u), R^(11v), R^(11w), R^(12a), R^(12c), R^(12d), R^(12f), R^(12f2), R^(12g), R^(12h), R^(12i), R¹⁴, R^(15a), R^(15b), R^(15c), R^(15d), R^(15e), R^(15f), R^(15f2), R^(15g), R^(15g2), R^(15h), R^(15i), R^(16a), R^(16b), R^(16c), R^(16d), R^(16e), R^(16f), R^(16f2), R^(16g), R^(16h), R^(17a), R^(17b), R^(17c), and R^(17d) are each independently the same or different hydrogen atom, C₁₋₆ alkyl (the C₁₋₆ alkyl is optionally substituted with 1 to 3 of the same or different substituents selected from a hydroxyl group, cyano group, C₁₋₆ alkoxy, and —NR^(18a)R^(18b)), or C₁₋₆ alkoxycarbonyl, and

R^(18a) and R^(18b) are each independently the same or different hydrogen atom or C₁₋₆ alkyl.

In an exemplary embodiment, hydrogen of any hydroxyl group in substituent groups α1 and β1 is optionally substituted with a protecting group.

Examples of preferred substituents as the substituent used when “optionally substituted” herein include the following.

Substituent group α2 preferably includes

1) halogen atom 2) hydroxyl group 3) carboxyl group 4) cyano group 5) C₁₋₆ alkyl 6) C₁₋₆ alkoxy 7) C₁₋₆ alkylthio 8) C₁₋₆ alkylcarbonyl (however, each substituent from 5) to 8) is optionally substituted with 1 to 5 same or different substituents selected from substituent group (2) 9) C₃₋₁₀ alicyclic group 10) C₃₋₁₀ alicyclic oxy 11) C₆₋₁₀ aryloxy 12) 5- to 6-membered heteroaryloxy 13) 4- to 10-membered non-aryl heterocyclyloxy 14) C₃₋₁₀ alicyclic thio 15) C₆₋₁₀ arylthio 16) 5- to 6-membered heteroarylthio 17) 4- to 10-membered non-aryl heterocyclylthio 18) C₆₋₁₀ aryl 19) 5- to 6-membered heteroaryl 20) 4- to 10-membered non-aryl heterocycle 21) C₃₋₁₀ alicyclic carbonyl 22) C₆₋₁₀ arylcarbonyl 23) 5- to 6-membered heteroarylcarbonyl 24) 4- to 10-membered non-aryl heterocyclylcarbonyl (however, each substituent from 9) to 24) is optionally substituted with 1 to 5 substituents in substituent group β2 or 1) C₁₋₆ alkyl) 25) —NR^(10a)R^(11a) 26) —SO₂—NR^(10b)R^(11b) 27) —NR^(10c)—C(═O)R^(11c) 28) —NR^(12a)—C(═O) NR^(10d)R^(11d) 29) —NR^(10e)_SO₂—R^(11e) 30) —NR^(12b)—SO₂—NR^(10f)R^(11f) 31) —C(═O)—NR^(10g)R^(11g) 32) —C(═NR^(13a))R^(10h) 33) —C(═NR^(13b))R^(10i)R^(11h) 34) —NR^(11f2)—C(═NR^(13c))R^(10g2), and 35) —NR^(12c)—C(═NR^(13d)) and

substituent group (2 is preferably a group consisting of

1) halogen atom 2) hydroxyl group 3) cyano group 4) C₃₋₁₀ alicyclic group 5) C₁₋₆ alkoxy 6) C₁₋₆ alkylthio 7) 5- to 6-membered heteroarylthio 8) 5- to 6-membered heteroaryl 9) 4- to 10-membered non-aryl heterocycle 10) C₁₋₆ alkylcarbonyl 11) C₃₋₁₀ alicyclic carbonyl 12) C₆₋₁₀ arylcarbonyl 13) 5- to 6-membered heteroarylcarbonyl 14) 4- to 10-membered non-aryl heterocyclylcarbonyl 15) —NR^(15a)R^(16a) 16) —NR^(15b)—C(═O)R^(16b) 17) —NR^(17a)—C(═O)NR^(15c)R^(16c) 18) —C(═O)NR^(15d)R^(16d) 19) —C(═NR^(13e))R^(15e) 20) —C(═NR^(13f))NR^(15f)R^(16e) 21) —NR^(16f)—C(═NR^(13g))R^(15g) 22) —NR^(17b)—C(═NR^(13h))—NR^(15h)R^(16g) 23) —C(═N—OR^(13e2))R^(15e2), and 24) —C(═N—OR^(13f2))NR^(15f2)R^(16e2) (however, each substituent from 4) to 14) in substituent group β2 is optionally substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, carboxyl group, and —NR^(18a)R^(18b),

R^(13a), R^(13a2), R^(13b), R^(13b2), R^(13c), R^(13d), R^(13e), R^(13e2), R^(13f), R^(13f2), R^(13g), and R^(13h) are each independently the same or different hydrogen atom, hydroxyl group, C₁₋₆ alkyl, C₁₋₆ alkoxy, or C₁₋₆ alkoxycarbonyl,

R^(10a), R^(10b), R^(10c), R^(10d), R^(10e), R^(10f), R^(10g), R^(10g2), R^(10h), R^(10h2), R^(10i), R^(10i2), R^(10j), R^(11a), R^(11b), R^(11c), R^(11d), R^(11e), R^(11f), R^(11f2), R^(11g), R^(11h), R^(11h2), R^(11i), R^(12a), R^(12b), R^(12c), R^(15a), R^(15b), R^(15c), R^(15d), R^(15e), R^(15e2), R^(15f), R^(15f2), R^(15g), R^(15h), R^(16a), R^(16b), R^(16c), R^(16d), R^(16e), R^(16e2), R^(16f), R^(16g), R^(17a), and R^(17b) are each independently the same or different hydrogen atom, C₁₋₆ alkyl (the C₁₋₆ alkyl is optionally substituted with 1 to 3 same or different substituents selected from a hydroxyl group, cyano group, C₁₋₆ alkoxy, and —NR^(18a)R^(18b)), or C₁₋₆ alkoxycarbonyl, and

R^(18a) and R^(18b) are each independently the same or different hydrogen atom or C₁₋₆ alkyl.

In an exemplary embodiment, hydrogen of any hydroxy group in substituent groups α2 and β2 is optionally substituted with a protecting group.

Examples of more preferred substituents used when “optionally substituted” herein include the following substituents.

Substituent group α3 more preferably includes

1) halogen atom 2) hydroxyl group 3) cyano group 4) C₁₋₆ alkyl 5) C₁₋₆ alkoxy 6) C₁₋₆ alkylthio 7) C₁₋₆ alkylcarbonyl (however, each substituent from 4) to 7) is optionally substituted with 1 to 5 same or different substituents selected from substituent group β3) 8) C₃₋₁₀ alicyclic group 9) 5- to 6-membered heteroaryloxy 10) 4- to 10-membered non-aryl heterocyclyloxy 11) 5- to 6-membered heteroarylthio 12) 4- to 10-membered non-aryl heterocyclylthio 13) C₆₋₁₀ aryl 14) 5- to 6-membered heteroaryl 15) 4- to 10-membered non-aryl heterocycle (however, each substituent from 8) to 15) is optionally substituted with 1 to 5 substituents in substituent group β3 or 1) C₁₋₆ alkyl) 16) —NR^(10a)R^(11a) 17) —NR^(11b)—C(═O)R^(10b) 18) —NR^(12a)—C(═O) NR^(10c)R^(11c) 19) —C(═O)—NR^(10d)R^(11d) 20) —C(═NR^(13a))R^(10e) 21) —C(═NR^(13b))NR^(10f)R^(11e) 22) —NR^(11f)—C(═NR^(13c)) R^(10g), and 23) —NR^(12b)—C(═NR^(13d))—NR^(10h)R^(11g), and substituent group β3 is more preferably 1) halogen atom, 2) hydroxyl group, 3) cyano group, 4) —NR^(15a)R^(16a), 5) —NR^(15b)—C(═O)R^(16b), 6) —NR^(17a)—C(═O) NR^(15c)R^(16c), 7) —C(═O) NR^(15d)R^(16d), 8) —C(═NR^(13e))R^(15e), 9) —C(═NR^(13f)) NR^(15f)R^(16e), 10) —NR^(16f)—C(═NR^(13g))R^(15g), and 11) —NR^(17b)—C(═NR^(13h))—NR^(15h)R^(16g), wherein

R^(13a), R^(13a2), R^(13b), R^(13b2), R^(13c), R^(13d), R^(13e), R^(13e2), R^(13f), R^(13f2), R^(13g), and R^(13h) are each independently the same or different hydrogen atom, hydroxyl group, C₁₋₆ alkyl, C₁₋₆ alkoxy, or C₁₋₆ alkoxycarbonyl,

R^(10a), R^(10b), R^(10c), R^(10d), R^(10e), R^(10f), R^(10e2), R^(10f2), R^(10g), R^(10h), R^(11a), R^(11b), R^(11c), R^(11d), R^(11e), R^(11e2), R^(11f), R^(11g), R^(12a), R^(12b), R^(15a), R^(15b), R^(15c), R^(15d), R^(15e), R^(15e2), R^(15f), R^(15f2), R^(15g), R^(15h), R^(16a), R^(16b), R^(16c), R^(16d), R^(16e), R^(16e2), R^(16f), R^(16g), R^(17a), and R^(17b) are each independently the same or different hydrogen atom, C₁₋₆ alkyl (the C₁₋₆ alkyl is optionally substituted with 1 to 3 same or different substituents selected from hydroxyl group, cyano group, C₁₋₆ alkoxy, and —NR^(18a)R^(18b)), or C₁₋₆ alkoxycarbonyl, and

R^(18a), and R^(18b) are each independently the same or different hydrogen atom or C₁₋₆ alkyl.

In an exemplary embodiment, hydrogen of any hydroxyl group in substituent groups α3 and β3 is optionally substituted with a protecting group.

In an exemplary embodiment, a hydroxyl group in the aforementioned substituent group (e.g., α (α1 or the like) β (β1 or the like), or I to VI) is also optionally substituted with a protecting group. In an exemplary embodiment, an amino group in substituent groups I to VI is also optionally protected with a nitrogen protecting group.

As used herein, “C₁₋₆” means that the number of carbon atoms is 1 to 6. The same applies to other numbers. For example, “C₁₋₄” means that the number of carbon atoms is 1 to 4, and “C₁₋₃” means that the number of carbon atoms is 1 to 3. A description with a limitation in the number of carbons herein is only a preferred numerical range. It is intended so that groups with a substituent with a number of carbons other than the number of carbons specified in the present disclosure are also within the scope of the present disclosure.

As used herein, “hydrocarbon group” is also referred to as a hydrocarbyl group, referring to a group generated by removing at least one hydrogen from “hydrocarbon” comprising at least one carbon and at least one hydrogen.

As used herein, “functional group” refers to any group conferring some type of functionality, encompassing a carboxyl group, nitrile group, carbonyl group, hydroxyl group, amino group, imino group, nitro group, halogen group, as well as alkyl group, and more broadly acid anhydrides and groups formed by a bond such as an ester bond, amide bond, or ether bond.

As used herein, “heteroatom” refers to atoms other than carbon atoms and hydrogen atoms such as oxygen atoms, nitrogen atoms, and sulfur atoms. A group comprising a heteroatom is also known as a hetero . . . group (e.g., heteroaryl group (means that an aryl group comprises at least a heteroatom) or heterocyclic group (means that a cyclic group (carbon ring group) comprises at least one heteroatom)) or the like.

As used herein, “halogen atom” is an atom belonging to the halogen group, referring to a fluorine atom, chlorine atom, bromine atom, iodine atom, or the like, and is preferably a fluorine atom or chlorine atom, and still more preferably a fluorine atom. A “halogen atom” is also referred to as “halogen” or “halo”.

As used herein, “hydroxyl group” is a monovalent group of —OH. This group is also referred to as a “hydroxy group” or “hydroxy”.

As used herein, “carboxyl group” is a monovalent group of —COOH. This group is also referred to as a “carboxy group”, “carboxy”, or “carboxyl”.

As used herein, “cyano group” is a monovalent group of —CN.

As used herein, “amino” is a monovalent group of —NH₂.

This group is also referred to as an “amino group”.

As used herein, “alkyl” refers to a linear or branched saturated aliphatic hydrocarbon group. “C₁₋₁₂ alkyl” is an alkyl group with 1 to 12 carbon atoms. Examples thereof include, but are not limited to, C₁₋₆ alkyl, heptyl, isoheptyl, octyl, isooctyl, nonyl, isnonyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isododecy, and the like. “C₁₋₆ alkyl” is an alkyl group with 1 to 6 carbon atoms, which is preferably “C₁₋₄ alkyl”, more preferably “C₁₋₃ alkyl”, and still more preferably “C₁₋₂ alkyl”. Specific examples of “C₁₋₄ alkyl” include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, and the like. Specific examples of “C₁₋₆alkyl” include, but are not limited to, C₁₋₄ alkyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1,2-dimethylpropyl, n-hexyl, and the like.

As used herein, “alkenyl” refers to a linear or branched unsaturated aliphatic hydrocarbon group comprising at least one carbon-carbon double bond. “C₂₋₁₂ alkenyl” is an alkenyl group with 2 to 12 carbon atoms. Examples thereof include, but are not limited to, heptenyl, isoheptenyl, octenyl, isooctenyl, nonenyl, isononenyl, decenyl, isodecenyl, undecenyl, isoundecenyl, dodecenyl, isododecenyl, and the like. “C₂₋₆ alkenyl” is an alkenyl group with 2 to 6 carbon atoms. Preferred examples thereof include “C₂₋₄ alkenyl”. Specific examples of “C₂₋₆ alkenyl” include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, and the like.

As used herein, “alkynyl” refers to a linear or branched unsaturated aliphatic hydrocarbon group comprising at least one carbon-carbon triple bond. “C₂₋₁₂ alkynyl” is an alkynyl group with 2 to 12 carbon atoms. Examples thereof include, but are not limited to, heptynyl, isoheptynyl, octynyl, isooctynyl, nonynyl, isononynyl, decynyl, isodecynyl, undecynyl, isoundecynyl, dodecynyl, isododecynyl, and the like. “C₂₋₆ alkynyl” is an alkynyl group with 2 to 6 carbon atoms. Preferred examples thereof include “C₂₋₄ alkynyl”. Specific examples of “C₂₋₆ alkynyl” include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 1-methyl-2-propynyl, 3-butynyl, 1-pentynyl, 1-hexynyl, and the like.

As used herein, “aryl” refers to a monovalent group of a monocyclic or bicyclic aromatic hydrocarbon ring. “C₆₋₁₀ aryl” refers to an aryl group with 6 to 10 carbon atoms. Examples of “aryl” include, but are not limited to, C₆ aryl, C₁₀ aryl, and the like. Specific examples of C₆ aryl include, but are not limited to, phenyl and the like. Specific examples of C₁₀ aryl include, but are not limited to, 1-naphthyl, 2-naphthyl, and the like.

An aryl group as a substituent or a portion thereof may be fused to an alicyclic group. For example, a phenyl group may be fused to a cyclohexane ring to form a 1,2,3,4-tetrahydronaphthalenyl group. In such a case, one of the possible carbon atoms on a benzene ring attaches to the backbone, or to a group near the backbone, or to its atom. An aryl group encompasses 5,6,7,8-tetrahydronaphthalen-1-yl and 5,6,7,8-tetrahydronaphthalen-2-yl.

As used herein, “arylalkyl” refers to alkyl substituted with at least one aryl. C₀“₆₋₁ aryl C₁₋₆ alkyl” refers to C₁₋₆ alkyl substituted with at least one C₆₋₁₀ aryl. Specific examples of C₆₋₁₀ aryl C₁₋₆ alkyl include, but are not limited to, benzyl(phenyl-CH₂—), phenethyl (phenyl-CH₂CH₂—), naphthalen-1-ylmethyl, naphthalen-2-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(naphthalen-2-yl)ethyl, and the like.

As used herein, “(optionally substituted amino)-arylalkyl” refers to arylalkyl substituted with an optionally substituted amino group, wherein the alkyl group, the aryl group, or both is substituted with an amino group. An amino group of such an arylalkyl group may be unsubstituted, or substituted with 1, 2, or 3 substituents, such as optionally substituted alkyl (e.g., unsubstituted C₁₋₆ alkyl, C₃₋₆ cycloalkyl-C₁₋₆ alkyl, C₃₋₆ cycloalkylcarbonyl, or the like). Examples of (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl include, but are not limited to, (di(alkyl)amino)benzyl, ((cycloalkylalkyl)amino)benzyl, ((cycloalkylcarbonyl)amino)benzyl, ((carbamoylalkyl) carbonylamino)benzyl, ((carboxyalkyl)carbonyl)aminobenzyl, (di(alkyl)amino)naphthalenylmethyl, ((cycloalkylalkyl)amino)naphthalenylmethyl, ((cycloalkylcarbonyl)amino)naphthalenylmethyl, ((carbamoylalkyl)carbonylamino)naphthalenylmethyl, ((carboxyalkyl)carbonyl)aminonaphthalenylmethyl, and the like.

As used herein, the aryl moiety of “arylthio” is defined the same as the aforementioned aryl. Preferred examples of “C₆₋₁₀ arylthio” include “C₆ or C₁₀ arylthio”. Specific examples of “C₆₋₁₀ aryloxy” include, but are not limited to, phenylthio, 1-naphthylthio, 2-naphthylthio, and the like.

As used herein, “aryl sulfonyl” refers to sulfonyl substituted with the aforementioned “aryl”. “C₆₋₁₀ aryl sulfonyl” is preferably “C₆ or C₁₀ aryl sulfonyl”. Specific examples of “C₆₋₁₀ aryl sulfonyl” include, but are not limited to, phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl, and the like.

As used herein, “heteroaryl” refers to a monovalent group of a monocyclic or bicyclic aromatic heterocycle comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.

As used herein, “5- to 6-membered heteroaryl” refers to a monovalent group of a monocyclic aromatic heterocycle consisting 5 to 6 atoms, comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom. Specific examples of “5- to 6-membered heteroaryl” include, but are not limited to, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, pyridyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, and the like.

As used herein, “5- to 10-membered heteroaryl” refers to a monovalent group of a monocyclic or bicyclic aromatic heterocycle consisting of 5 to 10 atoms, comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom. Specific examples of “5- to 10-membered heteroaryl” include, but are not limited to, 5- to 6-membered heteroaryl, quinolyl, isoquinolyl, naphthyridinyl, quinoxalinyl, cinnolinyl, quinazolinyl, phthalazinyl, imidazopyridyl, imidazothiazolyl, imidazooxazolyl, benzothiazolyl, benzooxazolyl, benzoimidazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridyl, thienopyridyl, furopyridyl, benzothiadiazolyl, benzooxadiazolyl, pyridopyrimidinyl, benzofuryl, benzothienyl, benzo[1,3]dioxole, thienofuryl, chromenyl, chromanyl, coumarinyl, quinolonyl, and the like.

As used herein, “heteroarylalkyl” refers to alkyl substituted with at least one heteroaryl. “5- to 10-membered heteroaryl C₁₋₆ alkyl” refers to C₁₋₆ alkyl substituted with at least one 5- to 10-membered heteroaryl. Specific examples of 5- to 10-membered heteroaryl C₁₋₆ alkyl include, but are not limited to, pyridin-2-ylmethyl, pyridin-4-ylmethyl, 2-(quinolin-8-yl)ethyl, 2-(quinolin-5-yl)ethyl, 2-(quinoxalin-5-yl)ethyl, 2-(1H-indol-3-yl)ethyl, and the like.

As used herein, “alicyclic group” refers to a monovalent group of a monocyclic, bicyclic, or tricyclic non-aromatic hydrocarbon ring, including those that have a partially unsaturated bond, those that have a partially crosslinked structure, those that are partially a spiro, and those having 1, 2, or more carbonyl structures. An “alicyclic group” encompasses cycloalkyl, cycloalkenyl, and cycloalkynyl. “C₃₋₂₀ alicyclic group” is preferably a “C₃₋₁₀ alicyclic group”, more preferably a “C₃₋₆ alicyclic group”. Specific examples of “C₃₋₂₀ alicyclic group” include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexadinyl, cycloheptadinyl, cyclooctadinyl, adamantyl, norbornyl, and the like.

An alicyclic group can be a fused ring between a non-aryl ring and an aryl and/or heteroaryl ring. For example, cycloalkyl fused with C₆₋₁₀ aryl or 5- to 6-membered heteroaryl is encompassed by an alicyclic group. Examples of fused alicyclic groups include a monovalent group with one hydrogen atom removed from 1,2,3,4-tetrahydronaphthalene, indane, 1,2,3,4-tetrahydroanthracene, and 5,6,7,8-tetrahydroquinoline. Specific examples thereof include 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, indan-1-yl, indan-2-yl, 5,6,7,8-tetrahydroquinolin-5-yl, 5,6,7,8-tetrahydroquinolin-6-yl, and the like. A fused alicyclic group attaches from any one of the possible cyclic structure atoms on a non-aryl ring to the backbone.

As used herein, “C₃₋₁₀ alicyclic group” refers to a substituent with “C₃₋₁₀ alicyclic group” that is a monovalent group among the aforementioned C₀“₃₋₂ alicyclic group”.

As used herein, “alicyclic oxy” refers to an (alicyclic group)-O— group, and the alicyclic moiety is defined the same as an alicyclic group. “C₃₋₆ alicyclic oxy” refers to a (C₃₋₆ alicyclic group)-O— group, and the C₃₋₆ alicyclic moiety is defined the same as a C₃₋₆ alicyclic group. “C₃₋₆ alicyclic oxy” is preferably “C₃₋₅ alicyclic oxy”. Specific examples of “C₃₋₆ alicyclic oxy” include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

As used herein, “alicyclic carbonyl” refers to carbonyl substituted with the “alicyclic group” described above. “C₃₋₁₀ alicyclic carbonyl” is preferably “C₃₋₆ alicyclic carbonyl”. Specific examples of “C₃₋₁₀ alicyclic carbonyl” include, but are not limited to, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, and the like.

As used herein, “alicyclic thio” refers to an (alicyclic group)-S— group, and the alicyclic moiety is defined the same as above. “C₃₋₁₀ alicyclic thio” is preferably “C₃₋₆ alicyclic thio”. Specific examples of “C₃₋₆ alicyclic thio” include, but are not limited to, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.

As used herein, “alicyclic sulfonyl” refers to a sulfonyl group substituted with the “alicyclic group” described above. “C₃₋₁₀ alicyclic sulfonyl” is preferably “C₃₋₆ alicyclic sulfonyl”. Specific examples of “C₃₋₁₀ alicyclic sulfonyl” include, but are not limited to, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl, and the like.

As used herein, “cycloalkyl” refers to a non-aromatic saturated hydrocarbon ring group, including those that have a partially crosslinked structure, those that are partially spiro, those having 1, 2, or more carbonyl structures. “C₃₋₂₀ cycloalkyl” refers to monocyclic or bicyclic cycloalkyl with 3 to 20 carbon atoms. “C₃₋₆ cycloalkyl” refers to monocyclic cycloalkyl with 3 to 6 carbon atoms. Specific examples of C₃₋₆ cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

A cycloalkyl group can be fused to aryl and/or heteroaryl ring as a substituent or a portion thereof. For example, a cyclohexyl group can be fused to a benzene ring to form a 1,2,3,4-tetrahydronaphthalenyl group. In such a case, one of the possible carbon atoms on the cyclohexane ring attaches to the backbone, to a group near the backbone, or to its atom. A cycloalkyl group encompasses 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, indan-1-yl, indan-2-yl, 5,6,7,8-tetrahydroquinolin-5-yl, and 5,6,7,8-tetrahydroquinolin-6-yl.

As used herein, “cycloalkylalkyl” refers to alkyl substituted with at least one cycloalkyl. “C₃₋₆ cycloalkyl C₁₋₆ alkyl” refers to C₁₋₆ alkyl substituted with at least one C₃₋₆ cycloalkyl. Specific examples of C₃₋₆ cycloalkyl C₁₋₆ alkyl include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, 3-cyclopropylpropyl, 3-cyclobutylpropyl, 3-cyclopentylpropyl, 3-cyclohexylpropyl, and the like.

As used herein, “heterocycloalkyl” refers to a non-aromatic saturated or partially unsaturated heterocycle comprised of 3 or more atoms, copmrising 1, 2, or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom, including those that have a partially crosslinked structure and those that are partially spiro. “Heterocycloalkyl” encompasses “non-aryl heterocycle”. Heterocycloalkyl can have a structure where a non-aromatic heterocycle is fused to an aryl ring and/or heteroaryl ring.

As used herein, “non-aryl heterocycle” refers to a monocyclic or bicyclic non-aromatic heterocycle comprised of 3 or more atoms, comprising 1, 2, or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom, including saturated non-aryl heterocycles, those that have a partially unsaturated attachment, those that have a partially crosslinked structure, and those that are partially spiro. A non-aryl heterocycle can form a fused ring with aryl or heteroaryl. For example, a non-aryl heterocycle fused to C₆₋₁₀ aryl or 5- to 6-membered heteroaryl is also encompassed by a heterocycle. 1, 2, or more carbonyl, thiocarbonyl, sulfinyl, or sulfonyl can be comprised to constitute the non-aryl heterocycle. For example, lactam, thiolactam, lactone, thiolactone, cyclic imide, cyclic carbamate, cyclic thiocarbamate, and other cyclic groups are also encompassed by the non-aryl heterocycle. In this regard, an oxygen atom of carbonyl, sulfinyl, and sulfonyl and a sulfur atom of thiocarbonyl are not included in the number of members of the ring (ring size) or the number of heteroatoms constituting the ring.

As used herein, “4- to 10-membered non-aryl heterocycle” refers to a substituent with “4- to 10-membered non-aryl heterocycle” that is a monovalent group among the “non-aryl heterocycle” described above.

As used herein, the non-aryl heterocycle moiety of “non-aryl heterocyclyloxy” is defined the same as the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclyloxy” is preferably “4- to 6-membered non-aryl heterocyclyloxy”. Specific examples of “4- to 10-membered non-aryl heterocyclyloxy” include, but are not limited to, tetrahydrofuranyloxy, tetrahydropyranyloxy, azetidinyloxy, pyrrolidinyloxy, piperidinyloxy, and the like.

As used herein, the non-aryl heterocycle moiety of “non-aryl heterocyclylthio” is defined the same as the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclylthio” is preferably “4- to 6-membered non-aryl heterocyclylthio”. Specific examples of “4- to 10-membered non-aryl heterocyclylthio” include, but are not limited to, tetrahydropyranylthio, piperidinylthio, and the like.

As used herein, “non-aryl heterocyclylcarbonyl” refers to a carbonyl group substituted with the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclylcarbonyl” is preferably “4- to 6-membered non-aryl heterocyclylcarbonyl”. Specific examples of “4- to 10-membered non-aryl heterocyclylcarbonyl” include, but are not limited to, azetidinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, and the like.

As used herein, “non-aryl heterocyclylsulfonyl” refers to a sulfonyl group substituted with the “non-aryl heterocycle” described above. “4- to 10-membered non-aryl heterocyclylsulfonyl” is preferably “4- to 6-membered non-aryl heterocyclylsulfonyl”. Specific examples of “4- to 10-membered non-aryl heterocyclylsulfonyl” include, but are not limited to, azetidinylsulfonyl, pyrrolidinylsulfonyl, piperidinylsulfonyl, morpholinylsulfonyl, and the like.

As used herein, “5- to 6-membered heterocycloalkyl” refers to heterocycloalkyl comprised of 5 to 6 cyclic atoms, comprising 1 or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.

As used herein, “heterocycloalkylalkyl” refers to alkyl substituted with at least one heterocycloalkyl.

As used herein, “alkylcarbonyl” is a monovalent group of —C(═O)-alkyl. Preferred examples of alkylcarbonyl include C₁₋₆ alkylcarbonyl. Specific examples of C₁₋₆ alkylcarbonyl include, but are not limited to, acetyl (CH₃C(═O)—), n-propanoyl (CH₃CH₂C(═O)—), n-butanoyl (CH₃CH₂CH₂C(═O)—), n-pentanoyl (CH₃ (CH₂)₃C(═O)—), n-hexanoyl (CH₃ (CH₂)₄C(═O)—), n-heptanoyl (CH₃ (CH₂)₅C(═O)—), and the like.

As used herein, “alkoxy” is a monovalent group of —O-alkyl. Preferred examples of alkoxy include C₁₋₆ alkoxy (i.e., C₁₋₆ alkyl-O—), C₁₋₄ alkoxy (i.e., C₁₋₄ alkyl-O—), and the like. Specific examples of C₁₋₄ alkoxy include methoxy (CH₃O—), ethoxy (CH₃CH₂O—), n-propoxy (CH₃(CH₂)₂O—), isopropoxy ((CH₃)₂CHO—), n-butoxy (CH₃(CH₂)₃O—), isobutoxy ((CH₃)₂CHCH₂O—), tert-butoxy ((CH₃)₃CO—), sec-butoxy (CH₃CH₂CH(CH₃)O—), and the like. Specific examples of C₁₋₆ alkoxy include, but are not limited to, C₁₋₄ alkoxy, n-pentyloxy (CH₃(CH₂)₄O—), isopentyloxy ((CH₃)₂CHCH₂CH₂O—), neopentyloxy ((CH₃)₃CCH₂O—), tert-pentyloxy (CH₃CH₂C(CH₃)₂O—), 1,2-dimethylpropoxy (CH₃CH(CH₃)CH(CH₃)O—), and the like.

As used herein, “alkoxycarbonyl” is a monovalent group of —C(═O)—O-alkyl. Examples of alkoxycarbonyl include, but are not limited to, C₁₋₆ alkoxycarbonyl, preferably C₁₋₄ alkoxycarbony. Specific examples of C₁₋₄ alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, isobutoxycarbonyl, and the like. Specific examples of C₁₋₆ alkoxycarbonyl include, but are not limited to, C₁₋₄ alkoxycarbonyl, n-pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert-pentyloxycarbonyl, 1,2-dimethylpropyloxycarbonyl, n-hexyloxycarbonyl, and the like.

As used herein, “alkoxycarbonylamino” is a monovalent group of —NH—C(═O)—O-alkyl. Examples of alkoxycarbonylamino include, but are not limited to, C₁₋₆ alkoxycarbonylamino, preferably C₁₋₄ alkoxycarbonylamino. Specific examples of C₁₋₄ alkoxycarbonylamino include methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, n-butoxycarbonylamino, sec-butoxycarbonylamino, tert-butoxycarbonylamino, isobutoxycarbonylamino, and the like. Specific examples of C₁₋₆ alkoxycarbonylamino include, but are not limited to, C₁₋₄ alkoxycarbonylamino, n-pentyloxycarbonylamino, isopentyloxycarbonylamino, neopentyloxycarbonylamino, tert-pentyloxycarbonylamino, 1,2-dimethylpropyloxycarbonylamino, n-hexyloxycarbonylamino, and the like.

As used herein, “haloalkyl” is a monovalent group of halogenated alkyl, having one or more hydrogen on an alkyl group substituted with halogen. The term “perhaloalkyl” refers to haloalkyl with all hydrogen on the alkyl group substituted with halogen. For example, perfluoroethyl is —CF₂CF₃, and perchloro-n-propyl is —CCl₂CCl₂CCl₃. Examples of haloalkyl include C₁₋₆ haloalkyl, C₁₋₄ haloalkyl, C₁₋₃ haloalkyl, and the like. Specific examples of C₁₋₃ alkyl include, but are not limited to, fluoromethyl, chloromethyl, bromomethyl, difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, fluorochloromethyl, difluorochloromethyl, fluorodichloromethyl, fluoroethyl, chloroethyl, bromoethyl, trifluoroethyl, trichloroethyl, tribromoethyl, perfluoroethyl, perchloroethyl, perbromoethyl, perfluoropropyl, perchloropropyl, perbromopropyl, perfluoroisopropyl, perchloroisopropyl, perbromoisopropyl, and the like. Specific examples of C₁₋₄ alkyl include, but are not limited to, C₁₋₃ haloalkyl, perfluorobutyl, perchlorobutyl, perbromobutyl, perfluoroisobutyl, perfluoro-t-butyl, and the like. Specific examples of C₁₋₆ alkyl include, but are not limited to, C₁₋₄ haloalkyl, perfluoro-n-pentyl, perfluoroisopentyl, perfluoroneopentyl, perfluorotert-pentyl, perfluoro-1,2-dimethylpropyl, and the like.

As used herein, “haloalkoxy” as well as “haloalkyloxy” is a monovalent group of —O-haloalkyl with one or more hydrogen on the alkyl group substitututed with halogen. The term “perhaloalkoxy” refers to haloalkoxy with all hydrogen on the alkyl group substituted with halogen. For example, perfluoroethoxy is —OCF₂CF₃, and perchloro-n-propoxy is —OCCl₂CCl₂CCl₃. Preferred examples of haloalkoxy include C₁₋₆ haloalkoxy, C₁₋₄ haloalkoxy, C₁₋₃ haloalkoxy, and the like. Specific examples of C₁₋₃ alkoxy include, but are not limited to, fluoromethoxy, chloromethoxy, bromomethoxy, difluoromethoxy, dichloromethoxy, dibromomethoxy, tri fluoromethoxy, trichloromethoxy, tribromomethoxy, fluorochloromethoxy, difluorochloromethoxy, fluorodichloromethoxy, fluoroethoxy, chloroethoxy, bromoethoxy, trifluoroethoxy, trichloroethoxy, tribromoethoxy, perfluoroethoxy, perchloroethoxy, perbromoethoxy, perfluoropropoxy, perchloropropoxy, perbromopropoxy, perfluoroisopropoxy, perchloroisopropoxy, perbromoisopropoxy, and the like. Specific examples of C₁₋₄ alkoxy include, but are not limited to, C₁₋₃ haloalkoxy, perfluorobutoxy, perchlorobutoxy, perbromobutoxy, perfluoroisobutoxy, perfluoro-t-butoxy, and the like. Specific examples of C₁₋₆ alkoxy include, but are not limited to, C₁₋₄ haloalkoxy, perfluoro-n-pentyloxy, perfluoroisopentyloxy, perfluoroneopentyloxy, perfluorotert-pentyloxy, perfluoro-1,2-dimethylpropoxy, and the like.

As used herein, “alkylsulfonyl” refers to a sulfonyl group substituted with the “alkyl” described above. “C₁₋₆ alkylsulfonyl” is preferably “C₁₋₄ alkylsulfonyl”. Specific examples of “C₁₋₆ alkylsulfonyl” include, but are not limited to, methylsulfonyl, propionylsulfonyl, butyrylsulfonyl, and the like.

As used herein, the alkyl moiety of “alkylthio” is defined the same as the alkyl described above. Examples of “C₁₋₆ alkylthio” include “C₁₋₄ alkylthio”, and preferred examples thereof include “C₁₋₃ alkylthio”. Specific examples of “C₁₋₆ alkylthio” include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, isopropylthio, isobutylthio, tert-butylthio, sec-butylthio, isopentylthio, neopentylthio, tert-pentylthio, 1,2-dimethylpropylthio, and the like.

As used herein, “arylcarbonyl” is a monovalent group of —C(═O)-aryl. Preferred examples of arylcarbonyl include C₆₋₁₀ arylcarbonyl. Specific examples of C₆₋₁₀ arylcarbonyl include, but are not limited to, benzoyl (i.e., phenyl-C(═O)—), 1-naphthylcarbonyl, 2-naphthylcarbonyl, and the like.

As used herein, the aryl moiety of “aryloxy” is defined the same as the aryl described above. Preferred examples of “C₆₋₁₀ aryloxy” include “C₆ or C₁₀ aryloxy”. Specific examples of “C₆₋₁₀ aryloxy group” include, but are not limited to, a phenoxy group, 1-naphthyloxy group, 2-naphthyloxy group, and the like.

As used herein, “heteroarylcarbonyl” is a monovalent group of —C(═O)-heteroaryl.

As used herein, “heteroarylcarbonyl group” refers to a carbonyl group substituted with the “heteroaryl” described above. Specific examples of “5- to 6-membered heteroarylcarbonyl group” include, but are not limited to, pyrazoylcarbonyl group, triazoylcarbonyl group, triazoylcarbonyl group, thiadiazoylcarbonyl group, pyridylcarbonyl group, pyridazoylcarbonyl group, and the like.

As used herein, the heteroaryl moiety of the “heteroaryloxy group” is defined the same as the “heteroaryl” described above. The 5- to 6-membered heteroaryl moiety of the “5- to 6-membered heteroaryloxy group” is defined the same as “5-membered heteroaryl” or “6-membered heteroaryl”, respectively. Specific examples of “5- to 6-membered heteroaryloxy group” include, but are not limited to, a pyrazoyloxy group, triazoyloxy group, triazoyloxy group, thiadiazoyloxy group, pyridyloxy group, pyridazoyloxy group, and the like.

As used herein, the heteroaryl moiety of a “heteroarylthio group” is defined the same as the “heteroaryl” described above. The 5- to 6-membered heteroaryl moiety of “5- to 6-membered heteroarylthio group” is defined the same as “5-membered heteroaryl” or “6-membered heteroaryl”, respectively. Specific examples of “5- to 6-membered heteroarylthio group” include, but are not limited to, pyrazoylthio group, triazoylthio group, thiazoylthio group, thiadiazoylthio group, pyridylthio group, pyridazoylthio group, and the like.

As used herein, the heteroaryl moiety of a “heteroarylsulfonyl group” is defined the same as the “heteroaryl” described above. A “5- to 6-membered heteroarylsulfonyl group” refers to a sulfonyl group substituted with a “5- to 6-membered heteroaryl”. Specific examples of “5- to 6-membered heteroarylsulfonyl group” include, but are not limited to, pyrazoylsulfonyl group, triazoylsulfonyl group, triazoylsulfonyl group, thiadiazoylsulfonyl group, pyridylsulfonyl group, pyridazoylsulfonyl group, and the like.

As used herein, “acyl” refers to a monovalent group of —C(═O)—R_(acyl), wherein R_(acyl) is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl. Specific examples of acyl include, but are not limited to, formyl, groups exemplified as alkylcarbonyl, arylcarbonyl, and heteroarylcarbonyl, and the like.

As used herein, “optionally substituted carbonyl” group refers to a monovalent group of —C(═O)— (hydrogen or any group selected from a substituent group described herein). Examples of “optionally substituted carbonyl” group include, but are not limited to, formyl, and optionally substituted carbamoyl, alkylcarbonyl, alkoxycarbonyl, alkenylcarbonyl, alkenyloxycarbonyl, alkynylcarbonyl, alkynyloxycarbonyl, arylcarbonyl, aryloxycarbonyl, cycloalkylcarbonyl, cycloalkyloxycarbonyl, heteroarylcarbonyl, heteroaryloxycarbonyl, heterocycloalkylcarbonyl, heterocycloalkyloxycarbonyl, and the like. A carbonyl group substituted with hydrogen is a formyl group. A carbonyl group substituted with amino is a carbamoyl group.

As used herein, “optionally substituted oxy” group refers to a monovalent group of —O— (hydrogen or any group selected from a substituent group described herein). Examples of “optionally substituted oxy” group include, but are not limited to, hydroxy, and optionally substituted alkyloxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, heterocycloalkylcarbonyloxy, and the like. An oxy group substituted with hydrogen is a hydroxy group.

As used herein, “carbamoyl” is a monovalent group of —C(═O)—NH₂.

As used herein, “amidinoamino” is a monovalent group of —NH—C(═NH)—NH₂.

As used herein, the phrase “a substituent-substituted group” means that the group is substituted with at least one substituent. For example, “hydroxy-substituted C₁₋₆ alkyl” refers to C₁₋₆ alkyl that has at least one hydroxy substitution.

As used herein, “carbamoyl-substituted C₁₋₆alkyl” is C₁₋₆ alkyl substituted with at least one —C(═O)—NH₂ group. Examples of “carbamoyl-substituted C₁₋₆ alkyl” include, but are not limited to, carbamoyl-substituted C₁₋₄ alkyl. Specific examples of “carbamoyl-substituted C₁₋₄ alkyl” include, but are not limited to, 2-amino-2-oxoethyl (i.e., H₂NC(═O)—CH₂— or carbamoylmethyl), 3-amino-3-oxopropyl (i.e., H₂NC(═O)—CH₂CH₂— or carbamoylethyl), 4-amino-4-oxobutyl (i.e., H₂NC(═O)—(CH₂)₃— or carbamoylpropyl), 5-amino-5-oxopentyl (i.e., H₂NC(═O)—(CH₂)₄— or carbamoylbutyl), and the like. Specific examples of “carbamoyl-substituted C₁₋₆ alkyl” include, but are not limited to, carbamoyl-substituted C₁₋₄ alkyl, 6-amino-6-oxohexyl (i.e., H₂NC(═O)—(CH₂)₅— or carbamoylpentyl), 7-amino-7-oxoheptyl (i.e., H₂NC(═O)—(CH₂)₆— or carbamoylhexyl), and the like.

As used herein, “amidinoamino-substituted alkyl” or “guanidino-substituted alkyl” is alkyl substituted with at least one —NH—C(═NH)—NH₂ group, wherein the nitrogen atom of the amidinoamino group can be protected with a nitrogen protecting group (e.g., tert-butoxycarbonyl group). Examples of “amidinoamino-substituted C₁₋₆ alkyl” include, but are not limited to, “amidinoamino-substituted C₁₋₄ alkyl” and the like. Specific examples of “amidinoamino-substituted C₁₋₄ alkyl” include, but are not limited to, (amidinoamino)methyl, 2-(amidinoamino)ethyl, 3-(amidinoamino)propyl, 4-(amidinoamino)butyl, and the like. Specific examples of “amidinoamino-substituted C₁₋₆ alkyl” include, but are not limited to, amidinoamino-substituted C₁₋₄ alkyl, 5-(amidinoamino)pentyl, 6-(amidinoamino)hexyl, and the like. Examples of amidinoamino groups protected with a nitrogen protecting group include

As used herein, “amidinoamino” is synonymous with “guanidino”.

As used herein, “carboxy-substituted alkyl” is alkyl substituted with at least one —COOH group. Examples of “carboxy-substituted C₁₋₆ alkyl” include, but are not limited to, “carboxy-substituted C₁₋₄ alkyl” and the like. Specific examples of “carboxy-substituted C₁₋₄ alkyl” include, but are not limited to, carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, and the like. Specific examples of “carboxy-substituted C₁₋₆ alkyl” include, but are not limited to, carboxy-substituted C₁₋₄ alkyl, 5-carboxypentyl, 6-carboxyhexyl, and the like.

A “protecting group” refers to a group of atoms that blocks, reduces, or prevents reactivity of a functional group when attached to a reactive functional group in a molecule. The compound of the present disclosure can have a substitution with a protecting group when appropriate or needed at any of R₁ to R₄ or any position of a substituent thereof or other substituents or the like. Compounds comprising such a protecting group are also within the scope of the present disclosure. Typically, a protecting group can be selectively removed during a synthesis process if desired. Examples of protecting groups are found in Greene and Wuts, Protective Groups in Organic Chemistry, 5th Edition, 2014, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vol. 1 to 8, John Wiley & Sons, NY, or the like. As used herein, a “protecting group” can fall under the definitions for 1) to 53) of substituent a and 1) to 26) of substituent β. In such a case, “54) protecting group” can be described as “54) protecting group other than 1) to 53)” in substituent group α1, and “27) protecting group” can be described as “protecting group other than 1) to 26)” in substituent group β1. Representative examples of nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilylethanesulfonyl (“TES”), trityl and substituted trityl group, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitro-veratryloxycarbonyl (“NVOC”), groups represented by “Protect” herein, and the like. Representative examples of hydroxyl protecting groups include, but are not limited to, groups that acylate (esterify) or alkylate a hydroxyl group, such as benzyl and trityl ether, as well as alkyl ether, tetrahydropyranyl ether, trialkylsilyl ether (e.g., TMS, triethylsilyl, t-butyldimethylsilyl (TBDMS), and triisopropylsilyl (TIPS)), alkyldiarylsilyl ether (e.g., t-butyldiphenylsilyl (TBDPS)), triarylsilyl ether (e.g., triphenylsilyl), glycol ether (e.g., ethylene glycol ether, propylene glycol ether, and the like), and allyl ether.

An amino group of the compound of the present disclosure (e.g., amino group of the backbone, amino group as a substituent, amino group in a substituent of said compound, or the like) can be protected with a nitrogen protecting group or a group represented by “Protect”. An amino group in a substituent listed in a substituent group can be further protected with a nitrogen protecting group or a group represented by “Protect”. A protected substituent can also be used as a substituent.

A hydroxy group of the compound of the present disclosure (e.g., hydroxy group as a substituent, a hydroxy group in a substituent of said compound, a hydroxy group in a substituent group described above, or the like) can also be protected with a protecting group of a hydroxy group. A hydroxy group in a substituent listed in a substituent group can be further protected with a hydroxyl protecting group described herein. A protected substituent can also be used as a substituent.

Preferred Embodiments

The preferred embodiments of the present disclosure are described hereinafter. It is understood that the embodiments provided hereinafter are provided for the better understanding of the present disclosure, so that the scope of the present disclosure should not be limited by the following descriptions. Thus, it is apparent that those skilled in the art can refer to the descriptions herein to make appropriate modifications within the scope of the present disclosure. It is also understood that the following embodiments of the present disclosure can be used individually or as a combination.

(Compound and Composition of the Present Disclosure)

In one aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₃, and R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R₂₃, together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

If one of R_(2A) or R_(2B) is hydrogen herein, it is understood that the same definition as R₂ described herein can be used.

In another aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R₁, R_(2a), R_(2B), and R₃ are defined the same as those for formula XXIF described herein.

In still another aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R₁, R_(2A), R_(2B), and R₃ are defined the same as those for formula XXIF described herein.

In still another aspect, the compound of the present disclosure can be exemplified as a compound represented by formula XXIIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R₁, R₂, and R₃ are defined the same as those for formula XXIF described herein.

In one embodiment, the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R₁, R₃, and if present R₄ are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and

the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, and the non-aryl heterocycle and the heteroaryl ring of R_(2A) and R_(2B) are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.

In one embodiment, R₁, R₃, and if present R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

In some cases for substituents in this embodiment, R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl and/or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycles are each independently and optionally substituted.

Alternatively, in another embodiment for (an imine form), R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, and R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

In some cases, R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, and R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, and/or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycles are each independently and optionally substituted.

In one embodiment, R₁, R₃, and if present R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.

In some cases, R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted C₆₋₁₀ aryl, or optionally substituted 5- to 10-membered heteroaryl, and/or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycles are each independently and optionally substituted.

In one embodiment, R₁, R₃, and if present R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁, R₃, and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.

In one embodiment, R₁, R₃, and if present R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁, R₃, and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, and

R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted 5- to 10-membered heteroarylcarbonyl, optionally substituted 5- to 10-membered heteroaryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group V.

In some cases, R_(2A) and R_(2B) are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃-cycloalkyl, optionally substituted 5- to 10-membered heterocycloalkyl, or formyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In some cases, R₁ and if present R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, or formyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, carbamoyl, or optionally substituted alkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, carbamoyl, or optionally substituted C₁₋₁₂ alkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro, formyl, substituted carbonyl, or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₁ and R₄ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, C₃₋₁₀ cycloalkyl, and substituted C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro, formyl, substituted carbonyl, or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₁ and R₄ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₁ and R₃ are each independently hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₃ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, and R₃ are each independently hydrogen, optionally substituted C₁₋₁₂ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₁₂ alkyl, optionally substituted C₃₋₁₀ cycloalkyl, formyl, optionally substituted C₁₋₁₂ alkylcarbonyl, optionally substituted C₁₋₁₂ alkoxycarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₆₋₁₀ aryloxycarbonyl, optionally substituted C₃₋₁₀ cycloalkylcarbonyl, optionally substituted C₃₋₁₀ cycloalkyloxycarbonyl, optionally substituted 5- to 10-membered heterocycloalkylcarbonyl, optionally substituted 5- to 10-membered heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted C₁₋₁₂ alkylcarbamoyl, optionally substituted C₁₋₁₂ alkoxycarbamoyl, optionally substituted C₆₋₁₀ arylcarbamoyl, optionally substituted 5- to 10-membered heteroarylcarbamoyl, optionally substituted C₃₋₁₀ cycloalkylcarbamoyl, or optionally substituted 5- to 10-membered heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₃ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy, formyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, carbamoyl, alkylcarbamoyl, or arylalkylcarbamoyl, wherein the substituted amino each independently has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₁ and if present R₄ are each independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, and C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, amino, substituted amino, nitro, and hydroxy, formyl, C₁₋₁₂ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkyloxycarbonyl, C₁₋₁₂ alkoxycarbonyl, C₆₋₁₀ arylcarbonyl, C₆₋₁₀ aryloxycarbonyl, carbamoyl, C₁₋₁₂ alkylcarbamoyl, or C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₁ and if present R₄ are each independently, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, and C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, amino, substituted amino, nitro, and hydroxy, wherein the substituted amino optionally has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R₃ each independently and optionally have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In some cases, R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R₃ each independently and optionally have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₃ can be hydrogen, alkyl, formyl, alkylcarbonyl, arylalkylcarbonyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl.

In some cases, R₃ can be hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl.

In one embodiment, R₃ can be hydrogen, C₁₋₁₂ alkyl, formyl, C₁₋₆ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₆ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino, 5- to 10-membered heteroaryl C₁₋₆ alkyl, or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl.

In some cases, R₃ can be hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₆ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino, 5- to 10-membered heteroaryl C₁₋₆ alkyl, or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl.

In one embodiment, R₃ can be C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₆ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

In one embodiment, R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy, wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₃ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy.

In one embodiment, R₃ is hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, tri-C₁₋₆ alkylsilyloxy, amino, C₁₋₆ alkoxycarbonylamino, and C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl, and hydroxy.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, or substituted cycloalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy, heteroarylalkyl, alkoxycarbonyl-substituted heteroarylalkyl, or cycloalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, and 5- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and hydroxy, 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl, R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In some cases, R_(2A) and R_(2B) are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, substituted oxy, substituted carbonyl, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, substituted oxy, amino, substituted amino, alkyl, and substituted alkyl, heteroarylalkyl, or substituted heteroarylalkyl, wherein the substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkyl, and substituted heteroarylalkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, alkylcarbonyl, arylalkylcarbonyl, hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, carbamoyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In some cases, R_(2A) and R_(2B) are each independently hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, trialkylsilyloxy, alkoxy, alkoxycarbonylamino, cycloalkyl, carboxy, amino, amidinoamino, alkoxycarbonyl-substituted amidinoamino, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, monoalkylamino, dialkylamino, alkyl, haloalkyl, alkoxy, carboxyalkylcarbonylamino, carbamoylalkylcarbonylamino, cycloalkylcarbonylamino, and cycloalkylalkylamino, heteroarylalkyl, or alkoxycarbonyl-substituted heteroarylalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, C₁₋₆ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino, 5- to 10-membered heteroaryl C₁₋₁₂ alkyl, or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁-12 alkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

In some cases, R_(2A) and R_(2B) are each independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, and 5- to 6-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino, 5- to 10-membered heteroaryl C₁₋₁₂ alkyl, or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁-12 alkyl, or R_(2A) and R_(n), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

In one embodiment, R_(2A) and R_(2B) are each independently hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of hydroxy, tri-C₁₋₆ alkylsilyloxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, C₃₋₁₀ cycloalkyl, carboxy, amino, amidinoamino, C₁₋₆ alkoxycarbonyl-substituted amidinoamino, carbamoyl, and 5- to 6-membered heterocycloalkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl, C₆₋₁₀ aryl C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, nitro, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, carboxy C₁₋₆ alkylcarbonylamino, carbamoyl C₁₋₆ alkylcarbonylamino, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino, 5- to 10-membered heteroaryl C₁₋₁₂ alkyl, or C₁₋₆ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₁₂ alkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group consisting of halogen, nitro, hydroxy, amino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₃₋₆ cycloalkylcarbonylamino, and C₃₋₆ cycloalkyl C₁₋₆ alkylamino.

In one embodiment, R₁ is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV. Alternatively, R₁ is alkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R₁ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV. Alternatively, R₁ is C₁₋₁₂ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.

In one embodiment, R_(2A) is hydrogen, and R_(2B) is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; or cycloalkyl. Alternatively, R_(2A) is hydrogen, and R_(2B) is alkyl; arylalkyl; arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy; or cycloalkyl.

In one embodiment, R_(2A) is hydrogen, and R_(2B) is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and hydroxy; or C₃₋₁₀ cycloalkyl. Alternatively, R_(2A) is hydrogen, and R_(2B) is C₁₋₁₂ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and hydroxy; or C₃₋₁₀ cycloalkyl.

In one embodiment, R₃ is alkyl; alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl; arylalkyl; or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy. Alternatively, R₃ is alkyl or arylalkyl.

In one embodiment, R₃ is C₁₋₁₂ alkyl; C₁₋₁₂ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and C₃₋₁₀ cycloalkyl; C₆₋₁₀ aryl C₁₋₆ alkyl; or C₆₋₁₀ aryl C₁₋₆ alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of C₁₋₆ alkyl and hydroxy.

Alternatively, in one embodiment, R₃ is C₁₋₁₂ alkyl or C₆₋₁₀ aryl C₁₋₆ alkyl.

In one embodiment, R₄ is hydrogen, alkyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, carbamoyl, or arylalkylcarbamoyl.

In one embodiment, R₄ is hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkylcarbonyl, C₆₋₁₀ aryl C₁₋₆ alkyloxycarbonyl, C₁₋₁₂ alkoxycarbonyl, carbamoyl, or C₆₋₁₀ aryl C₁₋₆ alkylcarbamoyl.

In one embodiment, R₁ is hydrogen, methyl, ethyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, tert-butylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, ethoxybenzyl, tert-butoxybenzyl, aminobenzyl, (cyclopentylcarbonylamino)benzyl, (cyclopentylmethylamino)benzyl, (dimethylamino)benzyl, (carbamoylethylcarbonylamino)benzyl, (carboxyethylcarbonylamino)benzyl, nitrobenzyl, hydroxybenzyl, 3-methylbutanoyl, isobutylcarbonyl, 2-phenylacetyl, isopropyloxycarbonyl, benzoyl, or phenyloxycarbonyl.

In another embodiment, R₁ is methyl, n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxypropyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, aminopropyl, 2-(tert-butyl-dimethylsilyloxy)ethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, phenylethyl, naphthalenylmethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, methylbenzyl, (tert-butyl)benzyl, methoxybenzyl, ethoxybenzyl, (tert-butoxy)benzyl, (trifluoromethoxy)benzyl, (dimethylamino)benzyl, nitrobenzyl, or hydroxybenzyl.

In one embodiment, R_(2A) is hydrogen, and R_(2B) is methyl, isopropyl, isobutyl, n-pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, carbamoylmethyl, carbamoylethyl, carboxyethyl, hydroxyethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, (tetrahydro-2H-pyran-2-yl)methyl, benzyl, phenylethyl, naphthalenylmethyl, naphthalenylethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, tert-butoxybenzyl, hydroxybenzyl, α-hydroxymethylphenethyl, 1-hydroxyphenethyl, pyridinylmethyl, (1H-indol-3-yl)ethyl, (1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, cyclopentyl, or cyclohexyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.

In one embodiment, R_(2A) and R_(2B) are each independently isopropyl, isobutyl, sec-butyl, pentyl, isopentyl, n-hexyl, heptyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, tert-butoxyethyl, tert-butoxycarbonylmethyl, (tert-butoxycarbonyl)ethylcarbamoylethyl, carboxyethyl, hydroxyethyl, aminopropyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, (1,2,3,4-tetrahydronaphthalenyl)methyl, (tetrahydro-2H-pyranyl)methyl, benzyl, phenylethyl, naphthalenylmethyl, (naphthalenyl)ethyl, β-hydroxyphenethyl, α-(hydroxymethyl)phenethyl, fluorobenzyl, chlorobenzyl, dichlorobenzyl, (fluorophenyl)ethyl, methylbenzyl, (trifluoromethyl)benzyl, methoxybenzyl, (tert-butoxy)benzyl, hydroxybenzyl, pyridinylmethyl, quinolinylethyl, (1-(tert-butoxycarbonyl)-1H-indolyl)ethyl, cyclopentyl, or cyclohexyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a pyrrolidine ring or piperidine ring.

In one embodiment, R₃ is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carbamoylmethyl, carboxyethyl, hydroxymethyl, hydroxyethyl, (tert-butyldimethylsilyloxy)ethyl, aminobutyl, ((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, or hydroxybenzyl.

In one embodiment, R₃ is n-propyl, isobutyl, isopentyl, amidinoaminopropyl, tert-butoxycarbonyl-substituted amidinoaminopropyl, (methoxycarbonyl)ethyl, (tert-butoxycarbonyl)ethyl, carboxyethyl, hydroxyethyl, aminopropyl, (tert-butyldimethylsilyloxy)ethyl, ((tert-butoxycarbonyl)amino)butyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, phenylpropyl, phenylbutyl, naphthalenylmethyl, naphthalenylethyl, chlorobenzyl, methylbenzyl, (methylphenyl)ethyl, (isopropylphenyl)ethyl, (tert-butoxy)benzyl, or hydroxybenzyl.

In one embodiment, R₄ is hydrogen, methyl, ethyl, isobutyl, formyl, acetyl, 3-methylbutanoyl, 2-phenylacetyl, methoxycarbonyl, ethoxycarbonyl, 2-methylpropyloxycarbonyl, tert-butoxycarbonyl, benzoyl, benzyl, benzyloxycarbonyl, aminocarbonyl, N-benzylaminocarbonyl, propylcarbamoyl, N-isobutylaminocarbonyl, or N-benzylaminocarbonyl.

In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein

R₁, R₂, and R₃ are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl, and

R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, or optionally substituted carbamoyl.

In one embodiment, R₁, R₂, and R₃ are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.

In one embodiment, R₁, R₂, and R₃ are each independently optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, or optionally substituted C₃₋₆ cycloalkyl C₁₋₆ alkyl.

In one embodiment, R₁, R₂, and R₃ are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted alkoxycarbonyl, or optionally substituted alkylcarbamoyl.

In one embodiment, R₁, R₂, and R₃ are each independently C₁₋₆ alkyl, hydroxy-substituted C₁₋₆ alkyl, carbamoyl-substituted C₁₋₆ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₆ alkyl, carboxy-substituted C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₆ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₆ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₆alkyl, or C₃₋₆ cycloalkyl C₁₋₆ alkyl.

In one embodiment, R₁, R₂, and R₃ are each independently C₁₋₆ alkyl, hydroxy-substituted C₁₋₆ alkyl, carbamoyl-substituted C₁₋₆ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₆ alkyl, carboxy-substituted C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₆ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₆ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₆ alkyl, or C₃₋₆ cycloalkyl C₁₋₆ alkyl.

In one embodiment, R₁, R₂, and R₃ are each independently alkyl or optionally substituted arylalkyl.

In one embodiment, R₁, R₂, and R₃ are each independently C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

In one embodiment, R₁, R₂, and R₃ are each independently C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, or (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl.

In one embodiment, R₁, R₂, and R₃ are each independently C₁₋₆ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, chloro-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₆ alkyl, or (optionally substituted amino)-C₆₋₁₀ aryl C₁₋₆ alkyl.

In one embodiment, R₁ is C₁₋₆ alkyl or C₆ aryl C₁₋₄ alkyl, R₂ is C₁₋₆ alkyl or C₁₋₄ alkyl-substituted benzyl, and R₃ is C₁₋₆ alkyl or C₆ aryl C₁₋₄ alkyl.

In one embodiment, R₁ and R₃ are each independently alkyl or optionally substituted benzyl, and R₂ is optionally substituted benzyl.

In one embodiment, R₁ and R₃ are each independently C₁₋₆ alkyl, benzyl, C₁₋₄ alkyl-substituted benzyl, chloro-substituted benzyl, C₁₋₄ alkoxy-substituted benzyl, or amino-substituted benzyl, and R₂ is benzyl or chloro-substituted benzyl.

In one embodiment, R₁ and R₃ are each independently isobutyl, isopentyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R₂ is benzyl, 3-chlorobenzyl, or 3,4-dichlorobenzyl.

In one embodiment, R₁ is isobutyl, benzyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, R₂ is isobutyl, benzyl, naphthalen-1-ylmethyl, 4-methylbenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R₃ is isobutyl, isopentyl, or benzyl.

In one embodiment, R₁ is C₁₋₆ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₆ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, halo-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

In one embodiment, R₁ is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, or cyclohexylmethyl.

In one embodiment, R₁ is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, hydroxymethyl, cyclohexylmethyl, or

In one embodiment, R₁ is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.

In one embodiment, R₁ is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.

In one embodiment, R₁ is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, or hydroxyethyl.

In one embodiment, R₁ is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.

In one embodiment, R₁ is isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or

In one embodiment, R₁ is isobutyl, 3-hydroxypropyl, 3-amino-3-oxopropyl, 6-aminohexyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, or cyclohexylmethyl.

In one embodiment, R₂ is C₁₋₄ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₄ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C₁₋₄ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, halogen-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonylamino-substituted C₁₋₄ alkyl, 5- to 6-membered heterocycloalkyl-substituted C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

In one embodiment, R₂ is naphthalen-1-ylmethyl or optionally substituted benzyl.

In one embodiment, R₂ is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.

In one embodiment, R₂ is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, cyclohexylmethyl, or

In one embodiment, R₂ is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.

In one embodiment, R₂ is 1-methylpropyl, isopropyl, isobutyl, isopentyl, n-hexyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or cyclohexylmethyl.

In one embodiment, R₂ is isopropyl, 1-methylpropyl, isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or

In one embodiment, R₂ is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.

In one embodiment, R₂ is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, cyclohexylmethyl, or 2-(1H-indol-3-yl)ethyl.

In one embodiment, R₂ is 1-methylpropyl, isopropyl, isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino) propyl, or naphthalen-1-ylmethyl.

In one embodiment, R₃ is C₁₋₄ alkyl, hydroxy-substituted C₁₋₄ alkyl, carbamoyl-substituted C₁₋₄ alkyl, C₁₋₄ alkoxycarbonyl-substituted C₁₋₄ alkyl, amino-substituted C₁₋₄ alkyl, amidinoamino-substituted C₁₋₄ alkyl, carboxy-substituted C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, C₁₋₄ alkyl-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, hydroxy-substituted C₆₋₁₀ aryl C₁₋₄ alkyl, or C₅₋₆ cycloalkyl C₁₋₄ alkyl.

In one embodiment, R₃ is isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, 4-fluorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.

In one embodiment, R₃ is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 4-(tert-butoxy)benzyl, 3-methoxy-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, or

In one embodiment, R₃ is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.

In one embodiment, R₃ is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.

In one embodiment, R₃ is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxymethyl, or naphthalen-1-ylmethyl.

In one embodiment, R₃ is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.

In one embodiment, R₃ is isobutyl, 2-carboxyethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or

In one embodiment, R₃ is isobutyl, hydroxymethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, 2-naphthylmethyl, 4-hydroxybenzyl, or cyclohexylmethyl.

In one embodiment, R₁ is C₁₋₆ alkyl or C₆₋₁₀ aryl C₁₋₆ alkyl, and R₂ and R₃ are each independently C₁₋₆ alkyl or optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl.

In one embodiment, R₁ is isobutyl, isopentyl, or benzyl, R₂ is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl, and R₃ is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.

In one embodiment, R₁ is isobutyl, R₂ is benzyl, and R₃ is benzyl.

In one embodiment, R₁ is benzyl, R₂ is benzyl, and R₃ is isobutyl.

In one embodiment, R₁ is isobutyl, R₂ is benzyl, and R₃ is 3-methylbenzyl.

In one embodiment, R₁ is benzyl, R₂ is 3,4-dichlorobenzyl, and R₃ is isobutyl.

In one embodiment, R₁ is isobutyl, R₂ is 4-methylbenzyl, and R₃ is benzyl.

In one embodiment, R₁ is benzyl, R₂ is isobutyl, and R₃ is isobutyl.

In one embodiment, R₄ is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, or optionally substituted alkoxycarbonyl.

In one embodiment, R₄ is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkylcarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, optionally substituted C₁₋₆ alkoxycarbonyl, or optionally substituted C₁₋₆ alkylcarbamoyl.

In one embodiment, R₄ is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkylcarbonyl, optionally substituted C₆₋₁₀ arylcarbonyl, or optionally substituted C₁₋₆ alkoxycarbonyl.

In one embodiment, R₄ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₆₋₁₀ arylcarbonyl, C₁₋₆ alkoxycarbonyl, or C₁-6 alkylcarbamoyl.

In one embodiment, R₄ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkylcarbonyl, C₆₋₁₀ arylcarbonyl, or C₁₋₆ alkoxycarbonyl.

In one embodiment, R₄ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylcarbonyl, C₆ arylcarbonyl, C₁₋₄ alkoxycarbonyl, or C₁₋₄ alkylcarbamoyl.

In one embodiment, R₄ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylcarbonyl, C₆ arylcarbonyl, or C₁₋₄ alkoxycarbonyl.

In one embodiment, R₄ is hydrogen or alkyl.

In one embodiment, R₄ is hydrogen or C₁₋₆ alkyl.

In one embodiment, R₄ is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, tert-butoxycarbonyl, or propylcarbamoyl.

In one embodiment, R₄ is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, or tert-butoxycarbonyl.

In one embodiment, R₄ is hydrogen or ethyl. In a preferred embodiment, R₄ is hydrogen.

A hydroxyl group, amino group, and/or carboxyl group in R₁, R₂, R₃, and/or R₄, when present, can be independently protected with a protecting group. Such a compound is also within the scope of the present disclosure.

In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof. R₁, R₂, and R₃ in formula IB are defined the same as those in formula IF.

In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof. R₁, R₂, and R₃ in formula IIF are defined the same as those in formula IF.

In some embodiments, the compound of the present disclosure can be exemplified as a compound represented by formula IIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof. R₁, R₂, and R₃ in formula IIB are defined the same as those in formula IF.

The compound of the present disclosure is further described hereinafter.

While the compound of the present disclosure can have enantiomers and stereoisomers such as tautomers and geometric isomers depending on the type of substituent, they are also encompassed by the present disclosure. Specifically, if there is one or more asymmetric carbon atoms in the compound of the present disclosure, there is a diastereomer or enantiomer, and a mixture of such a diastereomer and enantiomer, and isolated diastereomers and enantiomers are also encompassed by the compound of the present disclosure.

The present disclosure is also intended to encompass various hydrates, solvates, and crystalline polymorphisms.

Furthermore, the compound of the present disclosure can be substituted with an isotope (e.g., ²H (or D), ³H (or T), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ³⁵S, ¹⁸F, ¹²⁵I, or the like). These compounds are also encompassed by the compound of the present disclosure.

Furthermore, the scope of the present disclosure encompasses prodrugs of the compound of the present disclosure. In the present disclosure, a prodrug refers to a derivative that yields a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula by acid hydrolysis or enzymatic degradation in the body. For example, if a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula thereof has a functional group such as a hydroxyl group, amino group, or carboxyl group or other substituents, these groups can be modified by a conventional method to manufacture a prodrug. Prodrug technologies are described in, for example, C. G. Wermuth, “The Practice of Medicinal Chemistry”, 4^(th) Ed., Academic Press, (2015), Chapter 28.

Examples for compounds having a carboxy group include compound whose carboxyl group is modified to be an alkoxycarbonyl group, alkylthiocarbonyl group, or alkylaminocarbonyl group.

Examples of compounds having an amino group include compounds whose amino group is substituted with an alkanoyl group to be an alkanoylamino group, compounds substituted with an alkoxycarbonyl group to be an alkoxycarbonylamino group, compounds modified to have an alkanoyloxymethylamino group, and compounds modified to have hydroxylamine.

Examples for compounds having a hydroxyl group include compounds whose hydroxyl group is substituted with an alkanoyl group to be an alkanoyloxy group, phosphate ester, or alkanoyloxymethyloxy group.

Examples of the alkyl moiety of a group used for preparing a prodrug thereof include the alkyl group. The alkyl group is optionally substituted with, for example, an alkoxy group or the like. Preferred examples thereof include the following.

For compounds whose carboxyl group is modified to be an alkoxycarbonyl group, examples thereof include alkoxycarbonyl such as methoxycarbonyl and ethoxycarbony, and alkoxycarbonyl substituted with an alkoxy group such as methoxymethoxycarbonyl, ethoxymethoxycarbonyl, 2-methoxyethoxycarbonyl, and 2-methoxyethoxymethoxycarbonyl, or privaloyloxymethoxycarbonyl.

As used herein, “pharmaceutically acceptable salt” refers to an acid addition salt or base addition salt which is pharmaceutically acceptable for use. Specific examples of “pharmaceutically acceptable salts” include, but are not limited to, acid addition salts such as acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonate, para-toluenesulfonate (tosylate), laurylsulfate, malate, ascorbate, mandelate, saccharinate, xinafoate, pamoate, cinnamate, adipate, cysteine salt, N-acetyl cysteine salt, hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate, acrylic acid polymer salt, and carboxyvinyl polymer; inorganic base addition salts such as lithium salt, sodium salt, potassium salt, and calcium salt; organic base addition salts such as morpholine and piperidine; amino acid addition salts such as aspartic acid and glutamic acid; and the like.

In one embodiment, the compound of the present disclosure can be administered directly, or as a formulation, medicament, or a pharmaceutical composition using a suitable dosage form, by oral or parenteral administration. Specific examples of such dosage forms include, but are not limited to, tablets, capsules, powdered agents, granules, liquid agents, suspension, injection agents, patch-on agents, poultice, and the like. These formulations can be manufactured by a known method using an additive that is commonly used as a pharmaceutical additive.

As these additives, an excipient, disintegrant, binding agent, fluidizer, lubricant, coating agent, solubilizing agent, solubilizing promotor, thickener, dispersant, stabilizer, sweetener, flavoring agent, or the like can be used depending on the objective. Specific examples of these additives include, but are not limited to, lactose, mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, talc, and the like.

The dosage of the compound of the present disclosure is appropriately selected depending on the subject targeted for administration, route of administration, disease, age of subject, body weight, and symptom. For example, the dosage is 0.01 mg as the lower limit (preferably 100 mg) and 10000 mg as the upper limit (preferably 6000 mg) per day for adults for oral administration. This amount can be administered once daily, or divided into several doses.

In one embodiment, the compound of the present disclosure is a compound with an antiviral activity for a virus in the Lyssavirus genus. The virus in the Lyssavirus genus comprises a rabies virus, Lagos bat virus, mokola virus, Duvenhage virus, European bat 1 lyssavirus, European bat 2 lyssavirus, Australian bat lyssavirus, and the like. The virus in the Lyssavirus genus preferably comprises a rabies virus.

In one embodiment, the compound of the present disclosure is a compound with the ability to suppress or kill tumor or cancer. The tumor or cancer can be any tumor or cancer such as carcinoma, lymphoma, blastoma, sarcoma, or leukemia. Tumor and cancer can be squamous cell carcinoma, lung cancer such as small cell lung cancer, non-small cell lung cancer, or pulmonary adenocarcinoma, squamous cell carcinoma of the lung, peritoneal cancer, hepatoma, esophageal cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, uterine cancer such as cervical cancer, ovarian cancer, liver cancer, hepatocellular cancer, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, colorectal cancer, epithelial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver carcinoma, various types of head and neck cancer, blood cancer (leukemia), prostate cancer, gastric cancer, fibrous cancer, glioma, melanoma, or the like.

The timing of dosing of the compound of the present disclosure and therapeutic agents thereof is not limited. The compound and therapeutic agent can be administered concurrently or sequentially to a subject being administered therewith. The compound of the present disclosure and therapeutic agent thereof can be formulated as a combined agent. The dosage of the therapeutic agent can be appropriately selected based on the clinically used dose. The ratio of the compound of the present disclosure and therapeutic agent thereof can be appropriately selected depending on the subject of administration, route of administration, target disease, symptom, combination, or the like.

In one embodiment of the present disclosure, the compound of the present disclosure can be combined and administered concurrently or at different times upon use of a pharmaceutical composition. Such a pharmaceutical composition is also within the scope of the present disclosure.

Such a medicament, formulation, or pharmaceutical composition can be manufactured by mixing the compound of the present disclosure and/or an addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like) with any suitable component, together or separately, as a combined agent, or as separate agents using any technology that is known in the art. An appropriate formulation such as a tablet, capsule, powder, granule, liquid agent, suspension, injection, patch, or poultice can be formulated by using any technology that is known in the art. If the compound of the present disclosure and/or an addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like) are prepared as separate agents, they can be provided as a kit of two agents. The kit can provide one of the components as a single agent, with instructions (package insert or the like) instructing to combine and administer the other component (for the compound of the present disclosure, the additional agent; for the addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like), the compound of the present disclosure) concurrently or at different times.

If the compound of the present disclosure is used as an active ingredient of a medicament, the compound is intended for use in not just humans, but also other animals other than humans (cat, dog, cow, horse, bat, fox, mangoose, raccoon, and the like).

(Method of Manufacturing the Compound of the Present Disclosure)

Hereinafter, the method of manufacturing the compound of the present disclosure is described with examples, but the present disclosure is not limited thereto.

The compound of the present disclosure can be manufactured by, for example, the following manufacturing methods, but are not limited to such methods. These manufacturing methods can be appropriately improved upon based on the expertise of those skilled in the art of organic synthetic chemistry. Salts of the compounds used as a raw material can be used in the following manufacturing method, as long as the reaction is not affected.

In the following manufacturing methods, even if use of a protecting group is not specifically described, a functional group other than those at the reaction point can be protected as needed and deprotected after the completion of a reaction or after a series of reations to obtain a compound of interest if one of the functional groups other than those at the reaction point is altered under the reaction condition or if it is unsuitable for post-reaction processing. Common protecting groups described in the document (Peter G. M. Wuts, “Greene's Protective Groups in Organic Synthesis”, 5^(th) Ed., John Wiley & Sons, Inc., Hoboken, N.J. (2014)) or the like can be used as the protecting groups used in these processes. A protecting group can be introduced or removed by a method that is commonly used in organic synthetic chemistry (e.g., method described in the aforementioned document or the like) or a method in accordance thereto.

The starting material and intermediate in the following manufacturing methods can be purchased as a commercially available product or are available by synthesis in accordance with a method described in a known document or a known method from a known compound. Salts of the starting material and intermediate can also be used, as long as the reaction is not affected.

The intermediate and compound of interest in the following manufacturing methods can also be converted into another compound encompassed by the present disclosure by appropriately converting their functional groups. A functional group can be converted in doing so by a method that is commonly used in organic synthetic chemistry (e.g., method described in R. C. Larock, “Comprehensive Organic Transformations”, 2^(nd) Ed., John Wiley and Sons, Inc., New York (1999) or the like) or a method in accordance therewith.

An inert solvent in the following manufacturing methods refers to a solvent that does not react with a raw material, reagent, base, acid, catalyst, ligand, or the like used in the reaction (hereinafter, also referred to as “raw material or the like used in the reaction”). A solvent used in each step can be used as an inert solvent even if the solvent reacts with the raw material or the like used in the reaction, as long as the reaction of interest proceeds to result in a compound of interest.

The overview of compound synthesis related to the present disclosure is shown below. “B” and “F” following the Roman numeral compound number indicate that a 5-membered ring comprising nitrogen is located in the “back” and “front”, respectively. In other words, a —C(═O)NH—R₂ group attached to a 5-membered ring comprising nitrogen referred to as “back”, and a —C(═O)NH—R₂ that is not attached to a 5-membered ring comprising nitrogen is referred to as “front”.

Synthesis Scheme 1

Synthesis of compound III

Compound III can be manufactured by, for example, the following manufacturing method.

(1) Route 1-1 Synthesis from Compound VII and Compound VIII

(2) Route 1-2 Synthesis from Compound VII and Compound VIII Through Protection of Amine

(3) Route 1-3 Synthesis from Compound XI and Compound XII

wherein X_(L) represents a leaving group in a nucleophilic substitution reaction. Examples thereof include halogen (e.g., chlorine, bromine, or iodine), sulfate esters (—OSO₃H and the like), and sulfonyl-O— groups (e.g., methanesulfonyl-O—, toluenesulfonyl-O—, and the like). (4) Route 1-4 Synthesis from Compound XI and Compound XIII

(5) Route 1-5 Synthesis from Compound VII and Compound XIV

wherein if R₁ in compound III can be expressed as —CH₂—R₁′, R₁ in compound III can be replaced with —CH₂—R₁′ to express compound III as compound III′.

In the formula, R₁ is as defined in item 1 or A1 herein, and “Protect” is a protecting group of amino group. Examples of protecting groups of an amino group include an ethoxycarbonyl group, tert-butoxycarbonyl group, acetyl group, benzoyl group, trifluoroacetyl group, benzyloxycarbonyl group, 3- or 4-chlorobenzyloxycarbonyl group, triphenylmethyl group, methanesulfonyl group, p-toluenesulfonyl group, trimethylsilyl group, benzyloxycarbonyl group, 3- or 4-chlorobenzyloxycarbonyl group, benzylsulfonyl group, benzyl group, 4-nitrobenzyl group, 4-methoxybenzyl group, methyl group, ethyl group, and the like.

A compound that is commercially available or a compound manufactured by a known method can be used as a starting raw material compound.

Synthesis Scheme 2

Synthesis of Compound V

A compound of formula V can be manufactured by, for example, the following manufacturing method.

(1) Route 2-1 Synthesis from Compound XVI and Compound XVII

wherein R₈ indicates alkoxy, aryloxy, hydroxy, or halogen. Examples thereof include an ethoxy group. This synthesis is achieved by various reactions known to those skilled in the art. If R₂ is aryl, compound V can be synthesized in accordance with the method described in C. W. Cheung, M. L. Ploeger, and X. Hu, Nature Communications 2017, 8, 14878. (2) Route 2-2 Synthesis from Compound XVIII

wherein R₂ is as defined in item 1 or A1 herein. A compound that is commercially available or a compound that is manufactured by a known method can be used as the starting compound.

Synthesis Scheme 3

Synthesis of Compound VI

A compound of formula VI can be manufactured from compound III and compound IV by, for example, the following manufacturing method.

wherein R₁ and R₃ are as defined in item 1 or A1 herein.

Synthesis Scheme 4

Compound of Formula IIF and Compound of Formula IIB-Route 1

A compound of formula IIF and compound of formula IIB can be manufactured, for example, from three components through one-pot synthesis in accordance with a known method (e.g., method described in Bioorg. Med. Chem. 23 (2015) 2629-2635, Tetrahedron 63 (2007) 6004-6014, Eur. J. Org. Chem. 2009, 2185-2189, Eur. J. Org. Chem. 2011, 2354-2359 or the like).

wherein R₁, R₂, and R₃ are as defined in item 1 or A1 herein.

Synthesis Scheme 5

Compound of formula IIF and compound of formula IIB-Route 2

A compound of formula IIF and compound of formula IIB can be manufactured, for example, from two components as described below.

wherein R₁, R₂, and R₃ are as defined in item 1 or A1 herein.

Synthesis Scheme 6

Synthesis of Compound IF and Compound IB

Step 6-1

Reduction of Imine

Compound IF (i.e., compound of formula IF) or compound

IB (i.e., compound of formula IB) can be manufactured, for example, from compound IIF (i.e., compound of formula IIF) or compound IIB (i.e., compound of formula IIB) by reduction as described below. However, R₄ therein is H.

Step 6-2

Modification of Amine of Piperidine Ring

Amine of a piperidine ring of compound IF or compound IB can be modified, for example by alkylation, amidation, or the like as follows.

Synthesis Scheme 7

Synthesis of Compound V′

A compound of formula V′ can be manufactured by, for example, the following manufacturing method.

(1) Route 7-1 Synthesis from Compound XVI and Compound XVII′

A compound of formula V′ can be manufactured under the same condition as Route 2-1 of Synthesis Scheme 2. R₈ indicates alkoxy, aryloxy, hydroxy, or halogen.

(2) Route 7-2 Synthesis from Compound XVIII′

wherein R_(2A) and R_(2B) are as defined in item 1 herein. A compound that is commercially available or a compound manufactured by a known method can be used as a starting raw material compound.

Synthesis Scheme 8

Synthesis of Compound of Formula XXIIF and Compound of Formula XXIIB-Route 1

A compound of formula XXIIF and a compound of formula XXIIB can be synthesized under the same condition as Synthesis Scheme 4.

wherein R₁, R_(2A), R_(2B), and R₃ are as defined in item 1 herein.

Synthesis Scheme 9

Synthesis of Compound of Formula XXIIF and Compound of Formula XXIIB-Route 2

A compound of formula XXIIF and compound of formula XXIIB can be manufactured, for example, from two components as described below.

wherein R₁, R_(2A), R_(2B), and R₃ are as defined in item 1 herein.

Synthesis Scheme 10

Synthesis of Compound XXIF and Compound XXIB

Step 10-1

Reduction of Imine

Under the same condition as step 6-1 of Synthesis Scheme 6, compound XXIF (i.e., compound of formula XXIF) or compound XXIB (i.e., compound of formula XXIB) can be manufactured, for example, from compound XXIIF (i.e., compound of formula XXIIF) or compound XXIIB (i.e., compound of formula XXIIB) by reduction as described below. However, R₄ therein is H.

Step 10-2

Modification of Amine of Piperidine Ring

Amine of a piperidine ring in compound XXIF or compound XXIB can be modified by, for example, alkylation, amidation, or the like as follows.

R₄ in the product of this step is a group defined herein other than H.

The intermediate and compound of interest in the manufacturing methods described above can be isolated and purified by subjecting them to a purification method that is commonly used in organic synthesis chemistry (e.g., neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography, or the like). Each intermediate can also be subjected to the subsequent reaction without any particular purification.

Optically active forms of the compound of the present disclosure can be manufactured by using an optically active starting material or intermediate, or by optically resolving a racemate of the final product or intermediate. Examples of optional resolution methods include, but are not limited to, separation method using an optically active column or a separation method such as fractional crystallization method. A diastereomer of the compound of the present disclosure can be manufactured by, for example, but not limited to, a separation method such as column chromatography or fractional crystallization.

A pharmaceutically acceptable salt of a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula can be manufactured by, for example, but not limited to, mixing a compound represented by formula IF, IB, IIF, IIB, XXIF, XXIB, XXIIF, or XXIIB, or a related structural formula with a pharmaceutically acceptable acid or base in a solvent such as water, methanol, ethanol, 2-propanol, ethyl acetate, or acetone.

As used herein, “or” is used when “at least one or more” of the listed matters in the sentence can be employed. When explicitly described herein as “within the range of two values”, the range also includes the two values themselves.

Reference literatures such as scientific literatures, patents, and patent applications cited herein are incorporated herein by reference to the same extent that the entirety of each document is specifically described.

The present disclosure has been described while showing preferred embodiments to facilitate understanding. While the present disclosure is described hereinafter based on the Examples, the above descriptions and the following Examples are provided for the sole purpose of exemplification, not limitation of the present disclosure. Thus, the scope of the present disclosure is not limited to the embodiments and Examples that are specifically described herein and is limited only by the scope of claims.

EXAMPLES

The present disclosure is specifically described based on the Examples. The scope of the present disclosure is not limited to the Examples described below.

For Thin Layer Chromatography (TLC), Merck's TLC Silica gel 60 F254 (25 glass plate, 20×20 cm) and Fuji Silysia Chemical's CHROMATOREX NH-TLC Plates (20×20 cm) were used. As the developing solvent, chloroform-methanol mixed solvent system, ethyl acetate-methanol mixed solvent system, or ethyl acetate-hexane mixed solvent system was used. Spots were checked using coloring with UV irradiation, ninhydrin, iodine, or phosphomolybdic acid (ethanol solution). An organic solvent was dried using anhydrous sodium sulfate and anhydrous magnesium sulfate. For column chromatography, Fuji Silysia Chemical's cartridge column CHROMATOREX Q-PACKS 130 (SIZE 10, 20, or 60) and DNH (SIZE 20) or Shoko Science's Purif-Pack®-EX SI50 (SIZE 20 or 60) were used in accordance with the amount of raw product to be purified. Silica gel thin layer chromatography for separation (PTLC: Preparative Thin Layer Chromatography) used Merck's PLC Silica gel 60 F254 (20×20 cm; thickness: 0.5 mm; product number: 1.05744.0001; thickness: 1 mm; product number: 1.13895.0001) and Fuji Silysia Chemical's CHROMATOREX NH-PLCO5 (20×20 cm; thickness: 0.5 mm). Synthesized compounds were identified by LC/MS (Liquid Chromatography/Mass Spectrometry). Tables 1 to 4 show the retention (t_(R)) and m/z value [M+1]⁺. For measurement, Shimadzu's LCMS-2020 system was used, and Chemicals Evaluation and Research Institute's L-column2 ODS, 3 μm, 3.0×50 mm was used as the analysis column. The column oven was set to 40° C., and compounds were detected by using both UV absorption (220 nm, 254 nm) and mass spectrometry. Elution condition A or B shown below was used.

Elution Condition A:

Flow rate 1.5 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile; 0-0.9 minutes, linear gradient, A:B (95:5)-A:B (10:90), 0.9-2 minutes

Elution Condition B:

Flow rate 1.0 mL/min, mobile phase a=aqueous 0.05% (v/v) formic acid solution, mobile phase b=0.05% (v/v) formic acid containing acetonitril; 0-0.9 minutes, linear gradient, A:B (95:5)-A:B (10:90), 0.9-2 minutes

Elution Condition B1:

Flow rate 1.0 mL/min, mobile phase a=aqueous 0.05% (v/v) formic acid solution, mobile phase b=0.05% (v/v) formic acid containing acetonitrile; 0.1-2.0 minutes, linear gradient, A:B (95:5)-A:B (60:40), 2.0-3.0 minutes, linear gradient, A:B (60:40)-A:B (10:90), 3.0-4.0 minutes

Furthermore, LC/MS measurement used the following instrument and measurement conditions.

Measurement Condition C:

Shimadzu's LCMS-2020 system was used, and Chemicals Evaluation and Research Institute's L-column2 ODS, 3 μm, 3.0×50 mm was used as the analysis column. The column oven was set to 40° C., and the compound was detected by using both UV absorption (220 nm, 254 nm) and mass spectrometry.

Elution condition: flow rate of 1.5 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile

TABLE A1 Ratio of mobile Time (min) phase b (%) 0.0   5 0.01-0..89 5-90 linear gradient 0.9  90 2.00 90

Measurement Condition D:

The same apparatus as measurement condition C was used.

Elution condition: flow rate of 1.5 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile

TABLE A2 Ratio of mobile Time (min) phase b (%) 0.0   0 0.5   0 0.51-1.39 0-70 linear gradient 1.4  70 1.5  90 2.00 90

Measurement Condition E:

The same apparatus as measurement condition C was used.

Elution condition: flow rate of 1.5 mL/min, mobile phase a=5 mM NH₄HCO₃ containing water/acetonitrile=900/100 (v/v), mobile phase b=5 mM NH₄HCO₃ containing water/acetonitrile=100/900 (v/v)

TABLE A3 Ratio of mobile Time (min) phase b (%) 0.0   0 0.5   0 0.51-1.39 0-70 linear gradient 1.4  70 1.5  90 2.00 90

Measurement Condition F:

Waters' Alliance 2695 Separation Module system was used, and YMC's YMC-Triart C18, 5 μm, 3.0×50 mm was used as the analysis column. The column oven was set to 30° C., and the compound was detected using both UV absorption (220 nm) and mass spectrometry.

Elution condition: flow rate of 1.27 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile

TABLE A4 Ratio of mobile Time (min) phase b (%) 0.0 10 1.0 10 1.0-1.5 10-30 gradient 1.5-4.5 30-70 gradient 4.5-5.0 70-90 gradient 6.0 90

Measurement Condition G:

The same apparatus as measurement condition F was used.

Elution condition: flow rate of 1.27 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile

TABLE A5 Ratio of mobile Time (min) phase b (%) 0.0  1 1.0  1 1.0-4.0 1-40 gradient 4.0-5.0 40-90 gradient 6.0 90

Measurement Condition H:

Waters' 2767 system was used, and YMC's YMC-Triart C18, 5 μm, 4.6×50 mm was used as the analysis column. The column oven was set to 25° C., and compound was detected using UV absorption (220 nm), mass spectrometry, and ELS (Evaporative Light Scattering).

Elution condition: flow rate of 2 mL/min, mobile phase a=aqueous 0.1% (v/v) trifluoroacetic acid solution, mobile phase b=0.1% (v/v) trifluoroacetic acid containing acetonitrile

TABLE A6 Ratio of mobile Time (min) phase b (%) 0.0  5 0.5  5 0.5-3.0 5-95 gradient 5.0 95

Measurement Condition I:

Waters' H-class/SQD2 system was used, and Waters' ACQUITY UPLC BEH C18 1.7 μm, 2.1×50 mm was used as the analysis column. A compound was detected using both UV absorption (220 nm) and mass spectrometry.

Elution condition: flow rate of 0.6 mL/min, mobile phase a=aqueous 0.1% (v/v) formic acid solution, mobile phase b=0.1% (v/v) formic acid containing acetonitrile

TABLE A7 Ratio of mobile Time (min) phase b (%) 0.0  2 2.0-2.6 2-100 2.6-3.0 100

Measurement Condition J:

The same apparatus as measurement condition F was used.

Elution condition: flow rate of 1.27 mL/min, mobile phase a=aqueous 0.05% (v/v) trifluoroacetic acid solution, mobile phase b=0.05% (v/v) trifluoroacetic acid containing acetonitrile

TABLE A8 Ratio of mobile Time (min) phase b (%) 0.0 10 1.0 10 1.0-2.0 10-60 gradient 2.0-5.0 60-99 gradient 5.0-6.0 99

Nuclear Magnetic Resonance (NMR) was measured using Bruker AVANCE III 400 MHz Spectrometer (resonant frequency: ¹H: 400 MHz, ¹³C: 100 MHz) and Bruker AVANCE III 300 MHz Spectrometer (resonant frequency: ¹H: 300 MHz, ¹³C: 75 MHz). For the measurement of X-ray crystal structure, Rigaku Corporation's single crystal X-ray diffractometer XtaLAB P200 was used. Cu—K_(α) rays monochromed with a multilayer mirror were used as the source. The structure was determined by a direct method using SIR2008. The structure was refined by the full-matrix least-squares method with respect to F2 using SHELEX-2014/7. Non-hydrogen atoms were refined with anisotropic atomic displacement parameters.

The abbreviations described above and the following abbreviations are also used in the Examples to simplify the description.

s: singlet d: doublet t: triplet m: multiplet dd: double doublet J: coupling constant

Hz: Hertz

δ: chemical shift min: minute RT and tR: retention CDCl₃: deuterated chloroform Me: methyl Et: ethyl Pr: propyl i-Pr: isopropyl i-Bu: isobutyl s-Bu and sec-Bu: secondary butyl ^(t)Bu, tBu and tert-Bu: tertiary butyl i-Pnt: isopentyl Hxy: n-hexyl Ac: acetyl Bz: benzoyl Bnzl: benzyl 3-Me-Bnzl: 3-methylbenzyl 4-Me-Bnzl: 4-methylbenzyl 3-MeO-Bnzl: 3-methoxybenzyl 4-MeO-Bnzl: 4-methoxybenzyl 4-OH-Bnzl: 4-hydroxybenzyl 3-F-Bnzl: 3-fluorobenzyl 4-F-Bnzl: 4-fluorobenzyl 3-Cl-Bnzl: 3-chlorobenzyl 4-Cl-Bnzl: 4-chlorobenzyl 3,4-Cl₂-Bnzl: 3,4-dichlorobenzyl 4-tBuO-Bnzl: 4-(tert-butoxy)benzyl 4-Nt-Bnzl: 4-nitrobenzyl Cbx-E and 2-Cbx-Et: 2-carboxyethyl Cbm-M: 2-amino-2-oxoethyl or carbamoylmethyl Cbm-E: 3-amino-3-oxopropyl or 2-carbamoylethyl tBOC-E: 2-(tert-butoxycarbonyl)ethyl or 3-(tert-butoxy)-3-oxopropyl Gun-Pr and 3-Gun-Pr: 3-guanidinopropyl Hdr-M: hydroxymethyl Hdr-E and 2-OH-Et: 2-hydroxyethyl tBuO-E and 2-OtBu-Et: 2-(tert-butoxy)ethyl Ph-Et: 2-phenylethyl Ph-Pr: 3-phenylpropyl Ph-Bu: 4-phenylbutyl Np-M and 1-Npm: naphthalen-1-ylmethyl 2-Npm: naphthalen-2-ylmethyl Np-E: 2-(naphthalen-1-yl)ethyl Cpm: cyclopentylmethyl Chm: cyclohexylmethyl Boc and tBOC and tBOC: tert-butoxycarbonyl TBSO-E and 2-0TBS-Et: 2-(tert-butyldimethylsilyloxy)ethyl

Example 1: Synthesis of Compound Synthesis Example for Compound V Synthesis of N-benzyl-1,2,4-triazine-3-carboxamide

Ethyl 1,2,4-triazine-3-carboxylate (1.53 g, 10.0 mmol) was dissolved in methanol (10.0 mL), and phenylmethaneamine (1.18 g, 11.0 mmol) was added. The mixture was then stirred for 3 hours at 50° C. Methanol was evaporated under reduced pressure, and the resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 60, eluent: ethyl acetate-methanol (gradient from 0% to 15%)). A fraction of a compound of interest was concentrated. The eluted crystal was filtered out to obtain the aforementioned compound (1.25 g, yield: 58%).

Under the same conditions as this reaction, the following compounds were synthesized. N-(naphthalen-1-ylmethyl)-1,2,4-triazine-3-carboxamide tert-butyl (4-(1,2,4-triazine-3-carboxamide)butyl)carbamate N-(4-(tert-butoxy)benzyl)-1,2,4-triazine-3-carboxamide N-isobutyl-1,2,4-triazine-3-carboxamide N-(4-methylbenzyl)-1,2,4-triazine-3-carboxamide N-phenethyl-1,2,4-triazine-3-carboxamide N-(3-methylbenzyl)-1,2,4-triazine-3-carboxamide N-(3-chlorobenzyl)-1,2,4-triazine-3-carboxamide N-(4-chlorobenzyl)-1,2,4-triazine-3-carboxamide N-(2-(naphthalen-1-yl)ethyl)-1,2,4-triazine-3-carboxamide tert-butyl 3-(2-(1,2,4-triazine-3-carboxamide)ethyl)-1H-indol-1-carboxylate N-(3,4-dichlorobenzyl)-1,2,4-triazine-3-carboxamide

Synthesis Example for Compound V Synthesis of N-(2-hydroxyethyl)-1,2,4-triazine-3-carboxamide

Ethyl 1,2,4-triazine-3-carboxylate (76.5 mg, 0.500 mmol) was dissolved in ethanol (1.00 mL), and 2-aminoethanol (24.2 mg, 0.525 mmol) was added. The mixture was then stirred for 3 hours at room temperature. Methanol was evaporated under reduced pressure, and the resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 20, eluent: ethyl acetate-methanol (gradient from 0% to 30%)). A fraction of a compound of interest was concentrated to obtain the aforementioned compound (44.8 mg, yield: 53%).

Under the same conditions as this reaction, the following compound was synthesized. N-(cyclohexylmethyl)-1,2,4-triazine-3-carboxamide

Synthesis Example for Compound V Synthesis of Tert-Butyl 3-(1,2,4-triazine-3-carboxamide)propanoate

Triethylamine (0.245 mL, 1.75 mmol) was added to an ethanol (2.00 mL) solution of tert-butyl 3-aminopropanoate.HCl (272 mg, 1.50 mmol). A methanol (1.00 mL) suspension of ethyl 1,2,4-triazine-3-carboxylate (76.0 mg, 0.500 mmol) was added thereto. The mixture was stirred for 4 hours at room temperature. Ethanol was evaporated under reduced pressure. The residue was dissolved in ethyl acetate. The organic layer was washed with 10% citric acid water and 5% bicarbonate aqueous solution and dried with anhydrous sodium sulfate. The solvent was evaporated. The resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 20, eluent: hexane-ethyl acetate (gradient from 60% to 100%)) to obtain the aforementioned compound (65.7 mg, yield: 52%).

Synthesis Example for Compound XV Synthesis of 4-methylpentanal

A methylene chloride (40.0 mL) solution of acetic acid (0.0994 mL, 1.30 mmol) and 4-methylpentan-1-ol (1.49 mL, 11.8 mmol) was slowly added dropwise into a methylene chloride (45.0 mL) solution of 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (Dess-Martin periodinane) (5.25 g, 12.4 mmol) at room temperature. After completion of the addition, the mixture was stirred for another hour, and then diethyl ether (280 mL) was added. An aqueous 1.30M sodium hydroxide solution (200 mL) was added to the organic layer and stirred for 10 minutes at room temperature. The organic layer was washed with an aqueous 1.30M sodium hydroxide solution (90.0 mL) and (50.0 mL). After drying with anhydrous sodium magnesium sulfate, the solvent was carefully evaporated to obtain the aforementioned compound (1.01 g, 86%).

Under the same conditions as this reaction, the following compound was synthesized. 5-methylhexanal

Synthesis Example for Compound III Synthesis of N-benzylprop-2-en-1-amine

(Bromomethyl)benzene (0.992 mL, 8.35 mmol) was gradually added dropwise to a suspension of anhydrous potassium carbonate (1.39 g, 10.0 mmol) and prop-2-en-1-amine (7.53 mL, 100 mmol) and then stirred for 3 hours at room temperature. The solids were filtered and washed with methylene chloride. The combined organic layer was evaporated under reduced pressure. The resulting residue was purified with CHROMATOREX Q-PACK SI30 SIZE 20 (hexane: ethyl acetate=50%:50% to 0%:100%) to obtain the aforementioned compound (934 mg, yield: 76%).

Under the same conditions as this reaction, the following compound was synthesized. N-(3,4-dichlorobenzyl)prop-2-en-1-amine

Synthesis Example for Compound III Synthesis of N-(cyclohexylmethyl)prop-2-en-1-amine

Prop-2-en-1-amine (3.42 g, 60.0 mmol) was added dropwise to a methanol (40.0 mL) solution of cyclohexanecarbaldehyde (7.06 g, 63.0 mmol) while cooling with ice. After the completion of the addition, sodium tetrahydroborate (0.850 g, 22.0 mmol) was resolved and added while cooling with ice, and the mixture was stirred for another hour. Methanol was evaporated under reduced pressure. Ethyl ether was added to the residue. The organic layer was washed with saturated saline and dried with anhydrous sodium sulfate and then concentrated under reduce pressure. The residue was evaporated under reduced pressure to obtain the aforementioned compound (7.35 g, 80%, boiling point, 79 to 84° C./9.1 mmHg).

Under the same conditions as this reaction, the following compounds were synthesized. N-isobutylprop-2-en-1-amine N-allyl-3-methylbutan-1-amine

Synthesis Example for Compound III Synthesis of N-(4-tert-butoxybenzyl)prop-2-en-1-amine

A methanol (2.00 mL) solution of 4-tert-butoxybenzaldehyde (468 mg, 2.63 mmol) was added dropwise to a methanol (3.00 mL) solution of prop-2-en-1-amine (143 mg, 2.50 mmol) while cooling with ice. After the completion of the addition, sodium tetrahydroborate (35.0 mg, 0.920 mmol) was resolved and added while cooling with ice, and the mixture was stirred for another hour. Methanol was evaporated under reduced pressure. Ethyl acetate was added to the residue. The organic layer was washed with saturated saline and dried with anhydrous sodium sulfate and then concentrated under reduce pressure. The resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 60, eluent: hexane-ethyl acetate (gradient from 20% to 100%) and then ethyl acetate-methanol (gradient from 0% to 15%)) to obtain the aforementioned compound (370 mg, yield: 68%).

Under the same conditions as this reaction, the following compounds were synthesized. N-(naphthalen-1-ylmethyl)prop-2-en-1-amine N-(3,4-dichlorobenzyl)prop-2-en-1-amine

Synthesis Example: IIB-1 and IIF-1 Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-1) and (3S*, 3aR*, 6S*, 7R*, 7aR*)—N, 7-dibenzyl-1-isobutyl-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-1)

4A molecular sieves (850 mg), 3-phenylpropanal (0.157 mL, 1.19 mmol), and N-isobutylprop-2-en-1-amine (purity: 90%, 150 mg, 1.19 mmol) were added to a chloroform (8.50 mL) solution of N-benzyl-1,2,4-triazine-3-carboxamide (III) (170 mg, 0.794 mmol), and heated and refluxed for 10 hours. The molecular sieves were filtered and washed twice with chloroform (5.00 mL). The combined organic layer was evaporated under reduced pressure. The resulting residue was purified with CHROMATOREX Q-PACK SI30 SIZE 60 (ethyl acetate:methanol=100%: 0% to 960:40) to obtain the aforementioned compounds (IIF-1) (86.9 mg, yield: 26%, RT=1.14 minutes (B method), [M+1]⁺=416) and (IIB-1) (149 mg, yield: 45%, RT=1.19 minutes (B method), [M+1]⁺=416).

Synthesis Example: IIB-29 Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N-(4-aminobutyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-29)

Formic acid (300 μL) was added to (3S*, 3aS*, 6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(4-((tert-butoxycarbonyl)amino)butyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-30) (9.30 mg, 0.0187 mmol) and incubated overnight at room temperature. Formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (7.70 mg, yield: 84%, RT=0.71 minutes (A method), [M+1]⁺=397).

Synthesis Example: IIF-26 Synthesis of 3-((3S*, 3aR*, 6S*, 7R*, 7aR*)-7-benzyl-1-isobutyl-1,2,3,3a, 7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide) propanoic acid (11-26)

Formic acid (1.00 mL) was added to (3S*, 3aR*, 6S*, 7R*, 7aR*)-7-benzyl-1-isobutyl-N— (2-(tert-butoxy)-2-oxoethyl)-1,2,3,3a, 7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-27) (30.4 mg, 0.0660 mmol), and heated overnight at 50° C. Formic acid was evaporated under reduced pressure to obtain a monoformic acid salt of the aforementioned compound (29.7 mg, yield: 100%, RT=0.75 minutes (A method), [M+1]+=398).

Synthesis Example: IIB-28 Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N-(3-amino-3-oxopropyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-28)

3-((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide)propanoic acid (IIB-26) (15.0 mg, 0.0380 mmol) was dissolved in methanol (2.00 mL), and ammonium water (25.0 μL) and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (110 mg, 0.397 mmol) were resolved and added 4 times each at room temperature. The solvent was evaporated under reduced pressure. The resulting residue was purified by preparative PLC (Fuji Silysia Chemical's CHROMATOREX NH-PLCO5 (layer thickness 0.500 mm) (ethyl acetate:methanol=9:1) to obtain the aforementioned compound (7.10 mg, yield: 47%, RT=0.79 minutes (A method), [M+1]⁺=397).

Tables 1 to 4 summarize the synthesized compounds of formula IIB and compounds of IIF. The following abbreviations are used in the following tables.

INT-iBu: N-isobutyl-1,2,4-triazine-3-carboxamide

INT-Bnzl: N-benzyl-1,2,4-triazine-3-carboxamide

SM1-iBu: N-isobutylprop-2-en-1-amine

SM1-Bnzl: N-benzylprop-2-en-1-amine

SM2-Ph: 3-phenylpropanal

SM2-Pnt: 4-methylpentanal

Since samples with a blank entry under Mass in the following tables are prepared based on Mass Number in HPLC, it can be understood that the molecular weight is inferred and confirmed based on the time of retension (UV) of HPLC to identify the structure.

TABLE 1-1

Compound Synthesis number R₁ R₂ R₃ method Intermediate Raw material 1 Raw material 2 IIB-1 i-Bu Bnzl Bnzl EX INT-Bnzl SM1-iBu SM2-Ph

TABLE 1-2 IIB- i-Bu i-Bu i-Bu IIB-1, INT-iBu SM1-iBu SM2-Pnt 2 IIF-1 IIB- i-Bu i-Bu Bnzl IIB-1, INT-iBu SM1-iBu SM2-Ph 3 IIF-1 IIB- Bnzl i-Bu i-Bu IIB-1, INT-iBu SM1-Bnzl SM2-Pnt 4 IIF-1 IIB- i-Bu Bnzl i-Bu IIB-1, INT-Bnzl SM1-iBu SM2-Pnt 5 IIF-1 IIB- Bnzl i-Bu Bnzl IIB-1, INT-iBu SM1-Bnzl SM2-Ph 6 IIF-1 IIB- Bnzl Bnzl i-Bu IIB-1, INT-Bnzl SM1-Bnzl SM2-Pnt 7 IIF-1 IIB- Bnzl Bnzl Bnzl IIB-1, INT-Bnzl SM1-Bnzl SM2-Ph 8 IIF-1 IIB- i-Pnt Bnzl Bnzl IIB-1, INT-Bnzl N-allyl- SM2-Ph 9 IIF-1 3- methylbutan- 1-amine IIB- Bnzl Bnzl i-Pnt IIB-1, INT-Bnzl SM1-Bnzl 5- 10 IIF-1 methylhexanal IIB- i-Bu Bnzl Ph-Et IIB-1, INT-Bnzl SM1-iBu 4- 11 IIF-1 phenylbutanal IIB- i-Bu Ph-Et Bnzl IIB-1, N- SM1-iBu SM2-Ph 12 IIF-1 phenethyl- 1,2,4- triazine-3- carboxamide IIB- i-Bu Bnzl 3-Me- IIB-1, INT-Bnzl SM1-iBu 3-(m-tolyl) 13 Bnzl IIF-1 propanal IIB- i-Bu Bnzl 4-Me- IIB-1, INT-Bnzl SM1-iBu 3-(p-tolyl) 14 Bnzl IIF-1 propanal IIB- i-Bu 3-Me- Bnzl IIB-1, N-(3- SM1-iBu SM2-Ph 15 Bnzl IIF-1 methylbenzyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu 4-Me- Bnzl IIB-1, N-(4- SM1-iBu SM2-Ph 16 Bnzl IIF-1 methylbenzyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu 3-Cl- Bnzl IIB-1, N-(3- SM1-iBu SM2-Ph 17 Bnzl IIF-1 chlorobenzyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu 4-Cl- Bnzl IIB-1, N-(4- SM1-iBu SM2-Ph 18 Bnzl IIF-1 chlorobenzyl)- 1,2,4- triazine-3- carboxamide IIB- 3,4- Bnzl i-Bu IIB-1, INT-Bnzl N-(3,4- SM2-Pnt 19 Cl₂- IIF-1 dichlorobenzyl) Bnzl prop-2-en-1- amine IIB- Bnzl 3,4-Cl₂- i-Bu IIB-1, N-(3,4- SM1-Bnzl SM2-Pnt 20 Bnzl IIF-1 dichlorobenzyl)- 1,2,4- triazine-3- carboxamide IIB- Me Np-E Bnzl IIB-1, N-(2- N- SM2-Ph 21 IIF-1 (naphthalen-1- methylprop- yl)ethyl)- 2-en-1-amine 1,2,4- triazine-3- carboxamide

TABLE 1-3 IIB- i-Bu 4-(tert- Bnzl IIB-1, N-(4-tert- SM1-iBu SM2-Ph 23 butoxy) IIF-1 butoxybenzyl)- benzyl 1,2,4- triazine-3- carboxamide IIB- i-Bu Np-M Bnzl IIB-1, N- SM1-iBu SM2-Ph 24 IIF-1 ((naphthalen- 1-yl)methyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu Hdr-E Bnzl IIB-1, N-(2- SM1-iBu SM2-Ph 25 IIF-1 hydroxyethyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu Cbx-E Bnzl IB-40 IIB-27 26 IIB- i-Bu 2-(tert- Bnzl IIB-1, tert-butyl SM1-iBu SM2-Ph 27 butoxy)- IIF-1 3-(1,2,4- 2- triazine-3- oxoethyl carboxamide) propanoate IIB- i-Bu Cbm-E Bnzl EX IIB-26 28 IIB- i-Bu 4- Bnzl EX IIB-30 29 aminobutyl IIB- i-Bu 4- Bnzl IIB-1, tert-butyl SM1-iBu SM2-Ph 30 ((tert- IIF-1 4-(1,2,4- butoxycarbonyl) triazine-3- amino)butyl carboxamide) butylcarbamate IIB- i-Bu Chm Bnzl IIB-1, N- SM1-iBu SM2-Ph 31 IIF-1 (cyclohexyl- methyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu (tetrahydro- Bnzl IIB-1, N- SM1-iBu SM2-Ph 32 2H- IIF-1 ((tetrahydro- pyran-2- 2H-pyran- yl)methyl 2-yl)methyl)- 1,2,4- triazine-3- carboxamide IIB- i-Bu Bnzl 4- IIB-1, INT-Bnzl SM1-iBu tert- 34 ((tert- IIF-1 butyl butoxy- 5- carbonyl) formyl- amino) pentyl- butyl carbamate IIB- i-Bu Bnzl 3- IIB-1, INT-Bnzl SM1-iBu methyl 36 methoxy- IIF-1 4-formyl- 3- butanoate oxopropyl IIB- i-Bu Bnzl Chm IIB-1, INT-Bnzl SM1-iBu 3- 38 IIF-1 cyclo- hexylpropanal IIB- Chm Bnzl Bnzl IIB-1, INT-Bnzl N- SM2-Ph 39 IIF-1 (cyclohexylmethyl) prop- 2-en-1- amine IIB- 4-OH- Bnzl Bnzl IB-40 IIB-41 40 Bnzl IIB- 4- Bnzl Bnzl IIB-1, INT-Bnzl N-(4- SM2-Ph 41 (tert- IIF-1 tert- butoxy) butoxybenzyl) benzyl prop-2-en- 1-amine IIB- Np-M Bnzl Bnzl IIB-1, INT-Bnzl N- SM2-Ph 42 IIF-1 ((naphthalen- 1-yl)methyl) prop- 2-en-1- amine

TABLE 1-4 IIB- 3- Bnzl Bnzl IIB-1, INT-Bnzl N-(3- SM2-Ph 76 (tert- IIF-1 (tert- butoxy)- butoxy)- 3- 3- oxopropyl oxopropyl)- prop-2-en-1- amine IIB- Bnzl Bnzl 4-OH- IIB-1, INT-Bnzl SM1-Bnzl 3-(4- 77 Bnzl IIF-1 hydroxy- phenyl) propanal IIB- Me 2-(1- Bnzl IIB-1, N-(2-(1- N- SM2-Ph 78 (tert- IIF-1 (tert- methyl- butoxycarbonyl)- butoxycarbonyl)- prop-2- 1H- 1H- en-1- indol-3- indol-3- amine yl)ethyl yl)ethyl)- 1,2,4- triazine-3- carboxamide IIB- Np-M Bnzl Pr IIB-1, INT-Bnzl N- pentanal 80 IF-1 ((naphthalen- 1- yl)methyl) prop- 2-en-1- amine IIB- benzyl naphthalen- isobutyl IIB-1, 81 1-ylmethyl IF-1 EX: described in the Examples

TABLE 1-5 LCMS Mass Compound tR (M + Measurement number R₁ R₂ R₃ (min) H)⁺ condition IIB-81 benzyl naphthalen- isobutyl 1.29 467 B 1-ylmethyl IIB-82 benzyl 4-(trifluoromethyl) isobutyl 1.29 484 B benzyl IIB-83 4-chlorobenzyl benzyl isobutyl 1.29 450 B IIB-84 3-chlorobenzyl benzyl isobutyl 1.30 450 B IIB-85 4-methoxybenzyl benzyl isobutyl 1.23 446 B IIB-86 4-methylbenzyl benzyl isobutyl 1.27 430 B IIB-88 isobutyl isobutyl 4-chlorobenzyl 1.26 416 B IIB-89 isobutyl 4-chlorobenzyl isobutyl 1.27 416 B IIB-90 isobutyl benzyl isopentyl 1.26 396 B IIB-91 isopentyl benzyl isobutyl 1.26 396 B IIB-92 isobutyl isopentyl benzyl 1.27 396 B IIB-93 4-hydroxybenzyl benzyl isobutyl 1.19 432 B IIB-94 4-(dimethylamino) benzyl isobutyl 1.27 459 B benzyl

TABLE 1-6 IIB-95 4-(tert-butyl) benzyl isobutyl 1.31 472 B benzyl IIB-96 4-(trifluoro- benzyl isobutyl 1.32 500 B methoxy)benzyl IIB-97 4-ethoxybenzyl benzyl isobutyl 1.25 460 B IIB-98 isopentyl isobutyl benzyl 1.26 396 B IIB-99 benzyl 4-hydroxy- isobutyl 1.17 432 B benzyl IIB-100 4-methoxybenzyl 4-hydroxy- isobutyl 1.17 462 B benzyl IIB-101 4-hydroxybenzyl benzyl isopentyl 1.20 446 B IIB-102 benzyl naphthalen-2- isobutyl 1.27 466 B ylmethyl IIB-103 isopentyl 4-chlorobenzyl isobutyl 1.28 431 B IIB-104 isopentyl 4-fluorobenzyl isobutyl 1.26 414 B IIB-105 benzyl pyridin-4-yl isobutyl 1.06 417 B methyl IIB-106 4-methoxybenzyl benzyl benzyl 0.99 480 C IIB-107 phenethyl benzyl 2-(tert- 1.12 532 C butyl- dimethyl- silyloxy) ethyl IIB-108 cyclopentyl- 4-hydroxy- 2-carboxy- 0.78 440 C methyl benzyl ethyl IIB-109 4-nitrobenzyl 4-(tert-butoxy) 2-(tert- 1.03 605 C benzyl butoxy- carbonyl) ethyl IIB-110 i-Bu i-Pr Bnzl 3.09 368 F IIB-111 i-Bu i-Bu 4-tBuO- 3.95 454 F Bnzl IIB-112 i-Bu Bnzl 4-tBuO- 4.05 488 F Bnzl IIB-113 i-Bu tBOC-E 4-tBuO- 4.12 526 F Bnzl IIB-114 i-Bu s-Bu 4-tBuO- 3.93 454 F Bnzl IIB-115 i-Bu 1-Npm 4-tBuO- 4.48 538 F Bnzl

TABLE 1-7 IIB-116 i-Bu i-Pr 4-tBuO- 3.64 440 F Bnzl IIB-117 i-Bu 1-Npm tBOC-E 4.11 504 F IIB-118 i-Bu i-Pr tBOC-E 3.18 406 F IIB-119 i-Bu 1-Npm 1-Npm 4.39 516 F IIB-120 i-Bu i-Pr 1-Npm 3.52 418 F IIB-121 Bnzl 4-tBuO-Bnzl Bnzl 4.23 522 F IIB-122 Bnzl i-Bu 4-tBuO- 4.11 488 F Bnzl IIB-123 Bnzl Bnzl 4-tBuO- 4.20 522 F Bnzl IIB-124 Bnzl tBOC-E 4-tBuO- 4.27 560 F Bnzl IIB-125 Bnzl Bnzl tBOC-E 3.72 488 F IIB-126 Bnzl 4-tBuO-Bnzl tBOC-E 4.22 560 F IIB-127 Bnzl 1-Npm tBOC-E 4.18 538 F IIB-128 Bnzl i-Bu 1-Npm 3.98 466 F IIB-129 Bnzl Bnzl 1-Npm 4.09 500 F IIB-130 Bnzl 4-tBuO-Bnzl 1-Npm 4.55 572 F IIB-131 Bnzl tBOC-E 1-Npm 4.17 538 F IIB-132 Bnzl s-Bu 1-Npm 3.96 466 F IIB-133 Bnzl 1-Npm 1-Npm 4.49 550 F IIB-134 Bnzl i-Pr 1-Npm 3.71 452 F IIB-135 4-tBuO-Bnzl i-Bu Bnzl 3.92 488 F IIB-136 4-tBuO-Bnzl Bnzl Bnzl 4.57 522 F IIB-137 4-tBuO-Bnzl 1-Npm Bnzl 5.10 572 F IIB-138 4-tBuO-Bnzl Bnzl tBOC-E 3.95 560 F IIB-139 4-tBuO-Bnzl 1-Npm tBOC-E 4.35 610 F IIB-140 4-tBuO-Bnzl i-Bu 1-Npm 4.07 538 F IIB-141 4-tBuO-Bnzl Bnzl 1-Npm 5.00 572 F IIB-142 4-tBuO-Bnzl tBOC-E 1-Npm 4.14 610 F IIB-143 4-tBuO-Bnzl s-Bu 1-Npm 4.27 538 F IIB-144 4-tBuO-Bnzl 1-Npm 1-Npm 5.40 622 F IIB-145 i-Bu 4-tBuO-Bnzl Bnzl 4.13 488 F IIB-146 i-Bu tBOC-E Bnzl 3.66 454 F IIB-147 i-Bu s-Bu Bnzl 3.38 382 F IIB-148 i-Bu i-Bu tBOC-E 3.44 420 F IIB-149 i-Bu Bnzl tBOC-E 3.63 454 F

TABLE 1-8 IIB-150 i-Bu 4-tBuO-Bnzl tBOC-E 4.18 526 F IIB-151 i-Bu s-Bu tBOC-E 3.46 420 F IIB-152 i-Bu i-Bu 1-Npm 3.87 432 F IIB-153 i-Bu Bnzl 1-Npm 3.98 466 F IIB-154 i-Bu 4-tBuO-Bnzl 1-Npm 4.44 538 F IIB-155 i-Bu tBOC-E 1-Npm 4.04 504 F IIB-156 Bnzl tBOC-E Bnzl 3.82 488 F IIB-157 Bnzl s-Bu Bnzl 3.55 416 F IIB-158 Bnzl 1-Npm Bnzl 4.21 500 F IIB-159 Bnzl i-Pr Bnzl 3.31 402 F IIB-160 Bnzl s-Bu 4-tBuO- 4.08 488 F Bnzl IIB-161 Bnzl 1-Npm 4-tBuO- 4.61 572 F Bnzl IIB-162 Bnzl i-Pr 4-tBuO- 3.83 474 F Bnzl IIB-163 Bnzl s-Bu tBOC-E 3.60 454 F IIB-164 Bnzl i-Pr tBOC-E 3.28 440 F IIB-165 4-tBuO-Bnzl i-Pr Bnzl 3.70 474 F IIB-166 4-tBuO-Bnzl i-Pr tBOC-E 3.75 512 F IIB-167 4-tBuO-Bnzl i-Pr 1-Npm 4.07 524 F IIB-168 tBOC-E i-Bu Bnzl 3.77 454 F IIB-169 tBOC-E Bnzl Bnzl 3.86 488 F IIB-170 tBOC-E 4-tBuO-Bnzl Bnzl 4.34 560 F IIB-171 tBOC-E s-Bu Bnzl 3.76 454 F IIB-172 tBOC-E 1-Npm Bnzl 4.34 538 F IIB-173 tBOC-E i-Bu 4-tBuO- 4.30 526 F Bnzl IIB-174 tBOC-E Bnzl 4-tBuO- 4.40 560 F Bnzl IIB-175 tBOC-E s-Bu 4-tBuO- 4.31 526 F Bnzl IIB-176 tBOC-E 1-Npm 4-tBuO- 4.80 610 F Bnzl IIB-177 tBOC-E i-Pr 4-tBuO- 4.05 512 F Bnzl IIB-178 tBOC-E i-Bu 1-Npm 4.13 504 F IIB-179 tBOC-E 4-tBuO-Bnzl 1-Npm 4.66 610 F IIB-180 tBOC-E s-Bu 1-Npm 4.09 504 F IIB-181 tBOC-E 1-Npm 1-Npm 4.63 588 F IIB-182 1-Npm 4-tBuO-Bnzl Bnzl 4.18 572 F IIB-183 1-Npm s-Bu Bnzl 3.82 466 F

TABLE 1-9 IIB-184 1-Npm Bnzl 4-tBuO- 4.68 572 F Bnzl IIB-185 1-Npm tBOC-E 4-tBuO- 4.24 610 F Bnzl IIB-186 1-Npm s-Bu 4-tBuO- 4.84 538 F Bnzl IIB-187 1-Npm 1-Npm 4-tBuO- 4.85 622 F Bnzl IIB-188 1-Npm i-Pr 4-tBuO- 4.20 524 F Bnzl IIB-189 1-Npm i-Bu tBOC-E 3.80 504 F IIB-190 1-Npm Bnzl tBOC-E 4.45 538 F IIB-191 1-Npm 4-tBuO-Bnzl tBOC-E 4.84 610 F IIB-192 1-Npm s-Bu tBOC-E 4.29 504 F IIB-193 1-Npm 1-Npm tBOC-E 4.49 588 F IIB-194 1-Npm Bnzl 1-Npm 4.75 550 F IIB-195 1-Npm 4-tBuO-Bnzl 1-Npm 4.74 622 F IIB-196 1-Npm tBOC-E 1-Npm 4.59 588 F IIB-197 1-Npm s-Bu 1-Npm 4.57 516 F IIB-198 i-Bu 4-tBuO-Bnzl i-Bu 4.04 454 F IIB-199 i-Bu tBOC-E i-Bu 3.35 420 F IIB-200 i-Bu s-Bu i-Bu 3.25 348 F IIB-201 i-Bu 1-Npm i-Bu 4.00 432 F IIB-202 i-Bu i-Pr i-Bu 2.97 334 F IIB-203 i-Bu (tBOC)Gun-Pr 4-tBuO- 2.81 641 J Bnzl IIB-204 i-Bu 1-Npm (tBOC)Gun- 3.27 675 J Pr IIB-205 i-Bu s-Bu 1-Npm 3.85 432 F IIB-206 Bnzl 4-tBuO-Bnzl i-Bu 4.13 488 F IIB-207 Bnzl s-Bu i-Bu 3.45 382 F IIB-208 Bnzl i-Pr i-Bu 3.14 368 F IIB-209 Bnzl i-Bu (tBOC)Gun- 3.22 625 J Pr IIB-210 Bnzl 4-tBuO-Bnzl (tBOC)Gun- 2.96 675 J Pr IIB-211 tBOC-E i-Bu i-Bu 3.63 420 F IIB-212 tBOC-E Bnzl i-Bu 3.83 454 F IIB-213 tBOC-E 4-tBuO-Bnzl i-Bu 4.35 526 F IIB-214 tBOC-E s-Bu i-Bu 3.68 420 F IIB-215 tBOC-E 1-Npm i-Bu 4.32 504 F IIB-216 tBOC-E i-Pr i-Bu 3.41 406 F IIB-217 tBOC-E Bnzl 1-Npm 4.19 538 F

TABLE 1-10 IIB-218 tBOC-E i-Pr 1-Npm 3.87 490 F IIB-219 1-Npm Bnzl i-Bu 3.62 466 F IIB-220 1-Npm i-Bu Bnzl 3.67 466 F IIB-221 1-Npm (tBOC)Gun-Pr Bnzl 3.97 709 F IIB-222 1-Npm i-Bu 4-tBuO- 4.18 538 F Bnzl IIB-223 1-Npm i-Pr tBOC-E 3.62 490 F IIB-224 1-Npm 1-Npm (tBOC)Gun- 5.14 759 F Pr IIB-225 1-Npm i-Pr (tBOC)Gun- 3.15 661 F Pr IIB-226 1-Npm i-Bu 1-Npm 4.07 516 F IIB-227 1-Npm (tBOC)Gun-Pr 1-Npm 2.99 459 F IIB-228 1-Npm i-Pr 1-Npm 3.90 502 F IIB-229 i-Bu (tBOC)Gun-Pr i-Bu 3.10 591 J IIB-230 i-Bu (tBOC)Gun-Pr Bnzl 3.03 625 J IIB-231 i-Bu i-Bu (tBOC)Gun- 3.01 591 J Pr IIB-232 i-Bu Bnzl (tBOC)Gun- 3.02 625 J Pr IIB-233 i-Bu 4-tBuO-Bnzl (tBOC)Gun- 2.84 641 J Pr IIB-234 i-Bu s-Bu (tBOC)Gun- 2.99 591 J Pr IIB-235 i-Bu i-Pr (tBOC)Gun- 2.90 577 J Pr IIB-236 i-Bu (tBOC)Gun-Pr 1-Npm 3.17 675 J IIB-237 Bnzl (tBOC)Gun-Pr i-Bu 3.19 625 J IIB-238 Bnzl (tBOC)Gun-Pr Bnzl 3.26 659 J IIB-239 Bnzl (tBOC)Gun-Pr 4-tBuO- 2.84 675 J Bnzl IIB-240 Bnzl i-Bu tBOC-E 3.56 454 F IIB-241 Bnzl Bnzl (tBOC)Gun- 3.28 659 J Pr IIB-242 Bnzl s-Bu (tBOC)Gun- 3.04 625 J Pr IIB-243 Bnzl i-Pr (tBOC)Gun- 2.99 611 J Pr IIB-244 Bnzl (tBOC)Gun-Pr 1-Npm 3.36 709 J IIB-245 tBOC-E i-Pr Bnzl 3.45 440 F IIB-246 (tBOC)Gun-Pr 1-Npm i-Bu 3.65 657 J IIB-247 (tBOC)Gun-Pr i-Pr i-Bu 3.21 577 J IIB-248 (tBOC)Gun-Pr 1-Npm Bnzl 3.75 709 J IIB-249 (tBOC)Gun-Pr i-Pr Bnzl 3.24 611 J IIB-250 (tBOC)Gun-Pr 1-Npm 4-tBuO- 3.30 725 J Bnzl IIB-251 (tBOC)Gun-Pr i-Pr 4-tBuO- 2.92 627 J Bnzl

TABLE 1-11 IIB-252 (tBOC)Gun-Pr 1-Npm 1-Npm 3.86 759 J IIB-253 (tBOC)Gun-Pr i-Pr 1-Npm 3.38 661 J IIB-254 1-Npm (tBOC)Gun-Pr i-Bu 4.29 675 F IIB-255 1-Npm 1-Npm i-Bu 4.05 516 F IIB-256 1-Npm 1-Npm Bnzl 4.92 550 F IIB-257 Bnzl tBOC-E i-Bu 3.73 454 F IIB-258 Bnzl 1-Npm (tBOC)Gun- 3.80 709 J Pr IIB-259 4-tBuO-Bnzl i-Bu i-Bu 3.67 454 F IIB-260 4-tBuO-Bnzl Bnzl i-Bu 3.67 488 F IIB-261 4-tBuO-Bnzl tBOC-E i-Bu 3.82 526 F IIB-262 4-tBuO-Bnzl (tBOC)Gun-Pr i-Bu 3.38 641 F IIB-263 4-tBuO-Bnzl s-Bu i-Bu 3.75 454 F IIB-264 4-tBuO-Bnzl 1-Npm i-Bu 4.22 538 F IIB-265 4-tBuO-Bnzl i-Pr i-Bu 3.47 440 F IIB-266 4-tBuO-Bnzl tBOC-E Bnzl 3.88 560 F IIB-267 4-tBuO-Bnzl (tBOC)Gun-Pr Bnzl 3.24 675 F IIB-268 4-tBuO-Bnzl s-Bu Bnzl 3.85 488 F IIB-269 4-tBuO-Bnzl i-Bu tBOC-E 3.88 526 F IIB-270 4-tBuO-Bnzl s-Bu tBOC-E 3.79 526 F IIB-271 4-tBuO-Bnzl i-Bu (tBOC)Gun- 3.45 641 F Pr IIB-272 4-tBuO-Bnzl Bnzl (tBOC)Gun- 3.82 675 F Pr IIB-273 4-tBuO-Bnzl s-Bu (tBOC)Gun- 3.38 641 F Pr IIB-274 4-tBuO-Bnzl 1-Npm (tBOC)Gun- 3.88 725 F Pr IIB-275 4-tBuO-Bnzl i-Pr (tBOC)Gun- 3.27 627 F Pr IIB-276 4-tBuO-Bnzl (tBOC)Gun-Pr 1-Npm 3.74 725 F IIB-277 (tBOC)Gun-Pr i-Bu i-Bu 4.52 591 F IIB-278 (tBOC)Gun-Pr Bnzl i-Bu 4.25 625 F IIB-279 (tBOC)Gun-Pr 4-tBuO-Bnzl i-Bu 3.79 641 F IIB-280 (tBOC)Gun-Pr s-Bu i-Bu 4.04 591 F IIB-281 (tBOC)Gun-Pr i-Bu Bnzl 4.39 625 F IIB-282 (tBOC)Gun-Pr Bnzl Bnzl 4.30 659 F IIB-283 (tBOC)Gun-Pr 4-tBuO-Bnzl Bnzl 3.82 675 F IIB-284 (tBOC)Gun-Pr s-Bu Bnzl 4.09 625 F IIB-285 (tBOC)Gun-Pr i-Bu 4-tBuO- 3.80 641 F Bnzl

TABLE 1-12 IIB-286 (tBOC)Gun-Pr Bnzl 1-Npm 4.57 709 F IIB-287 (tBOC)Gun-Pr s-Bu 1-Npm 4.49 675 F IIB-288 1-Npm i-Bu i-Bu 3.65 432 F IIB-289 1-Npm 4-tBuO-Bnzl i-Bu 4.09 538 F IIB-290 1-Npm tBOC-E i-Bu 3.77 504 F IIB-291 1-Npm s-Bu i-Bu 3.71 432 F IIB-292 1-Npm i-Pr i-Bu 3.54 418 F IIB-293 1-Npm tBOC-E Bnzl 3.99 538 F IIB-294 1-Npm i-Pr Bnzl 3.69 452 F IIB-295 1-Npm (tBOC)Gun-Pr 4-tBuO- 3.59 725 F Bnzl IIB-296 1-Npm i-Bu (tBOC)Gun- 4.00 675 F Pr IIB-297 1-Npm Bnzl (tBOC)Gun- 4.17 709 F Pr IIB-298 1-Npm 4-tBuO-Bnzl (tBOC)Gun- 3.65 725 F Pr IIB-299 Bnzl 1-Npm 3-Gun-Pr 2.70 509 F IIB-300 4-OH-Bnzl 3-Gun-Pr i-Bu 2.47 441 F IIB-301 4-OH-Bnzl 1-Npm 3-Gun-Pr 2.90 525 F IIB-302 1-Npm 3-Gun-Pr 4-OH-Bnzl 2.70 525 F IIB-303 1-Npm i-Bu 3-Gun-Pr 2.82 475 F IIB-304 1-Npm Bnzl 3-Gun-Pr 2.97 509 F IIB-305 1-Npm 4-OH-Bnzl 3-Gun-Pr 2.77 525 F IIB-306 1-Npm s-Bu 3-Gun-Pr 2.82 475 F IIB-307 Bnzl Ph-Et i-Bu 0.97 430 C IIB-308 Ph-Et i-Bu Bnzl 1.00 430 C IIB-309 Chm i-Bu Bnzl 1.05 422 C IIB-310 Bnzl 4-F-Bnzl i-Bu 0.98 434 C IIB-311 Chm Bnzl i-Bu 1.04 422 C IIB-312 Bnzl Hxy i-Bu 1.08 410 C IIB-313 Ph-Et i-Bu i-Bu 0.99 396 C IIB-314 Ph-Et i-Bu 1-Npm 1.04 480 C IIB-315 Bnzl i-Bu Ph-Et 1.00 430 C IIB-316 4-F-Bnzl i-Bu Bnzl 1.00 434 C IIB-317 i-Bu 4-F-Bnzl Bnzl 0.99 434 C IIB-318 Ph-Et Bnzl i-Bu 0.98 430 C IIB-319 Bnzl i-Pnt i-Bu 1.00 396 C

TABLE 1-13 IIB-320 i-Bu Hxy Bnzl 1.05 410 C IIB-321 4-F-Bnzl Bnzl Bnzl 0.99 468 C IIB-322 Ph-Et Bnzl Bnzl 1.00 464 C IIB-323 Bnzl i-Bu i-Pnt 1.03 396 C IIB-324 4-F-Bnzl Bnzl i-Bu 0.98 434 C

TABLE 1-14 Formula XXII3

Compound LCMS Mass Measurement number R₁ R_(2A) R_(2B) R₃ RT (min) (M + H)⁺ condition IIB-325 2-Npm H Bnzl i-Bu 2.89 466  B1 IIB-326 i-Pnt H 3-Cl-Bnzl Bnzl 2.85 464  B1 IIB-327 i-Pnt H 4-Me-Bnzl Bnzl 2.83 444  B1 IIB-328 i-Pnt H 4-MeO-Bnzl Bnzl 2.71 460  B1 IIB-329 Me H quinolin-8-ylethyl Bnzl 2.09 439  B1 IIB-330 Me H quinolin-5-ylethyl Bnzl 1.62 439  B1 IIB-331 i-Bu H 4-Cl-Bnzl Ph-Et 2.84 464  B1 IIB-332 i-Bu H 3-Cl-Bnzl Ph-Et 2.68 464  B1 IIB-333 i-Bu H 4-MeO-Bnzl Ph-Et 2.70 460  B1 IIB-334 i-Bu H 4-Me-Bnzl Ph-Et 2.83 445  B1 IIB-335 i-Bu H 2-Npm Ph-Et 2.92 480  B1 IIB-336 i-Bu H Bnzl Ph-Pr 2.82 444  B1 IIB-337 i-Bu H 3-Cl-Bnzl Ph-Pr 1.29 478 B IIB-338 i-Bu H 3-F-Bnzl Ph-Pr 1.33 462 B IIB-339 Cpm H 4-OH-Bnzl Cbx-E 1.10 440 B IIB-340 i-Bu H 3-Me-Bnzl Ph-Pr 1.33 458 B IIB-341 i-Bu H 3-MeO-Bnzl Ph-Pr 1.29 474 B IIB-342 i-Bu H 3-Cl-Bnzl Ph-Bu 1.33 492 B IIB-343 i-Bu H 3-F-Bnzl Ph-Bu 1.29 476 B IIB-344 i-Bu H 3-Me-Bnzl Ph-Bu 1.31 473 B IIB-345 i-Bu H 3-MeO-Bnzl Ph-Bu 1.36 488 B IIB-346 i-Bu H Bnzl Ph-Bu 1.29 458 B IIB-347 i-Pnt H 3-F-Bnzl Ph-Pr 1.25 476 B IIB-348 1-Npm H pentyl Ph-Et 1.08 494 C IIB-349 1-Npm pyrrolidine ^(†) Ph-Et 0.96 478 C

TABLE 1-15 IIB- 1-Npm H cyclo- Ph-Et 1.07 506 C 350 hexyl IIB- 1-Npm H cyclo- Ph-Et 1.05 492 C 351 pentyl IIB- 1-Npm piperidine ^(†) Ph-Et 1.01 492 C 352 IIB- 1-Npm H heptyl Ph-Et 1.14 522 C 353 IIB- Hdr-E H 4- 1-Npm 0.93 486 C 354 fluoro- phenethyl IIB- tBuO-E H 4- 1-Npm 1.07 542 C 355 fluoro- phenethyl IIB- Pr H Chm Bnzl 1.00 408 C 356 IIB- 1-Npm H Hxy 4-methyl- 1.13 522 C 357 phenethyl IIB- 1-Npm H Hxy 4- 1.18 550 C 358 Isopropyl phenethyl IIB- 1-Npm H Hxy 2- 1.15 558 C 359 (naphthalen- 2-yl)ethyl IIB- 1-Npm H Hxy cyclohexyl- 1.19 514 C 360 ethyl IIB- tBuO-E H 4- 1-Npm 1.07 545 C 361 Cl-Bnzl IIB- tBuO-E H 4- 1-Npm 1.07 524 C 362 Me-Bnzl IIB- Pr H Bnzl Chm 1.00 408 C 363 IIB- Pr H 2- Bnzl 0.95 416 C 364 methyl- benzyl IIB- Pr H (1,2,3,4- Bnzl 1.01 456 C 365 tetra- hydro- naphthalen- 1-yl)methyl IIB- Pr H Cpm Bnzl 0.96 394 C 366 IIB- Pr H Bnzl Cpm 0.95 394 C 367 IIB- 1-Npm H Hxy 3- 1.13 522 C 368 methyl- phenethyl IIB- 4-Nt-Bnzl H Bnzl Bnzl 0.96 495 C 369 IIB- 4-Nt-Bnzl H Hxy Ph-Et 1.04 503 C 370 IIB- i-Pnt H 4-F- Bnzl 2.73 448 B1 371 Bnzl IIB- i-Pnt H Ph- Bnzl 2.76 444 B1 372 Et IIB- i-Pnt H 1- Bnzl 2.93 480 B1 373 Npm IIB- i-Bu H 4-F- Ph-Et 2.73 448 B1 374 Bnzl IIB- i-Bu H Ph- Ph-Et 2.76 444 B1 375 Et IIB- i-Bu H 1- Ph-Et 2.93 480 B1 376 Npm IIB- 4-F-Bnzl H 1- Bnzl 2.98 518 B1 377 Npm IIB- 4-F-Bnzl H 1- i-Bu 1.30 484 B 378 Npm IIB- tBuO-E H 4-F- 1-Npm 1.06 528 C 379 Bnzl IIB- tBOC-E H Bnzl Ph-Et 1.02 502 C 380 IIB- 4-tBuO- H Bnzl Ph-Et 1.06 536 C 381 Bnzl IIB- tBuO-E H Bnzl 1-Npm 1.05 510 C 382 IIB- Chm H tBuO-E 1-Npm 1.07 516 C 383 IIB- 1-Npm H 4-F- TBSO-E 1.16 586 C 384 Bnzl IIB- i-Pnt H Bnzl Ph-Et 1.01 444 C 385 IIB- 1-Npm H 4-F- Hdr-E 0.91 472 C 386 Bnzl IIB- Hdr-E H 4-F- 1-Npm 0.91 472 C 387 Bnzl IIB- Cbx-E H Bnzl Ph-Et 0.88 446 C 388 IIB- TBSO-E H Ph- 1-Npm 1.07 524 C 389 Et IIB- Ph-Et H Hxy 1-Npm 1.08 508 C 390 IIB- Ph-Et H i-Bu 4-tBuO- 1.06 502 C 391 Bnzl IIB- Ph-Et H i-Bu 4-OH-Bnzl 0.89 446 C 392

TABLE 1-16 IIB-393 Ph-Et H i-Bu TBSO-E 1.13 498 C IIB-394 Ph-Et H i-Bu Hdr-E 0.82 384 C IIB-395 Ph-Et H i-Bu i-Pnt 1.02 410 C IIB-396 i-Bu H i-Bu 4-OH-Bnzl 0.85 398 C IIB-397 i-Bu H Bnzl 4-OH-Bnzl 0.87 432 C IIB-398 i-Bu H 2- 4-OH-Bnzl 0.69 414 C Cbx-Et IIB-399 i-Bu H s-Bu 4-OH-Bnzl 0.85 398 C IIB-400 i-Bu H 1-Npm 4-OH-Bnzl 0.95 482 C IIB-401 i-Bu H i-Pr 4-OH-Bnzl 0.80 384 C IIB-402 i-Bu H 1-Npm 2-Cbx-Et 0.89 448 C IIB-403 i-Bu H i-Pr 2-Cbx-Et 0.72 350 C IIB-404 Bnzl H 4- Bnzl 0.90 466 C OH-Bnzl IIB-405 Bnzl H i-Bu 4-OH-Bnzl 0.89 432 C IIB-406 Bnzl H 2-Cbx-Et 4-OH-Bnzl 0.74 448 C IIB-407 Bnzl H Bnzl 2-Cbx-Et 0.82 432 C IIB-408 Bnzl H 4- 2-Cbx-Et 0.73 448 C OH-Bnzl IIB-409 Bnzl H 1-Npm 2-Cbx-Et 0.90 482 C IIB-410 Bnzl H 4- 1-Npm 0.93, 516 C * OH-Bnzl 0.95 IIB-411 Bnzl H 2-Cbx-Et 1-Npm 0.88 482 C IIB-412 4-OH-Bnzl H i-Bu Bnzl 0.89 432 C IIB-413 4-OH-Bnzl H 1-Npm Bnzl 0.97 516 C IIB-414 4-OH-Bnzl H Bnzl 2-Cbx-Et 0.76 448 C IIB-415 4-OH-Bnzl H 1-Npm 2-Cbx-Et 0.84 498 C IIB-416 4-OH-Bnzl H i-Bu 1-Npm 0.93, 482 C 0.94 IIB-417 4-OH-Bnzl H Bnzl 1-Npm 0.95 516 C IIB-418 4-OH-Bnzl H 2-Cbx-Et 1-Npm 0.82 498 C IIB-419 4-OH-Bnzl H s-Bu 1-Npm 0.94 482 C IIB-420 4-OH-Bnzl H 1-Npm 1-Npm 0.98, 566 C 1.00 IIB-421 i-Bu H 4- Bnzl 0.88 432 C OH-Bnzl IIB-422 i-Bu H i-Bu 2-Cbx-Et 0.78 364 C IIB-423 i-Bu H Bnzl 2-Cbx-Et 0.81 398 C IIB-424 i-Bu H 4- 2-Cbx-Et 0.71 414 C OH-Bnzl IIB-425 i-Bu H s-Bu 2-Cbx-Et 0.77 364 C IIB-426 i-Bu H 4- 1-Npm 0.94 482 C OH-Bnzl IIB-427 i-Bu H 2-Cbx-Et 1-Npm 0.87 448 C IIB-428 Bnzl H 2- Bnzl 0.83 432 C Cbx-Et IIB-429 Bnzl H s-Bu 4-OH-Bnzl 0.88 432 C IIB-430 Bnzl H 1-Npm 4-OH-Bnzl 0.97 516 C IIB-431 Bnzl H i-Pr 4-OH-Bnzl 0.84 418 C IIB-432 Bnzl H s-Bu 2-Cbx-Et 0.79 398 C IIB-433 Bnzl H i-Pr 2-Cbx-Et 0.74 384 C IIB-434 4-OH-Bnzl H i-Pr Bnzl 0.85 418 C IIB-435 4-OH-Bnzl H i-Pr 2-Cbx-Et 0.68 400 C IIB-436 4-OH-Bnzl H i-Pr 1-Npm 0.90 468 C IIB-437 2-Cbx-Et H i-Bu Bnzl 0.82 398 C IIB-438 2-Cbx-Et H Bnzl Bnzl 0.84 432 C IIB-439 2-Cbx-Et H 4- Bnzl 0.76 448 C OH-Bnzl IIB-440 2-Cbx-Et H s-Bu Bnzl 0.81 398 C IIB-441 2-Cbx-Et H 1-Npm Bnzl 0.91 482 C IIB-442 2-Cbx-Et H i-Bu 4-OH-Bnzl 0.76 414 C

TABLE 1-17 IIB-443 2-Cbx-Et H Bnzl 4-OH-Bnzl 0.78 448 C IIB-444 2-Cbx-Et H s-Bu 4-OH-Bnzl 0.75 414 C IIB-445 2-Cbx-Et H 1-Npm 4-OH-Bnzl 0.86 498 C IIB-446 2-Cbx-Et H i-Pr 4-OH-Bnzl 0.71 400 C IIB-447 2-Cbx-Et H i-Bu 1-Npm 0.88 448 C IIB-448 2-Cbx-Et H 4-OH-Bnzl 1-Npm 0.83 498 C IIB-449 2-Cbx-Et H s-Bu 1-Npm 0.87 448 C IIB-450 2-Cbx-Et H 1-Npm 1-Npm 0.96 532 C IIB-451 1-Npm H 4-OH-Bnzl Bnzl 0.95 516 C IIB-452 1-Npm H Bnzl 4-OH-Bnzl 0.95 516 C IIB-453 1-Npm H 2-Cbx-Et 4-OH-Bnzl 0.80 498 C IIB-454 1-Npm H s-Bu 4-OH-Bnzl 0.94 482 C IIB-455 1-Npm H 1-Npm 4-OH-Bnzl 1.01 566 C IIB-456 1-Npm H i-Pr 4-OH-Bnzl 0.90 468 C IIB-457 1-Npm H i-Bu 2-Cbx-Et 0.88 448 C IIB-458 1-Npm H Bnzl 2-Cbx-Et 0.89 482 C IIB-459 1-Npm H 4-OH-Bnzl 2-Cbx-Et 0.81 498 C IIB-460 1-Npm H s-Bu 2-Cbx-Et 0.88 448 C IIB-461 1-Npm H 1-Npm 2-Cbx-Et 0.96 532 C IIB-462 1-Npm H 4-OH-Bnzl 1-Npm 0.97, 1.00 566 C * IIB-463 1-Npm H 2-Cbx-Et 1-Npm 0.93, 0.95 532 C * IIB-464 i-Bu H 4-OH-Bnzl i-Bu 0.86 398 C IIB-465 i-Bu H 2-Cbx-Et i-Bu 0.78 364 C IIB-466 i-Bu H 1-Npm 3-Gun-Pr 0.78 475 C IIB-467 Bnzl H i-Bu 3-Gun-Pr 0.69 425 C IIB-468 2-Cbx-Et H i-Bu i-Bu 0.81 364 C IIB-469 2-Cbx-Et H Bnzl i-Bu 0.83 398 C IIB-470 2-Cbx-Et H 4-OH-Bnzl i-Bu 0.75 414 C IIB-471 2-Cbx-Et H s-Bu i-Bu 0.81 364 C IIB-472 2-Cbx-Et H 1-Npm i-Bu 0.91 448 C IIB-473 2-Cbx-Et H i-Pr i-Bu 0.76 350 C IIB-474 2-Cbx-Et H Bnzl 1-Npm 0.89 482 C IIB-475 2-Cbx-Et H i-Pr 1-Npm 0.84 434 C IIB-476 1-Npm H 3-Gun-Pr Bnzl 0.78 509 C IIB-477 1-Npm H i-Bu 4-OH-Bnzl 0.94 482 C IIB-478 1-Npm H i-Pr 2-Cbx-Et 0.83 434 C IIB-479 1-Npm H 1-Npm 3-Gun-Pr 0.84 559 C IIB-480 1-Npm H i-Pr 3-Gun-Pr 0.72 461 C IIB-481 1-Npm H 3-Gun-Pr 1-Npm 0.83 559 C IIB-482 i-Bu H 3-Gun-Pr i-Bu 0.69 391 C IIB-483 i-Bu H 3-Gun-Pr Bnzl 0.70 425 C IIB-484 i-Bu H i-Bu 3-Gun-Pr 0.68 391 C IIB-485 i-Bu H Bnzl 3-Gun-Pr 0.71 425 C IIB-486 i-Bu H s-Bu 3-Gun-Pr 0.67 391 C IIB-487 i-Bu H i-Pr 3-Gun-Pr 0.63 377 C IIB-488 i-Bu H 3-Gun-Pr 1-Npm 0.76 475 C IIB-489 Bnzl H 3-Gun-Pr i-Bu 0.71 425 C IIB-490 Bnzl H 3-Gun-Pr Bnzl 0.73 459 C IIB-491 Bnzl H Bnzl 3-Gun-Pr 0.71 459 C IIB-492 Bnzl H s-Bu 3-Gun-Pr 0.68 425 C

TABLE 1-18 IIB-493 Bnzl H i-Pr 3-Gun-Pr 0.64 411 C IIB-494 Bnzl H 3-Gun-Pr 1-Npm 0.78 509 C IIB-495 2-Cbx-Et H i-Pr Bnzl 0.77 384 C IIB-496 3-Gun-Pr H 1-Npm i-Bu 0.79 475 C IIB-497 3-Gun-Pr H i-Pr i-Bu 0.66 377 C IIB-498 3-Gun-Pr H 1-Npm Bnzl 0.79 509 C IIB-499 3-Gun-Pr H i-Pr Bnzl 0.66, 0.67 411 C IIB-500 3-Gun-Pr H 1-Npm 1-Npm 0.82 559 C IIB-501 3-Gun-Pr H i-Pr 1-Npm 0.71, 0.74 461 C * IIB-502 1-Npm H 3-Gun-Pr i-Bu 0.77 475 C IIB-503 3- H 4-F- 1-Npm 1.05 542 C tertbutoxy- Bnzl propyl IIB-504 3- H 4-F- 1-Npm 0.9 486 C hydroxy- Bnzl propyl IIB-505 Hdr-E H 4-Cl- 1-Npm 0.93 488 C Bnzl IIB-506 3- H 3- 3- 1.06 751 C aminopropyl amino- amino- propy propyl IIB-507 1-Npm H β- Ph-Et 0.98 544 C hydroxy- phenethy IIB-508 1-Npm H α- Ph-Et 0.97 558 C (hydroxy- methyl)- phenethyl IIB-509 1-Npm H α- Ph-Et 1.00 558 C (hydroxy- methyl)- phenethyl IIB-510 4-Nt-Bnzl H Bnzl tBOC-E 0.96 533 C IIB-511 2-OH-Et H Ph-Et 1-Npm 0.89 468.3 C IIB-512 Chm H 2-OH- 1-Npm 0.86 460.3 C Et IIB-513 i-Bu H i-Pr 3-Gun-Pr 0.58 377.3 C IIB-514 Bnzl H 4-OH- i-Bu 0.81 432.2 C Bnzl IIB-515 Bnzl H i-Bu 4-OH-Bnzl 0.81 432.2 C IIB-516 i-Bu H Bnzl 4-OH-Bnzl 0.81 432.3 C IIB-517 i-Bu H 4-OH- Bnzl 0.81 432.3 C Bnzl IIB-518 2-OH-Et H Bnzl 1-Npm 0.87 454.3 C IIB-519 Ph-Et H 1-Npm Hxy 1.10 508.4 C IIB-520 1-Npm H Ph-Et Hxy 1.10 508.4 C IIB-521 Hxy H Ph-Et 1-Npm 1.08 508.4 C IIB-522 Hxy H 1-Npm Ph-Et 1.09 508.4 C IIB-523 i-Pnt H i-Pr i-Bu 3.52 348 F IIB-524 Chm H i-Pr i-Bu 3.94 374 F IIB-525 Chm H i-Pr i-Pnt 4.35 388 F IIB-526 i-Bu H s-Bu i-Pnt 3.95 362 F IIB-527 i-Pnt H s-Bu i-Bu 3.75 362 F IIB-528 i-Pnt H s-Bu Ph-Et 4.29 410 F IIB-529 Chm H s-Bu i-Bu 4.22 388 F IIB-530 Chm H s-Bu Ph-Et 4.32 436 F IIB-531 Chm H s-Bu i-Pnt 4.52 402 F IIB-532 Chm H i-Pnt i-Bu 4.7 402 F IIB-533 i-Pnt H Hxy i-Bu 4.55 390 F IIB-534 2-Cbx-Et H Bnzl 2-OH-Et 2.27 386 F IIB-535 2-Cbx-Et H Bnzl i-Pnt 3.49 412 F IIB-536 Ph-Et H Bnzl 2-Cbx-Et 3.02 446 F IIB-537 4-F-Bnzl H Bnzl 2-Cbx-Et 3.13 450 F

TABLE 1-19 IIB-538 2-OH-Et H Bnzl 2-Cbx-Et 2.52 386 F IIB-539 i-Pnt H Bnzl 2-Cbx-Et 3.15 412 F IIB-540 i-Pnt H Bnzl 2-OH-Et 3.07 384 F IIB-541 Chm H Bnzl 2-Cbx-Et 3.42 438 F IIB-542 2-Cbx-Et H i-Bu Ph-Et 3.3 412 F IIB-543 2-Cbx-Et H i-Bu i-Pnt 3.29 378 F IIB-544 Ph-Et H i-Bu 2-Cbx-Et 3.13 412 F IIB-545 4-F-Bnzl H i-Bu 2-Cbx-Et 2.98 416 F IIB-546 2-OH-Et H i-Bu 2-Cbx-Et 3.57 352 G IIB-547 i-Pnt H i-Bu 4-OH-Bnzl 3.38 412 F IIB-548 i-Pnt H i-Bu 2-Cbx-Et 2.99 378 F IIB-549 Chm H i-Bu 4-OH-Bnzl 3.63 438 F IIB-550 Chm H i-Bu 2-Cbx-Et 3.29 404 F IIB-551 2-Cbx-Et H 1-Npm Ph-Et 3.84 496 F IIB-552 2-Cbx-Et H 1-Npm 2-OH-Et 2.82 436 F IIB-553 2-Cbx-Et H 1-Npm i-Pnt 3.92 462 F IIB-554 Ph-Et H 1-Npm 2-Cbx-Et 3.72 496 F IIB-555 4-F-Bnzl H 1-Npm 2-Cbx-Et 3.62 500 F IIB-556 2-OH-Et H 1-Npm 2-Cbx-Et 2.95 436 F IIB-557 i-Pnt H 1-Npm 2-Cbx-Et 3.65 462 F IIB-558 Chm H 1-Npm 2-Cbx-Et 3.94 488 F IIB-559 4-OH-Bnzl H i-Pr Ph-Et 3.3 432 F IIB-560 4-OH-Bnzl H i-Pr i-Pnt 3.1 398 F IIB-561 2-Cbx-Et H i-Pr Ph-Et 3.04 398 F IIB-562 2-Cbx-Et H i-Pr 2-OH-Et 2.82 338 G IIB-563 2-Cbx-Et H i-Pr i-Pnt 3 364 F IIB-564 Ph-Et H i-Pr 2-Cbx-Et 2.87 398 F IIB-565 Ph-Et H i-Pr 2-OH-Et 2.82 370 F IIB-566 4-F-Bnzl H i-Pr 2-OH-Et 2.77 374 F IIB-567 2-OH-Et H i-Pr Bnzl 2.77 356 F IIB-568 2-OH-Et H i-Pr 1-Npm 3.24 406 F IIB-569 2-OH-Et H i-Pr 4-OH-Bnzl 2.52 372 F IIB-570 2-OH-Et H i-Pr 2-Cbx-Et 3.09 338 G IIB-571 2-OH-Et H i-Pr Ph-Et 3.02 370 F IIB-572 i-Pnt H i-Pr 4-OH-Bnzl 3.04 398 F IIB-573 i-Pnt H i-Pr 2-Cbx-Et 2.69 364 F IIB-574 i-Pnt H i-Pr 2-OH-Et 2.65 336 F IIB-575 Chm H i-Pr 4-OH-Bnzl 3.34 424 F IIB-576 Chm H i-Pr 2-Cbx-Et 2.94 390 F IIB-577 i-Bu H s-Bu 2-OH-Et 2.62 336 F IIB-578 4-OH-Bnzl H s-Bu Ph-Et 3.50 446 F IIB-579 4-OH-Bnzl H s-Bu i-Pnt 3.38 412 F IIB-580 2-Cbx-Et H s-Bu Ph-Et 3.22 412 F IIB-581 2-Cbx-Et H s-Bu i-Pnt 3.27 378 F IIB-582 Ph-Et H s-Bu 2-Cbx-Et 3.10 412 F IIB-583 4-F-Bnzl H s-Bu 2-Cbx-Et 2.88 416 F IIB-584 2-OH-Et H s-Bu 4-OH-Bnzl 2.69 386 F IIB-585 2-OH-Et H s-Bu 2-Cbx-Et 3.47 352 G IIB-586 2-OH-Et H s-Bu i-Pnt 3.24 350 F IIB-587 i-Pnt H s-Bu 4-OH-Bnzl 3.34 412 F

TABLE 1-20 IIB-588 i-Pnt H s-Bu 2-Cbx-Et 2.90 378 F IIB-589 i-Pnt H s-Bu 2-OH-Et 2.90 350 F IIB-590 Chm H s-Bu 4-OH-Bnzl 3.62 438 F IIB-591 Chm H s-Bu 2-Cbx-Et 3.24 404 F IIB-592 i-Bu H 4-OH- i-Pnt 3.52 412 F Bnzl IIB-593 2-Cbx-Et H 4-OH- Ph-Et 3.04 462 F Bnzl IIB-594 2-Cbx-Et H 4-OH- i-Pnt 2.92 428 F Bnzl IIB-595 Ph-Et H 4-OH- 2-Cbx-Et 2.85 462 F Bnzl IIB-596 4-F-Bnzl H 4-OH- 2-Cbx-Et 2.77 466 F Bnzl IIB-597 2-OH-Et H 4-OH- 2-Cbx-Et 3.24 402 G Bnzl IIB-598 i-Pnt H 4-OH- 2-Cbx-Et 2.72 428 F Bnzl IIB-599 Chm H 4-OH- 2-Cbx-Et 2.97 454 F Bnzl IIB-600 i-Bu H 2- Ph-Et 3.12 412 F Cbx-Et IIB-601 i-Bu H 2- i-Pnt 3.12 378 F Cbx-Et IIB-602 2-OH-Et H 2- i-Bu 3.5 352 G Cbx-Et IIB-603 i-Pnt H 2- i-Bu 3.04 378 F Cbx-Et IIB-604 i-Pnt H 2- 4-OH-Bnzl 2.63 428 F Cbx-Et IIB-605 Chm H 2- i-Bu 3.34 404 F Cbx-Et IIB-606 Chm H 2- 4-OH-Bnzl 2.85 454 F Cbx-Et IIB-607 Chm H 2- i-Pnt 3.59 418 F Cbx-Et IIB-608 Bnzl H 4-F- 4-OH-Bnzl 3.63 484 F Bnzl IIB-609 Bnzl H 4-F- 2-Cbx-Et 3.12 450 F Bnzl IIB-610 i-Bu H 4-F- 4-OH-Bnzl 3.44 450 F Bnzl IIB-611 i-Bu H 4-F- 2-Cbx-Et 3.02 416 F Bnzl IIB-612 1-Npm H 4-F- 4-OH-Bnzl 3.99 534 F Bnzl IIB-613 1-Npm H 4-F- 2-Cbx-Et 3.57 500 F Bnzl IIB-614 4-OH-Bnzl H 4-F- 2-Cbx-Et 2.85 466 F Bnzl IIB-615 4-OH-Bnzl H 4-F- Ph-Et 3.63 498 F Bnzl IIB-616 4-OH-Bnzl H 4-F- i-Pnt 3.57 464 F Bnzl IIB-617 2-Cbx-Et H 4-F- 4-OH-Bnzl 2.95 466 F Bnzl IIB-618 2-Cbx-Et H 4-F- Ph-Et 3.48 464 F Bnzl IIB-619 2-Cbx-Et H 4-F- i-Pnt 3.42 430 F Bnzl IIB-620 Ph-Et H 4-F- 4-OH-Bnzl 3.67 498 F Bnzl IIB-621 Ph-Et H 4-F- 2-Cbx-Et 3.32 464 F Bnzl IIB-622 2-OH-Et H 4-F- 4-OH-Bnzl 2.95 438 F Bnzl IIB-623 2-OH-Et H 4-F- 2-Cbx-Et 2.57 404 F Bnzl IIB-624 i-Pnt H 4-F- 4-OH-Bnzl 3.54 464 F Bnzl IIB-625 i-Pnt H 4-F- 2-Cbx-Et 3.19 430 F Bnzl IIB-626 Chm H 4-F- 4-OH-Bnzl 3.80 490 F Bnzl IIB-627 Chm H 4-F- 2-Cbx-Et 3.45 456 F Bnzl IIB-628 i-Bu H i-Pnt 2-Cbx-Et 3.05 378 F IIB-629 4-OH-Bnzl H i-Pnt 2-Cbx-Et 2.80 428 F IIB-630 2-Cbx-Et H i-Pnt i-Bu 3.25 378 F IIB-631 2-Cbx-Et H i-Pnt 4-OH-Bnzl 2.90 428 F IIB-632 2-OH-Et H i-Pnt i-Bu 3.20 350 F IIB-633 2-OH-Et H i-Pnt 2-Cbx-Et 2.59 366 F IIB-634 Chm H i-Pnt 2-Cbx-Et 3.54 418 F IIB-635 i-Bu H 2-OH- i-Bu 2.69 336 F Et IIB-636 i-Bu H 2-OH- 4-OH-Bnzl 2.35 386 F Et IIB-637 1-Npm H 2-OH- 4-OH-Bnzl 2.94 470 F Et

TABLE 1-21 IIB-638 1-Npm H 2-OH—Et 2-Cbx-Et 2.63 436 F IIB-639 4-OH-Bnzl H 2-OH—Et Bnzl 2.67 420 F IIB-640 4-OH-Bnzl H 2-OH—Et 1-Npm 3.04 470 F IIB-641 4-OH-Bnzl H 2-OH—Et Ph—Et 2.75 434 F IIB-642 4-OH-Bnzl H 2-OH—Et i-Pnt 2.60 400 F IIB-643 2-Cbx-Et H 2-OH—Et Bnzl 3.60 386 F IIB-644 2-Cbx-Et H 2-OH—Et i-Bu 3.40 352 F IIB-645 2-Cbx-Et H 2-OH—Et 1-Npm 2.84 436 F IIB-646 2-Cbx-Et H 2-OH—Et Ph—Et 2.57 400 F IIB-647 2-Cbx-Et H 2-OH—Et i-Pnt 2.52 366 F IIB-648 Ph—Et H 2-OH—Et 2-Cbx-Et 2.37 400 F IIB-649 4-F-Bnzl H 2-OH—Et 2-Cbx-Et 2.12 404 F IIB-650 i-Pnt H 2-OH—Et i-Bu 2.94 350 F IIB-651 i-Pnt H 2-OH—Et 2-Cbx-Et 3.34 366 F IIB-652 Chm H 2-OH—Et 1-Bu 3.17 376 F IIB-653 Chm H 2-OH—Et 2-Cbx-Et 2.47 392 F IIB-654 Bnzl H Ph—Et 4-OH-Bnzl 3.69 480 F IIB-655 Bnzl H Ph—Et 2-Cbx-Et 3.15 446 F IIB-656 i-Bu H Ph—Et 4-OH-Bnzl 3.47 446 F IIB-657 i-Bu H Ph—Et 2-Cbx-Et 3.05 412 F IIB-658 1-Npm H Ph—Et 4-OH-Bnzl 4.02 530 F IIB-659 1-Npm H Ph—Et 2-Cbx-Et 3.62 496 F IIB-660 4-OH-Bnzl H Ph—Et 2-Cbx-Et 2.85 462 F IIB-661 4-OH-Bnzl H Ph—Et i-Pnt 3.74 460 F IIB-662 2-Cbx-Et H Ph—Et 4-OH-Bnzl 3.02 462 F IIB-663 2-Cbx-Et H Ph—Et i-Pnt 3.55 426 F IIB-664 4-F-Bnzl H Ph—Et 4-OH-Bnzl 3.69 498 F IIB-665 4-F-Bnzl H Ph—Et 2-Cbx-Et 3.22 464 F IIB-666 2-OH—Et H Ph—Et 4-OH-Bnzl 2.99 434 F IIB-667 2-OH—Et H Ph—Et 2-Cbx-Et 2.62 400 F IIB-668 i-Pnt H Ph—Et 4-OH-Bnzl 3.63 460 F IIB-669 i-Pnt H Ph—Et 2-Cbx-Et 3.27 426 F IIB-670 Chm H Ph—Et 4-OH-Bnzl 3.92 486 F IIB-671 Chm H Ph—Et 2-Cbx-Et 3.55 452 F IIB-672 Bnzl H Hxy 2-Cbx-Et 3.54 426 F IIB-673 i-Bu H Hxy 2-Cbx-Et 3.42 392 F IIB-674 1-Npm H Hxy 2-Cbx-Et 4 476 F IIB-675 4-OH-Bnzl H Hxy 2-Cbx-Et 3.17 442 F IIB-676 2-Cbx-Et H Hxy i-Bu 3.54 392 F IIB-677 2-Cbx-Et H Hxy 4-OH-Bnzl 3.25 442 F IIB-678 2-Cbx-Et H Hxy i-Pnt 3.84 406 F IIB-679 Ph—Et H Hxy 2-Cbx-Et 3.75 440 F IIB-680 4-F-Bnzl H Hxy 2-Cbx-Et 3.6 444 F IIB-681 2-OH—Et H Hxy i-Bu 3.6 364 F IIB-682 2-OH—Et H Hxy 4-OH-Bnzl 3.29 414 F IIB-683 2-OH—Et H Hxy 2-Cbx-Et 2.88 380 F IIB-684 2-OH—Et H Hxy i-Pnt 3.87 378 F IIB-685 i-Pnt H Hxy 4-OH-Bnzl 3.98 440 F IIB-686 i-Pnt H Hxy 2-Cbx-Et 3.59 406 F IIB-687 i-Pnt H Hxy 2-OH—Et 3.52 378 F

TABLE 1-22 IIB-688 Chm H Hxy 4-OH-Bnzl 4.24 466 F IIB-689 Chm H Hxy 2-Cbx-Et 3.88 432 F IIB-690 tBOC-E H Bnzl i-Pnt 4.47 468 F IIB-691 Ph—Et H Bnzl tBOC-E 4.34 502 F IIB-692 4-F-Bnzl H Bnzl tBOC-E 4.09 506 F IIB-693 2-OtBu—Et H Bnzl tBOC-E 4.27 498 F IIB-694 i-Pnt H Bnzl tBOC-E 4.25 468 F IIB-695 Chm H Bnzl tBOC-E 4.5 494 F IIB-696 tBOC-E H i-Bu Ph—Et 4.25 468 F IIB-697 tBOC-E H i-Bu i-Pnt 4.3 434 F IIB-698 Ph—Et H i-Bu tBOC-E 4.18 468 F IIB-699 2-OtBu—Et H i-Bu tBOC-E 4.09 464 F IIB-700 i-Pnt H i-Bu 4-tBuO- 4.43 468 F Bnzl IIB-701 i-Pnt H i-Bu tBOC-E 3.97 434 F IIB-702 Chm H i-Bu 4-tBuO- 4.67 494 F Bnzl IIB-703 Chm H i-Bu tBOC-E 4.43 460 F IIB-704 tBOC-E H 1-Npm Ph—Et 4.78 552 F IIB-705 tBOC-E H 1-Npm i-Pnt 4.89 518 F IIB-706 Ph—Et H 1-Npm tBOC-E 4.72 552 F IIB-707 4-F-Bnzl H 1-Npm tBOC-E 4.52 556 F IIB-708 2-OtBu—Et H 1-Npm tBOC-E 5.37 548 F IIB-709 i-Pnt H 1-Npm tBOC-E 4.68 518 F IIB-710 Chm H 1-Npm tBOC-E 4.9 544 F IIB-711 4-tBuO-Bnzl H i-Pr Ph—Et 4.29 488 F IIB-712 tBOC-E H i-Pr Ph—Et 3.92 454 F IIB-713 tBOC-E H i-Pr i-Pnt 4 420 F IIB-714 Ph—Et H i-Pr tBOC-E 3.92 454 F IIB-715 2-OtBu—Et H i-Pr Bnzl 3.77 412 F IIB-716 2-OtBu—Et H i-Pr 1-Npm 4.24 462 F IIB-717 2-OtBu—Et H i-Pr 4-tBuO- 4.37 484 F Bnzl IIB-718 2-OtBu—Et H i-Pr tBOC-E 3.94 450 F IIB-719 2-OtBu—Et H i-Pr i-Pnt 4.04 392 F IIB-720 i-Pnt H i-Pr 4-tBuO- 4.22 454 F Bnzl IIB-721 i-Pnt H i-Pr tBOC-E 4.82 420 F IIB-722 Chm H i-Pr 4-tBuO- 4.57 480 F Bnzl IIB-723 4-tBuO-Bnzl H s-Bu Ph—Et 4.5 502 F IIB-724 4-tBuO-Bnzl H s-Bu i-Pnt 4.62 468 F IIB-725 tBOC-E H s-Bu Ph—Et 4.29 468 F IIB-726 tBOC-E H s-Bu i-Pnt 4.3 434 F IIB-727 Ph—Et H s-Bu tBOC-E 4.14 468 F IIB-728 4-F-Bnzl H s-Bu tBOC-E 4.52 472 F IIB-729 2-OtBu—Et H s-Bu 4-tBuO- 4.68 498 F Bnzl IIB-730 2-OtBu—Et H s-Bu tBOC-E 4.17 464 F IIB-731 i-Pnt H s-Bu 4-tBuO- 4.74 468 F Bnzl IIB-732 i-Pnt H s-Bu tBOC-E 4.27 434 F IIB-733 Chm H s-Bu 4-tBuO- 4.74 494 F Bnzl IIB-734 i-Bu H 4-tBuO- i-Pnt 4.57 468 F Bnzl IIB-735 tBOC-E H 4-tBuO- Ph—Et 5.2 574 F Bnzl IIB-736 tBOC-E H 4-tBuO- i-Pnt 4.6 540 F Bnzl IIB-737 Ph—Et H 4-tBuO- tBOC-E 4.59 574 F Bnzl

TABLE 1-23 IIB-738 4-F-Bnzl H 4-tBuO- tBOC-E 4.5 578 F Bnzl IIB-739 2-OtBu—Et H 4-tBuO- tBOC-E 4.79 570 F Bnzl IIB-740 i-Pnt H 4-tBuO- tBOC-E 4.8 540 F Bnzl IIB-741 Chm H 4-tBuO- tBOC-E 4.99 566 F Bnzl IIB-742 i-Bu H tBOC- Ph—Et 4.12 468 F E IIB-743 i-Bu H tBOC- i-Pnt 4.18 434 F E IIB-744 2-OtBu—Et H tBOC- i-Bu 4.1 464 F E IIB-745 i-Pnt H tBOC- i-Bu 4.17 434 F E IIB-746 Chm H tBOC- 4-tBuO- 4.95 566 F E Bnzl IIB-747 Chm H tBOC- i-Pnt 4.55 474 F E IIB-748 Bnzl H 4-F- 4-tBuO- 4.54 540 F Bnzl Bnzl IIB-749 Bnzl H 4-F- tBOC-E 4.05 506 F Bnzl IIB-750 i-Bu H 4-F- 4-tBuO- 4.39 506 F Bnzl Bnzl IIB-751 i-Bu H 4-F- tBOC-E 3.97 472 F Bnzl IIB-752 1-Npm H 4-F- 4-tBuO- 4.92 590 F Bnzl Bnzl IIB-753 1-Npm H 4-F- tBOC-E 4.57 556 F Bnzl IIB-754 4-tBuO-Bnzl H 4-F- tBOC-E 4.62 578 F Bnzl IIB-755 4-tBuO-Bnzl H 4-F- Ph—Et 4.6 554 F Bnzl IIB-756 4-tBuO-Bnzl H 4-F- i-Pnt 4.47 520 F Bnzl IIB-757 tBOC-E H 4-F- 4-tBuO- 4.74 578 F Bnzl Bnzl IIB-758 tBOC-E H 4-F- Ph—Et 4.24 520 F Bnzl IIB-759 tBOC-E H 4-F- i-Pnt 4.4 486 F Bnzl IIB-760 Ph—Et H 4-F- 4-tBuO- 4.59 554 F Bnzl Bnzl IIB-761 Ph—Et H 4-F- tBOC-E 4.4 520 F Bnzl IIB-762 2-OtBu—Et H 4-F- 4-tBuO- 4.72 550 F Bnzl Bnzl IIB-763 2-OtBu—Et H 4-F- tBOC-E 4.3 516 F Bnzl IIB-764 i-Pnt H 4-F- 4-tBuO- 4.57 520 F Bnzl Bnzl IIB-765 i-Pnt H 4-F- tBOC-E 4.22 486 F Bnzl IIB-766 Chm H 4-F- 4-tBuO- 4.89 546 F Bnzl Bnzl IIB-767 Chm H 4-F- tBOC-E 4.39 512 F Bnzl IIB-768 i-Bu H i-Pnt tBOC-E 4 434 F IIB-769 4-tBuO-Bnzl H i-Pnt tBOC-E 4.77 540 F IIB-770 tBOC-E H i-Pnt i-Bu 4.37 434 F IIB-771 tBOC-E H i-Pnt 4-tBuO- 4.79 540 F Bnzl IIB-772 2-OtBu—Et H i-Pnt i-Bu 4.5 406 F IIB-773 2-OtBu—Et H i-Pnt tBOC-E 4.67 478 F IIB-774 i-Bu H 2- i-Bu 3.49 392 F OtBu—Et IIB-775 i-Bu H 2- 4-tBuO- 4.34 498 F OtBu—Et Bnzl IIB-776 i-Bu H 2- tBOC-E 3.74 464 F OtBu—Et IIB-777 1-Npm H 2- 4-tBuO- 4.75 582 F OtBu—Et Bnzl IIB-778 1-Npm H 2- tBOC-E 4.42 548 F OtBu—Et IIB-779 4-tBuO-Bnzl H 2- Bnzl 4.42 532 F OtBu—Et IIB-780 4-tBuO-Bnzl H 2- 1-Npm 4.82 582 F OtBu—Et IIB-781 4-tBuO-Bnzl H 2- tBOC-E 4.4 570 F OtBu—Et IIB-782 4-tBuO-Bnzl H 2- i-Pnt 4.64 512 F OtBu—Et IIB-783 tBOC-E H 2- Bnzl 3.99 498 F OtBu—Et IIB-784 tBOC-E H 2- i-Bu 4.15 464 F OtBu—Et IIB-785 tBOC-E H 2- 4-tBuO- 4.54 570 F OtBu—Et Bnzl IIB-786 tBOC-E H 2- i-Pnt 4.22 478 F OtBu—Et IIB-787 Ph—Et H 2- tBOC-E 4.04 512 F OtBu—Et

TABLE 1-24 IIB-788 Chm H 2- i-Bu 4.12 432 F OtBu—Et IIB-789 Chm H 2- tBOC-E 4.32 504 F OtBu—Et IIB-790 Bnzl H Ph—Et 4-tBuO- 4.62 536 F Bnzl IIB-791 Bnzl H Ph—Et tBOC-E 4.15 502 F IIB-792 i-Bu H Ph—Et 4-tBuO- 4.47 502 F Bnzl IIB-793 i-Bu H Ph—Et tBOC-E 4.09 468 F IIB-794 1-Npm H Ph—Et 4-tBuO- 4.95 586 F Bnzl IIB-795 1-Npm H Ph—Et tBOC-E 4.62 552 F IIB-796 4-tBuO-Bnzl H Ph—Et tBOC-E 4.72 574 F IIB-797 4-tBuO-Bnzl H Ph—Et i-Pnt 4.74 516 F IIB-798 tBOC-E H Ph—Et i-Pnt 4.65 482 F IIB-799 4-F-Bnzl H Ph—Et 4-tBuO- 4.67 554 F Bnzl IIB-800 4-F-Bnzl H Ph—Et tBOC-E 4.24 520 F IIB-801 2-OtBu—Et H Ph—Et 4-tBuO- 4.8 546 F Bnzl IIB-802 2-OtBu—Et H Ph—Et tBOC-E 4.3 512 F IIB-803 i-Pnt H Ph—Et 4-tBuO- 4.67 516 F Bnzl IIB-804 i-Pnt H Ph—Et tBOC-E 4.34 482 F IIB-805 Chm H Ph—Et 4-tBuO- 4.93 542 F Bnzl IIB-806 Chm H Ph—Et tBOC-E 4.6 508 F IIB-807 Bnzl H Hxy tBOC-E 4.49 482 F IIB-808 1-Npm H Hxy tBOC-E 5 532 F IIB-809 4-tBuO-Bnzl H Hxy 1-Npm 5.37 566 F IIB-810 4-tBuO-Bnzl H Hxy tBOC-E 5.05 554 F IIB-811 tBOC-E H Hxy i-Bu 4.75 448 F IIB-812 tBOC-E H Hxy 1-Npm 4.92 532 F IIB-813 tBOC-E H Hxy 4-tBuO- 5.04 554 F Bnzl IIB-814 tBOC-E H Hxy i-Pnt 5 462 F IIB-815 Ph—Et H Hxy tBOC-E 4.72 496 F IIB-816 4-F-Bnzl H Hxy tBOC-E 4.6 500 F IIB-817 2- H Hxy 4-tBuO- 5.17 526 F OtBu—Et Bnzl IIB-818 2- H Hxy tBOC-E 4.87 492 F OtBu—Et IIB-819 2- H Hxy i-Pnt 4.95 434 F OtBu—Et IIB-820 i-Pnt H Hxy 4-tBuO- 5.05 496 F Bnzl IIB-821 i-Pnt H Hxy tBOC-E 4.7 462 F IIB-822 Chm H Hxy 4-tBuO- 5.29 522 F Bnzl IIB-823 i-Bu H i-Bu Ph—Et 3.33 396 H IIB-824 i-Bu H i-Bu i-Pnt 3.17 362 H IIB-825 1-Npm H i-Bu i-Pnt 3.45 446 H IIB-826 4-F-Bnzl H i-Bu i-Bu 3.03 400 H IIB-827 4-F-Bnzl H i-Bu 1-Npm 3.26 484 H IIB-828 4-F-Bnzl H i-Bu Ph—Et 3.15 448 H IIB-829 4-F-Bnzl H i-Bu i-Pnt 3.15 414 H IIB-830 i-Pnt H i-Bu i-Bu 3.13 362 H IIB-831 i-Pnt H i-Bu 1-Npm 3.3 446 H IIB-832 i-Pnt H i-Bu Ph—Et 3.17 410 H IIB-833 Chm H i-Bu i-Bu 3.26 388 H IIB-834 Chm H i-Bu 1-Npm 3.48 472 H IIB-835 Chm H i-Bu Ph—Et 3.32 436 H IIB-836 Bnzl H Bnzl Ph—Et 3.39 464 H IIB-837 1-Npm H Bnzl i-Pnt 3.37 480 H

TABLE 1-25 IIB- Ph—Et H Bnzl 1-Npm 3.4 514 H 838 IIB- Ph—Et H Bnzl i-Pnt 3.26 444 H 839 IIB- 4-F-Bnzl H Bnzl 1-Npm 3.34 518 H 840 IIB- 4-F-Bnzl H Bnzl Ph—Et 3.17 482 H 841 IIB- 4-F-Bnzl H Bnzl i-Pnt 3.21 448 H 842 IIB- i-Pnt H Bnzl 1-Npm 3.36 480 H 843 IIB- Chm H Bnzl 1-Npm 3.47 506 H 844 IIB- Chm H Bnzl Ph—Et 3.33 470 H 845 IIB- Chm H Bnzl i-Pnt 3.37 436 H 846 IIB- Bnzl H 1-Npm Ph—Et 3.39 514 H 847 IIB- Bnzl H 1-Npm i-Pnt 3.44 480 H 848 IIB- i-Bu H 1-Npm i-Pnt 3.3 446 H 849 IIB- 1-Npm H 1-Npm Ph—Et 3.56 564 H 850 IIB- 1-Npm H 1-Npm i-Pnt 3.59 530 H 851 IIB- Ph—Et H 1-Npm Bnzl 3.41 514 H 852 IIB- Ph—Et H 1-Npm i-Bu 3.38 480 H 853 IIB- Ph—Et H 1-Npm 1-Npm 3.53 564 H 854 IIB- Ph—Et H 1-Npm i-Pnt 3.46 494 H 855 IIB- 4-F-Bnzl H 1-Npm 1-Npm 3.48 568 H 856 IIB- 4-F-Bnzl H 1-Npm Ph—Et 3.39 532 H 857 IIB- 4-F-Bnzl H 1-Npm i-Pnt 3.4 498 H 858 IIB- i-Pnt H 1-Npm i-Bu 3.42 446 H 859 IIB- i-Pnt H 1-Npm 1-Npm 3.51 530 H 860 IIB- i-Pnt H 1-Npm Ph—Et 3.42 494 H 861 IIB- Chm H 1-Npm Bnzl 3.58 506 H 862 IIB- Chm H 1-Npm i-Bu 3.54 472 H 863 IIB- Chm H 1-Npm 1-Npm 3.67 556 H 864 IIB- Chm H 1-Npm Ph—Et 3.57 520 H 865 IIB- Chm H 1-Npm i-Pnt 3.59 486 H 866 IIB- Bnzl H i-Pr Ph—Et 3.16 416 H 867 IIB- Bnzl H i-Pr i-Pnt 3.17 382 H 868 IIB- i-Bu H i-Pr Ph—Et 3.12 382 H 869 IIB- 1-Npm H i-Pr Ph—Et 3.34 466 H 870 IIB- 1-Npm H i-Pr i-Pnt 3.38 432 H 871 IIB- Ph—Et H i-Pr Bnzl 3.15 416 H 872 IIB- Ph—Et H i-Pr i-Bu 3.12 382 H 873 IIB- Ph—Et H i-Pr 1-Npm 3.34 466 H 874 IIB- Ph—Et H i-Pr i-Pnt 3.22 396 H 875 IIB- 4-F-Bnzl H i-Pr Bnzl 3.11 420 H 876 IIB- 4-F-Bnzl H i-Pr i-Bu 3.04 386 H 877 IIB- 4-F-Bnzl H i-Pr 1-Npm 3.28 470 H 878 IIB- 4-F-Bnzl H i-Pr Ph—Et 3.13 434 H 879 IIB- 4-F-Bnzl H i-Pr i-Pnt 3.11 400 H 880 IIB- i-Pnt H i-Pr Bnzl 3.08 382 H 881 IIB- i-Pnt H i-Pr 1-Npm 3.31 432 H 882 IIB- i-Pnt H i-Pr Ph—Et 3.19 396 H 883 IIB- Chm H i-Pr Bnzl 3.27 408 H 884 IIB- Chm H i-Pr 1-Npm 3.45 458 H 885 IIB- Chm H i-Pr Ph—Et 3.32 422 H 886 IIB- Bnzl H s-Bu Ph—Et 3.22 430 H 887

TABLE 1-26 IIB- Bnzl H s-Bu i-Pnt 3.25 396 H 888 IIB- i-Bu H s-Bu Ph—Et 3.19 396 H 889 IIB- 1-Npm H s-Bu Ph—Et 3.41 480 H 890 IIB- 1-Npm H s-Bu i-Pnt 3.42 446 H 891 IIB- Ph—Et H s-Bu Bnzl 3.24 430 H 892 IIB- Ph—Et H s-Bu i-Bu 3.22 396 H 893 IIB- Ph—Et H s-Bu 1-Npm 3.39 480 H 894 IIB- Ph—Et H s-Bu i-Pnt 3.32 410 H 895 IIB- 4-F-Bnzl H s-Bu Bnzl 3.25 434 H 896 IIB- 4-F-Bnzl H s-Bu i-Bu 3.13 400 H 897 IIB- 4-F-Bnzl H s-Bu 1-Npm 3.35 484 H 898 IIB- 4-F-Bnzl H s-Bu Ph—Et 3.23 448 H 899 IIB- 4-F-Bnzl H s-Bu i-Pnt 3.25 414 H 900 IIB- i-Pnt H s-Bu Bnzl 3.23 396 H 901 IIB- i-Pnt H s-Bu 1-Npm 3.39 446 H 902 IIB- Chm H s-Bu Bnzl 3.38 422 H 903 IIB- Chm H s-Bu 1-Npm 3.51 472 H 904 IIB- Bnzl H Ph—Et Bnzl 3.24 464 H 905 IIB- Bnzl H Ph—Et 1-Npm 3.43 514 H 906 IIB- Bnzl H Ph—Et i-Pnt 3.28 444 H 907 IIB- i-Bu H Ph—Et i-Bu 3.15 396 H 908 IIB- i-Bu H Ph—Et 1-Npm 3.38 480 H 909 IIB- i-Bu H Ph—Et i-Pnt 4.41 410 H 910 IIB- 1-Npm H Ph—Et Bnzl 3.47 514 H 911 IIB- 1-Npm H Ph—Et i-Bu 3.43 480 H 912 IIB- 1-Npm H Ph—Et 1-Npm 3.58 564 H 913 IIB- 4-F-Bnzl H Ph—Et Bnzl 3.23 482 H 914 IIB- 4-F-Bnzl H Ph—Et i-Bu 3.17 448 H 915 IIB- 4-F-Bnzl H Ph—Et 1-Npm 3.38 532 H 916 IIB- 4-F-Bnzl H Ph—Et i-Pnt 3.26 462 H 917 IIB- i-Pnt H Ph—Et i-Bu 3.24 410 H 918 IIB- i-Pnt H Ph—Et 1-Npm 3.42 494 H 919 IIB- Chm H Ph—Et Bnzl 3.38 470 H 920 IIB- Chm H Ph—Et i-Bu 3.33 436 H 921 IIB- Chm H Ph—Et 1-Npm 3.49 520 H 922 IIB- Chm H Ph—Et i-Pnt 3.45 450 H 923 IIB- Bnzl H 4-F- Bnzl 3.2 468 H 924 Bnzl IIB- Bnzl H 4-F- 1-Npm 3.34 518 H 925 Bnzl IIB- Bnzl H 4-F- Ph—Et 3.2 482 H 926 Bnzl IIB- Bnzl H 4-F- i-Pnt 3.23 448 H 927 Bnzl IIB- i-Bu H 4-F- i-Bu 3.13 400 H 928 Bnzl IIB- i-Bu H 4-F- 1-Npm 3.32 484 H 929 Bnzl IIB- i-Bu H 4-F- i-Pnt 3.21 414 H 930 Bnzl IIB- 1-Npm H 4-F- Bnzl 3.47 518 H 931 Bnzl IIB- 1-Npm H 4-F- i-Bu 3.43 484 H 932 Bnzl IIB- 1-Npm H 4-F- 1-Npm 3.63 568 H 933 Bnzl IIB- 1-Npm H 4-F- Ph—Et 3.48 532 H 934 Bnzl IIB- 1-Npm H 4-F- i-Pnt 3.5 498 H 935 Bnzl IIB- Ph—Et H 4-F- Bnzl 3.28 482 H 936 Bnzl IIB- Ph—Et H 4-F- i-Bu 3.27 448 H 937 Bnzl

TABLE 1-27 IIB- Ph—Et H 4-F- 1-Npm 3.42 532 H 938 Bnzl IIB- Ph—Et H 4-F- i-Pnt 3.33 462 H 939 Bnzl IIB- i-Pnt H 4-F- 1-Npm 3.33 498 H 940 Bnzl IIB- i-Pnt H 4-F- Ph—Et 3.28 462 H 941 Bnzl IIB- Chm H 4-F- Bnzl 3.31 474 H 942 Bnzl IIB- Chm H 4-F- i-Bu 3.29 440 H 943 Bnzl IIB- Chm H 4-F- 1-Npm 3.47 524 H 944 Bnzl IIB- Chm H 4-F- Ph—Et 3.42 488 H 945 Bnzl IIB- Chm H 4-F- i-Pnt 3.38 454 H 946 Bnzl IIB- Bnzl H i-Pnt Bnzl 3.27 430 H 947 IIB- Bnzl H i-Pnt 1-Npm 3.42 480 H 948 IIB- Bnzl H i-Pnt Ph—Et 3.29 444 H 949 IIB- i-Bu H i-Pnt 1-Npm 3.38 446 H 950 IIB- i-Bu H i-Pnt Ph—Et 3.3 410 H 951 IIB- 1-Npm H i-Pnt Bnzl 3.45 480 H 952 IIB- 1-Npm H i-Pnt i-Bu 3.42 446 H 953 IIB- 1-Npm H i-Pnt 1-Npm 3.56 530 H 954 IIB- Ph—Et H i-Pnt Bnzl 3.29 444 H 955 IIB- Ph—Et H i-Pnt i-Bu 3.28 410 H 956 IIB- Ph—Et H i-Pnt 1-Npm 3.43 494 H 957 IIB- 4-F-Bnzl H i-Pnt Bnzl 3.27 448 H 958 IIB- 4-F-Bnzl H i-Pnt i-Bu 3.2 414 H 959 IIB- 4-F-Bnzl H i-Pnt 1-Npm 3.42 498 H 960 IIB- 4-F-Bnzl H i-Pnt Ph—Et 3.28 462 H 961 IIB- Chm H i-Pnt Bnzl 3.44 436 H 962 IIB- Chm H i-Pnt 1-Npm 3.58 486 H 963 IIB- Chm H i-Pnt Ph—Et 3.45 450 H 964 IIB- Bnzl H Hxy Bnzl 3.42 444 H 965 IIB- Bnzl H Hxy 1-Npm 3.53 494 H 966 IIB- Bnzl H Hxy i-Pnt 3.43 424 H 967 IIB- i-Bu H Hxy 1-Npm 3.49 460 H 968 IIB- 1-Npm H Hxy 1-Npm 3.67 544 H 969 IIB- 1-Npm H Hxy i-Pnt 3.63 474 H 970 IIB- Ph—Et H Hxy Bnzl 3.43 458 H 971 IIB- Ph—Et H Hxy i-Bu 3.39 424 H 972 IIB- Ph—Et H Hxy i-Pnt 3.49 438 H 973 IIB- 4-F-Bnzl H Hxy Bnzl 3.41 462 H 974 IIB- 4-F-Bnzl H Hxy i-Bu 3.33 428 H 975 IIB- 4-F-Bnzl H Hxy 1-Npm 3.52 512 H 976 IIB- 4-F-Bnzl H Hxy Ph—Et 3.4 476 H 977 IIB- 4-F-Bnzl H Hxy i-Pnt 3.42 442 H 978 IIB- i-Pnt H Hxy Bnzl 3.41 424 H 979 IIB- i-Pnt H Hxy 1-Npm 3.58 474 H 980 IIB- Chm H Hxy Bnzl 3.54 450 H 981 IIB- Chm H Hxy 1-Npm 3.64 500 H 982 IIB- 2- H i-Bu Bnzl 4.35 426 H 983 OtBu—Et IIB- 2- H i-Bu 1-Npm 4.49 476 H 984 OtBu—Et IIB- 2- H Bnzl i-Pnt 4.48 440 H 985 OtBu—Et IIB- i-Pnt H Bnzl 4-tBuO- 3.42 502 H 986 Bnzl IIB- Chm H Bnzl 4-tBuO- 3.53 528 H 987 Bnzl

TABLE 1-28 IIB- 4-tBuO-Bnzl H 1-Npm Ph—Et 3.58 586 H 988 IIB- 4-tBuO-Bnzl H 1-Npm i-Pnt 3.58 552 H 989 IIB- Ph—Et H 1-Npm 4-tBuO- 3.53 586 H 990 Bnzl IIB- 4-F-Bnzl H 1-Npm 4-tBuO- 3.54 590 H 991 Bnzl IIB- 2-OtBu—Et H 1-Npm Bnzl 4.52 510 H 992 IIB- 2-OtBu—Et H 1-Npm i-Bu 4.52 476 H 993 IIB- 2-OtBu—Et H 1-Npm 1-Npm 4.6 560 H 994 IIB- i-Pnt H 1-Npm 4-tBuO- 3.58 552 H 995 Bnzl IIB- Chm H 1-Npm 4-tBuO- 3.69 578 H 996 Bnzl IIB- Bnzl H 4-tBuO- Ph—Et 3.46 536 H 997 Bnzl IIB- Bnzl H 4-tBuO- i-Pnt 3.46 502 H 998 Bnzl IIB- i-Bu H 4-tBuO- Ph—Et 3.42 502 H 999 Bnzl IIB- 1-Npm H 4-tBuO- Ph—Et 3.6 586 H 1000 Bnzl IIB- 1-Npm H 4-tBuO- i-Pnt 3.61 552 H 1001 Bnzl IIB- Ph—Et H 4-tBuO- Bnzl 3.47 536 H 1002 Bnzl IIB- Ph—Et H 4-tBuO- 1-Npm 3.53 586 H 1003 Bnzl IIB- Ph—Et H 4-tBuO- i-Pnt 3.53 516 H 1004 Bnzl IIB- 4-F-Bnzl H 4-tBuO- Bnzl 3.39 540 H 1005 Bnzl IIB- 4-F-Bnzl H 4-tBuO- 1-Npm 3.53 590 H 1006 Bnzl IIB- 4-F-Bnzl H 4-tBuO- Ph—Et 3.43 554 H 1007 Bnzl IIB- 4-F-Bnzl H 4-tBuO- i-Pnt 3.44 520 H 1008 Bnzl IIB- 2-OtBu—Et H 4-tBuO- 1-Npm 3.63 582 H 1009 Bnzl IIB- i-Pnt H 4-tBuO- i-Bu 3.38 468 H 1010 Bnzl IIB- i-Pnt H 4-tBuO- 1-Npm 3.58 552 H 1011 Bnzl IIB- i-Pnt H 4-tBuO- Ph—Et 3.48 516 H 1012 Bnzl IIB- Chm H 4-tBuO- Bnzl 3.54 528 H 1013 Bnzl IIB- Chm H 4-tBuO- i-Bu 3.43 494 H 1014 Bnzl IIB- Chm H 4-tBuO- 1-Npm 3.66 578 H 1015 Bnzl IIB- Chm H 4-tBuO- Ph—Et 3.63 542 H 1016 Bnzl IIB- Chm H 4-tBuO- i-Pnt 3.63 508 H 1017 Bnzl IIB- Bnzl H tBOC- Ph—Et 3.27 502 H 1018 E IIB- Bnzl H tBOC- i-Pnt 3.25 468 H 1019 E IIB- 1-Npm H tBOC- Ph—Et 3.45 552 H 1020 E IIB- 1-Npm H tBOC- i-Pnt 3.47 518 H 1021 E IIB- 4-tBuO-Bnzl H tBOC- Ph—Et 3.48 574 H 1022 E IIB- 4-tBuO-Bnzl H tBOC- i-Pnt 3.53 540 H 1023 E IIB- Ph—Et H tBOC- Bnzl 3.23 502 H 1024 E IIB- Ph—Et H tBOC- i-Bu 3.29 468 H 1025 E IIB- Ph—Et H tBOC- 1-Npm 3.41 552 H 1026 E IIB- Ph—Et H tBOC- 4-tBuO- 3.47 574 H 1027 E Bnzl IIB- Ph—Et H tBOC- i-Pnt 3.32 482 H 1028 E IIB- 4-F-Bnzl H tBOC- Bnzl 3.26 506 H 1029 E IIB- 4-F-Bnzl H tBOC- i-Bu 3.21 472 H 1030 E IIB- 4-F-Bnzl H tBOC- 1-Npm 3.42 556 H 1031 E IIB- 4-F-Bnzl H tBOC- 4-tBuO- 3.44 578 H 1032 E Bnzl IIB- 4-F-Bnzl H tBOC- Ph—Et 3.27 520 H 1033 E IIB- 4-F-Bnzl H tBOC- i-Pnt 3.29 486 H 1034 E IIB- 2-OtBu—Et H tBOC- Bnzl 3.34 498 H 1035 E IIB- 2-OtBu—Et H tBOC- 1-Npm 3.46 548 H 1036 E IIB- 2-OtBu—Et H tBOC- 4-tBuO- 3.52 570 H 1037 E Bnzl

TABLE 1-29 IIB- 2-OtBu—Et H tBOC- Ph—Et 3.36 512 H 1038 E IIB- 1-Pnt H tBOC- Bnzl 3.25 468 H 1039 E IIB- i-Pnt H tBOC- 1-Npm 3.38 518 H 1040 E IIB- 1-Pnt H tBOC- Ph—Et 3.27 482 H 1041 E IIB- Chm H tBOC- Bnzl 3.39 494 H 1042 E IIB- Chm H tBOC- 1-Npm 3.54 544 H 1043 E IIB- Chm H tBOC- Ph—Et 3.5 508 H 1044 E IIB- Ph—Et H i-Pr 4-tBuO- 3.36 488 H 1045 Bnzl IIB- 4-F-Bnzl H i-Pr 4-tBuO- 3.33 492 H 1046 Bnzl IIB- Ph—Et H s-Bu 4-tBuO- 3.43 502 H 1047 Bnzl IIB- 4-F-Bnzl H s-Bu 4-tBuO- 3.46 506 H 1048 Bnzl IIB- 2-OtBu—Et H s-Bu Bnzl 3.28 426 H 1049 IIB- 2-OtBu—Et H s-Bu i-Bu 3.26 392 H 1050 IIB- 2-OtBu—Et H s-Bu 1-Npm 3.48 476 H 1051 IIB- 2-OtBu—Et H s-Bu Ph—Et 3.39 440 H 1052 IIB- 4-tBuO-Bnzl H Ph—Et Bnzl 3.48 536 H 1053 IIB- 4-tBuO-Bnzl H Ph—Et i-Bu 3.38 502 H 1054 IIB- 4-tBuO-Bnzl H Ph—Et 1-Npm 3.58 586 H 1055 IIB- tBOC-E H Ph—Et Bnzl 3.3 502 H 1056 IIB- tBOC-E H Ph—Et i-Bu 3.28 468 H 1057 IIB- tBOC-E H Ph—Et 1-Npm 3.47 552 H 1058 IIB- 2-OtBu—Et H Ph—Et Bnzl 3.29 474 H 1059 IIB- 2-OtBu—Et H Ph—Et i-Bu 3.27 440 H 1060 IIB- 2-OtBu—Et H Ph—Et i-Pnt 3.36 454 H 1061 IIB- 4-tBuO-Bnzl H 4-F- Bnzl 3.52 540 H 1062 Bnzl IIB- 4-tBuO-Bnzl H 4-F- i-Bu 3.42 506 H 1063 Bnzl IIB- 4-tBuO-Bnzl H 4-F- 1-Npm 3.6 590 H 1064 Bnzl IIB- tBOC-E H 4-F- Bnzl 3.27 506 H 1065 Bnzl IIB- tBOC-E H 4-F- 1-Bu 3.28 472 H 1066 Bnzl IIB- tBOC-E H 4-F- 1-Npm 3.45 556 H 1067 Bnzl IIB- 2-OtBu—Et H 4-F- i-Bu 3.22 444 H 1068 Bnzl IIB- 2-OtBu—Et H 4-F- Ph—Et 3.33 492 H 1069 Bnzl IIB- 2-OtBu—Et H 4-F- i-Pnt 3.33 458 H 1070 Bnzl IIB- Bnzl H 2- Bnzl 4.32 460 H 1071 OtBu—Et IIB- Bnzl H 2- i-Bu 4.25 426 H 1072 OtBu—Et IIB- Bnzl H 2- 1-Npm 4.42 510 H 1073 OtBu—Et IIB- Bnzl H 2- Ph—Et 4.31 474 H 1074 OtBu—Et IIB- Bnzl H 2- i-Pnt 4.34 440 H 1075 OtBu—Et IIB- i-Bu H 2- Bnzl 4.33 426 H 1076 OtBu—Et IIB- i-Bu H 2- 1-Npm 4.42 476 H 1077 OtBu—Et IIB- i-Bu H 2- Ph—Et 4.35 440 H 1078 OtBu—Et IIB- 1-Npm H 2- Bnzl 4.45 510 H 1079 OtBu—Et IIB- 1-Npm H 2- i-Bu 4.48 476 H 1080 OtBu—Et IIB- 1-Npm H 2- Ph—Et 4.48 524 H 1081 OtBu—Et IIB- 1-Npm H 2- i-Pnt 4.53 490 H 1082 OtBu—Et IIB- 4-tBuO- H 2- i-Bu 4.43 498 H 1083 Bnzl OtBu—Et IIB- Ph—Et H 2- Bnzl 4.33 474 H 1084 OtBu—Et IIB- Ph—Et H 2- i-Bu 4.33 440 H 1085 OtBu—Et IIB- Ph—Et H 2- 1-Npm 4.47 524 H 1086 OtBu—Et IIB- Ph—Et H 2- 4-tBuO- 4.49 546 H 1087 OtBu—Et Bnzl

TABLE 1-30 IIB- Ph—Et H 2- i-Pnt 4.41 454 H 1088 OtBu—Et IIB- 4-F-Bnzl H 2- Bnzl 4.33 478 H 1089 OtBu—Et IIB- 4-F-Bnzl H 2- i-Bu 4.26 444 H 1090 OtBu—Et IIB- 4-F-Bnzl H 2- 1-Npm 4.43 528 H 1091 OtBu—Et IIB- 4-F-Bnzl H 2- 4-tBuO- 4.47 550 H 1092 OtBu—Et Bnzl IIB- 4-F-Bnzl H 2- Ph—Et 4.32 492 H 1093 OtBu—Et IIB- 4-F-Bnzl H 2- i-Pnt 4.37 458 H 1094 OtBu—Et IIB- i-Pnt H 2- Bnzl 4.29 440 H 1095 OtBu—Et IIB- i-Pnt H 2- 1-Npm 4.43 490 H 1096 OtBu—Et IIB- i-Pnt H 2- 4-tBuO- 4.47 512 H 1097 OtBu—Et Bnzl IIB- Chm H 2- Bnzl 4.43 466 H 1098 OtBu—Et IIB- Chm H 2- 4-tBuO- 4.56 538 H 1099 OtBu—Et Bnzl IIB- Chm H 2- Ph—Et 4.46 480 H 1100 OtBu—Et IIB- Bnzl H i-Pnt 4-tBuO- 3.43 502 H 1101 Bnzl IIB- Bnzl H i-Pnt tBOC-E 3.23 468 H 1102 IIB- 1-Npm H i-Pnt 4-tBuO- 3.6 552 H 1103 Bnzl IIB- 1-Npm H i-Pnt tBOC-E 3.45 518 H 1104 IIB- 4-tBuO-Bnzl H i-Pnt Bnzl 3.48 502 H 1105 IIB- 4-tBuO-Bnzl H i-Pnt i-Bu 3.47 468 H 1106 IIB- 4-tBuO-Bnzl H i-Pnt 1-Npm 3.64 552 H 1107 IIB- 4-tBuO-Bnzl H i-Pnt Ph—Et 3.53 516 H 1108 IIB- tBOC-E H i-Pnt Bnzl 3.33 468 H 1109 IIB- tBOC-E H i-Pnt 1-Npm 3.49 518 H 1110 IIB- tBOC-E H i-Pnt Ph—Et 3.38 482 H 1111 IIB- Ph—Et H i-Pnt 4-tBuO- 3.53 516 H 1112 Bnzl IIB- Ph—Et H i-Pnt tBOC-E 3.34 482 H 1113 IIB- 4-F-Bnzl H i-Pnt 4-tBuO- 3.44 520 H 1114 Bnzl IIB- 4-F-Bnzl H i-Pnt tBOC-E 2.47 486 H 1115 IIB- Chm H i-Pnt 4-tBuO- 2.82 508 H 1116 Bnzl IIB- Bnzl H Hxy 4-tBuO- 2.73 516 H 1117 Bnzl IIB- i-Bu H Hxy 4-tBuO- 2.7 482 H 1118 Bnzl IIB- 1-Npm H Hxy 4-tBuO- 2.88 566 H 1119 Bnzl IIB- 4-tBuO-Bnzl H Hxy Bnzl 2.78 516 H 1120 IIB- 4-tBuO-Bnzl H Hxy Ph—Et 2.83 530 H 1121 IIB- 4-tBuO-Bnzl H Hxy i-Pnt 2.85 496 H 1122 IIB- tBOC-E H Hxy Bnzl 2.62 482 H 1123 IIB- tBOC-E H Hxy Ph—Et 2.68 496 H 1124 IIB- Ph—Et H Hxy 4-tBuO- 2.77 530 H 1125 Bnzl IIB- 4-F-Bnzl H Hxy 4-tBuO- 2.75 534 H 1126 Bnzl IIB- 2-OtBu—Et H Hxy Bnzl 2.48 454 H 1127 IIB- 2-OtBu—Et H Hxy 1-Npm 2.75 504 H 1128 IIB- 2-OtBu—Et H Hxy Ph—Et 2.68 468 H 1129 ^(†)Ring formed together by R_(2A) and R_(2B) *IIB-410, 416, 420, 462, 463, 499, and 501 are mixtures of conformational isomers.

TABLE 1-31 LCMS Compound t_(R) Mass Measurement Yield number Name of compound (min) (M + H)⁺ condition (%) IIB-1 (3S*,3aS*,6R*,7R*,7aS*)-N,7- 1.19 416 B 18 dibenzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-2 (3S*,3aS*,6R*,7R*,7aS*)-N,1,7- 1.17 348 B 33 triisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-3 (3S*,3aS*,6R*,7R*,7aS*)-7- 1.18 382 B 26 benzyl-N,1-diisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-4 (3S*,3aS*,6R*,7R*,7aS*)-1- 1.17 382 B 40 benzyl-N,7-diisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-5 (3S*,3aS*,6R*,7R*,7aS*)-N- 1.18 382 B 36 benzyl-1,7-diisobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-6 (3S*,3aS*,6R*,7R*,7aS*)-1,7- 1.19 416 B 47 dibenzyl-N-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-7 (3S*,3aS*,6R*,7R*,7aS*)-N,1- 1.19 416 B 35 dibenzyl-7-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-8 (3S*,3aS*,6R*,7R*,7aS*)-N,1,7- 1.21 450 B 36 tribenzyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-9 (3S*,3aS*,6R*,7R*,7aS*)-N,7- 1.22 430 B 35 dibenzyl-1-isopentyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-10 (3S*,3aS*,6R*,7R*,7aS*)-N,1- 1.22 430 B 27 dibenzyl-7-isopentyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-11 (3S*,3aS*,6R*,7R*,7aS*)-N- 1.21 430 B 35 benzyl-1-isobutyl-7-phenethyl-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-12 (3S*,3aS*,6R*,7R*,7aS*)-1- 1.21 430 B 19 benzyl-7-isobutyl-N-phenethyl-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide

TABLE 1-32 IIB-13 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.22 430 B 39 isobutyl-7-(3-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-14 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.21 430 B 37 isobutyl-7-(4-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-15 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.22 430 B 20 isobutyl-N-(3-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-16 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.23 430 B 30 isobutyl-N-(4-methylbenzyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-17 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N- 1.22 450 B 34 (3-chlorobenzyl)-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-18 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N- 1.22 450 B 24 (4-chlorobenzyl)-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-19 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.28 484 B 27 (3,4-dichlorobenzyl)-7-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-20 (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N- 1.25 484 B 31 (3,4-dichlorobenzyl)-7-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-21 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.18 438 B 54 isobutyl-N-(2-(naphthalen-1-yl)ethyl)-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-23 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.05 488 A 28 isobutyl-N-(4-(tert-butoxy)benzyl)-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-24 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.03 466 A 30 isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-25 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N- 0.79 370 A 20 (2-hydroxyethyl)-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-26 3-((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl- 0.80 398 A 95 1-isobutyl-1,2,3,6,7,7a-hexahydro-1H-3,6-methanopyrrolo [3,2-b]pyridine-3a-carboxamide)propanoic acid IIB-27 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 0.98 454 A 11 isobutyl-N-(2-(tert-butoxy)-2-oxoethyl)-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-28 (3S*,3aS*,6R*,7R*,7aS*)-N-(3-amino- 0.79 397 A 80 3-oxopropyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-29 (3S*,3aS*,6R*,7R*,7aS*)-N-(4- 0.71 397 A 93 aminobutyl)-7-benzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-30 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 0.97 497 A 18 isobutyl-N-(4-((tert-butoxycarbonyl)amino)butyl)-1,2,3,6,7,7a- hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide IIB-31 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N- 1.04 422 A 5 cyclohexylmethyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a-carboxamide

TABLE 1-33 IIB-32 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl- 0.93 424 A 38 1-isobutyl-N-((tetrahydro-2H-pyran- 2-yl)methyl)-1,2,3,6,7,7a- hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-34 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl- 0.99 497 A 36 1-isobutyl-7-(4-((tert- butoxycarbonyl)amino)butyl)- 1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-36 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl- 0.89 412 A 22 1-isobutyl-7-(3-methoxy-3- oxopropyl)-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IIB-38 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl- 1.05 422 A 59 7-(cyclohexylmethyl)-1-isobutyl- 1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-39 (3S*,3aS*,6R*,7R*,7aS*)-N,7- 1.04 456 A 12 dibenzyl-1-cyclohexylmethyl- 1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-40 (3S*,3aS*,6R*,7R*,7aS*)-N,7- 0.91 466 A 92 dibenzyl-1-(4-hydroxybenzyl)- 1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-41 (3S*,3aS*,6R*,7R*,7aS*)-N,7- 1.05 522 A 10 dibenzyl-1-(4-(tert- butoxy)benzyl)-1,2,3,6,7,7a- hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-42 (3S*,3aS*,6R*,7R*,7aS*)-N,7- 1.04 500 A  4 dibenzyl-1-(naphthalen-1- ylmethyl)-1,2,3,6,7,7a-hexahydro- 3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IIB-76 tert-butyl 3- 0.83 488 B 34 ((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl- 3a-(benzylcarbamoyl)- 2,3,3a,6,7,7a-hexahydro-1H-3,6- methanopyrrolo[3,2-b]pyridin- 1-yl)propanoate IIB-77 (3S*,3aS*,6R*,7R*,7aS*)-N,1- 0.85 466 B 34 dibenzyl-7-(4-hydroxybenzyl)- 1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IIB-78 tert-butyl 3- 1.00 527 B 49 ((3S*,3aS*,6R*,7R*,7aS*)-2-(7- benzyl-1-methyl-2,3,3a,6,7,7a- hexahydro-1H-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide)ethyl)-1H-indole-1- carboxylate IIB-80 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl- 0.95 452 A  9 1-(naphthalen-1-ylmethyl)-7-propyl- 1,2,3,6,7,7a-hexahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide

TABLE 2-1

Compound Synthesis Raw Raw number R₁ R₂ R₃ method Intermediate material material 1 2

TABLE 2-2 IIF-1 i-Bu Bnzl Bnzl EX INT-Bnzl SM1-iBu SM2-Ph IIF-2 i-Bu i-Bu i-Bu IIB-1, INT-iBu SM1-iBu SM2-Pnt IIF-1 IIF-3 i-Bu i-Bu Bnzl IIB-1, INT-iBu SM1-iBu SM2-Ph IIF-1 IIF-4 Bnzl i-Bu i-Bu IIB-1, INT-iBu SM1-Bnzl SM2-Pnt IIF-1 IIF-5 i-Bu Bnzl i-Bu IIB-1, INT-Bnzl SM1-iBu SM2-Pnt IIF-1 IIF-6 Bnzl i-Bu Bnzl IIB-1, INT-iBu SM1-Bnzl SM2-Ph IIF-1 IIF-7 Bnzl Bnzl i-Bu IIB-1, N-(benzyl- SM1-Bnzl SM2-Pnt IIF-1 1,2,4-triazine- 3-carboxamide IIF-8 Bnzl Bnzl Bnzl IIB-1, INT-Bnzl SM1-Bnzl SM2-Ph IIF-1 IIF-9 i-Pnt Bnzl Bnzl IIB-1, INT-Bnzl N-allyl-3- SM2-Ph IIF-1 methylbutan- 1-amine IIF-10 Bnzl Bnzl i-Pnt IIB-1, INT-Bnzl SM1-Bnzl 5- IIF-1 methylhexanal IIF-11 i-Bu Bnzl Ph-Et IIB-1, INT-Bnzl SM1-iBu 4- IIF-1 phenylbutanal IIF-12 i-Bu Ph-Et Bnzl IIB-1, N-phenethyl- SM1-iBu SM2-Ph IIF-1 1,2,4-triazine-3- carboxamide IIF-13 i-Bu Bnzl 3-Me- IIB-1, INT-Bnzl SM1-iBu 3-(m-tolyl)propanal Bnzl IIF-1 IIF-14 i-Bu Bnzl 4-Me- IIB-1, INT-Bnzl SM1-iBu 3-(p-tolyl)propanal Bnzl IIF-1 IIF-15 i-Bu 3-Me- Bnzl IIB-1, N-(3-methylbenzyl)- SM1-iBu SM2-Ph Bnzl IIF-1 1,2,4-triazine-3- carboxamide IIF-16 i-Bu 4-Me- Bnzl IIB-1, N-(4-methylbenzyl)- SM1-iBu SM2-Ph Bnzl IIF-1 1,2,4-triazine-3- carboxamide IIF-17 i-Bu 3-Cl- Bnzl IIB-1, N-(3-chlorobenzyl)- SM1-iBu SM2-Ph Bnzl IIF-1 1,2,4-triazine-3- carboxamide IIF-18 i-Bu 4-Cl- Bnzl IIB-1, N-(4-chlorobenzyl)- SM1-iBu SM2-Ph Bnzl IIF-1 1,2,4-triazine-3- carboxamide IIF-19 3,4- Bnzl i-Bu IIB-1, INT-Bnzl N-(3,4- SM2-Pnt Cl₂- IIF-1 dichlorobenzyl) Bnzl prop-2-en-1-amine IIF-20 Bnzl 3,4- i-Bu IIB-1, N-(3,4- SM1-Bnzl SM2-Pnt Cl₂- IIF-1 dichlorobenzyl)- Bnzl 1,2,4-triazine-3- carboxamide IIF-23 i-Bu 4- Bnzl IIB-1, N-(4-tert- SM1-iBu SM2-Ph (tert- IIF-1 butoxybenzyl)- butoxy) 1,2,4-triazine-3- benzyl carboxamide

TABLE 2-3 IIF-24 i-Bu Np-M Bnzl IIB-1, N- SM1-iBu SM2-Ph IIF-1 ((naphthalen-1-yl) methyl)-1,2,4-triazine- 3-carboxamide IIF-25 i-Bu Hdr-E Bnzl IIB-1, N-(2- SM1-iBu SM2-Ph IIF-1 hydroxyethyl)- 1,2,4-triazine- 3-carboxamide IIF-26 i-Bu Cbx-E Bnzl EX IIB-27 IIF-27 i-Bu 2-(tert- Bnzl IIB-1, tert-butyl SM1-iBu SM2-Ph butoxy)- IIF-1 3-(1,2,4- 2-oxoethyl triazine-3- carboxamide) propanoate IIF-28 i-Bu Cbm-E Bnzl IIB-28 IIF-26 IIF-29 i-Bu 4-aminobutyl Bnzl IIB-29 IIF-30 IIF-30 i-Bu 4-((tert- Bnzl IIB-1, tert-butyl SM1-iBu SM2-Ph butoxycarbonyl) IIF-1 4-(1,2,4- amino)butyl triazine-3- carboxamide) butylcarbamate IIF-31 i-Bu Chm Bnzl IIB-1, N- SM1-iBu SM2-Ph IIF-1 (cyclohexyl methyl)- 1,2,4-triazine- 3-carboxamide IIF-32 i-Bu (tetrahydro- Bnzl IIB-1, N-((tetrahydro-2H- SM1-iBu SM2-Ph 2H-pyran-2-yl) IIF-1 pyran-2-yl)methyl)- methyl 1,2,4-triazine- 3-carboxamide IIF-34 i-Bu Bnzl 4- IIB-1, INT-Bnzl SM1-iBu tert-butyl ((tert- IIF-1 5- butoxycarbonyl) formylpentylcarbamate amino)butyl IIF-36 i-Bu Bnzl 3-methoxy- IIB-1, INT-Bnzl SM1-iBu methyl 3-oxopropyl IIF-1 4-formylbutanoate IIF-38 i-Bu Bnzl Chm IIB-1, INT-Bnzl SM1-iBu 3-cyclohexylpropanal IIF-1 IIF-39 Chm Bnzl Bnzl IIB-1, INT-Bnzl N- SM2-Ph IIF-1 (cyclohexylmethyl) prop-2-en-1-amine IIF-40 4-OH-Bnzl Bnzl Bnzl IF-40 IIF-41 IIF-41 4-(tert- Bnzl Bnzl IIB-1, INT-Bnzl N-(4-tert- SM2-Ph butoxy) IIF-1 butoxybenzyl) benzyl prop-2-en-1-amine IIF-42 Np-M Bnzl Bnzl IIB-1, INT-Bnzl N- SM2-Ph IIF-1 ((naphthalen-1-yl) methyl)prop-2-en- 1-amine

TABLE 2-4 IIF-76 3-(tert- Bnzl Bnzl IIB-1, N-benzyl- N-(3-(tert- SM2-Ph butoxy)- IIF-1 1,2,4- butoxy)- 3- triazine-3- 3-oxopropyl)- oxopropyl carboxamide prop-2-en-1- amine IIF-77 Bnzl Bnzl 4- IIB-1, N-benzyl- SM1-Bnzl 3-(4- OH- IIF-1 1,2,4- hydroxyphenyl) Bnzl triazine-3- propanal carboxamide IIF-80 Np-M Bnzl Pr IIB-1, N-benzyl N- pentanal IIF-1 1,2,4- ((naphthalen-1-yl) triazine-3- methyl)prop-2-en- carboxamide 1-amine

TABLE 2-5 LCMS Compound t R Mass Measurement number R1 R2 R3 (min) (M + H) ⁺ condition IIF-81 benzyl naphthalen-1- isobutyl 1.29 467 B ylmethyl IIF-82 benzyl 4-(trifluoromethyl) isobutyl 1.29 484 B benzyl IIF-83 4-chlorobenzyl benzyl isobutyl 1.29 450 B IIF-84 3-chlorobenzyl benzyl isobutyl 1.30 450 B IIF-85 4-methoxybenzyl benzyl isobutyl 1.23 446 B IIF-86 4-methylbenzyl benzyl isobutyl 1.24 430 B IIF-88 isobutylbenzyl isobutyl 4-chloro 1.26 416 B IIF-89 isobutyl 4-chlorobenzyl isobutyl 1.22 416 B IIF-90 isobutyl benzyl isopentyl 1.23 396 B IIF-91 isopentyl benzyl isobutyl 1.26 396 B IIF-92 isobutyl isopentyl benzyl 1.23 396 B IIF-93 4-hydroxybenzyl benzyl isobutyl 1.19 432 B IIF-94 4-(dimethylamino) benzyl isobutyl 1.27 459 B benzyl IIF-95 4-(tert-butyl) benzyl isobutyl 1.29 472 B benzyl IIF-96 4-(trifluoromethoxy) benzyl isobutyl 1.32 500 B benzyl IIF-97 4-ethoxybenzyl benzyl isobutyl 1.25 460 B IIF-98 isopentyl isobutyl benzyl 1.22 396 B IIF-99 benzyl 4-hydroxybenzyl isobutyl 1.17 432 B

TABLE 2-6 IIF-100 4-methoxybenzyl 4-hydroxybenzyl isobutyl 1.17 462 B IIF-101 4-hydroxybenzyl benzyl isopentyl 1.20 446 B IIF-102 benzyl naphthalen-2- isobutyl 1.27 466 B ylmethyl IIF-103 isopentyl 4-chlorobenzyl isobutyl 1.28 431 B IIF-104 isopentyl 4-fluorobenzyl isobutyl 1.26 414 B IIF-105 benzyl pyridin-4- isobutyl 1.06 417 B ylmethyl IIF-106 4-methoxybenzyl benzyl benzyl 0.93 480 c IIF-107 phenethyl benzyl 2-(tert- 1.08 532 C butyldimethylsilyloxy) ethyl IIF-109 4-nitrobenzyl 4-(tert-butoxy) 2-(tert- 1.00 605 C benzyl butoxycarbonyl) ethyl IIF-110 i-Bu i-Pr Bnzl 2.92 368 F IIF-111 i-Bu i-Bu 4-tBuO-Bnzl 3.64 454 F IIF-112 i-Bu Bnzl 4-tBuO-Bnzl 3.75 488 F IIF-113 i-Bu tBOC-E 4-tBuO-Bnzl 3.73 526 F IIF-114 i-Bu s-Bu 4-tBuO-Bnzl 3.64 454 F IIF-115 i-Bu 1-Npm 4-tBuO-Bnzl 4.18 538 F IIF-116 i-Bu i-Pr 4-tBuO-Bnzl 3.4 440 F IIF-117 i-Bu 1-Npm tBOC-E 3.92 504 F IIF-118 i-Bu 1-Npm 1-Npm 4.25 516 F IIF-119 i-Bu i-Pr 1-Npm 3.4 418 F IIF-120 Bnzl 4-tBuO-Bnzl Bnzl 3.95 522 F IIF-121 Bnzl i-Bu 4-tBuO-Bnzl 3.79 488 F IIF-122 Bnzl Bnzl 4-tBuO-Bnzl 3.91 522 F IIF-123 Bnzl tBOC-E 4-tBuO-Bnzl 3.94 560 F IIF-124 Bnzl Bnzl tBOC-E 3.47 488 F IIF-125 Bnzl 4-tBuO-Bnzl tBOC-E 3.98 560 F IIF-126 Bnzl 1-Npm tBOC-E 3.96 538 F IIF-127 Bnzl i-Bu 1-Npm 3.74 466 F

TABLE 2-7 IIF-128 Bnzl Bnzl 1-Npm 3.92 500 F IIF-129 Bnzl 4-tBuO-Bnzl 1-Npm 4.27 572 F IIF-130 Bnzl tBOC-E 1-Npm 3.8 538 F IIF-131 Bnzl s-Bu 1-Npm 3.74 466 F IIF-132 Bnzl 1-Npm 1-Npm 4.31 550 F IIF-133 4-tBuO-Bnzl Bnzl Bnzl 4.1 522 F IIF-134 4-tBuO-Bnzl tBOC-E Bnzl 3.6 560 F IIF-135 4-tBuO-Bnzl s-Bu Bnzl 3.47 488 F IIF-136 4-tBuO-Bnzl 1-Npm Bnzl 4.75 572 F IIF-137 4-tBuO-Bnzl Bnzl tBOC-E 3.69 560 F IIF-138 4-tBuO-Bnzl 1-Npm tBOC-E 4.04 610 F IIF-139 4-tBuO-Bnzl i-Bu 1-Npm 3.82 538 F IIF-140 4-tBuO-Bnzl Bnzl 1-Npm 4.68 572 F IIF-141 4-tBuO-Bnzl tBOC-E 1-Npm 3.8 610 F IIF-142 4-tBuO-Bnzl s-Bu 1-Npm 3.92 538 F IIF-143 4-tBuO-Bnzl 1-Npm 1-Npm 4.65 622 F IIF-144 i-Bu 4-tBuO-Bnzl Bnzl 3.87 488 F IIF-145 i-Bu tBOC-E Bnzl 3.25 454 F IIF-146 i-Bu s-Bu Bnzl 3.12 382 F IIF-147 i-Bu i-Bu tBOC-E 3.19 420 F IIF-148 i-Bu Bnzl tBOC-E 3.37 454 F IIF-149 i-Bu 4-tBuO-Bnzl tBOC-E 3.93 526 F IIF-150 i-Bu i-Pr tBOC-E 2.93 406 F IIF-151 i-Bu i-Bu 1-Npm 3.68 432 F IIF-152 i-Bu Bnzl 1-Npm 3.72 466 F IIF-153 i-Bu 4-tBuO-Bnzl 1-Npm 4.24 538 F IIF-154 i-Bu tBOC-E 1-Npm 3.74 504 F IIF-155 Bnzl tBOC-E Bnzl 3.44 488 F IIF-156 Bnzl s-Bu Bnzl 3.24 416 F IIF-157 Bnzl 1-Npm Bnzl 3.87 500 F IIF-158 Bnzl i-Pr Bnzl 3.01 402 F IIF-159 Bnzl s-Bu 4-tBuO-Bnzl 3.82 488 F IIF-160 Bnzl 1-Npm 4-tBuO-Bnzl 4.43 572 F IIF-161 Bnzl i-Pr 4-tBuO-Bnzl 3.51 474 F

TABLE 2-8 IIF-162 Bnzl s-Bu tBOC-E 3.34 454 F IIF-163 Bnzl i-Pr tBOC-E 3.15 440 F IIF-164 Bnzl i-Pr 1-Npm 3.5 452 F IIF-165 4-tBuO-Bnzl i-Pr Bnzl 3.49 474 F IIF-166 4-tBuO-Bnzl i-Pr tBOC-E 3.38 512 F IIF-167 4-tBuO-Bnzl i-Pr 1-Npm 3.82 524 F IIF-168 tBOC-E i-Bu Bnzl 3.5 454 F IIF-169 1-Npm i-Bu Bnzl 3.54 466 F IIF-170 1-Npm 4-tBuO-Bnzl Bnzl 3.95 572 F IIF-171 1-Npm s-Bu Bnzl 3.52 466 F IIF-172 1-Npm i-Pr Bnzl 3.19 452 F IIF-173 1-Npm Bnzl 4-tBuO-Bnzl 4.3 572 F IIF-174 1-Npm tBOC-E 4-tBuO-Bnzl 3.95 610 F IIF-175 1-Npm s-Bu 4-tBuO-Bnzl 3.87 538 F IIF-176 1-Npm 1-Npm 4-tBuO-Bnzl 4.62 622 F IIF-177 1-Npm i-Pr 4-tBuO-Bnzl 3.84 524 F IIF-178 1-Npm Bnzl tBOC-E 3.8 538 F IIF-179 1-Npm 4-tBuO-Bnzl tBOC-E 4.5 610 F IIF-180 1-Npm s-Bu tBOC-E 3.62 504 F IIF-181 1-Npm 1-Npm tBOC-E 4.15 588 F IIF-182 1-Npm Bnzl 1-Npm 4.3 550 F IIF-183 1-Npm 4-tBuO-Bnzl 1-Npm 4.75 622 F IIF-184 1-Npm tBOC-E 1-Npm 4.02 588 F IIF-185 1-Npm s-Bu 1-Npm 4.25 516 F IIF-186 i-Bu 4-tBuO-Bnzl i-Bu 3.68 454 F IIF-187 i-Bu tBOC-E i-Bu 3.05 420 F IIF-188 i-Bu s-Bu i-Bu 2.84 348 F IIF-189 i-Bu 1-Npm i-Bu 3.71 432 F IIF-190 i-Bu i-Pr i-Bu 2.66 334 F IIF-191 i-Bu (tBOC)Gun-Pr 4-tBuO-Bnzl 2.71 641 J IIF-192 i-Bu 1-Npm (tBOC)Gun-Pr 3.47 675 J IIF-193 i-Bu s-Bu 1-Npm 3.64 432 F IIF-194 Bnzl 4-tBuO-Bnzl i-Bu 3.93 488 F IIF-195 Bnzl i-Pr i-Bu 3.01 368 F

TABLE 2-9 IIF-196 Bnzl i-Bu tBOC-E 3.32 454 F IIF-197 tBOC-E Bnzl i-Bu 3.52 454 F IIF-198 tBOC-E 4-tBuO-Bnzl i-Bu 4.01 526 F IIF-199 tBOC-E s-Bu i-Bu 3.26 420 F IIF-200 tBOC-E 1-Npm i-Bu 4.09 504 F IIF-201 tBOC-E i-Pr i-Bu 3.03 406 F IIF-202 tBOC-E 1-Npm Bnzl 4.06 538 F IIF-203 tBOC-E Bnzl 4-tBuO-Bnzl 4.19 560 F IIF-204 tBOC-E 1-Npm 4-tBuO-Bnzl 4.62 610 F IIF-205 tBOC-E i-Bu 1-Npm 3.96 504 F IIF-206 tBOC-E 4-tBuO-Bnzl 1-Npm 4.41 610 F IIF-207 tBOC-E 1-Npm 1-Npm 4.48 588 F IIF-208 tBOC-E i-Pr 1-Npm 3.71 490 F IIF-209 1-Npm i-Bu i-Bu 3.32 432 F IIF-210 1-Npm Bnzl i-Bu 3.38 466 F IIF-211 1-Npm 4-tBuO-Bnzl i-Bu 3.67 538 F IIF-212 1-Npm s-Bu i-Bu 3.35 432 F IIF-213 1-Npm 1-Npm i-Bu 3.8 516 F IIF-214 1-Npm i-Pr i-Bu 3.17 418 F IIF-215 1-Npm i-Bu 4-tBuO-Bnzl 3.92 538 F IIF-216 1-Npm i-Bu tBOC-E 3.5 504 F IIF-217 1-Npm i-Pr tBOC-E 3.34 490 F IIF-218 1-Npm i-Bu 1-Npm 3.79 516 F IIF-219 1-Npm (tBOC)Gun-Pr 1-Npm 3.82 759 F IIF-220 1-Npm i-Pr 1-Npm 3.65 502 F IIF-221 i-Bu (tBOC)Gun-Pr i-Bu 2.89 591 J IIF-222 i-Bu (tBOC)Gun-Pr Bnzl 2.96 625 J IIF-223 i-Bu s-Bu tBOC-E 3.13 420 F IIF-224 i-Bu i-Bu (tBOC)Gun-Pr 2.96 591 J IIF-225 i-Bu Bnzl (tBOC)Gun-Pr 3 625 J IIF-226 i-Bu 4-tBuO-Bnzl (tBOC)Gun-Pr 2.78 641 J IIF-227 i-Bu s-Bu (tBOC)Gun-Pr 2.95 591 J IIF-228 i-Bu i-Pr (tBOC)Gun-Pr 2.81 577 J IIF-229 i-Bu (tBOC)Gun-Pr 1-Npm 3.08 675 J

TABLE 2-10 IIF-230 Bnzl (tBOC)Gun-Pr i-Bu 2.93 625 J IIF-231 Bnzl s-Bu i-Bu 3.23 382 F IIF-232 Bnzl (tBOC)Gun-Pr Bnzl 2.94 659 J IIF-233 Bnzl (tBOC)Gun-Pr 4-tBuO-Bnzl 2.74 675 J IIF-234 Bnzl i-Bu (tBOC)Gun-Pr 3.49 698? J IIF-235 Bnzl Bnzl (tBOC)Gun-Pr 3.18 659 J IIF-236 Bnzl 4-tBuO-Bnzl (tBOC)Gun-Pr 2.95 675 J IIF-237 Bnzl s-Bu (tBOC)Gun-Pr 3.04 625 J IIF-238 Bnzl 1-Npm (tBOC)Gun-Pr 4.09 709 J IIF-239 Bnzl (tBOC)Gun-Pr 1-Npm 3.36 709 J IIF-240 tBOC-E i-Bu i-Bu 3.25 420 F IIF-241 tBOC-E Bnzl Bnzl 3.62 488 F IIF-242 tBOC-E 4-tBuO-Bnzl Bnzl 4.1 560 F IIF-243 tBOC-E s-Bu Bnzl 4.48 454 F IIF-244 tBOC-E i-Pr Bnzl 3.24 440 F IIF-245 tBOC-E i-Bu 4-tBuO-Bnzl 4.15 526 F IIF-246 tBOC-E i-Pr 4-tBuO-Bnzl 3.89 512 F IIF-247 tBOC-E Bnzl 1-Npm 4.03 538 F IIF-248 tBOC-E s-Bu 1-Npm 3.96 504 F IIF-249 (tBOC) 1-Npm i-Bu 3.77 657 J Gun-Pr IIF-250 (tBOC) i-Pr i-Bu 3.16 577 J Gun-Pr IIF-251 (tBOC) 1-Npm Bnzl 3.71 709 J Gun-Pr IIF-252 (tBOC) i-Pr Bnzl 3.18 611 J Gun-Pr IIF-253 (tBOC) 1-Npm 4-tBuO-Bnzl 3.39 725 J Gun-Pr IIF-254 (tBOC) i-Pr 4-tBuO-Bnzl 2.96 627 J Gun-Pr IIF-255 (tBOC) 1-Npm 1-Npm 3.97 759 J Gun-Pr IIF-256 (tBOC) i-Pr 1-Npm 3.47 661 J Gun-Pr IIF-257 1-Npm 1-Npm Bnzl 4.5 550 F IIF-258 Bnzl tBOC-E i-Bu 3.51 454 F IIF-259 Bnzl i-Pr (tBOC)Gun-Pr 2.99 611 J IIF-260 4-tBuO- i-Bu i-Bu 3.42 454 F Bnzl IIF-261 4-tBuO- Bnzl i-Bu 3.44 488 F Bnzl IIF-262 4-tBuO- tBOC-E i-Bu 3.5 526 F Bnzl IIF-263 4-tBuO- (tBOC)Gun-Pr i-Bu 3.29 641 F Bnzl

TABLE 2-11 IIF-264 4-tBuO-Bnzl s-Bu i-Bu 3.45 454 F IIF-265 4-tBuO-Bnzl 1-Npm i-Bu 3.9 538 F IIF-266 4-tBuO-Bnzl i-Pr i-Bu 3.24 440 F IIF-267 4-tBuO-Bnzl i-Bu Bnzl 3.57 488 F IIF-268 4-tBuO-Bnzl (tBOC)Gun-Pr Bnzl 3.1 675 F IIF-269 4-tBuO-Bnzl i-Bu tBOC-E 3.6 526 F IIF-270 4-tBuO-Bnzl s-Bu tBOC-E 3.59 526 F IIF-271 4-tBuO-Bnzl i-Bu (tBOC)Gun-Pr 3.38 641 F IIF-272 4-tBuO-Bnzl Bnzl (tBOC)Gun-Pr 3.72 675 F IIF-273 4-tBuO-Bnzl s-Bu (tBOC)Gun-Pr 3.38 641 F IIF-274 4-tBuO-Bnzl 1-Npm (tBOC)Gun-Pr 3.79 725 F IIF-275 4-tBuO-Bnzl i-Pr (tBOC)Gun-Pr 3.27 627 F IIF-276 4-tBuO-Bnzl (tBOC)Gun-Pr 1-Npm 3.54 725 F IIF-277 tBOC-E s-Bu 4-tBuO-Bnzl 4.09 526 F IIF-278 (tBOC)Gun-Pr i-Bu i-Bu 4.24 591 F IIF-279 (tBOC)Gun-Pr Bnzl i-Bu 3.99 625 F IIF-280 (tBOC)Gun-Pr 4-tBuO-Bnzl i-Bu 3.51 641 F IIF-281 (tBOC)Gun-Pr s-Bu i-Bu 3.82 591 F IIF-282 (tBOC)Gun-Pr i-Bu Bnzl 4.27 625 F IIF-283 (tBOC)Gun-Pr Bnzl Bnzl 4.14 659 F IIF-284 (tBOC)Gun-Pr 4-tBuO-Bnzl Bnzl 3.72 675 F IIF-285 (tBOC)Gun-Pr s-Bu Bnzl 3.99 625 F IIF-286 (tBOC)Gun-Pr i-Bu 4-tBuO-Bnzl 3.59 641 F IIF-287 (tBOC)Gun-Pr Bnzl 4-tBuO-Bnzl 4.32 675 F IIF-288 (tBOC)Gun-Pr Bnzl 1-Npm 4.57 709 F IIF-289 (tBOC)Gun-Pr s-Bu 1-Npm 4.49 675 F IIF-290 1-Npm tBOC-E i-Bu 3.35 504 F IIF-291 1-Npm (tBOC)Gun-Pr i-Bu 3.95 675 F IIF-292 1-Npm (tBOC)Gun-Pr Bnzl 3.7 709 F IIF-293 1-Npm (tBOC)Gun-Pr 4-tBuO-Bnzl 3.3 725 F IIF-294 1-Npm i-Bu (tBOC)Gun-Pr 3.77 675 F IIF-295 1-Npm Bnzl (tBOC)Gun-Pr 3.82 709 F IIF-296 1-Npm 4-tBuO-Bnzl (tBOC)Gun-Pr 3.6 725 F IIF-297 1-Npm s-Bu (tBOC)Gun-Pr 4.15 675 F

TABLE 2-12 IIF-298 1-Npm 1-Npm (tBOC)Gun-Pr 4.91 759 F IIF-299 1-Npm i-Pr (tBOC)Gun-Pr 3.5 661 F IIF-300 1-Npm tBOC-E Bnzl 3.47 538 F IIF-301 Bnzl i-Pr 3-Gun-Pr 1.47 411 F IIF-302 4-OH-Bnzl i-Pr 3-Gun-Pr 1.37 427 F IIF-303 1-Npm 3-Gun-Pr i-Bu 2.75 475 F IIF-304 1-Npm i-Bu 3-Gun-Pr 2.6 475 F IIF-305 1-Npm Bnzl 3-Gun-Pr 2.69 509 F IIF-306 1-Npm i-Pr 3-Gun-Pr 2.49 461 F IIF-307 Bnzl Ph-Et i-Bu 0.93 430 C IIF-308 Chm i-Bu Bnzl 0.97 422 C IIF-309 Bnzl 4-F-Bnzl i-Bu 0.93 434 C IIF-310 Chm Bnzl i-Bu 0.97 422 C IIF-311 Bnzl Hxy i-Bu 1.02 410 C IIF-312 Ph-Et i-Bu i-Bu 0.94 396 C IIF-313 Ph-Et i-Bu 1-Npm 1.01 480 C IIF-314 Bnzl i-Bu Ph-Et 0.97 430 C IIF-315 4-F-Bnzl i-Bu Bnzl 0.94 434 C IIF-316 i-Bu 4-F-Bnzl Bnzl 0.93 434 C IIF-317 Ph-Et Bnzl i-Bu 0.94 430 C IIF-318 Bnzl i-Pnt i-Bu 0.96 396 C IIF-319 i-Bu Hxy Bnzl 0.98 410 C IIF-320 4-F-Bnzl Bnzl Bnzl 0.94 468 C IIF-321 Ph-Et Bnzl Bnzl 0.96 464 C IIF-322 Bnzl i-Bu i-Pnt 0.97 396 C IIF-323 4-F-Bnzl Bnzl i-Bu 0.94 434 C

TABLE 2-13 Formula XXIIF

Compound LCMS Mass Measurement number R₁ R_(2A) R_(2B) R₃ RT (min) (M + H)⁺ condition IIF-324 2-Npm H Bnzl i-Bu 2.89 466  B1 IIF-325 i-Pnt H 3-Cl-Bnzl Bnzl 2.85 464  B1 IIF-326 i-Pnt H 4-Cl-Bnzl Bnzl 2.85 464  B1 IIF-327 i-Pnt H 4-F-Bnzl Bnzl 2.73 448  B1 IIF-328 i-Pnt H 4-Me-Bnzl Bnzl 2.83 444  B1 IIF-329 i-Pnt H 4-MeO-Bnzl Bnzl 2.71 460  B1 IIF-330 i-Bu H 4-Cl-Bnzl Ph-Et 2.68 464  B1 IIF-331 i-Bu H 3-Cl-Bnzl Ph-Et 2.85 464  B1 IIF-332 i-Bu H 4-MeO-Bnzl Ph-Et 2.50 460  B1 IIF-333 i-Bu H 4-Me-Bnzl Ph-Et 2.65 444  B1 IIF-334 i-Bu H 2-Npm Ph-Et 2.77 480  B1 IIF-335 i-Bu H Bnzl Ph-Pr 2.65 444  B1 IIF-336 i-Bu H 3-Cl-Bnzl Ph-Pr 1.27 478 B IIF-337 i-Bu H 3-F-Bnzl Ph-Pr 1.25 462 B IIF-338 Cpm H 4-OH-Bnzl Cbx-E 0.96 440 B IIF-339 i-Bu H 3-Me-Bnzl Ph-Pr 1.26 458 B IIF-340 i-Bu H 3-MeO-Bnzl Ph-Pr 1.25 474 B IIF-341 i-Bu H 3-Cl-Bnzl Ph-Bu 1.30 492 B IIF-342 i-Bu H 3-F-Bnzl Ph-Bu 1.26 476 B IIF-343 i-Bu H 3-Me-Bnzl Ph-Bu 1.29 472 B IIF-344 i-Bu H 3-MeO-Bnzl Ph-Bu 1.26 488 B IIF-345 i-Bu H Bnzl Ph-Bu 1.25 458 B IIF-346 i-Pnt H 3-F-Bnzl Ph-Pr 1.25 476 B IIF-347 Hdr-E H 4-fluorophenethyl 1-Npm 0.9 486 C IIF-348 1-Npm H cyclohexyl Ph-Et 1.02 506 C IIF-349 1-Npm H cyclopentyl Ph-Et 0.99 492 C IIF-350 1-Npm H pentyl Ph-Et 1.01 494 C IIF-351 1-Npm H heptyl Ph-Et 1.08 522 C IIF-352 propyl H Chm Bnzl 0.95 408 C IIF-353 1-Npm H hexyl 4-methylphenethyl 1.07 522 C IIF-354 1-Npm H hexyl 2-(naphthalen-2-yl)ethyl 1.10 558 C IIF-355 1-Npm H hexyl 4-isopropylphenethyl 1.12 550 C IIF-356 1-Npm H hexyl cyclohexylethyl 1.13 514 C IIF-357 tBuO-E H 4-fluorophenethyl 1-Npm 1.01 542 C IIF-358 tBuO-E H 4-Cl-Bnzl 1-Npm 1.03 545 C IIF-359 tBuO-E H 4-Me-Bnzl 1-Npm 1.02 524 C IIF-360 1-Npm piperidine ^(†) Ph-Et 0.95 492 C

TABLE 2-14 IIF-361 1-Npm pyrrolidine ^(†) Ph-Et 0.93 478 C IIF-362 propyl H Bnzl Chm 0.94 408 C IIF-363 propyl H 2-methylbenzyl Bnzl 0.91 416 C IIF-364 propyl H (1,2,3,4- Bnzl 0.97 456 C tetrahydronaphthalen- 1-yl)methyl IIF-365 propyl H Cpm Bnzl 0.92 394 C IIF-366 propyl H Bnzl Cpm 0.91 394 C IIF-367 1-Npm H Hxy 3- 1.07 522 C methylphenethyl IIF-368 4- H Bnzl Bnzl 0.92 495 C Nt-Bnzl IIF-369 4- H Hxy Ph-Et 1.01 503 C Nt-Bnzl IIF-370 i-Pnt H Ph-Et Bnzl 2.76 444 B1 IIF-371 i-Pnt H 1-Npm Bnzl 2.93 480 B1 IIF-372 i-Bu H 4-F-Bnzl Ph-Et 2.56 448 B1 IIF-373 i-Bu H Ph-Et Ph-Et 2.60 444 B1 IIF-374 i-Bu H 1-Npm Ph-Et 2.79 480 B1 IIF-375 4-F- H 1-Npm Bnzl 2.80 518 B1 Bnzl IIF-376 4-F- H 1-Npm i-Bu 1.26 484 B Bnzl IIF-377 tBuO-E H 4-F-Bnzl 1-Npm 1.01 528 C IIF-378 4-tBuO- H Bnzl Ph-Et 1.01 536 C Bnzl IIF-379 tBuO-E H Bnzl 1-Npm 1.00 510 C IIF-380 Chm H tBuO-E 1-Npm 1.01 516 C IIF-381 tBOC-E H Bnzl Ph-Et 0.97 502 C IIF-382 i-Pnt H Bnzl Ph-Et 0.96 444 C IIF-383 1-Npm H 4-F-Bnzl Hdr-E 0.83 472 C IIF-384 Hdr-E H 4-F-Bnzl 1-Npm 0.88 472 C IIF-385 Cbx-E H Bnzl Ph-Et 0.86 446 C IIF-386 tBuO-E H Ph-Et 1-Npm 1.02 524 C IIF-387 Ph-Et H Hxy 1-Npm 1.06 508 C IIF-388 Ph-Et H i-Bu TBSO-E 1.09 498 C IIF-389 Ph-Et H i-Bu Hdr-E 0.77 384 C IIF-390 Ph-Et H i-Bu i-Pnt 0.96 410 C IIF-391 Ph-Et H i-Bu 4-tBuO-Bnzl 1.02 502 C IIF-392 Ph-Et H i-Bu 4-OH-Bnzl 0.85 446 C IIF-393 i-Bu H i-Bu 4-OH-Bnzl 0.80 398 C IIF-394 i-Bu H Bnzl 4-OH-Bnzl 0.82 432 C IIF-395 i-Bu H 2-Cbx-Et 4-OH-Bnzl 0.63 414 C IIF-396 i-Bu H s-Bu 4-OH-Bnzl 0.79 398 C IIF-397 i-Bu H 1-Npm 4-OH-Bnzl 0.89 482 C IIF-398 i-Bu H i-Pr 4-OH-Bnzl 0.75 384 C IIF-399 i-Bu H 1-Npm 2-Cbx-Et 0.82 448 C IIF-400 Bnzl H 4-OH-Bnzl Bnzl 0.83 466 C IIF-401 Bnzl H i-Bu 4-OH-Bnzl 0.82 432 C IIF-402 Bnzl H 2-Cbx-Et 4-OH-Bnzl 0.67 448 C IIF-403 Bnzl H Bnzl 2-Cbx-Et 0.76 432 C IIF-404 Bnzl H 4-OH-Bnzl 2-Cbx-Et 0.68 448 C IIF-405 Bnzl H 1-Npm 2-Cbx-Et 0.84 482 C IIF-406 Bnzl H 4-OH-Bnzl 1-Npm 0.89 516 C IIF-407 Bnzl H 2-Cbx-Et 1-Npm 0.83 482 C IIF-408 4- H 2-Cbx-Et Bnzl 0.69 448 C OH-Bnzl

TABLE 2-15 IIF-409 4-OH- H s-Bu Bnzl 0.84 432 C Bnzl IIF-410 4-OH- H 1-Npm Bnzl 0.93 516 C Bnzl IIF-411 4-OH- H Bnzl 2-Cbx-Et 0.73 448 C Bnzl IIF-412 4-OH- H 1-Npm 2-Cbx-Et 0.81 498 C Bnzl IIF-413 4-OH- H i-Bu 1-Npm 0.91 482 C Bnzl IIF-414 4-OH- H Bnzl 1-Npm 0.92 516 C Bnzl IIF-415 4-OH- H 2-Cbx- 1-Npm 0.76 498 C Bnzl Et IIF-416 4-OH- H s-Bu 1-Npm 0.91 482 C Bnzl IIF-417 4-OH- H 1-Npm 1-Npm 0.98 566 C Bnzl IIF-418 i-Bu H 4-OH- Bnzl 0.81 432 C Bnzl IIF-419 i-Bu H i-Bu 2-Cbx-Et 0.71 364 C IIF-420 i-Bu H Bnzl 2-Cbx-Et 0.73 398 C IIF-421 i-Bu H 4-OH- 2-Cbx-Et 0.65 414 C Bnzl IIF-422 i-Bu H i-Pr 2-Cbx-Et 0.65 350 C IIF-423 i-Bu H 4-OH- 1-Npm 0.87 482 C Bnzl IIF-424 i-Bu H 2-Cbx- 1-Npm 0.81 448 C Et IIF-425 Bnzl H 2-Cbx- Bnzl 0.76 432 C Et IIF-426 Bnzl H s-Bu 4-OH-Bnzl 0.81 432 C IIF-427 Bnzl H 1-Npm 4-OH-Bnzl 0.90 516 C IIF-428 Bnzl H i-Pr 4-OH-Bnzl 0.77 418 C IIF-429 Bnzl H s-Bu 2-Cbx-Et 0.73 398 C IIF-430 Bnzl H i-Pr 2-Cbx-Et 0.69 384 C IIF-431 4-OH- H i-Pr Bnzl 0.8 418 C Bnzl IIF-432 4-OH- H i-Pr 2-Cbx-Et 0.65 400 C Bnzl IIF-433 4-OH- H i-Pr 1-Npm 0.87 468 C Bnzl IIF-434 2-Cbx- H i-Bu Bnzl 0.80 398 C Et IIF-435 1-Npm H 4-OH- Bnzl 0.89 516 C Bnzl IIF-436 1-Npm H Bnzl 4-OH-Bnzl 0.87 516 C IIF-437 1-Npm H 2-Cbx- 4-OH-Bnzl 0.73 498 C Et IIF-438 1-Npm H s-Bu 4-OH-Bnzl 0.86 482 C IIF-439 1-Npm H 1-Npm 4-OH-Bnzl 0.94 566 C IIF-440 1-Npm H i-Pr 4-OH-Bnzl 0.82 468 C IIF-441 1-Npm H Bnzl 2-Cbx-Et 0.81 482 C IIF-442 1-Npm H 4-OH- 2-Cbx-Et 0.74 498 C Bnzl IIF-443 1-Npm H s-Bu 2-Cbx-Et 0.79 448 C IIF-444 1-Npm H 1-Npm 2-Cbx-Et 0.88 532 C IIF-445 1-Npm H 4-OH- 1-Npm 0.96 566 C Bnzl IIF-446 1-Npm H 2-Cbx- 1-Npm 0.88 532 C Et IIF-447 i-Bu H 4-OH- i-Bu 0.78 398 C Bnzl IIF-448 i-Bu H 2-Cbx- i-Bu 0.70 364 C Et IIF-449 i-Bu H 1-Npm 3-Gun-Pr 0.72 475 C IIF-450 Bnzl H i-Bu 2-Cbx-Et 0.73 398 C IIF-451 2-Cbx- H Bnzl i-Bu 0.80 398 C Et IIF-452 2-Cbx- H 4-OH- i-Bu 0.70 414 C Et Bnzl IIF-453 2-Cbx- H s-Bu i-Bu 0.78 364 C Et IIF-454 2-Cbx- H 1-Npm i-Bu 0.88 448 C Et IIF-455 2-Cbx- H i-Pr i-Bu 0.74 350 C Et IIF-456 2-Cbx- H 1-Npm Bnzl 0.88 482 C Et IIF-457 2-Cbx- H Bnzl 4-OH-Bnzl 0.77 448 C Et IIF-458 2-Cbx- H 1-Npm 4-OH-Bnzl 0.84 498 C Et

TABLE 2-16 IIF-459 2-Cbx- H i-Bu 1-Npm 0.86 448 C Et IIF-460 2-Cbx- H 4-OH 1-Npm 0.77 498 C Et Bnzl IIF-461 2-Cbx- H 1-Npm 1-Npm 0.94 532 C Et IIF-462 2-Cbx- H i-Pr 1-Npm 0.82 434 C Et IIF-463 1-Npm H 4-OH- i-Bu 0.87 482 C Bnzl IIF-464 1-Npm H i-Bu 4-OH- 0.85 482 C Bnzl IIF-465 1-Npm H i-Bu 2-Cbx- 0.78 448 C Et IIF-466 1-Npm H i-Pr 2-Cbx- 0.75 434 C Et IIF-467 1-Npm H 3-Gun- 1-Npm 0.78 559 C Pr IIF-468 i-Bu H 3-Gun- i-Bu 0.63 391 C Pr IIF-469 i-Bu H 3-Gun- Bnzl 0.66 425 C Pr IIF-470 i-Bu H s-Bu 2-Cbx- 0.70 364 C Et IIF-471 i-Bu H i-Bu 3-Gun- 0.62 391 C Pr IIF-472 i-Bu H Bnzl 3-Gun- 0.65 425 C Pr IIF-473 i-Bu H s-Bu 3-Gun- 0.62 391 C Pr IIF-474 i-Bu H i-Pr 3-Gun- 0.58 377 C Pr IIF-475 i-Bu H 3-Gun- 1-Npm 0.72 475 C Pr IIF-476 Bnzl H 3-Gun- i-Bu 0.67 425 C Pr IIF-477 Bnzl H 3-Gun- Bnzl 0.69 459 C Pr IIF-478 Bnzl H i-Bu 3-Gun- 0.64 425 C Pr IIF-479 Bnzl H Bnzl 3-Gun- 0.66 459 C Pr IIF-480 Bnzl H s-Bu 3-Gun- 0.64 425 C Pr IIF-481 Bnzl H 1-Npm 3-Gun- 0.73 509 C Pr IIF-482 Bnzl H 3-Gun- 1-Npm 0.74 509 C Pr IIF-483 2-Cbx- H i-Bu i-Bu 0.79 364 C Et IIF-484 2-Cbx- H Bnzl Bnzl 0.81 432 C Et IIF-485 2-Cbx- H 4-OH- Bnzl 0.72 448 C Et Bnzl IIF-486 2-Cbx- H s-Bu Bnzl 0.79 398 C Et IIF-487 2-Cbx- H i-Pr Bnzl 0.75 384 C Et IIF-488 2-Cbx- H i-Bu 4-OH- 0.75 414 C Et Bnzl IIF-489 2-Cbx- H i-Pr 4-OH- 0.70 400 C Et Bnzl IIF-490 2-Cbx- H Bnzl 1-Npm 0.87 482 C Et IIF-491 2-Cbx- H s-Bu 1-Npm 0.86 448 C Et IIF-492 3-Gun- H 1-Npm i-Bu 0.79 475 C Pr IIF-493 3-Gun- H i-Pr i-Bu 0.67 377 C Pr IIF-494 3-Gun- H i-Pr Bnzl 0.66 411 C Pr IIF-495 3-Gun- H 1-Npm 1-Npm 0.83 559 C Pr IIF-496 3-Gun- H i-Pr 1-Npm 0.73 461 C Pr IIF-497 3- H 4-F- 1-Npm 1.00 542 C tert- Bnzl butoxy- propyl IIF-498 3- H 4-F- 1-Npm 0.88 486 C hydroxy- Bnzl propyl IIF-499 3-amino- H 3- 3- 1.02 751 C propyl amino- amino- propyl propyl IIF-500 1-Npm H β- Ph—Et 0.93 544 C hydroxy- phenethyl IIF-501 1-Npm H α- Ph—Et 0.92 558 C (hydroxy- methyl) phenethyl IIF-502 1-Npm H α- Ph—Et 0.95 558 C (hydroxy- methyl) phenethyl

TABLE 2-17 IIF-503 4-Nt- H Bnzl tBOC-E 0.93 533 C Bnzl IIF-504 2-OH- H Ph—Et 1-Npm 0.89 468.3 C Et IIF-505 Chm H 2- 1-Npm 0.86 460.3 C OH—Et IIF-506 2-OH—Et H Benzl 1-Npm 0.87 454.3 C IIF-507 Ph—Et H 1-Npm Hxy 1.06 508.4 C IIF-508 1-Npm H Ph—Et Hxy 1.04 508.4 C IIF-509 Hxy H Ph—Et 1-Npm 1.04 508.4 C IIF-510 Hxy H 1-Npm Ph—Et 1.03 508.4 C IIF-511 i-Pnt H i-Pr i-Bu 3.25 348 F IIF-512 Chm H i-Pr i-Bu 3.49 374 F IIF-513 Chm H i-Pr i-Pnt 3.74 388 F IIF-514 i-Bu H s-Bu i-Pnt 3.55 362 F IIF-515 i-Pnt H s-Bu i-Bu 3.45 362 F IIF-516 Chm H s-Bu i-Bu 3.72 388 F IIF-517 Chm H s-Bu Ph—Et 4 436 F IIF-518 Chm H s-Bu i-Pnt 4.02 402 F IIF-519 i-Bu H i-Pnt i-Bu 3.52 362 F IIF-520 Chm H i-Pnt i-Bu 3.99 402 F IIF-521 i-Bu H Hxy i-Bu 3.88 376 F IIF-522 Chm H Hxy i-Bu 4.34 416 F IIF-523 2-Cbx- H Bnzl i-Pnt 3.3 412 F Et IIF-524 Ph—Et H Bnzl 2-Cbx- 3.02 446 F Et IIF-525 4-F- H Bnzl 2-Cbx- 2.85 450 F Bnzl Et IIF-526 2- H Bnzl 2-Cbx- 2.45 386 F OH—Et Et IIF-527 i-Pnt H Bnzl 2-Cbx- 2.85 412 F Et IIF-528 i-Pnt H Bnzl 2- 2.84 384 F OH—Et IIF-529 Chm H Bnzl 2-Cbx- 3 438 F Et IIF-530 2-Cbx- H i-Bu Ph—Et 3.17 412 F Et IIF-531 2-Cbx- H i-Bu i-Pnt 3.12 378 F Et IIF-532 4-F-Bnzl H i-Bu 2-Cbx- 2.69 416 F Et IIF-533 2- H i-Bu 2-Cbx- 3.49 352 G OH—Et Et IIF-534 i-Pnt H i-Bu 4-OH- 3.12 412 F Bnzl IIF-535 Chm H i-Bu 2-Cbx- 2.84 404 F Et IIF-536 2- H 1-Npm Ph—Et 3.72 496 F Cbx- Et IIF-537 2-Cbx- H 1-Npm i-Pnt 3.65 462 F Et IIF-538 Ph—Et H 1-Npm 2-Cbx- 3.47 496 F Et IIF-539 4-F-Bnzl H 1-Npm 2-Cbx- 3.3 500 F Et IIF-540 2- H 1-Npm 2-Cbx- 2.87 436 F OH—Et Et IIF-541 i-Pnt H 1-Npm 2-Cbx- 3.34 462 F Et IIF-542 Chm H 1-Npm 2-Cbx- 3.4 488 F Et IIF-543 4- H i-Pr Ph—Et 3.19 432 F OH-Bnzl IIF-544 4- H i-Pr i-Pnt 3.09 398 F OH- Bnzl IIF-545 2-Cbx- H i-Pr Ph—Et 2.92 398 F Et IIF-546 2- H i-Pr 2- 3.02 338 G Cbx-Et OH—Et IIF-547 Ph—Et H i-Pr 2-Cbx- 2.65 398 F Et IIF-548 Ph—Et H i-Pr 2- 2.62 370 F OH—Et IIF-549 4-F- H i-Pr 2-Cbx- 2.5 402 F Bnzl Et IIF-550 4-F- H i-Pr 2- 2.47 374 F Bnzl OH—Et IIF-551 2- H i-Pr Bnzl 2.69 356 F OH—Et IIF-552 2- H i-Pr i-Bu 2.57 322 F OH—Et

TABLE 2-18 IIF-553 2- H I-Pr 1-Npm 3.07 406 F OH—Et IIF-554 2- H i-Pr 4- 2.45 372 F OH—Et OH-Bnzl IIF-555 2- H i-Pr 2-Cbx- 3.12 338 G OH—Et Et IIF-556 2- H i-Pr Ph—Et 2.9 370 F OH—Et IIF-557 2- H i-Pr i-Pnt 2.82 336 F OH—Et IIF-558 i-Pnt H i-Pr 4- 2.88 398 F OH- Bnzl IIF-559 i-Pnt H i-Pr 2-Cbx- 2.49 364 F Et IIF-560 i-Pnt H i-Pr 2- 3.67 336 G OH—Et IIF-561 i-Bu H s-Bu 2- 3.69 336 G OH—Et IIF-562 4- H s-Bu Ph—Et 3.35 446 F OH-Bnzl IIF-563 4- H s-Bu i-Pnt 3.2 412 F OH-Bnzl IIF-564 2- H s-Bu i-Pnt 3.09 378 F Cbx-Et IIF-565 Ph—Et H s-Bu 2-Cbx- 2.8 412 F Et IIF-566 4-F- H s-Bu 2-Cbx- 2.69 416 F Bnzl Et IIF-567 2- H s-Bu 4-OH- 2.67 386 F OH—Et Bnzl IIF-568 2- H s-Bu 2-Cbx- 3.47 352 G OH—Et Et IIF-569 i-Pnt H s-Bu 4-OH- 3.07 412 F Bnzl IIF-570 i-Pnt H s-Bu 2-Cbx- 2.67 378 F Et IIF-571 Chm H s-Bu 4- 3.2 438 F OH-Bnzl IIF-572 Chm H s-Bu 2-Cbx- 2.8 404 F Et IIF-573 i-Bu H 4- i-Pnt 3.1 412 F OH- Bnzl IIF-574 2-Cbx- H 4- Ph—Et 2.77 462 F Et OH- Bnzl IIF-575 2-Cbx- H 4- i-Pnt 2.72 428 F Et OH- Bnzl IIF-576 Ph—Et H 4- 2-Cbx- 2.67 462 F OH- Et Bnzl IIF-577 4-F-Bnzl H 4- 2-Cbx- 2.55 466 F OH- Et Bnzl IIF-578 2-OH-Et H 4- 2-Cbx- 3.2 402 G OH- Et Bnzl IIF-579 i-Pnt H 4- 2-Cbx- 2.52 428 F OH- Et Bnzl IIF-580 Chm H 4- 2-Cbx- 2.67 454 F OH- Et Bnzl IIF-581 i-Bu H 2- Ph—Et 2.82 412 F Cbx- Et IIF-582 i-Bu H 2- i-Pnt 2.72 378 F Cbx- Et IIF-583 i-Pnt H 2- i-Bu 2.74 378 F Cbx- Et IIF-584 i-Pnt H 2- 4-OH- 2.45 428 F Cbx- Bnzl Et IIF-585 Chm H 2- i-Bu 2.94 404 F Cbx- Et IIF-586 Chm H 2- i-Pnt 3.17 418 F Cbx- Et IIF-587 Bnzl H 4-F- 4-OH- 3.25 484 F Bnzl Bnzl IIF-588 Bnzl H 4-F- 2-Cbx- 2.88 450 F Bnzl Et IIF-589 i-Bu H 4-F- 4-OH- 3.12 450 F Bnzl Bnzl IIF-590 i-Bu H 4-F- 2-Cbx- 2.72 416 F Bnzl Et IIF-591 1-Npm H 4-F- 4-OH- 3.5 534 F Bnzl Bnzl IIF-592 1-Npm H 4-F- 2-Cbx- 3.13 500 F Bnzl Et IIF-593 4-OH- H 4-F- 2-Cbx- 2.7 466 F Bnzl Bnzl Et IIF-594 4-OH- H 4-F- Ph—Et 3.5 498 F Bnzl Bnzl IIF-595 4-OH- H 4-F- i-Pnt 3.44 464 F Bnzl Bnzl IIF-596 2-Cbx- H 4-F- 4-OH- 2.9 466 F Et Bnzl Bnzl IIF-597 2-Cbx- H 4-F- Ph—Et 3.32 464 F Et Bnzl IIF-598 2-Cbx- H 4-F- i-Pnt 3.25 430 F Et Bnzl IIF-599 Ph—Et H 4-F- 4-OH- 3.42 498 F Bnzl Bnzl IIF-600 Ph—Et H 4-F- 2-Cbx- 3.07 464 F Bnzl Et IIF-601 2-OH- H 4-F- 4-OH- 2.84 438 F Et Bnzl Bnzl IIF-602 2-OH- H 4-F- 2-Cbx- 2.52 404 F Et Bnzl Et

TABLE 2-19 IIF-603 i- H 4-F- 4-OH- 3.27 464 F Pnt Bnzl Bnzl IIF-604 Chm H 4-F- 4-OH- 3.37 490 F Bnzl Bnzl IIF-605 Chm H 4-F- 2-Cbx- 3 456 F Bnzl Et IIF-606 i-Bu H i-Pnt 2-Cbx- 2.72 378 F Et IIF-607 4- H i-Pnt 2-Cbx- 2.72 428 F OH- Et Bnzl IIF-608 2-Cbx- H i-Pnt i-Bu 3.1 378 F Et IIF-609 2-Cbx- H i-Pnt 4-OH- 2.94 428 F Et Bnzl IIF-610 2-OH- H i-Pnt i-Bu 3.04 350 F Et IIF-611 Chm H i-Pnt 2-Cbx- 3.05 418 F Et IIF-612 i-Bu H 2-OH- i-Bu 2.43 336 F Et IIF-613 i-Bu H 2-OH- 4-OH- 1.34 386 F Et Bnzl IIF-614 i-Bu H 2-OH- 2-Cbx- 2.57 352 F Et Et IIF-615 1-Npm H 2-OH- 4-OH- 2.62 470 F Et Bnzl IIF-616 1-Npm H 2-OH- 2-Cbx- 2.45 436 F Et Et IIF-617 4-OH- H 2-OH- Bnzl 2.43 420 F Bnzl Et IIF-618 4-OH- H 2-OH- 1-Npm 2.74 470 F Bnzl Et IIF-619 4-OH- H 2-OH- i-Pnt 2.45 400 F Bnzl Et IIF-620 2-Cbx- H 2-OH- Bnzl 3.32 386 F Et Et IIF-621 2-Cbx- H 2-OH- 4-OH- 2.94 402 G Et Et Bnzl IIF-622 2-Cbx- H 2-OH- i-Pnt 3.42 366 G Et Et IIF-623 Bnzl H Ph—Et 4-OH- 3.29 480 F Bnzl IIF-624 Bnzl H Ph—Et 2-Cbx- 2.9 446 F Et IIF-625 i-Bu H Ph—Et 4-OH- 3.15 446 F Bnzl IIF-626 i-Bu H Ph—Et 2-Cbx- 2.77 412 F Et IIF-627 1-Npm H Ph—Et 4-OH- 3.55 530 F Bnzl IIF-628 4-OH- H Ph—Et i-Pnt 3.57 460 F Bnzl IIF-629 2-Cbx- H Ph—Et 4-OH- 2.95 462 F Et Bnzl IIF-630 4-F- H Ph—Et 4-OH- 3.3 498 F Bnzl Bnzl IIF-631 2-OH- H Ph—Et 4-OH- 2.88 434 F Et Bnzl IIF-632 i-Pnt H Ph—Et 4-OH- 3.37 460 F Bnzl IIF-633 i-Pnt H Ph—Et 2-Cbx- 2.99 426 F Et IIF-634 Chm H Ph—Et 4-OH- 3.47 486 F Bnzl IIF-635 Chm H Ph—Et 2-Cbx- 3.1 452 F Et IIF-636 Bnzl H Hxy 2-Cbx- 3.15 426 F Et IIF-637 4-OH- H Hxy 1-Npm 4.15 510 F Bnzl IIF-638 4-OH- H Hxy 2-Cbx- 3 442 F Bnzl Et IIF-639 2-Cbx- H Hxy i-Bu 3.4 392 F Et IIF-640 2-Cbx- H Hxy 1-Npm 3.85 476 F Et IIF-641 2-Cbx- H Hxy 4-OH- 3.22 442 F Et Bnzl IIF-642 2-Cbx- H Hxy i-Pnt 3.65 406 F Et IIF-643 Ph—Et H Hxy 2-Cbx- 3.37 440 F Et IIF-644 4-F- H Hxy 2-Cbx- 3.2 444 F Bnzl Et IIF-645 2- H Hxy i-Bu 3.35 364 F OH—Et IIF-646 2- H Hxy 4-OH- 3.15 414 F OH—Et Bnzl IIF-647 2- H Hxy 2-Cbx- 2.79 380 F OH—Et Et IIF-648 2- H Hxy i-Pnt 3.55 378 F OH—Et IIF-649 i-Pnt H Hxy 4-OH- 3.69 440 F Bnzl IIF-650 i-Pnt H Hxy 2-Cbx- 3.24 406 F Et IIF-651 i-Pnt H Hxy 2- 3.24 378 F OH—Et IIF-652 Chm H Hxy 4-OH- 3.75 466 F Bnzl

TABLE 2-20 IIF-653 Chm H Hxy 2-Cbx- 3.35 432 F Et IIF-654 tBOC- H Bnzl i-Pnt 4.09 468 F E IIF-655 Ph—Et H Bnzl tBOC- 4.04 502 F E IIF-656 4-F- H Bnzl tBOC- 3.8 506 F Bnzl E IIF-657 tBOC- H i-Bu Ph—Et 3.92 468 F E IIF-658 4-F- H i-Bu tBOC- 3.7 472 F Bnzl E IIF-659 i-Pnt H i-Bu 4-tBuO- 4.39 468 F Bnzl IIF-660 Chm H i-Bu 4-tBuO- 4.35 494 F Bnzl IIF-661 Chm H i-Bu tBOC- 3.94 460 E E IIF-662 tBOC- H 1-Npm Ph—Et 4.47 552 F E IIF-663 tBOC- H 1-Npm i-Pnt 4.52 518 F E IIF-664 Ph—Et H 1-Npm tBOC- 4.39 552 F E IIF-665 4-F- H 1-Npm tBOC- 4.25 556 F Bnzl E IIF-666 2- H 1-Npm tBOC- 4.89 548 F OtBu- E Et IIF-667 i-Pnt H 1-Npm tBOC- 4.35 518 F E IIF-668 Chm H 1-Npm tBOC- 4.54 544 F E IIF-669 4- H i-Pr i-Pnt 4.07 454 F tBuO- Bnzl IIF-670 tBOC- H i-Pr Ph—Et 3.72 454 F E IIF-671 2- H i-Pr 1-Npm 3.87 462 F OtBu- Et IIF-672 2- H i-Pr 4-tBuO- 3.9 484 F OtBu- Bnzl Et IIF-673 Chm H i-Pr 4-tBuO- 4.07 480 F Bnzl IIF-674 4- H s-Bu Ph—Et 4.22 502 F tBuO- Bnzl IIF-675 4- H s-Bu i-Pnt 4.07 468 F tBuO- Bnzl IIF-676 tBOC- H s-Bu i-Pnt 3.82 434 F E IFF-677 Ph—Et H s-Bu tBOC- 3.84 468 F E IIF-678 4-F- H s-Bu tBOC- 3.95 472 F Bnzl E IIF-679 2- H s-Bu tBOC- 3.7 464 F OtBu- E Et IIF-680 i-Pnt H s-Bu 4-tBuO- 4.12 468 F Bnzl IIF-681 i-Pnt H s-Bu tBOC- 3.7 434 F E IIF-682 Chm H s-Bu 4-tBuO- 4.35 494 F Bnzl IIF-683 i-Bu H 4- i-Pnt 4.07 468 F tBuO- Bnzl IIF-684 tBOC- H 4- Ph—Et 4.52 574 F E tBuO- Bnzl IIF-685 tBOC- H 4- i-Pnt 4.42 540 F E tBuO- Bnzl IIF-686 Ph—Et H 4- tBOC- 4.52 574 F tBuO- E Bnzl IIF-687 4-F- H 4- tBOC- 4.22 578 F Bnzl tBuO- E Bnzl IIF-688 Chm H 4- tBOC- 4.54 566 F tBuO- E Bnzl IIF-689 i-Bu H tBOC- i-Pnt 3.7 434 F E IIF-690 Bnzl H 4-F- 4-tBuO- 4.17 540 F Bnzl Bnzl IIF-691 i-Bu H 4-F- 4-tBuO- 3.99 506 F Bnzl Bnzl IIF-692 i-Bu H 4-F- tBOC- 3.67 472 F Bnzl E IIF-693 1-Npm H 4-F- 4-tBuO- 4.59 590 F Bnzl Bnzl IIF-694 1-Npm H 4-F- tBOC- 4.17 556 F Bnzl E IIF-695 4- H 4-F- tBOC- 4.34 578 F tBuO- Bnzl E Bnzl IIF-696 4- H 4-F- Ph—Et 4.75 554 F tBuO- Bnzl Bnzl IIF-697 4- H 4-F- i-Pnt 4.42 520 F tBuO- Bnzl Bnzl IIF-698 tBOC- H 4-F- 4-tBuO- 4.39 578 F E Bnzl Bnzl IIF-699 tBOC- H 4-F- i-Pnt 4.09 486 F E Bnzl IIF-700 Ph—Et H 4-F- 4-tBuO- 4.34 554 F Bnzl Bnzl IIF-701 2- H 4-F- 4-tBuO- 4.32 550 F OtBu- Bnzl Bnzl Et

TABLE 2-21 IIF-703 Chm H 4-F- 4-tBuO- 4.39 546 F Bnzl Bnzl IIF-704 Chm H 4-F- tBOC- 4.05 512 F Bnzl E IIF-705 4- H i-Pnt tBOC- 4.32 540 F tBuO- E Bnzl IIF-706 tBOC- H i-Pnt 4-tBuO- 4.54 540 F E Bnzl IIF-707 i-Bu H 2- 4-tBuO- 3.87 498 F OtBu- Bnzl Et IIF-708 1-Npm H 2- 4-tBuO- 4.47 582 F OtBu- Bnzl Et IIF-709 1-Npm H 2- tBOC- 4 548 F OtBu- E Et IIF-710 4- H 2- Bnzl 4.02 532 F tBuO- OtBu- Bnzl Et IIF-711 4- H 2- i-Pnt 4.25 512 F tBuO- OtBu- Bnzl Et IIF-712 tBOC- H 2- Bnzl 3.67 498 F E OtBu- Et IIF-713 tBOC- H 2- 4-tBuO- 4.17 570 F E OtBu- Bnzl Et IIF-714 Bnzl H Ph—Et 4-tBuO- 4.25 536 F Bnzl IIF-715 i-Bu H Ph—Et 4-tBuO- 4.1 502 F Bnzl IIF-716 1-Npm H Ph—Et 4-tBuO- 4.59 586 F Bnzl IIF-717 1-Npm H Ph—Et tBOC- 4.2 552 F E IIF-718 4-F- H Ph—Et 4-tBuO- 4.29 554 F Bnzl Bnzl IIF-719 2- H Ph—Et 4-tBuO- 4.39 546 F OtBu- Bnzl Et IIF-720 i-Pnt H Ph—Et 4-tBuO- 4.37 516 F Bnzl IIF-721 Chm H Ph—Et 4-tBuO- 4.54 542 F IIF-722 Chm H Ph—Et tBOC- 4.05 508 F E IIF-723 4- H Hxy 1-Npm 5.09 566 F tBuO- Bnzl IIF-724 4- H Hxy tBOC- 4.74 554 F tBuO- E Bnzl IIF-725 tBOC- H Hxy 4-tBuO- 4.8 554 F E Bnzl IIF-726 Ph—Et H Hxy tBOC- 4.45 496 F E IIF-727 4-F- H Hxy tBOC- 4.27 500 F Bnzl E IIF-728 2- H Hxy 4-tBuO- 4.79 526 F OtBu- Bnzl Et IIF-729 2- H Hxy i-Pnt 4.42 434 F OtBu- Et IIF-730 i-Pnt H Hxy 4-tBuO- 4.74 496 F Bnzl IIF-731 Chm H Hxy 4-tBuO- 4.87 522 F Bnzl IIF-732 i-Bu H i-Bu Ph—Et 3.11 396 H IIF-733 i-Bu H i-Bu i-Pnt 2.96 362 H IIF-734 1-Npm H i-Bu i-Pnt 3.25 446 H IIF-735 4-F- H i-Bu i-Bu 2.88 400 H Bnzl IIF-736 4-F- H i-Bu 1-Npm 3.12 484 H Bnzl IIF-737 4-F- H i-Bu Ph—Et 2.98 448 H Bnzl IIF-738 4-F- H i-Bu i-Pnt 2.98 414 H Bnzl IIF-739 i-Pnt H i-Bu i-Bu 2.92 362 H IIF-740 i-Pnt H i-Bu 1-Npm 3.17 446 H IIF-741 i-Pnt H i-Bu Ph—Et 2.99 410 H IIF-742 Chm H i-Bu i-Bu 2.99 388 H IIF-743 Chm H i-Bu 1-Npm 3.31 472 H IIF-744 Chm H i-Bu Ph—Et 3.1 436 H IIF-745 Chm H i-Bu i-Pnt 3.13 402 H IIF-746 Bnzl H Bnzl Ph—Et 3.22 464 H IIF-747 1-Npm H Bnzl i-Pnt 3.17 480 H IIF-748 Ph—Et H Bnzl 1-Npm 3.27 514 H IIF-749 Ph—Et H Bnzl i-Pnt 3.12 444 H IIF-750 4-F- H Bnzl 1-Npm 3.19 518 H Bnzl IIF-751 4-F- H Bnzl Ph—Et 3.02 482 H Bnzl IIF-752 4-F- H Bnzl i-Pnt 3.05 448 H Bnzl

TABLE 2-22 IIF-753 i-Pnt H Bnzl 1-Npm 3.2 480 H IIF-754 Chm H Bnzl 1-Npm 3.3 506 H IIF-755 Chm H Bnzl Ph—Et 3.12 470 H IIF-756 Chm H Bnzl i-Pnt 3.15 436 H IIF-757 Bnzl H 1-Npm Ph—Et 3.22 514 H IIF-758 Bnzl H 1-Npm i-Pnt 3.27 480 H IIF-759 i-Bu H 1-Npm i-Pnt 3.13 446 H IIF-760 1-Npm H 1-Npm Ph—Et 3.34 564 H IIF-761 1-Npm H 1-Npm i-Pnt 3.38 530 H IIF-762 Ph—Et H 1-Npm Bnzl 3.27 514 H IIF-763 Ph—Et H 1-Npm i-Bu 3.22 480 H IIF-764 Ph—Et H 1-Npm 1-Npm 3.42 564 H IIF-765 Ph—Et H 1-Npm i-Pnt 3.32 494 H IIF-766 4-F- H 1-Npm 1-Npm 3.36 568 H Bnzl IIF-767 4-F- H 1-Npm Ph—Et 3.22 532 H Bnzl IIF-768 4-F- H 1-Npm i-Pnt 3.24 498 H Bnzl IIF-769 i-Pnt H 1-Npm i-Bu 3.22 446 H IIF-770 i-Pnt H 1-Npm 1-Npm 3.39 530 H IIF-771 i-Pnt H 1-Npm Ph—Et 3.27 494 H IIF-772 Chm H 1-Npm Bnzl 3.38 506 H IIF-773 Chm H 1-Npm i-Bu 3.3 472 H IIF-774 Chm H 1-Npm 1-Npm 3.49 556 H IIF-775 Chm H 1-Npm Ph—Et 3.36 520 H IIF-776 Chm H 1-Npm i-Pnt 3.38 486 H IIF-777 Bnzl H i-Pr Ph—Et 3 416 H IIF-778 Bnzl H i-Pr i-Pnt 3.01 382 H IIF-779 i-Bu H i-Pr Ph—Et 2.93 382 H IIF-780 1-Npm H i-Pr Ph—Et 3.14 466 H IIF-781 1-Npm H i-Pr i-Pnt 3.17 432 H IIF-782 Ph—Et H i-Pr Bnzl 2.99 416 H IIF-783 Ph—Et H i-Pr i-Bu 2.95 382 H IIF-784 Ph—Et H i-Pr 1-Npm 3.22 466 H IIF-785 Ph—Et H i-Pr i-Pnt 3.08 396 H IIF-786 4-F- H i-Pr Bnzl 2.92 420 H Bnzl IIF-787 4-F- H i-Pr i-Bu 2.92 386 H Bnzl IIF-788 4-F- H i-Pr 1-Npm 3.14 470 H Bnzl IIF-789 4-F- H i-Pr Ph—Et 2.98 434 H Bnzl IIF-790 4-F- H i-Pr i-Pnt 2.97 400 H Bnzl IIF-791 i-Pnt H i-Pr Bnzl 2.91 382 H IIF-792 i-Pnt H i-Pr 1-Npm 3.16 432 H IIF-793 i-Pnt H i-Pr Ph—Et 3.02 396 H IIF-794 Chm H i-Pr Bnzl 3.05 408 H IIF-795 Chm H i-Pr 1-Npm 3.28 458 H IIF-796 Chm H i-Pr Ph—Et 3.09 422 H IIF-797 Bnzl H s-Bu Ph—Et 3.07 430 H IIF-798 Bnzl H s-Bu i-Pnt 3.07 396 H IIF-799 i-Bu H s-Bu Ph—Et 3 396 H IIF-800 1-Npm H s-Bu Ph—Et 3.21 480 H IIF-801 1-Npm H s-Bu i-Pnt 3.22 446 H IIF-802 Ph—Et H s-Bu Bnzl 3.09 430 H

TABLE 2-23 IIF-803 Ph—Et H s-Bu i-Bu 3.05 396 H IIF-804 Ph—Et H s-Bu 1-Npm 3.28 480 H IIF-805 Ph—Et H s-Bu i-Pnt 3.17 410 H IIF-806 4-F- H s-Bu Bnzl 3.07 434 H Bnzl IIF-807 4-F- H s-Bu i-Bu 2.97 400 H Bnzl IIF-808 4-F- H s-Bu 1-Npm 3.22 484 H Bnzl IIF-809 4-F- H s-Bu Ph—Et 3.06 448 H Bnzl IIF-810 4-F- H s-Bu i-Pnt 3.1 414 H Bnzl IIF-811 i-Pnt H s-Bu Bnzl 3.05 396 H IIF-812 i-Pnt H s-Bu 1-Npm 3.25 446 H IIF-813 Chm H s-Bu Bnzl 3.15 422 H IIF-814 Chm H s-Bu 1-Npm 3.34 472 H IIF-815 Bnzl H Ph—Et Bnzl 3.07 464 H IIF-816 Bnzl H Ph—Et 1-Npm 3.31 514 H IIF-817 Bnzl H Ph—Et i-Pnt 3.15 444 H IIF-818 i-Bu H Ph—Et i-Bu 2.96 396 H IIF-819 i-Bu H Ph—Et 1-Npm 3.22 480 H IIF-820 i-Bu H Ph—Et i-Pnt 4.26 410 H IIF-821 1-Npm H Ph—Et Bnzl 3.29 514 H IIF-822 1-Npm H Ph—Et i-Bu 3.26 480 H IIF-823 1-Npm H Ph—Et 1-Npm 3.42 564 H IIF-824 4-F- H Ph—Et Bnzl 3.08 482 H Bnzol IIF-825 4-F- H Ph—Et i-Bu 3.04 448 H Bnzl IIF-826 4-F- H Ph—Et 1-Npm 3.24 532 H Bnzl IIF-827 4-F- H Ph—Et i-Pnt 3.13 462 H Bnzl IIF-828 i-Pnt H Ph—Et i-Bu 3.07 410 H IIF-829 i-Pnt H Ph—Et 1-Npm 3.28 494 H IIF-830 Chm H Ph—Et Bnzl 3.19 470 H IIF-831 Chm H Ph—Et i-Bu 3.12 436 H IIF-832 Chm H Ph—Et 1-Npm 3.34 520 H IIF-833 Chm H Ph—Et i-Pnt 3.24 450 H IIF-834 Bnzl H 4-F- Bnzl 3.03 468 H Bnzl IIF-835 Bnzl H 4-F- 1-Npm 3.19 518 H Bnzl IIF-836 Bnzl H 4-F- Ph—Et 3.06 482 H Bnzl IIF-837 Bnzl H 4-F- i-Pnt 3.08 448 H Bnzl IIF-838 i-Bu H 4-F- i-Bu 2.92 400 H Bnzl IIF-839 i-Bu H 4-F- 1-Npm 3.16 484 H Bnzl IIF-840 i-Bu H 4-F- i-Pnt 3.03 414 H Bnzl IIF-841 1-Npm H 4-F- Bnzl 3.31 518 H Bnzl IIF-842 1-Npm H 4-F- i-Bu 3.23 484 H Bnzl IIF-843 1-Npm H 4-F- 1-Npm 3.47 568 H Bnzl IIF-844 1-Npm H 4-F- Ph—Et 3.29 532 H Bnzl IIF-845 1-Npm H 4-F- i-Pnt 3.31 498 H Bnzl IIF-846 Ph—Et H 4-F- Bnzl 3.16 482 H Bnzl IIF-847 Ph—Et H 4-F- i-Bu 3.11 448 H Bnzl IIF-848 Ph—Et H 4-F- 1-Npm 3.31 532 H Bnzl IIF-849 Ph—Et H 4-F- i-Pnt 3.2 462 H Bnzl IIF-850 i-Pnt H 4-F- Bnzl 3.05 448 H Bnzl IIF-851 i-Pnt H 4-F- 1-Npm 3.21 498 H Bnzl IIF-852 i-Pnt H 4-F- Ph—Et 3.13 462 H Bnzl

TABLE 2-24 IIF-853 Chm H 4-F- Bnzl 3.12 474 H Bnzl IIF-854 Chm H 4-F- i-Bu 3.09 440 H Bnzl IIF-855 Chm H 4-F- 1-Npm 3.3 524 H Bnzl IIF-856 Chm H 4-F- Ph—Et 3.21 488 H Bnzl IIF-857 Chm H 4-F- i-Pnt 3.17 454 H Bnzl IIF-858 Bnzl H i-Pnt Bnzl 3.08 430 H IIF-859 Bnzl H i-Pnt 1-Npm 3.28 480 H IIF-860 Bnzl H i-Pnt Ph—Et 3.12 444 H IIF-861 i-Bu H i-Pnt 1-Npm 3.23 446 H IIF-862 i-Bu H i-Pnt Ph—Et 3.11 410 H IIF-863 1-Npm H i-Pnt Bnzl 3.25 480 H IIF-864 1-Npm H i-Pnt i-Bu 3.22 446 H IIF-865 1-Npm H i-Pnt 1-Npm 3.42 530 H IIF-866 Ph—Et H i-Pnt Bnzl 3.16 444 H IIF-867 Ph—Et H i-Pnt i-Bu 3.13 410 H IIF-868 Ph—Et H i-Pnt 1-Npm 3.33 494 H IIF-869 4-F- H i-Pnt Bnzl 3.09 448 H Bnzl IIF-870 4-F- H i-Pnt i-Bu 3.05 414 H Bnzl IIF-871 4-F- H i-Pnt 1-Npm 3.29 498 H Bnzl IIF-872 4-F- H i-Pnt Ph—Et 3.13 462 H Bnzl IIF-873 Chm H i-Pnt Bnzl 3.23 436 H IIF-874 Chm H i-Pnt 1-Npm 3.42 486 H IIF-875 Chm H i-Pnt Ph—Et 3.25 450 H IIF-876 Bnzl H Hxy Bnzl 3.24 444 H IIF-877 Bnzl H Hxy 1-Npm 3.39 494 H IIF-878 Bnzl H Hxy i-Pnt 3.27 424 H IIF-879 i-Bu H Hxy 1-Npm 3.36 460 H IIF-880 1-Npm H Hxy 1-Npm 3.54 544 H IIF-881 1-Npm H Hxy i-Pnt 3.43 474 H IIF-882 Ph—Et H Hxy Bnzl 3.3 458 H IIF-883 Ph—Et H Hxy i-Bu 3.24 424 H IIF-884 Ph—Et H Hxy i-Pnt 3.35 438 H IIF-885 4-F- H Hxy Bnzl 3.23 462 H Bnzl IIF-886 4-F- H Hxy i-Bu 3.17 428 H Bnzl IIF-887 4-F- H Hxy 1-Npm 3.4 512 H Bnzl IIF-888 4-F- H Hxy Ph—Et 3.24 476 H Bnzyl IIF-889 4-F- H Hxy i-Pnt 3.28 442 H Bnzl IIF-890 i-Pnt H Hxy Bnzl 3.26 424 H IIF-891 i-Pnt H Hxy 1-Npm 3.47 474 H IIF-892 Chm H Hxy Bnzl 3.34 450 H IIF-893 Chm H Hxy 1-Npm 3.5 500 H IIF-894 2- H i-Bu Bnzl 4.15 426 H OtBu- Et IIF-895 2- H i-Bu i-Bu 4.18 392 H OtBu- Et IIF-896 2- H i-Bu 1-Npm 4.31 476 H OtBu- Et IIF-897 2- H i-Bu 4- 4.37 498 H OtBu- tBuO- Et Bnzl IIF-898 2- H i-Bu Ph—Et 4.18 440 H OtBu- Et IIF-899 2- H i-Bu i-Pnt 4.28 406 H OtBu- Et IIF-900 2- H Bnzl Bnzl 4.2 460 H OtBu- Et IIF-901 2- H Bnzl i-Bu 4.17 426 H OtBu- Et IIF-902 2- H Bnzl 4- 4.32 532 H OtBu- tBuO- Et Bnzl

TABLE 2-25 IIF-903 2- H Bnzl Ph—Et 4.29 474 H OtBu- Et IIF-904 2- H Bnzl i-Pnt 4.27 440 H OtBu- Et IIF-905 i-Pnt H Bnzl 4-tBuO-Bnzl 3.26 502 H IIF-906 Chm H Bnzl 4-tBuO-Bnzl 3.32 528 H IIF-907 4- H 1-Npm Ph—Et 3.42 586 H tBuO- Bnzl IIF-908 4- H 1-Npm i-Pnt 3.42 552 H tBuO- Bnzl IIF-909 Ph—Et H 1-Npm 4-tBuO-Bnzl 3.4 586 H IIF-910 4-F- H 1-Npm 4-tBuO-Bnzl 3.4 590 H Bnzl IIF-911 2- H 1-Npm Bnzl 4.38 510 H OtBu- Et IIF-912 2- H 1-Npm i-Bu 4.35 476 H OtBu- Et IIF-913 2- H 1-Npm 1-Npm 4.5 560 H OtBu- Et IIF-914 i-Pnt H 1-Npm 4-tBuO-Bnzl 3.43 552 H IIF-915 Chm H 1-Npm 4-tBuO-Bnzl 3.5 578 H IIF-916 Bnzl H 4-tBuO- Ph—Et 3.31 536 H Bnzl IIF-917 Bnzl H 4-tBuO- i-Pnt 3.29 502 H Bnzl IIF-918 i-Bu H 4-tBuO- Ph—Et 3.22 502 H Bnzl IIF-919 1-Npm H 4-tBuO- Ph—Et 3.41 586 H Bnzl IIF-920 1-Npm H 4-tBuO- i-Pnt 3.41 552 H Bnzl IIF-921 Ph—Et H 4-tBuO- Bnzl 3.32 536 H Bnzl IIF-922 Ph—Et H 4-tBuO- 1-Npm 3.43 586 H Bnzl IIF-923 Ph—Et H 4-tBuO- i-Pnt 3.37 516 H Bnzl IIF-924 4-F- H 4-tBuO- Bnzl 3.22 540 H Bnzl Bnzl IIF-925 4-F- H 4-tBuO- 1-Npm 3.38 590 H Bnzl Bnzl IIF-926 4-F- H 4-tBuO- Ph—Et 3.28 554 H Bnzl Bnzl IIF-927 4-F- H 4-tBuO- i-Pnt 3.29 520 H Bnzl Bnzl IIF-928 2- H 4-tBuO- 1-Npm 3.46 582 H OtBu- Bnzl Et IIF-929 i-Pnt H 4-tBuO- i-Bu 3.2 468 H Bnzl IIF-930 i-Pnt H 4-tBuO- 1-Npm 3.42 552 H Bnzl IIF-931 i-Pnt H 4-tBuO- Ph—Et 3.33 516 H Bnzl IIF-932 Chm H 4-tBuO- Bnzl 3.33 528 H Bnzl IIF-933 Chm H 4-tBuO- i-Bu 3.24 494 H Bnzl IIF-934 Chm H 4-tBuO- 1-Npm 3.5 578 H Bnzl IIF-935 Chm H 4-tBuO- Ph—Et 3.41 542 H Bnzl IIF-936 Chm H 4-tBuO- i-Pnt 3.42 508 H Bnzl IIF-937 Bnzl H tBOC-E Ph—Et 3.08 502 H IIF-938 Bnzl H tBOC-E i-Pnt 3.08 468 H IIF-939 1-Npm H tBOC-E Ph—Et 3.25 552 H IIF-940 1-Npm H tBOC-E i-Pnt 3.26 518 H IIF-941 4- H tBOC-E Ph—Et 3.32 574 H tBuO- Bnzl IIF-942 4- H tBOC-E i-Pnt 3.34 540 H tBuO- Bnzl IIF-943 Ph—Et H tBOC-E Bnzl 3.08 502 H IIF-944 Ph—Et H tBOC-E i-Bu 3.12 468 H IIF-945 Ph—Et H tBOC-E 1-Npm 3.27 552 H IIF-946 Ph—Et H tBOC-E 4-tBuO-Bnzl 3.33 574 H IIF-947 Ph—Et H tBOC-E i-Pnt 3.18 482 H IIF-948 4-F- H tBOC-E Bnzl 3.06 506 H Bnzl IIF-949 4-F- H tBOC-E i-Bu 3.04 472 H Bnzl IIF-950 4-F- H tBOC-E 1-Npm 3.23 556 H Bnzl IIF-951 4-F- H tBOC-E 4-tBuO-Bnzl 3.27 578 H Bnzl IIF-952 4-F- H tBOC-E Ph—Et 3.12 520 H Bnzl

TABLE 2-26 IIF-953  4-F- H tBOC-E i-Pnt 3.13 486 H Bnzl IIF-954  2- H tBOC-E Bnzl 3.11 498 H OtBu- Et IIF-955  2- H tBOC-E 1-Npm 3.27 548 H OtBu- Et IIF-956  2- H tBOC-E 4-tBuO-Bnzl 3.37 570 H OtBu- Et IIF-957  2- H tBOC-E Ph—Et 3.17 512 H OtBu- Et IIF-958  i-Pnt H tBOC-E Bnzl 3.08 468 H IIF-959  i-Pnt H tBOC-E 1-Npm 3.22 518 H IIF-960  i-Pnt H tBOC-E Ph—Et 3.13 482 H IIF-961  Chm H tBOC-E Bnzl 3.17 494 H IIF-962  Chm H tBOC-E 1-Npm 3.34 544 H IIF-963  Ph—Et H i-Pr 4-tBuO-Bnzl 3.22 488 H IIF-964  4-F- H i-Pr 4-tBuO-Bnzl 3.16 492 H Bnzl IIF-965  Ph—Et H s-Bu 4-tBuO-Bnzl 3.29 502 H IIF-966  4-F- H s-Bu 4-tBuO-Bnzl 3.29 506 H Bnzl IIF-967  2- H s-Bu Bnzl 3.04 426 H OtBu- Et IIF-968  2- H s-Bu i-Bu 3.03 392 H OtBu- Et IIF-969  2- H s-Bu 1-Npm 3.3 476 H OtBu- Et IIF-970  2- H s-Bu Ph—Et 3.15 440 H OtBu- Et IIF-971  4- H Ph—Et Bnzl 3.33 536 H tBuO- Bnzl IIF-972  4- H Ph—Et i-Bu 3.25 502 H tBuO- Bnzl IIF-973  4- H Ph—Et 1-Npm 3.47 586 H tBuO- Bnzl IIF-974  tBOC- H Ph—Et Bnzl 3.16 502 H E IIF-975  tBOC- H Ph—Et i-Bu 3.13 468 H E IIF-976  tBOC- H Ph—Et 1-Npm 3.35 552 H E IIF-977  2- H Ph—Et Bnzl 3.1 474 H OtBu- Et IIF-978  2- H Ph—Et i-Bu 3.08 440 H OtBu- Et IIF-979  2- H Ph—Et i-Pnt 3.17 454 H OtBu- Et IIF-980  4- H 4-F-Bnzl Bnzl 3.35 540 H tBuO- Bnzl IIF-981  4- H 4-F-Bnzl i-Bu 3.28 506 H tBuO- Bnzl IIF-982  4- H 4-F-Bnzl 1-Npm 3.47 590 H tBuO- Bnzl IIF-983  tBOC- H 4-F-Bnzl Bnzl 3.14 506 H E IIF-984  tBOC- H 4-F-Bnzl i-Bu 3.11 472 H E IIF-985  tBOC- H 4-F-Bnzl 1-Npm 3.32 556 H E IIF-986  2- H 4-F-Bnzl i-Bu 3.03 444 H OtBu- Et IIF-987  2- H 4-F-Bnzl Ph—Et 3.13 492 H OtBu- Et IIF-988  2- H 4-F-Bnzl i-Pnt 3.13 458 H OtBu- Et IIF-989  Bnzl H 2-OtBu- Bnzl 4.08 460 H Et IIF-990  Bnzl H 2-OtBu- i-Bu 4.07 426 H Et IIF-991  Bnzl H 2-OtBu- 1-Npm 4.26 510 H Et IIF-992  Bnzl H 2-OtBu- Ph—Et 4.17 474 H Et IIF-993  Bnzl H 2-OtBu- i-Pnt 4.15 440 H Et IIF-994  i-Bu H 2-OtBu- Bnzl 4.12 426 H Et IIF-995  i-Bu H 2-OtBu- 1-Npm 4.29 476 H Et IIF-996  i-Bu H 2-OtBu- Ph—Et 4.16 440 H Et IIF-997  1-Npm H 2-OtBu- i-Bu 4.22 476 H Et IIF-998  1-Npm H 2-OtBu- i-Pnt 4.33 490 H Et IIF-999  4- H 2-OtBu- i-Bu 4.3 498 H tBuO- Et Bnzl IIF-1000 Ph—Et H 2-OtBu- Bnzl 4.2 474 H Et IIF-1001 Ph—Et H 2-OtBu- i-Bu 4.17 440 H Et IIF-1002 Ph—Et H 2-OtBu- 1-Npm 4.35 524 H Et

TABLE 2-27 IIF-1003 Ph—Et H 2-OtBu- 4-tBuO-Bnzl 4.36 546 H Et IIF-1004 Ph—Et H 2-OtBu- i-Pnt 4.28 454 H Et IIF-1005 4-F- H 2-OtBu- Bnzl 4.17 478 H Bnzl Et IIF-1006 4-F- H 2-OtBu- i-Bu 4.05 444 H Bnzl Et IIF-1007 4-F- H 2-OtBu- 1-Npm 4.3 528 H Bnzl Et IIF-1008 4-F- H 2-OtBu- 4-tBuO-Bnzl 4.35 550 H Bnzl Et IIF-1009 4-F- H 2-OtBu- Ph—Et 4.18 492 H Bnzl Et IIF-1010 4-F- H 2-OtBu- i-Pnt 4.18 458 H Bnzl Et IIF-1011 i-Pnt H 2-OtBu- Bnzl 4.15 440 H Et IIF-1012 i-Pnt H 2-OtBu- 1-Npm 4.32 490 H Et IIF-1013 i-Pnt H 2-OtBu- 4-tBuO-Bnzl 4.36 512 H Et IIF-1014 i-Pnt H 2-OtBu- Ph—Et 4.26 454 H Et IIF-1015 Chm H 2-OtBu- Bnzl 4.25 466 H Et IIF-1016 Chm H 2-OtBu- 4-tBuO-Bnzl 4.41 538 H Et IIF-1017 Chm H 2-OtBu- Ph—Et 4.28 480 H Et IIF-1018 Bnzl H i-Pnt 4-tBuO-Bnzl 3.27 502 H IIF-1019 Bnzl H i-Pnt tBOC-E 3.08 468 H IIF-1020 1-Npm H i-Pnt 4-tBuO-Bnzl 3.46 552 H IIF-1021 1-Npm H i-Pnt tBOC-E 3.25 518 H IIF-1022 4- H i-Pnt Bnzl 3.32 502 H tBuO- Bnzl IIF-1023 4- H i-Pnt i-Bu 3.3 468 H tBuO- Bnzl IIF-1024 4- H i-Pnt 1-Npm 3.53 552 H tBuO- Bnzl IIF-1025 4- H i-Pnt Ph—Et 3.37 516 H tBuO- Bnzl IIF-1026 tBOC- H i-Pnt Bnzl 3.18 468 H E IIF-1027 tBOC- H i-Pnt 1-Npm 3.38 518 H E IIF-1028 tBOC- H i-Pnt Ph—Et 3.22 482 H E IIF-1029 Ph—Et H i-Pnt 4-tBuO-Bnzl 3.39 516 H IIF-1030 Ph—Et H i-Pnt tBOC-E 3.22 482 H IIF-1031 4-F- H i-Pnt 4-tBuO-Bnzl 3.29 520 H Bnzl IIF-1032 4-F- H i-Pnt tBOC-E 2.35 486 H Bnzl IIF-1033 Chm H i-Pnt 4-tBuO-Bnzl 2.62 508 H IIF-1034 Bnzl H Hxy 4-tBuO-Bnzl 2.63 516 H IIF-1035 i-Bu H Hxy 4-tBuO-Bnzl 2.55 482 H IIF-1036 1-Npm H Hxy 4-tBuO-Bnzl 2.88 566 H IIF-1037 4- H Hxy Bnzl 2.63 516 H tBuO- Bnzl IIF-1038 4- H Hxy i-Bu 2.6 482 H tBuO- Bnzl IIF-1039 4- H Hxy Ph—Et 2.67 530 H tBuO- Bnzl IIF-1040 4- H Hxy i-Pnt 2.7 496 H tBuO- Bnzl IIF-1041 tBOC- H Hxy Ph—Et 2.55 496 H E IIF-1042 Ph—Et H Hxy 4-tBuO-Bnzl 2.68 530 H IIF-1043 4-F- H Hxy 4-tBuO-Bnzl 2.63 534 H Bnzl IIF-1044 2- H Hxy Bnzl 2.47 454 H OtBu—Et IIF-1045 2- H Hxy 1-Npm 2.63 504 H OtBu—Et IIF-1046 2- H Hxy Ph—Et 2.5 468 H OtBu—Et IIF-1047 1-Npm H 4-F-Bnzl 2-OTBS—Et 1.11 586.4 C ^(†) Ring formed together by R_(2A) and R_(2B)

TABLE 2-28 Compound LCMS t_(R) Mass Measurement Yield number Name of compound (min) (M + H)⁺ condition (%) IIF-1  (3S*,3aR*,6S*,7R*,7aR*)-N,7- 1.14 416 B 10 dibenzyl-1-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-2  (3S*,3aR*,6S*,7R*,7aR*)-N,1,7- 1.11 348 B 16 triisobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-3  (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 1.14 382 B 14 N,1-diisobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-4  (3S*,3aR*,6S*,7R*,7aR*)-1-benzyl- 1.14 382 B 8 N,7-diisobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-5  (3S*,3aR*,6S*,7R*,7aR*)-N-benzyl- 1.13 382 B 13 1,7-diisobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-6  (3S*,3aR*,6S*,7R*,7aR*)-1,7- 1.15 416 B 19 dibenzyl-N-isobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-7  (3S*,3aR*,6S*,7R*,7aR*)-N,1- 1.00 416 B 22 dibenzyl-7-isobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-8  (3S*,3aR*,6S*,7R*,7aR*)-N,1,7- 1.16 450 B 21 tribenzyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-9  (3S*,3aR*,6S*,7R*,7aR*)-N,7- 1.18 430 B 20 dibenzyl-1-isopentyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-10 (3S*,3aR*,6S*,7R*,7aR*)-N,1- 1.18 430 B 11 dibenzyl-7-isopentyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide

TABLE 2-29 IIF-11 (3S*,3aR*,6S*,7R*,7aR*)-N-benzyl- 1.16 430 B 12 1-isobutyl-7-phenethyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-12 (3S*,3aR*,6S*,7R*,7aR*)-1-benzyl- 1.16 430 B 12 7-isobutyl-N-phenethyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-13 (3S*,3aR*,6S*,7R*,7aR*)-N-benzyl- 1.17 430 B 17 1-isobutyl-7-(3-methylbenzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-14 (3S*,3aR*,6S*,7R*,7aR*)-N-benzyl- 1.16 430 B 15 1-isobutyl-7-(4-methylbenzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-15 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 1.18 430 B 16 1-isobutyl-N-(3-methylbenzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-16 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 1.18 430 B 15 1-isobutyl-N-(4-methylbenzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-17 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 1.18 450 B 14 N-(3-chlorobenzyl)-1-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-18 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 1.17 450 B 13 N-(4-chlorobenzyl)-1-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-19 (3S*,3aR*,6S*,7R*,7aR*)-N-benzyl- 1.28 484 B 22 1-(3,4-dichlorobenzyl)-7-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-20 (3S*,3aR*,6S*,7R*,7aR*)-1-benzyl- 1.25 484 B 21 N-(3,4-dichlorobenzyl)-7-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-23 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 0.99 488 A 33 1-isobutyl-N-(4-(tert-butoxy)benzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-24 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 0.98 466 A 14 1-isobutyl-N-(naphthalen-1-ylmethyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-25 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 0.74 370 A 5 N-(2-hydroxyethyl)-1-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-26 3-(3S*,3aR*,6S*,7R*,7aR*)-7- 0.75 398 A 100 benzyl-1-isobutyl-1,2,3,3a,7,7a- hexahydro-1H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide)propanoic acid IIF-27 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 0.92 454 A 20 1-isobutyl-N-(2-(tert-butoxy)-2- oxoethyl)-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-28 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl- 0.72 397 A 88 N-(3-amino-3-oxopropyl)-1-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-29 (3S*,3aR*,6S*,7R*,7aR*)-N-(4- 0.67 397 A 100 aminobutyl)-7-benzyl-1-isobutyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide

TABLE 2-30 IIF-30 (3S*,3aR*,6S*,7R*,7aR*)-7- 0.91 497 A 10 benzyl-1-isobutyl-N-(4-((tert- butoxycarbonyl)amino)butyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-31 (3S*,3aR*,6S*,7R*,7aR*)-7- 0.98 422 A 12 benzyl-N-cyclohexylmethyl-1- isobutyl-1,2,3,3a,7,7a-hexahydro- 6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IIF-32 (3S*,3aR*,6S*,7R*,7aR*)-7- 0.87 424 A 24 benzyl-1-isobutyl-N-((tetrahydro- 2H-pyran-2-yl)methyl)- 1,2,3,3a,7,7a-hexahydro-6H- 3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IIF-34 (3S*,3aR*,6S*,7R*,7aR*)- 0.93 497 A 17 N-benzyl-1-isobutyl-7-(4-((tert- butoxycarbonyl)amino)butyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-36 (3S*,3aR*,6S*,7R*,7aR*)- 0.82 412 A 5 N-benzyl-1-isobutyl-7-(3- methoxy-3-oxopropyl)- 1,2,3,3a,7,7a-hexahydro-6H- 3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IIF-38 (3S*,3aR*,6S*,7R*,7aR*)- 0.99 422 A 23 N-benzyl-7-(cyclohexylmethyl)- 1-isobutyl-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-39 (3S*,3aR*,6S*,7R*,7aR*)-N,7- 0.96 456 A 22 dibenzyl-1-cyclohexylmethyl- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-40 (3S*,3aR*,6S*,7R*,7aR*)-N,7- 0.86 466 A 76 dibenzyl-1-(4-hydroxybenzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-41 (3S*,3aR*,6S*,7R*,7aR*)-N,7- 1.00 522 A 14 dibenzyl-1-(4-(tert- butoxy)benzyl)-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-42 (3S*,3aR*,6S*,7R*,7aR*)-N,7- 0.97 500 A 4 dibenzyl-1-(naphthalen-1- ylmethyl)-1,2,3,3a,7,7a- hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IIF-76 tert-butyl 3- 0.70 488 B 22 (3S*,3aR*,6S*,7R*,7aR*)-7- benzyl-6-(benzylcarbamoyl)- 2,3,3a,6,7,7a-hexahydro-1H-3,6- methanopyrrolo[3,2-c]pyridin-1- yl)propanoate IIF-77 (3S*,3aR*,6S*,7R*,7aR*)-N,1- 0.80 466 B 19 dibenzyl-7-(4-hydroxybenzyl)- 1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IIF-80 (3S*,3aR*,6S*,7R*,7aR*)-N- 1.01 452 A 6 benzyl-1-(naphthalen-1-ylmethyl)- 7-propyl-1,2,3,3a,7,7a-hexahydro- 6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide

Synthesis Example: IF-1 Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide(IF-1)

Sodium tetrahydroborate (1.86 mg, 0.0490 mmol) was added to a methanol (0.500 mL) solution of (3S*,3aR*,6S*,7R*,7aR*)—N,7-dibenzyl-1-isobutyl-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-1) (10.2 mg, 0.0245 mmol) and stirred for 1 hour. After evaporating the solvent under reduced pressure, 5% sodium bicarbonate solution (1.00 mL) was added to the residue, which was extracted with ethyl acetate (3.00 mL). The organic layer was washed with water (1.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=85:15) to obtain the aforementioned compound (6.37 mg, yield: 62%, RT=0.99 minutes (B method), [M+1]⁺=418).

¹H-NMR spectrum (400 MHz, CDCl₃) δ (ppm): 0.52 (3H, d), 0.58 (3H, d), 0.89-0.97 (1H, m), 1.57-1.62 (1H, m), 1.83-1.94 (3H, m), 2.01-2.07 (1H, m), 2.18-2.24 (2H, m), 2.29 (1H, d), 2.40-2.44 (1H, m), 2.71-2.75 (2H, m), 2.86-2.89 (1H, m), 3.10-3.19 (2H, m), 4.39-4.48 (2H, m), 7.24-7.38 (11H, m). ¹³C-NMR spectrum (100 MHz, CDCl₃) δ (ppm): 20.20, 26.99, 33.45, 35.79, 36.41, 39.83, 42.13, 42.79, 46.40, 56.95, 61.37, 61.78, 61.97, 125.50, 126.96, 127.39, 127.73, 128.25, 129.41, 138.20, 139.59, 175.20.

The three-dimensional structure of the molecules was studied by X-ray crystallography. FIG. 1 shows an ORTEP diagram thereof. Daicel Corporation's chiral column, CHIRALPAK IG (5 μm, 4.6×150 mm), mobile phase: methanol: diethylamine (100:0.1) was used to confirm that the molecule was a racemate through analysis. FIG. 2 shows the chromatogram thereof.

Synthesis Example: IB-1 Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1)

Sodium tetrahydroborate (3.83 mg, 0.101 mmol) was added to a methanol (1.00 mL) solution of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-isobutyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IIB-1) (21.0 mg, 0.0506 mmol) and stirred for 1 hour. After evaporating the solvent under reduced pressure, 5% sodium bicarbonate solution (1.00 mL) was added to the residue, which was extracted with ethyl acetate (4.00 mL). The organic layer was washed with water (1.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=90:10) to obtain the aforementioned compound (17.0 mg, yield: 81%, RT=1.21 minutes (B method), [M+1]⁺=418).

¹H-NMR spectrum (400 MHz, CDCl₃) δ (ppm): 0.48 (3H, d), 0.57 (3H, d), 1.18-1.28 (1H, m), 1.35-1.39 (1H, m), 1.55 (1H, s), 1.83-1.88 (1H, m), 2.09-2.14 (3H, m), 2.24-2.28 (1H, m), 2.45 (1H, s), 2.70-2.75 (1H, m), 2.78-2.88 (1H, m), 2.97 (1H, s), 3.20-3.27 (1H, m), 3.28-3.31 (1H, m), 4.28-4.33 (1H, m), 4.48-4.53 (1H, m), 7.21-7.27 (1H, m), 9.56 (1H, t).

¹³C-NMR spectrum (400 MHz, CDCl₃) δ (ppm): 20.20, 20.37, 25.84, 26.43, 38.09, 38.60, 39.25, 42.99, 58.19, 61.48, 62.33, 66.49, 125.58, 126.77, 127.49, 127.93, 128.07, 128.70, 138.22, 140.32, 173.83.

Synthesis Example: IB-29 Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N-(4-aminobutyl)-7-benzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-29)

Formic acid (500 μL) was added to (3S*, 3aS*, 6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(4-((tert-butoxycarbonyl)amino)butyl) octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-30) (7.70 mg, 0.0154 mmol) and incubated overnight at room temperature. The formic acid was evaporated under reduced pressure to obtain a triformic acid salt of the aforementioned compound (7.60 mg, yield: 92%, RT=0.75 minutes (A method), [M+1]⁺=399).

Synthesis Example: IB-40 Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-(4-hydroxybenzyl)octahydro-3aH-3,6-methanopyrrolo[ 3,2-b]pyridine-3a-carboxamide (IB-40)

Formic acid (250 μL) was added to (3S*, 3aS*, 6R*, 7R*, 7aS*)—N, 7-dibenzyl-1-(4-(tert-butoxy)benzyl) octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-41) (7.80 mg, 0.0149 mmol) and incubated for 3 hours at room temperature. The formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (6.30 mg, yield: 99%, RT=0.89 minutes (A method), [M+1]⁺=468).

Synthesis Example: IB-74 Synthesis of tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*k)-3a-(benzylcarbamoyl)-1-isobutyl-7-(3-methoxy-3-oxopropyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-74)

(3S*, 3aS*, 6R*, 7R*, 7aS*)—N-benzyl-1-isobutyl-7-(3-methoxy-3-oxopropyl)octahydro-3aH-3,6-methanopyrrolo[ 3,2-b]pyridine-3a-carboxamide (IB-36) (23.5 mg, 0.0570 mmol) was dissolved in tetrahydrofuran (0.400 mL), and a 30% tetrahydrofuran solution (140 μL, 0.140 mmol) of di-tert-butyl dicarbonate was added and heated for 2 hours at 50° C. The solvent was evaporated under reduced pressure. The resulting residue was purified by preparative PLC (Merck 1.05744.0001 (layer thickness 0.500 mm) (ethyl acetate:methanol=9:1)) to obtain the aforementioned compound (22.0 mg, yield: 75%, RT=0.97 minutes (A method), [M+1]⁺=514).

Synthesis Example: IB-73 Synthesis of tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(2-carboxyethyl) octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-73)

tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(3-methoxy-3-oxopropyl) octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-74) (22.0 mg, 0.0430 mmol) was dissolved in methanol (1.00 mL), and lithium hydroxide monohydrate (18.0 mg, 0.430 mmol) was added and stirred overnight at room temperature. Methanol was evaporated under reduced pressure. 10% citric acid solvent (450 μL) and ethyl acetate were added thereto. The organic layer was dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the aforementioned compound (21.40 mg, yield: 100%, RT=0.91 minutes (A method), [M+1]⁺=500).

Synthesis Example: IB-75 Synthesis of tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(3-amino-3-oxopropyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-75)

tert-butyl (3S*,3aS*,6R*,7R*,7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(2-carboxyethyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-73) (6.9 mg, 0.0130 mmol) was dissolved in tetrahydrofuran (0.200 mL), and carbonyldiimidazole (4.2 mg, 0.0260 mmol) was added and stirred overnight at room temperature. Ammonium water (13 M) (20.0 μL, 0.260 mmol) was added thereto and stirred for 1 hour. The solvent was evaporated. The resulting residue was purified by preparative PLC (Fuji Silysia Chemical's CHROMATOREX NH-TLC (layer thickness 0.200 mm) (ethyl acetate)) to obtain the aforementioned compound (1.70 mg, yield: 26%, RT=0.86 minutes (A method), [M+1]⁺=499).

Synthesis Example: IB-79 Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N^(3a),7-dibenzyl-1-(cyclohexylmethyl)-N⁴-propylhexahydro-1H-3,6-methanopyrrolo[3,2-b]pyridine-3a,4-dicarboxamide (IB-79)

(3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-cyclohexylmethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-39) (4.6 mg, 0.0100 mmol) was dissolved in tetrahydrofuran (0.180 mL), then triethylamine (1.6 μL, 0.0120 mmol) and propylisocyanate (1.13 μL, 0.120 mmol) were added and incubated for 1 hour at room temperature. The reaction mixture was purified with preparative PLC silica gel 60F254 (layer thickness 0.250 mm) (ethyl acetate:methanol=5:1) to obtain the aforementioned compound (3.50 mg, yield: 65%, RT=1.05 minutes (A method), [M+1]⁺=543).

Synthesis of 3-((3S*,3aS*,6R*,7R*,7aS*)-3a-(benzylcarbamoyl)-1-isobutyloctahydro-1H-3,6-methanopyrrolo[3,2-b]pyridin-7-yl)propanoic Acid (IB-35)

Trifluoroacetic acid (200 μL) was added to tert-butyl (3S*, 3aS*, 6R*, 7R*, 7aS*)-3a-(benzylcarbamoyl)-1-isobutyl-7-(2-carboxyethyl)octahydro-4H-3,6-methanopyrrolo[3,2-b]pyridine-4-carboxylate (IB-73) (5.50 mg, 0.0110 mmol) and incubated overnight at room temperature. Trifluoroacetic acid was evaporated under reduced pressure to obtain a ditrifluoroacetic acid salt of the aforementioned compound (6.80 mg, yield: 100%, RT=0.83 minutes (A method), [M+1]⁺=400).

Synthesis Example: IF-26 Synthesis of ((3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyloctahydro-1H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide)propanoic Acid (IF-26)

Formic acid (0.500 mL) was added to (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(2-(tert-butoxy)-2-oxoethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-27) (15.0 mg, 0.0330 mmol) and heated overnight at 45° C. The formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (16.2 mg, yield: 100%, RT=0.66 minutes (A method), [M+1]⁺=400).

Synthesis Example: IF-33 Synthesis of (3S*,3aS*,6S*,7R*,7aS*)-7-(4-aminobutyl)-N-benzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-33)

Trifluoroacetic acid (200 μL) was added to (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-1-isobutyl-7-(4-((tert-butoxycarbonyl)amino)butyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-34) (7.80 mg, 0.0156 mmol) and incubated overnight at room temperature. The trifluoroacetic acid was evaporated under reduced pressure to obtain a tritrifluoroacetic acid salt of the aforementioned compound (7.80 mg, yield: 100%, RT=0.62 minutes (A method), [M+1]+=399).

Synthesis Example: IF-41 Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(4-(tert-butoxy)benzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-41)

9.50 mg of 10% palladium-carbon was added to a methanol (0.500 mL) solution of (3S*, 3aR*, 6S*, 7R*, 7aR*)—N, 7-dibenzyl-1-(4-(tert-butoxy)benzyl)-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IIF-41) (11 mg, 0.0210 mmol) and stirred for a week under a hydrogen gas atmosphere. After filtering out the palladium-carbon, the solution was concentrated. The residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=5:1) to obtain the aforementioned compound (5.70 mg, yield: 52%, RT=0.90 minutes (A method), [M+1]⁺=524).

Synthesis Example: IF-40 Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(4-hydroxybenzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-40)

Formic acid (250 μL) was added to (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(4-(tert-butoxy)benzyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-41) (5.70 mg, 10.9 mmol) and incubated for 3 hours at room temperature. The formic acid was evaporated under reduced pressure to obtain a diformic acid salt of the aforementioned compound (3.20 mg, yield: 52%, RT=0.75 minutes (A method), [M+1]⁺=468).

Synthesis Example: IF-71 Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyl-4-methyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-71)

A 37% formalin solution (0.06 mL, 0.736 mmol) was added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-1) (30.8 mg, 0.0736 mmol) and stirred for 15 minutes at room temperature. Sodium triacetoxyborohydride (46.8 mg, 0.221 mmol) was added to the reaction mixture, and stirred for 1 hour at room temperature. An aqueous 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and the organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=85:15) to obtain the aforementioned compound (12.1 mg, yield: 38%, RT=1.02 minutes (B method), [M+1]⁺=432).

Synthesis Example: IF-43 Synthesis of (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-43)

Triethylamine (0.0156 mL, 1.13 mmol) and acetyl chloride (0.00804 mL, 1.13 mmol) were added to a tetrahydrofuran (1.80 mL) solution of (3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-1) (31.4 mg, 0.0751 mmol), and stirred for 30 minutes while cooling with ice. A 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and the organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=85:15) to obtain the aforementioned compound (17.6 mg, yield: 51%, RT=1.08 minutes (B method),[M+1]⁺=460).

Synthesis Example: IB-68 Synthesis of (3S*,3aS*,6R*,7R*,7aS*)-4-benzoyl-N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-68)

Triethylamine (0.0152 mL, 0.110 mmol) and benzoyl chloride (0.0127 mL, 1.10 mmol) were added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (30.6 mg, 0.0733 mmol) and stirred for 30 minutes while cooling with ice. An aqueous 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and an organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=95:5) to obtain the aforementioned compound (14.8 mg, yield: 39%, RT=1.23 minutes (B method), [M+1]⁺=522).

Synthesis Example: IB-69 Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-4-ethyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-69)

An acetaldehyde 2% N,N-dimethylformamide solution (0.870 mL, 0.395 mmol) was added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (33.0 mg, 0.790 mmol) and stirred for 15 minutes at room temperature. Sodium triacetoxyborohydride (50.2 mg, 0.273 mmol) was added to the reaction mixture, and further stirred for 2 hours at room temperature. An aqueous 5% sodium bicarbonate solution (10.0 mL) was added to the reaction mixture, and an organic phase was extracted with ethyl acetate (30.0 mL). The organic layer was washed twice with water (10.0 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=95:5) to obtain the aforementioned compound (9.85 mg, yield: 28%, RT=1.24 minutes (B method), [M+1]⁺=446).

Synthesis Example: IB-70 Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyl-4-(methoxycarbonyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-70)

Triethylamine (0.0157 mL, 0.113 mmol) and chloroformic acid methyl (0.00870 mL, 0.113 mmol) were added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)—N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (31.5 mg, 0.0754 mmol), and stirred for 30 minutes while cooling with ice. After stirring for 30 minutes at room temperature, a 5% sodium bicarbonate solution (2.00 mL) was added to the reaction mixture, and the organic phase was extracted with ethyl acetate (5.00 mL). The organic layer was washed with water (2.00 mL), then dried with anhydrous sodium sulfate and filtered. The solvent was evaporated under reduced pressure. The resulting residue was purified with preparative PLC silica gel 60F254 (layer thickness 0.500 mm) (ethyl acetate:methanol=95:5) to obtain the aforementioned compound (31.0 mg, yield: 87%, RT=1.18 minutes (B method), [M+1]⁺=476).

The following compounds were synthesized by the same method as the Synthesis Examples.

Compounds with a guanidinopropyl group in one of the substituents R₁, R₂, and R₃ were synthesized by the following method. Representative examples are provided below.

Synthesis of (3S*,3aS*,6R*,7R*,7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-164) and (3S*,3aS*,6S*,7R*,7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-162)

1. Synthesis of tert-butyl (3S*,3aR*,6S*,7R*,7aS*)-(3-(7-isobutyl-3a-((naphthalen-1-ylmethyl)carbamoyl)-2,3,3a, 6,7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-b]pyridin-yl)propyl) carbamate and tert-butyl (3S*, 3aR*, 6S*, 7R*, 7aR*)-(3-(7-isobutyl-6-(naphthalen-1-ylmethyl) carbamoyl)-2,3,3a, 6,7,7a-hexahydro-1H-3,6-methanopyrrolo[3,2-c]pyridin-1-yl)propyl)carbamate

N, N-dimethylformamide (1 mL) was added to 4-methylpentanal (60.1 mg, 0.6 mmol), tert-butyl (3-(allylamino)propyl)carbamate (128.6 mg, 0.6 mmol), and molecular sieve 4A (100 mg), and then N-(naphthalen-1-ylmethyl)-1,2,4-triazine-3-carboxamide (79.3 mg, 0.3 mmol) was added. The reaction mixture was heated for 16 hours at 85° C., and then filtered. The filtrate was purified by preparative HPLC (High Performance Liquid Chromatography). A fraction of the substance of interest was concentrated to obtain a mixture of the aforementioned compound.

2. Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-aminopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*, 3aR*, 6S*, 7R*, 7aR*)-1-(3-aminopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,3a, 7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide

Trifluoroacetic acid (0.3 mL) was added to the compound (mixture) obtained in 1. and stirred for 1 hour at room temperature. The trifluoroacetic acid was evaporated to obtain a trifluoroacetic acid salt of the aforementioned compound (mixture).

3. Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*, 3aR*, 6S*, 7R*, 7aR*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide

1,3-di(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine (234.8 mg, 0.6 mmol), triethylamine (60.7 mg, 0.6 mmol), and tetrahydrofuran (0.5 mL) were added to the compound (mixture) obtained in 2. and stirred for 3 hours at room temperature. The solvent was evaporated to obtain a mixture comprising the aforementioned compound. The mixture obtained in this step was used in synthesis of the next step without purification.

4. Synthesis of (3S*,3aS*,6R*,7R*,7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*,3aS*,6S*,7R*,7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide

The reaction mixture obtained in 3. was dissolved in methanol (1 mL), then sodium borohydride (22.7 mg, 0.6 mmol) was added and stirred for 2 hours at room temperature. The reaction mixture was purified by preparative HPLC. Fractions of substances of interest were concentrated to obtain each of the aforementioned compounds separately.

5. Synthesis of (3S*,3aS*,6S*,7R*,7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide

Trifluoroacetic acid (0.3 mL) was added to (3S*,3aS*,6S*,7R*,7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide obtained in 4. and stirred for 1 hour at room temperature. The trifluoroacetic acid was evaporated to obtain a trifluoroacetic acid salt of the aforementioned compound.

6. Synthesis of (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-guanidinopropyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide

A trifluoroacetic acid salt of the aforementioned compound was obtained by the same method as 5. by using (3S*, 3aS*, 6R*, 7R*, 7aS*)-1-(3-(N,N′-di(tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide obtained in 4.

Synthesis of (3S*,3aS*,6R*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyl-1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*,3aR*,6S*,7R*,7aR*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyl-1,2,3,3a,7,7a-hexahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6H-carboxamide

Chloroform (1 mL) was added to N-phenethyl prop-2-en-1-amine (58.4 mg, 0.4 mmol), 4-((tert-butyldimethylsilyl)oxy)butanal (80.0 mg, 0.4 mmol), and molecular sieve 4A (400 mg), and then N-benzyl-1,2,4-triazine-3-carboxamide (43.8 mg, 0.2 mmol) and chloroform (1 mL) were further added. The reaction mixture was heated for 48 hours at 55° C. and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative TLC (Merck 1.13895.001, layer thickness 1 mm) (ethyl acetate:methanol=9:1) to obtain a mixture of the aforementioned compound (73.3 mg, yield 69%, RT=1.08 minutes, 1.12 minutes (C method), [M+1]+=532).

Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide and (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide

The mixture obtained in the above reaction (73.3 mg) was dissolved in methanol (1.5 mL), and sodium borohydride (9 mg, 0.24 mmol) was added and stirred for 12 hours at room temperature. Ethyl acetate was added to the reaction mixture, which was washed twice with saturated saline. The organic phase was dried with anhydrous sodium sulfate. The anhydrous sodium sulfate was filtered out. The filtrate was concentrated under reduced pressure and purified by preparative TLC (Merck 1.13895.001, layer thickness 1 mm) (ethyl acetate:methanol=4:1) to obtain (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (47.6 mg, two-step yield of 43%, RT=1.13 minutes (C method), [M+1]+=534) and (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (20.6 mg, two-step yield of 19%, RT=0.95 minutes (C method), [M+1]+=534).

Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-hydroxyethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3aH-carboxamide

(3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-a-carboxamide (46.7 mg, 0.087 mmol) was dissolved in tetrahydrofuran (1 mL), and tetrabutylammonium fluoride (approximately 1 mol/L tetrahydrofuran solution, 0.1 mL) was added and stirred overnight at room temperature. The reaction mixture was concentrated and ethyl acetate was added, and then transferred to a separatory funnel and washed with saturated saline. The organic phase was dried with anhydrous sodium sulfate, concentrated under reduced pressure, and purified by preparative TLC (Merck 1.05744.001, layer thickness 0.5 mm) (ethyl acetate:methanol=4:1) to obtain the aforementioned compound (35 mg, yield of 96%, RT=0.85 minutes (C method), [M+1]+=420).

Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-hydroxyethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6H-carboxamide

(3S*,3aS*,6S*,7R*,7aS*)—N-benzyl-7-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenethyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (20.6 mg, 0.039 mmol) was dissolved in tetrahydrofuran (0.5 mL), and tetrabutylammonium fluoride (approximately 1 mol/L tetrahydrofuran solution, 0.05 mL) was added and stirred overnight at room temperature. The reaction mixture was concentrated, ethyl acetate was added and transferred to a separatory funnel, and washed twice with saturated saline. The organic phase was dried with anhydrous sodium sulfate, concentrated under reduced pressure, and purified by preparative TLC (Merck 105744.001, layer thickness 0.5 mm) (ethyl acetate:methanol=4:1) to obtain the aforementioned compound (16 mg, yield of 91%, RT=0.72 minutes (C method), [M+1]⁺=420).

Synthesis of (3S*,3aS*,6S*,7R*,7aS*)—N,4,7-tribenzyl-1-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide

(3S*,3aS*,6S*,7R*,7aS*)—N,7-dibenzyl-1-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (compound IB-42, 5 mg, 0.01 mmol) was dissolved in tetrahydrofuran (0.2 mL), then benzaldehyde (2.1 mg, 0.02 mmol), trifluoroacetic acid (3.4 mg, 0.03 mmol), and molecular sieve 4A (40 mg) were added and heated for 18 hours at 50° C. Sodium triacetoxyborohydride (5 mg, 0.024 mmol) was added to the reaction mixture and stirred for 5 hours at room temperature. To the reaction mixture, ethyl acetate and saturated sodium bicarbonate water are added. The organic phase was washed twice with saturated saline. The organic phase was dried with anhydrous sodium sulfate, concentrated under reduced pressure, and purified by TLC (Merck 105715.001, layer thickness 0.25 mm) (hexane:ethyl acetate=2:1) to obtain the aforementioned compound (1.2 mg, yield of 20%, RT=1.14 minutes (C method), [M+1]⁺=592).

Tables 3 and 4 summarize the synthesized compounds of formula IB and compounds of IF. In the following tables, “EX” means that the synthesis method is described in the Examples.

TABLE 3-1

Compound Synthesis number R₁ R₂ R₃ R₄ method Intermediate IB-1 i-Bu Bnzl Bnzl H EX IIB-1 IB-2 i-Bu i-Bu i-Bu H IB-1 IIB-2 IB-3 i-Bu i-Bu Bnzl H IB-1 IIB-3 IB-4 Bnzl i-Bu i-Bu H IB-1 IIB-4 IB-5 i-Bu Bnzl i-Bu H IB-1 IIB-5 IB-6 Bnzl i-Bu Bnzl H IB-1 IIB-6 IB-7 Bnzl Bnzl i-Bu H IB-1 IIB-7 IB-8 Bnzl Bnzl Bnzl H IB-1 IIB-8 IB-9 i-Pnt Bnzl Bnzl H IB-1 IIB-9 IB-10 Bnzl Bnzl i-Pnt H IB-1 IIB-10 IB-11 i-Bu Bnzl Ph-Et H IB-1 IIB-11 IB-12 i-Bu Ph-Et Bnzl H IB-1 IIB-12 IB-13 i-Bu Bnzl 3-Me-Bnzl H IB-1 IIB-13 IB-14 i-Bu Bnzl 4-Me-Bnzl H IB-1 IIB-14 IB-15 i-Bu 3-Me-Bnzl Bnzl H IB-1 IIB-15 IB-16 i-Bu 4-Me-Bnzl Bnzl H IB-1 IIB-16 IB-17 i-Bu 3-Cl-Bnzl Bnzl H IB-1 IIB-17 IB-18 i-Bu 4-Cl-Bnzl Bnzl H IB-1 IIB-18 IB-19 3,4-Cl₂-Bnzl Bnzl i-Bu H IB-1 IIB-19 IB-20 Bnzl 3,4-Cl₂-Bnzl i-Bu H IB-1 IIB-20 IB-21 Me Np-E Bnzl H IB-1 IIB-21 IB-22 i-Bu 4-OH-Bnzl Bnzl H IB-40 IB-23 IB-23 i-Bu 4-(tert-butoxy)benzyl Bnzl H IB-1 IIB-23 IB-24 i-Bu Np-M Bnzl H IB-1 IIB-24 IB-25 i-Bu Hdr-E Bnzl H IB-1 IIB-25 IB-26 i-Bu Cbx-E Bnzl H IF-26 IB-27 IB-27 i-Bu 2-(tert-butoxy)-2-oxoethyl Bnzl H IB-1 IIB-27 IB-28 i-Bu Cbm-E Bnzl H IB-1 IIB-28 IB-29 i-Bu 4-aminobutyl Bnzl H EX IB-30 IB-30 i-Bu 4-((tert-butoxycarbonyl)amino)butyl Bnzl H IB-1 IIB-30 IB-31 i-Bu Chm Bnzl H IB-1 IIB-31

TABLE 3-2 IB-32 i-Bu (tetrahydro- Bnzl H IB-1  IIB-32 2H- pyran- 2-yl) methyl IB-33 i-Bu Bnzl 4- H IF-33 IB-34 aminobutyl IB-34 i-Bu Bnzl 4- H IB-1  IIB-34 ((tert- butoxy- carbonyl) amino) butyl IB-35 i-Bu Bnzl Cbx-E H EX IB-73 IB-36 i-Bu Bnzl 3- H IB-1  IIB-36 methoxy- 3- oxopropyl IB-37 i-Bu Bnzl Cbm-E H IF-33 IB-75 IB-38 i-Bu Bnzl Chm H IB-1  IIB-38 IB-39 Chm Bnzl Bnzl H IB-1  IIB-39 IB-40 4-OH- Bnzl Bnzl H EX IB-41 Bnzl IB-41 4- Bnzl Bnzl H IB-1  IIB-41 (tert- butoxy) benzyl IB-42 Np-M Bnzl Bnzl H IB-1  IIB-42 IB-43 i-Bu Bnzl Bnzl Ac IE-43 IB-1  IB-44 i-Bu i-Bu i-Bu Ac IF-43 IB-2  IB-45 i-Bu i-Bu Bnzl Ac IF-43 IB-3  IB-46 Bnzl i-Bu i-Bu Ac IF-43 IB-4  IB-47 i-Bu Bnzl i-Bu Ac IF-43 IB-5  IB-49 Bnzl Bnzl i-Bu Ac IF-43 IB-7  IB-50 Bnzl Bnzl Bnzl Ac IF-43 IB-8  IB-54 i-Bu Ph—Et Bnzl Ac IF-43 IB-12 IB-57 i-Bu 3-Me-Bnzl Bnzl Ac IF-43 IB-15 IB-58 i-Bu 4-Me-Bnzl Bnzl Ac IF-43 IB-16 IB-64 Me Np-E Bnzl Ac IF-43 IB-21 IB-68 i-Bu Bnzl Bnzl Bz EX IB-1  IB-69 i-Bu Bnzl Bnzl Et EX IB-1  IB-70 i-Bu Bnzl Bnzl methoxy- EX IB-1  carbonyl IB-71 i-Bu Bnzl Bnzl Me IF-71 IB-1  IB-72 Me Np-E Bnzl Et IB-69 IB-21 IB-73 i-Bu Bnzl Cbx-E tBOC EX IB-74 IB-74 i-Bu Bnzl 3- tBOC EX IB-36 methoxy- 3- oxopropyl IB-75 i-Bu Bnzl Cbm-E tBOC EX IB-73 IB-76 3- Bnzl Bnzl H IB-1  IIB-76 (tert- butoxy)- 3- oxopropyl IB-77 Bnzl Bnzl 4-OH-Bnzl H IB-1  IIB-77 IB-78 Me 2-(1- Bnzl H IB-1  IIB-78 (tert- butoxy- carbonyl)- 1H-indol- 3-yl) ethyl IB-79 Chm Bnzl Bnzl propyl- EX IB-39 carbamoyl IB-80 Np-M Bnzl Pr H IB-1  IIB-80

TABLE 3-3 Compound LCMS t_(R) Mass Elution Yield number Name of compound (min) (M + H)⁺ condition (%) IB-1  (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.21 418 B 81 1-isobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-2  (3S*,3aS*,6R*,7R*,7aS*)-N,1,7- 1.20 350 B 77 triisobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-3  (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N,1- 1.19 384 B 75 diisobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-4  (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7- 1.20 384 B 88 diisobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-5  (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1,7- 1.20 384 B 76 diisobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-6  (3S*,3aS*,6R*,7R*,7aS*)-1,7-dibenzyl- 1.20 418 B 54 N-isobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-7  (3S*,3aS*,6R*,7R*,7aS*)-N,1-dibenzyl- 1.21 418 B 81 7-isobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-8  (3S*,3aS*,6R*,7R*,7aS*)-N,1,7- 1.21 452 B 76 tribenzyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-9  (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.23 432 B 81 1-isopentyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-10 (3S*,3aS*,6R*,7R*,7aS*)-N,1-dibenzyl- 1.23 432 B 37 7-isopentyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-11 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.22 432 B 63 isobutyl-7-phenethyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-12 (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-7- 1.23 432 B 65 isobutyl-N-phenethyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-13 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.24 432 B 64 isobutyl-7-(3-methylbenzyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-14 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.23 432 B 74 isobutyl-7-(4-methylbenzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide

TABLE 3-4 IB-15 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.24 432 B 66 isobutyl-N-(3-methylbenzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-16 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.25 432 B 72 isobutyl-N-(4-methylbenzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-17 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(3- 1.03 452 B 85 chlorobenzyl)-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-18 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(4- 1.24 452 B 79 chlorobenzyl)-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-19 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 1.13 486 B 43 (3,4-dichlorobenzyl)-7-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-20 (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N- 1.26 486 B 84 (3,4-dichlorobenzyl)-7-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-21 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.19 440 B 82 isobutyl-N-(2-(naphthalen-1-yl)ethyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-22 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(4- 0.89 434 A 95 hydroxybenzyl)-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-23 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.06 490 A 88 isobutyl-N-(4-(tert-butoxy)benzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-24 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 1.05 468 A 84 isobutyl-N-(naphthalen-1-ylmethyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-25 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N-(2- 0.80 372 A 77 hydroxyethyl)-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-26 3-((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 0.82 400 A 95 isobutyloctahydro-1H-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide)propanoic acid IB-27 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 0.99 456 A 93 isobutyl-N-(2-(tert-butoxy)-2- oxoethyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-28 (3S*,3aS*,6R*,7R*,7aS*)-N-(3-amino-3- 0.79 399 A 80 oxopropyl)-7-benzyl-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-29 (3S*,3aS*,6R*,7R*,7aS*)-N-(4- 0.75 399 A 100 aminobutyl)-7-benzyl-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-30 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 0.97 499 A  62 isobutyl-N-(4-((tert- butoxycarbonyl)amino)butyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-31 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N- 1.05 424 A  42 cyclohexylmethyl-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide

TABLE 3-5 IB-32 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1- 0.96 426 A 97 isobutyl-N-((tetrahydro- 2H-pyran-2-yl)methyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-33 (3S*,3aS*,6R*,7R*,7aS*)-7-(4- 0.74 399 A 100 aminobutyl)-N-benzyl-1- isobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-34 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 0.99 499 A 77 isobutyl-7-(4-((tert- butoxycarbonyl)amino)butyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-35 3-((3S*,3aS*,6R*,7R*,7aS*)-3a- 0.83 400 A 100 (benzylcarbamoyl)-1- isobutyloctahydro-1H-3,6- methanopyrrolo[3,2-b]pyridin-7- yl)propanoic acid IB-36 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1- 0.90 414 A 73 isobutyl-7-(3-methoxy-3- oxopropyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-37 (3S*,3aS*,6R*,7R*,7aS*)-7-(3-amino-3- 0.78 399 A 100 oxopropyl)-N-benzyl-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-38 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-7- 1.07 424 A 82 (cyclohexylmethyl)-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-39 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.06 458 A 78 1-cyclohexylmethyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-40 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 0.89 468 A 99 1-(4-hydroxybenzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-41 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.05 524 A 65 1-(4-(tert-butoxy)benzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-42 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.05 502 A 63 1-(naphthalen-1-ylmethyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-43 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-N,7- 1.14 460 B 86 dibenzyl-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-44 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl- 1.10 392 B 86 N,1,7-triisobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-45 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7- 1.10 426 B 82 benzyl-N,1-diisobutyloctahydro-3aH- 3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-46 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-1- 1.10 426 B 91 benzyl-N,7-diisobutyloctahydro-3aH- 3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-47 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-N- 1.11 426 B 85 benzyl-1,7-diisobutyloctahydro-3aH- 3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-49 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-N,1- 1.13 460 B 86 dibenzyl-7-isobutyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide

TABLE 3-6 IB-50 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl- 1.16 494 B 81 N,1,7-tribenzyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-54 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-1- 1.15 474 B 82 benzyl-7-isobutyl-N-phenethyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-57 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7- 1.17 474 B 87 benzyl-1-isobutyl-N-(3- methylbenzyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-58 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7- 1.17 474 B 80 benzyl-1-isobutyl-N-(4- methylbenzyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-64 (3S*,3aS*,6R*,7R*,7aS*)-4-acetyl-7- 1.12 482 B 100  benzyl-1-isobutyl-N-(2-(naphthalen- 1-yl)ethyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-68 (3S*,3aS*,6R*,7R*,7aS*)-4-benzoyl- 1.23 522 B 39 N,7-dibenzyl-1-isobutyloctahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-69 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.24 446 B 28 4-ethyl-1-isobutyloctahydro-3aH- 3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-70 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.18 476 B 85 1-isobutyl-4-(methoxycarbonyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-71 (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl- 1.22 432 B 35 1-isobutyl-4-methyloctahydro-3aH- 3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-72 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-4- 1.24 468 B 70 ethyl-1-isobutyl-N-(2-(naphthalen- 1-yl)ethyl)octahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide IB-73 tert-butyl (3S*,3aS*,6R*,7R*,7aS*)- 0.91 500 A 100  3a-(benzylcarbamoyl)-1-isobutyl-7- (2-carboxyethyl)octahydro-4H-3,6- methanopyrrolo[3,2-b]pyridine-4- carboxylate IB-74 tert-butyl (3S*,3aS*,6R*,7R*,7aS*)- 0.97 514 A 75 3a-(benzylcarbamoyl)-1-isobutyl-7- (3-methoxy-3-oxopropyl)octahydro- 4H-3,6-methanopyrrolo[3,2-b]pyridine- 4-carboxylate IB-75 tert-butyl (3S*,3aS*,6R*,7R*,7aS*)- 0.86 499 A 26 3a-(benzylcarbamoyl)-1-isobutyl-7- (3-amino-3-oxopropyl)octahydro-4H- 3,6-methanopyrrolo[3,2-b]pyridine- 4-carboxylate IB-76 tert-butyl 3- 1.20 490 B 68 ((3S*,3aS*,6R*,7R*,7aS*)-7-benzyl- 3a-(benzylcarbamoyl)octahydro-1H-3,6- methanopyrrolo[3,2-b]pyridin-1- yl)propanoate IB-77 (3S*,3aS*,6R*,7R*,7aS*)-N,1-dibenzyl- 1.13 468 B 60 7-(4-hydroxybenzyl)octahydro- 3aH-3,6-methanopyrrolo[3,2-b]pyridine- 3a-carboxamide IB-78 tert-butyl 3- 1.25 529 B 71 ((3S*,3aS*,6R*,7R*,7aS*)-2- (7-benzyl-1-methyloctahydro-1H-3,6- methanopyrrolo[3,2-b]pyridine- 3a-carboxamide)ethyl)-1H-indole- 1-carboxylate

TABLE 3-7 IB-79 (3S*,3aS*,6R*,7R*,7aS*)-N^(3a),7- 1.05 543 A 65 dibenzyl-1-(cyclohexylmethyl)-N⁴- propylhexahydro-1H-3,6- methanopyrrolo[3,2-b]pyridine-3a,4- dicarboxamide IB-80 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl- 1.02 454 A 62 1-(naphthalen-1-ylmethyl)-7- propyloctahydro-3aH-3,6- methanopyrrolo[3,2-b]pyridine-3a- carboxamide

TABLE 3-8

Time of Compound retention Mass Measurement number R₁ R₂ R₃ TR (min) (M + H)⁺ condition IB-81 Cbm-M Np-M i-Bu 0.79 435 C IB-82 Cbm-M Np-M Bnzl 0.80 469 C IB-83 Cbm-M Np-M 4-OH-Bnzl 0.75 485 C IB-84 Cbm-M Np-M i-Pnt 0.83 449 C IB-85 Cbm-M Np-M Ph-Et 0.83 483 C IB-86 Cbm-M Ph-Et i-Bu 0.74 399 C IB-87 Cbm-M Ph-Et Bnzl 0.75 433 C IB-88 Cbm-M Ph-Et 4-OH-Bnzl 0.69 449 C IB-89 Cbm-M Ph-Et i-Pnt 0.78 413 C IB-90 Cbm-M Np-M Np-M 0.84 519 C IB-91 Cbm-M 4-F-Bnzl i-Bu 0.74 403 C IB-92 Cbm-M 4-F-Bnzl Bnzl 0.75 437 C IB-93 Cbm-M 4-F-Bnzl 4-OH-Bnzl 0.69 453 C IB-94 Cbm-M 4-F-Bnzl i-Pnt 0.78 417 C IB-95 Cbm-M 4-F-Bnzl Ph-Et 0.78 451 C IB-96 Cbm-M 4-F-Bnzl Np-M 0.80 487 C IB-97 Cbm-M Ph-Et Np-M 0.82 483 C IB-98 Cbm-M i-Pnt i-Bu 0.73 365 C IB-99 Cbm-M i-Pnt Bnzl 0.74 399 C IB-100 Cbm-M i-Pnt 4-OH-Bnzl 0.70 415 C IB-101 Cbm-M i-Pnt Cbx-E 0.64 381 C IB-102 Cbm-M i-Pnt Ph-Et 0.78 413 C IB-103 Cbm-M i-Pnt Np-M 0.80 449 C IB-104 Cbm-M Hxy i-Bu 0.78 379 C IB-105 Cbm-M Hxy Bnzl 0.79 413 C IB-106 Cbm-M Hxy 4-OH-Bnzl 0.74 429 C IB-107 Cbm-M Hxy Cbx-E 0.70 395 C

TABLE 3-9 IB-108 Cbm-M Hxy i-Pnt 0.82 393 C IB-109 Cbm-M Hxy Ph—Et 0.82 427 C IB-110 Cbm-M Hxy Np-M 0.84 463 C IB-111 Cbm-M i-Pr i-Bu 0.65 337 C IB-112 Cbm-M i-Pr Bnzl 0.66 371 C IB-113 Cbm-M i-Pr 4-OH-Bnzl 0.59 387 C IB-114 Cbm-M i-Pr Cbx-E 0.98 353 D IB-115 Cbm-M i-Pr i-Pnt 0.70 351 C IB-116 Cbm-M i-Pr Ph—Et 0.72 385 C IB-117 Cbm-M i-Pr Np-M 0.74 421 C IB-118 Cbm-M i-Bu i-Bu 0.71 351 C IB-119 Cbm-M i-Bu Bnzl 0.72 385 C IB-120 Cbm-M i-Bu 4-OH-Bnzl 0.65 401 C IB-121 Cbm-M i-Bu Cbx-E 0.60 367 C IB-122 Cbm-M i-Bu i-Pnt 0.76 365 C IB-123 Cbm-M i-Bu Ph—Et 0.77 399 C IB-124 Cbm-M i-Bu Np-M 0.79 435 C IB-125 Cbm-M Bnzl i-Bu 0.74 385 C IB-126 Cbm-M Bnzl Bnzl 0.75 419 C IB-127 Cbm-M Bnzl 4-OH-Bnzl 0.69 435 C IB-128 Cbm-M Bnzl Cbx-E 0.63 401 C IB-129 Cbm-M Bnzl i-Pnt 0.79 399 C IB-130 Cbm-M Bnzl Ph—Et 0.80 433 C IB-131 Cbm-M Bnzl Np-M 0.81 469 C IB-132 Cbm-M 4-OH-Bnzl i-Bu 0.67 401 C IB-133 Cbm-M 4-OH-Bnzl Bnzl 0.69 435 C IB-134 Cbm-M 4-OH-Bnzl Cbx-E 0.98 417 D IB-135 Cbm-M 4-OH-Bnzl i-Pnt 0.73 415 C IB-136 Cbm-M 4-OH-Bnzl Ph—Et 0.74 449 C IB-137 Cbm-M 4-OH-Bnzl Np-M 0.76 485 C IB-138 Cbm-M Cbx-E i-Bu 0.61 367 C IB-139 Cbm-M Cbx-E Bnzl 0.62 401 C IB-140 Cbm-M Cbx-E 4-OH-Bnzl 0.98 417 D IB-141 Cbm-M Cbx-E i-Pnt 0.67 381 C IB-142 Cbm-M Cbx-E Ph—Et 0.69 415 C IB-143 Cbm-M Cbx-E Np-M 0.71 451 C IB-144 Cbm-M Cbm-E i-Bu 0.59 366 C IB-145 Cbm-M Cbm-E Bnzl 0.61 400 C IB-146 Cbm-M Cbm-E 4-OH-Bnzl 0.97 416 D IB-147 Cbm-M Cbm-E Cbx-E 0.20 382 E IB-148 Cbm-M Cbm-E i-Pnt 0.65 380 C IB-149 Cbm-M Cbm-E Ph—Et 0.67 414 C IB-150 Cbm-M Cbm-E Np-M 0.69 450 C IB-151 Cbm-M Gun-Pr i-Bu 0.59 394 C IB-152 Cbm-M Gun-Pr Bnzl 0.60 428 C IB-153 Cbm-M Gun-Pr 4-OH-Bnzl 0.91 444 D

TABLE 3-10 IB-154 Cbm-M Gun-Pr i-Pnt 0.63 408 C IB-155 Cbm-M Gun-Pr Ph—Et 0.65 442 C IB-156 Cbm-M Gun-Pr Np-M 1.15 478 D IB-157 Cbm-M Hdr-E i-Bu 0.60 339 C IB-158 Cbm-M Hdr-E Bnzl 0.61 373 C IB-159 Cbm-M Hdr-E 4-OH-Bnz1 0.98 389 D IB-160 Cbm-M Hdr-E Cbx-E 0.20 355 E IB-161 Cbm-M Hdr-E i-Pnt 0.65 353 C IB-162 Cbm-M Hdr-E Ph—Et 0.67 387 C IB-163 Cbm-M Hdr-E Np-M 0.70 423 C IB-164 Gun-Pr Np-M i-Bu 1.25 477 D IB-165 Gun-Pr Np-M Bnzl 0.73 511 C IB-166 Gun-Pr Np-M 4-OH-Bnzl 0.71 527 C IB-167 Gun-Pr Np-M i-Pnt 1.30 491 D IB-168 Gun-Pr Np-M Ph—Et 1.31 525 D IB-169 Gun-Pr Np-M Np-M 1.31 561 D IB-170 Gun-Pr Hxy i-Bu 0.74 421 C IB-171 Gun-Pr Hxy Bnzl 0.74 455 C IB-172 Gun-Pr Hxy 4-OH-Bnzl 1.23 471 D IB-173 Gun-Pr Hxy i-Pnt 0.77 435 C IB-174 Gun-Pr Hxy Ph—Et 1.33 469 D IB-175 Gun-Pr Hxy Np-M 1.32 505 D IB-176 Gun-Pr i-Pr i-Bu 1.08 379 D IB-177 Gun-Pr i-Pr 4-OH-Bnzl 1.04 429 D IB-178 Gun-Pr i-Pr i-Pnt 1.15 393 D IB-179 Gun-Pr i-Pr Ph—Et 1.17 427 D IB-180 Gun-Pr i-Pr Np-M 1.18 463 D IB-181 Gun-Pr 4-F-Bnzl i-Bu 1.19 445 D IB-182 Gun-Pr 4-F-Bnzl Bnzl 0.70 479 C IB-183 Gun-Pr 4-F-Bnzl 4-OH-Bnzl 1.14 495 D IB-184 Gun-Pr 4-F-Bnzl i-Pnt 1.26 459 D IB-185 Gun-Pr 4-F-Bnzl Ph—Et 0.74 493 C IB-186 Gun-Pr 4-F-Bnzl Np-M 0.74 529 C IB-187 i-Bu i-Bu Gun-Pr 3.80 393 G IB-188 i-Bu Bnzl Gun-Pr 4.09 427 G IB-189 i-Bu 4-OH-Bnzl Gun-Pr 3.67 443 G IB-190 i-Bu Cbm-E Gun-Pr 3.04 408 G IB-191 i-Bu Hdr-E Gun-Pr 3.00 381 G IB-192 i-Bu i-Pnt Gun-Pr 4.15 407 G IB-193 i-Bu Ph—Et Gun-Pr 4.30 441 G IB-194 i-Bu Np-M Gun-Pr 4.70 477 G IB-195 i-Bu Hxy Gun-Pr 4.54 421 G IB-196 i-Bu i-Pr Gun-Pr 3.72 379 G IB-197 i-Bu 4-F-Bnzl Gun-Pr 4.29 445 G IB-198 Bnzl i-Bu Gun-Pr 2.65 427 F IB-199 Bnzl 4-OH-Bnzl Gun-Pr 3.88 477 G

TABLE 3-11 IB-200 Bnzl Cbm-E Gun-Pr 3.17 442 G IB-201 Bnzl Hdr-E Gun-Pr 3.20 415 G IB-202 Bnzl i-Pr Gun-Pr 3.82 413 F IB-203 4-OH-Bnzl i-Bu Gun-Pr 3.65 443 G IB-204 4-OH-Bnzl i-Pnt Gun-Pr 3.92 457 G IB-205 4-OH-Bnzl Ph—Et Gun-Pr 3.95 491 G IB-206 4-OH-Bnzl Np-M Gun-Pr 4.32 527 G IB-207 4-OH-Bnzl 4-F-Bnzl Gun-Pr 3.94 495 G IB-208 i-Pnt i-Bu Gun-Pr 2.54 407 F IB-209 i-Pnt Bnzl Gun-Pr 2.65 441 F IB-210 i-Pnt 4-OH-Bnzl Gun-Pr 2.43 457 F IB-211 i-Pnt Cbm-E Gun-Pr 3.07 422 G IB-212 i-Pnt Hdr-E Gun-Pr 3.07 395 G IB-213 i-Pnt Ph—Et Gun-Pr 2.75 455 F IB-214 i-Pnt Np-M Gun-Pr 3.07 491 F IB-215 i-Pnt Hxy Gun-Pr 2.84 435 F IB-216 i-Pnt i-Pr Gun-Pr 3.59 393 G IB-217 i-Pnt 4-F-Bnzl Gun-Pr 2.74 459 F IB-218 Ph—Et Hdr-E Gun-Pr 3.63 429 G IB-219 Np-M i-Bu Gun-Pr 3.02 477 F IB-220 Np-M Bnzl Gun-Pr 4.80 511 G IB-221 Np-M 4-OH-Bnzl Gun-Pr 4.35 527 G IB-222 Np-M Cbm-E Gun-Pr 3.85 492 G IB-223 Np-M Hdr-E Gun-Pr 3.92 465 G IB-224 Np-M i-Pnt Gun-Pr 3.22 491 F IB-225 Np-M Ph—Et Gun-Pr 3.10 525 F IB-226 Np-M Np-M Gun-Pr 3.24 561 F IB-227 Np-M Hxy Gun-Pr 5.09 505 G IB-228 Np-M i-Pr Gun-Pr 2.82 463 F IB-229 Np-M 4-F-Bnzl Gun-Pr 4.87 529 G IB-230 Chm i-Bu Gun-Pr 2.82 433 F IB-231 Chm Bnzl Gun-Pr 2.95 467 F IB-232 Chm 4-OH-Bnzl Gun-Pr 2.67 483 F IB-233 Chm Cbm-E Gun-Pr 3.49 448 G IB-234 Chm Hdr-E Gun-Pr 3.50 421 G IB-235 Chm i-Pnt Gun-Pr 3.04 447 F IB-236 Chm Ph—Et Gun-Pr 2.94 481 F IB-237 Chm Np-M Gun-Pr 3.22 517 F IB-238 Chm Hxy Gun-Pr 3.15 461 F IB-239 Chm i-Pr Gun-Pr 2.69 419 F IB-240 Chm 4-F-Bnzl Gun-Pr 2.99 485 F IB-241 4-F-Bnzl 4-OH-Bnzl Gun-Pr 4.00 495 G IB-242 4-F-Bnzl Cbm-E Gun-Pr 3.29 460 G IB-243 4-F-Bnzl Hdr-E Gun-Pr 3.27 433 F IB-244 4-F-Bnzl i-Pr Gun-Pr 3.84 431 G IB-245 Bnzl Bnzl Gun-Pr 2.69 461 F

TABLE 3-12 IB-246 Bnzl i-Pnt Gun-Pr 2.74 441 F IB-247 Bnzl Ph—Et Gun-Pr 2.77 475 F IB-248 Bnzl Np-M Gun-Pr 3.07 511 F IB-249 Bnzl Hxy Gun-Pr 2.97 455 F IB-250 Bnzl 4-F-Bnzl Gun-Pr 2.77 479 F IB-251 Ph—Et i-Bu Gun-Pr 2.75 441 F IB-252 Ph—Et Bnzl Gun-Pr 2.85 475 F IB-253 Ph—Et 4-OH-Bnzl Gun-Pr 2.60 491 F IB-254 Ph—Et i-Pnt Gun-Pr 2.85 455 F IB-255 Ph—Et Np-M Gun-Pr 3.25 525 F IB-256 Ph—Et Hxy Gun-Pr 3.15 469 F IB-257 Ph—Et i-Pr Gun-Pr 2.52 427 F IB-258 Ph—Et 4-F-Bnzl Gun-Pr 2.97 493 F IB-259 4-F-Bnzl i-Bu Gun-Pr 2.67 445 F IB-260 4-F-Bnzl Bnzl Gun-Pr 2.80 479 F IB-261 4-F-Bnzl i-Pnt Gun-Pr 2.84 459 F IB-262 4-F-Bnzl Ph—Et Gun-Pr 2.88 493 F IB-263 4-F-Bnzl Np-M Gun-Pr 3.20 529 F IB-264 4-F-Bnzl Hxy Gun-Pr 3.04 473 F IB-265 i-Bu Cbm-E Cbx-E 2.06 381 H IB-266 i-Bu Cbm-E i-Pnt 2.48 379 H IB-267 i-Bu Gun-Pr i-Bu 2.35 393 H IB-268 i-Bu Gun-Pr Bnzl 2.39 427 H IB-269 i-Bu Gun-Pr 4-OH-Bnzl 1.98 443 H IB-270 i-Bu Gun-Pr i-Pnt 2.24 407 H IB-271 i-Bu Gun-Pr Ph—Et 2.25 441 H IB-272 i-Bu Gun-Pr Np-M 2.28 477 H IB-273 Bnzl Cbm-E Cbx-E 1.90 415 H IB-274 Bnzl Cbm-E i-Pnt 2.28 413 H IB-275 Bnzl Gun-Pr i-Bu 2.17 427 H IB-276 Bnzl Gun-Pr Bnzl 2.25 461 H IB-277 Bnzl Gun-Pr 4-OH-Bnzl 2.07 477 H IB-278 Bnzl Gun-Pr i-Pnt 2.36 441 H IB-279 Bnzl Gun-Pr Ph—Et 2.28 475 H IB-280 Bnzl Gun-Pr Np-M 2.33 511 H IB-281 4-OH-Bnzl Cbm-E Cbx-E 1.71 431 H IB-282 4-OH-Bnzl Cbm-E i-Pnt 2.03 429 H IB-283 4-OH-Bnzl Gun-Pr i-Bu 1.96 443 H IB-284 4-OH-Bnzl Gun-Pr Bnzl 2.12 477 H IB-285 4-OH-Bnzl Gun-Pr i-Pnt 2.03 457 H IB-286 4-OH-Bnzl Gun-Pr Ph—Et 2.13 491 H IB-287 4-OH-Bnzl Gun-Pr Np-M 2.22 527 H IB-288 Cbx-E Cbm-E i-Pnt 2.10 395 H IB-289 Gun-Pr i-Bu i-Bu 2.02 393 H IB-290 Gun-Pr i-Bu Bnzl 2.01 427 H IB-291 Gun-Pr i-Bu 4-OH-Bnzl 1.95 443 H

TABLE 3-13 IB-292 Gun-Pr i-Bu i-Pnt 2.04 407 H IB-293 Gun-Pr i-Bu Ph—Et 2.12 441 H IB-294 Gun-Pr i-Bu Np-M 2.14 477 H IB-295 Gun-Pr Bnzl i-Bu 2.03 427 H IB-296 Gun-Pr Bnzl Bnzl 2.06 461 H IB-297 Gun-Pr Bnzl 4-OH-Bnzl 1.98 477 H IB-298 Gun-Pr Bnzl i-Pnt 2.16 441 H IB-299 Gun-Pr Bnzl Ph—Et 2.19 475 H IB-300 Gun-Pr Bnzl Np-M 2.21 511 H IB-301 Gun-Pr 4-OH-Bnzl i-Bu 1.93 443 H IB-302 Gun-Pr 4-OH-Bnzl Bnzl 1.95 477 H IB-303 Gun-Pr 4-OH-Bnzl i-Pnt 2.05 457 H IB-304 Gun-Pr 4-OH-Bnzl Ph—Et 2.07 491 H IB-305 Gun-Pr 4-OH-Bnzl Np-M 2.11 527 H IB-306 Gun-Pr Cbm-E i-Bu 1.83 408 H IB-307 Gun-Pr Cbm-E Bnzl 1.85 442 H IB-308 Gun-Pr Cbm-E 4-OH-Bnzl 1.75 458 H IB-309 Gun-Pr Cbm-E i-Pnt 1.91 422 H IB-310 Gun-Pr Cbm-E Ph—Et 1.96 456 H IB-311 Gun-Pr Cbm-E Np-M 1.98 492 H IB-312 Gun-Pr Hdr-E i-Bu 1.81 381 H IB-313 Gun-Pr Hdr-E Bnzl 1.85 415 H IB-314 Gun-Pr Hdr-E 4-OH-Bnzl 1.73 431 H IB-315 Gun-Pr Hdr-E i-Pnt 1.92 395 H IB-316 Gun-Pr Hdr-E Ph—Et 1.94 429 H IB-317 Gun-Pr Hdr-E Np-M 1.98 465 H IB-318 Gun-Pr i-Pnt i-Bu 2.10 407 H IB-319 Gun-Pr i-Pnt Bnzl 2.11 441 H IB-320 Gun-Pr i-Pnt 4-OH-Bnzl 2.03 457 H IB-321 Gun-Pr i-Pnt Ph—Et 2.12 455 H IB-322 Gun-Pr i-Pnt Np-M 2.22 491 H IB-323 Gun-Pr Ph—Et i-Bu 2.12 441 H IB-324 Gun-Pr Ph—Et Bnzl 2.09 475 H IB-325 Gun-Pr Ph—Et 4-OH-Bnzl 2.02 491 H IB-326 Gun-Pr Ph—Et i-Pnt 2.18 455 H IB-327 Gun-Pr Ph—Et Np-M 2.25 525 H IB-328 Hdr-E Cbm-E i-Pnt 1.98 367 H IB-329 Hdr-E Gun-Pr i-Bu 1.89 381 H IB-330 Hdr-E Gun-Pr Bnzl 1.96 415 H IB-331 Hdr-E Gun-Pr 4-OH-Bnzl 1.84 431 H IB-332 Hdr-E Gun-Pr i-Pnt 2.00 395 H IB-333 Hdr-E Gun-Pr Ph—Et 2.03 429 H IB-334 Hdr-E Gun-Pr Np-M 1.83 465 H IB-335 i-Pnt Cbm-E Cbx-E 1.85 395 H IB-336 i-Pnt Gun-Pr i-Bu 2.14 408 H IB-337 i-Pnt Gun-Pr Bnzl 2.17 441 H

TABLE 3-14 IB-338 i-Pnt Gun-Pr 4-OH-Bnzl 1.92 457 H IB-339 i-Pnt Gun-Pr Ph—Et 2.26 455 H IB-340 i-Pnt Gun-Pr Np-M 2.31 491 H IB-341 Ph—Et Cbm-E Cbx-E 2.00 429 H IB-342 Ph—Et Cbm-E i-Pnt 2.39 427 H IB-343 Ph—Et Gun-Pr i-Bu 2.22 441 H IB-344 Ph—Et Gun-Pr Bnzl 2.27 475 H IB-345 Ph—Et Gun-Pr 4-OH-Bnzl 2.10 491 H IB-346 Ph—Et Gun-Pr i-Pnt 2.33 455 H IB-347 Ph—Et Gun-Pr Np-M 2.38 525 H IB-348 Np-M Cbm-E Cbx-E 2.14 465 H IB-349 Np-M Cbm-E i-Pnt 2.57 463 H IB-350 Np-M Gun-Pr i-Bu 2.33 477 H IB-351 Np-M Gun-Pr Bnzl 2.31 511 H IB-352 Np-M Gun-Pr 4-OH-Bnzl 2.18 527 H IB-353 Np-M Gun-Pr i-Pnt 2.42 491 H IB-354 Np-M Gun-Pr Ph—Et 2.38 525 H IB-355 Np-M Gun-Pr Np-M 2.41 561 H IB-356 Chm Cbm-E Cbx-E 2.00 421 H IB-357 Chm Cbm-E i-Pnt 2.41 419 H IB-358 Chm Gun-Pr i-Bu 2.27 433 H IB-359 Chm Gun-Pr Bnzl 2.31 467 H IB-360 Chm Gun-Pr 4-OH-Bnzl 2.13 483 H IB-361 Chm Gun-Pr i-Pnt 2.33 447 H IB-362 Chm Gun-Pr Ph—Et 2.34 481 H IB-363 Chm Gun-Pr Np-M 2.42 517 H IB-364 4-F-Bnzl Cbm-E Cbx-E 1.93 433 H IB-365 4-F-Bnzl Cbm-E i-Pnt 2.29 431 H IB-366 4-F-Bnzl Gun-Pr i-Bu 2.21 445 H IB-367 4-F-Bnzl Gun-Pr Bnzl 2.26 478 H IB-368 4-F-Bnzl Gun-Pr 4-OH-Bnzl 2.09 495 H IB-369 4-F-Bnzl Gun-Pr i-Pnt 2.27 459 H IB-370 4-F-Bnzl Gun-Pr Ph—Et 2.28 493 H IB-371 4-F-Bnzl Gun-Pr Np-M 2.36 529 H IB-372 Hdr-E i-Bu i-Pnt 1.68 352 I IB-373 Ph—Et i-Bu i-Pnt 2.16 412 I IB-374 Np-M i-Bu i-Pnt 2.21 448 I IB-375 Chm i-Bu i-Pnt 2.28 404 I IB-376 4-F-Bnzl i-Bu i-Pnt 2.09 416 I IB-377 Bnzl i-Bu i-Pnt 2.09 398 I IB-378 i-Bu i-Bu i-Pnt 2.06 364 I IB-379 Hdr-E Cbx-E i-Bu 1.33 354 I IB-380 Hdr-E 4-OH-Bnzl Cbx-E 1.11 404 I IB-381 i-Pnt Cbx-E Np-M 1.87 464 I IB-382 Chm Cbx-E i-Bu 1.87 406 I IB-383 Chm 4-OH-Bnzl Cbx-E 1.68 456 I

TABLE 3-15 IB-384 4-F-Bnzl Cbx-E Np-M 1.90 502 I IB-385 4-F-Bnzl 4-OH-Bnzl Cbx-E 1.53 468 I IB-386 i-Pnt 4-F-Bnzl Cbx-E 1.85 432 I IB-387 Ph—Et Hdr-E Cbx-E 1.37 402 I IB-388 Np-M Hdr-E Cbx-E 1.54 438 I IB-389 Chm Np-M Cbx-E 1.99 490 I IB-390 4-F-Bnzl Np-M Cbx-E 1.86 502 I IB-391 Cbx-E Hdr-E Bnzl 1.35 388 I IB-392 Cbx-E Np-M i-Bu 1.80 450 I IB-393 Cbx-E Hxy Bnzl 1.79 428 I IB-394 Cbx-E 4-F-Bnzl Bnzl 1.70 452 I IB-395 Cbx-E Hdr-E i-Pnt 1.46 368 I IB-396 Cbx-E Hdr-E Ph—Et 1.45 402 I IB-397 Cbx-E Hdr-E Np-M 1.59 438 I IB-398 Cbx-E Np-M i-Pnt 1.83 464 I IB-399 Cbx-E 4-F-Bnzl i-Pnt 1.82 432 I IB-400 Cbx-E i-Bu Bnzl 1.53 400 I IB-401 Cbx-E Cbm-E Ph—Et 1.49 429 I IB-402 Cbx-E 4-OH-Bnzl i-Pnt 1.60 430 I IB-403 Bnzl Hdr-E Cbx-E 1.31 388 I IB-404 Bnzl Hxy Cbx-E 1.88 428 I IB-405 Bnzl 4-OH-Bnzl Cbx-E 1.54 450 I IB-406 i-Bu Hxy Cbx-E 1.88 394 I IB-407 i-Bu Cbx-E i-Bu 1.62 366 I IB-408 i-Bu i-Bu Cbx-E 1.71 366 I IB-409 i-Bu 4-OH-Bnzl Cbx-E 1.47 416 I IB-410 4-OH-Bnzl Cbx-E Np-M 1.70 500 I IB-411 Ph—Et i-Bu Np-M 2.32 482 I IB-412 Ph—Et 4-OH-Bnzl Np-M 2.02 532 I IB-413 Np-M i-Bu Ph—Et 2.23 482 I IB-414 Np-M i-Bu Np-M 2.25 518 I IB-415 Np-M i-Bu Bnzl 2.15 468 I IB-416 Np-M 4-OH-Bnzl Ph—Et 2.08 532 I IB-417 Np-M 4-OH-Bnzl Np-M 2.11 568 I IB-418 4-F-Bnzl i-Bu Np-M 2.15 486 I IB-419 4-F-Bnzl Ph—Et Np-M 2.17 534 I IB-420 Bnzl i-Bu Np-M 2.17 468 I IB-421 Bnzl 4-OH-Bnzl Ph—Et 1.92 482 I IB-422 i-Bu 4-OH-Bnzl Ph—Et 1.93 448 I IB-423 4-OH-Bnzl Ph—Et Np-M 1.97 532 I IB-424 4-OH-Bnzl i-Bu i-Pnt 1.82 414 I IB-425 Hdr-E Np-M Cbx-E 1.55 438 I IB-426 i-Pnt Np-M Hdr-M 1.91 422 I IB-427 4-F-Bnzl Np-M Hdr-M 1.96 460 I IB-428 Cbx-E Ph—Et 4-OH-Bnzl 1.59 464 I IB-429 Cbx-E Np-M Hdr-M 1.55 424 I

TABLE 3-16 IB-430 Cbx-E i-Bu Ph—Et 1.66 414 I IB-431 Cbx-E i-Bu Hdr-M 1.21 340 I IB-432 Cbx-E i-Bu 4-OH-Bnzl 1.40 416 I IB-433 Cbx-E Cbm-E Np-M 1.56 465 I IB-434 Cbx-E Cbm-E Bnzl 1.41 415 I IB-435 Cbx-E Cbm-E i-Bu 1.37 381 I IB-436 Cbx-E Cbm-E 4-OH-Bnzl 1.19 431 I IB-437 i-Bu Np-M Cbx-E 1.86 450 I IB-438 4-OH-Bnzl Ph—Et Cbx-E 1.60 464 I IB-439 4-OH-Bnzl Np-M Cbx-E 1.69 500 I IB-440 4-OH-Bnzl Np-M Hdr-M 1.70 458 I IB-441 Hdr-E Cbm-E 4-OH-Bnzl 1.18 403 I IB-442 Hdr-E 4-OH-Bnzl i-Pnt 1.58 402 I IB-443 Hdr-E 4-OH-Bnzl Ph—Et 1.60 436 I IB-444 Hdr-E 4-OH-Bnzl Bnzl 1.52 422 I IB-445 i-Pnt 4-OH-Bnzl Np-M 2.02 498 I IB-446 i-Pnt 4-OH-Bnzl i-Bu 1.90 414 I IB-447 Ph—Et 4-OH-Bnzl i-Pnt 2.02 462 I IB-448 Ph—Et 4-OH-Bnzl Bnzl 1.93 482 I IB-449 Ph—Et 4-OH-Bnzl i-Bu 1.90 448 I IB-450 Np-M 4-OH-Bnzl i-Pnt 2.08 498 I IB-451 Np-M 4-OH-Bnzl Bnzl 1.99 518 I IB-452 Np-M 4-OH-Bnzl i-Bu 2.00 484 I IB-453 Chm 4-OH-Bnzl i-Pnt 2.11 454 I IB-454 Chm 4-OH-Bnzl Ph—Et 2.08 488 I IB-455 Chm 4-OH-Bnzl Np-M 2.13 524 I IB-456 Chm 4-OH-Bnzl Bnzl 2.02 474 I IB-457 4-F-Bnzl 4-OH-Bnzl Np-M 2.02 536 I IB-458 4-F-Bnzl 4-OH-Bnzl i-Bu 1.87 452 I IB-459 Np-M Hdr-E 4-OH-Bnzl 1.64 472 I IB-460 Chm Hdr-E Bnzl 1.94 412 I IB-461 Ph—Et Hdr-E i-Pnt 1.86 400 I IB-462 Bnzl 4-OH-Bnzl i-Pnt 1.94 448 I IB-463 Bnzl 4-OH-Bnzl Bnzl 1.86 468 I IB-464 Bnzl 4-OH-Bnzl i-Bu 1.84 434 I IB-465 i-Bu 4-OH-Bnzl i-Pnt 1.96 414 I IB-466 i-Bu 4-OH-Bnzl Np-M 2.00 484 I IB-467 i-Bu 4-OH-Bnzl i-Bu 1.85 400 I IB-468 4-OH-Bnzl Hdr-E i-Bu 1.40 388 I IB-469 4-OH-Bnzl Hdr-E i-Pnt 1.55 402 I IB-470 Hdr-E 4-OH-Bnzl Np-M 1.68 472 I IB-471 Ph—Et i-Pr 4-OH-Bnzl 1.24 434 I IB-472 Np-M Bnzl 4-OH-Bnzl 1.98 518 I IB-473 Chm i-Pr 4-OH-Bnzl 1.20 426 I IB-474 4-F-Bnzl Bnzl Np-M 2.16 520 I IB-475 4-F-Bnzl i-Pr 4-OH-Bnzl 1.13 428 I

TABLE 3-17 IB-476 Hdr-E Hxy Bnzl 1.92 400 I IB-477 Hdr-E Hxy i-Bu 1.87 366 I IB-478 Hdr-E Hxy 4-OH-Bnzl 1.79 416 I IB-479 Hdr-E 4-F-Bnzl Bnzl 1.73 424 I IB-480 i-Pnt Hxy 4-OH-Bnzl 2.07 442 I IB-481 i-Pnt 4-F-Bnzl 4-OH-Bnzl 1.93 466 I IB-482 Np-M Hxy i-Bu 2.35 I IB-483 Np-M Hxy 4-OH-Bnzl 2.17 512 I IB-484 Chm Ph-Et Bnzl 2.36 I IB-485 Chm Hxy Bnzl 2.42 I IB-486 Chm Hxy i-Bu 2.44 I IB-487 Chm Hxy 4-OH-Bnzl 2.18 468 I IB-488 Chm 4-F-Bnzl i-Bu 2.22 442 I IB-489 4-F-Bnzl Ph-Et Bnzl 2.18 484 I IB-490 Hdr-E Hxy i-Pnt 1.99 380 I IB-491 Hdr-E Hxy Np-M 1.98 450 I IB-492 Hdr-E 4-F-Bnzl Ph-Et 1.80 438 I IB-493 Np-M Hdr-E Np-M 1.99 506 I IB-494 Chm Hxy i-Pnt 2.54 I IB-495 i-Bu Ph-Et i-Bu 2.16 398 I IB-496 i-Bu Hxy 4-OH-Bnzl 2.04 428 I IB-497 i-Bu 4-F-Bnzl i-Bu 2.05 402 I IB-498 i-Bu 4-F-Bnzl 4-OH-Bnzl 1.89 452 I IB-499 4-OH-Bnzl 4-F-Bnzl i-Bu 1.91 452 I IB-500 4-OH-Bnzl Bnzl Np-M 1.92 518 I IB-501 4-OH-Bnzl i-Pr i-Pnt 1.77 400 I IB-502 4-OH-Bnzl i-Pr Np-M 1.83 470 I IB-503 Hdr-E Bnzl Cbx-E 1.37 388 I IB-504 Hdr-E i-Bu Cbx-E 1.28 354 I IB-505 i-Pnt Bnzl Cbx-E 1.79 414 I IB-506 i-Pnt i-Bu Cbx-E 1.75 380 I IB-507 i-Pnt 4-OH-Bnzl Cbx-E 1.49 430 I IB-508 Ph-Et i-Bu Cbx-E 1.71 414 I IB-509 Np-M i-Bu Cbx-E 1.93 450 I IB-510 Chm i-Bu Cbx-E 1.91 406 I IB-511 4-F-Bnzl i-Pnt Cbx-E 1.88 432 I IB-512 Cbx-E i-Pnt 4-OH-Bnzl 1.55 430 I IB-513 Cbx-E i-Pnt Ph-Et 1.71 428 I IB-514 Cbx-E i-Pnt Np-M 1.83 464 I IB-515 Cbx-E 4-OH-Bnzl Ph-Et 1.63 464 I IB-516 Cbx-E 4-OH-Bnzl Np-M 1.68 500 I IB-517 i-Bu Cbx-E Np-M 1.81 450 I IB-518 4-OH-Bnzl i-Pnt Cbx-E 1.61 430 I IB-519 Hdr-E Cbm-E Np-M 1.54 437 I IB-520 Np-M Cbm-E i-Bu 1.83 449 I IB-521 Np-M Cbm-E 4-OH-Bnzl 1.64 499 I

TABLE 3-18 IB-522 Chm Cbm-E Np-M 1.95 489 I IB-523 Chm Cbm-E 4-OH-Bnzl 1.57 455 I IB-524 4-F-Bnzl Cbm-E Ph-Et 1.78 465 I IB-525 4-F-Bnzl Cbm-E Np-M 1.86 501 I IB-526 Hdr-E Ph-Et 4-OH-Bnzl 1.53 436 I IB-527 Hdr-E Np-M 4-OH-Bnzl 1.69 I IB-528 Chm Np-M i-Bu 2.35 474 I IB-529 Chm 4-F-Bnzl 4-OH-Bnzl 1.99 492 I IB-530 4-F-Bnzl Np-M 4-OH-Bnzl 1.98 536 I IB-531 Hdr-E Ph-Et i-Pnt 1.80 400 I IB-532 4-F-Bnzl Np-M i-Pnt 2.24 500 I IB-533 Bnzl 4-F-Bnzl i-Bu 2.07 436 I IB-534 Bnzl 4-F-Bnzl 4-OH-Bnzl 1.88 486 I IB-535 Bnzl Cbm-E Ph-Et 1.73 447 I IB-536 i-Bu Ph-Et 4-OH-Bnzl 1.85 448 I IB-537 i-Bu Np-M 4-OH-Bnzl 1.99 484 I IB-538 i-Bu Np-M i-Pnt 2.28 448 I IB-539 i-Bu Cbm-E Ph-Et 1.71 413 I IB-540 4-OH-Bnzl Ph-Et i-Bu 1.80 448 I IB-541 4-OH-Bnzl Np-M i-Bu 1.94 484 I IB-542 4-OH-Bnzl Hxy Bnzl 1.98 462 I IB-543 4-OH-Bnzl 4-F-Bnzl Bnzl 1.83 486 I IB-544 4-OH-Bnzl Ph-Et i-Pnt 1.92 462 I IB-545 4-OH-Bnzl Cbm-E Bnzl 1.53 449 I IB-546 Ph-Et Bnzl Np-M 2.22 516 I IB-547 4-F-Bnzl Bnzl Ph-Et 2.15 484 I IB-548 4-F-Bnzl Cbm-E 4-OH-Bnzl 1.48 467 I IB-549 Hdr-E 4-F-Bnzl 4-OH-Bnzl 1.51 440 I IB-550 i-Pnt Hxy Bnzl 2.22 426 I IB-551 i-Pnt Hxy i-Bu 2.24 392 I IB-552 i-Pnt 4-F-Bnzl Bnzl 2.11 450 I IB-553 i-Pnt 4-F-Bnzl i-Bu 2.10 416 I IB-554 Ph-Et Hxy Bnzl 2.27 460 I IB-555 Ph-Et 4-F-Bnzl Bnzl 2.13 484 I IB-556 Ph-Et 4-F-Bnzl i-Bu 2.12 450 I IB-557 i-Pnt Hxy Ph-Et 2.31 440 I IB-558 i-Pnt Hxy Np-M 2.35 476 I IB-559 Ph-Et 4-F-Bnzl i-Pnt 2.20 464 I IB-560 Chm 4-F-Bnzl Np-M 2.29 526 I IB-561 Bnzl i-Pnt i-Bu 2.13 398 I IB-562 Bnzl Hxy Bnzl 2.20 446 I IB-563 Bnzl Hxy i-Bu 2.22 412 I IB-564 Bnzl 4-F-Bnzl Bnzl 2.08 470 I IB-565 Bnzl Hxy i-Pnt 2.27 426 I IB-566 Bnzl Hxy Ph-Et 2.24 460 I IB-567 Bnzl 4-F-Bnzl i-Pnt 2.13 450 I

TABLE 3-19 IB-568 Bnzl 4-F-Bnzl Ph-Et 2.12 484 I IB-569 Bnzl Cbm-E 4-OH-Bnzl 1.47 449 I IB-570 i-Bu Hxy i-Bu 2.22 378 I IB-571 i-Bu Hxy i-Pnt 2.31 392 I IB-572 i-Bu Hxy Ph-Et 2.25 426 I IB-573 i-Bu Hxy Np-M 2.48 462 I IB-574 4-OH-Bnzl i-Pnt Bnzl 1.90 448 I IB-575 Cbx-E i-Bu Np-M 1.80 450 I IB-576 i-Pnt 4-OH-Bnzl Ph-Et 1.97 462 I IB-577 i-Pnt 4-OH-Bnzl Bnzl 1.87 448 I IB-578 Np-M Bnzl Np-M 2.24 552 I IB-579 Np-M i-Pr Ph-Et 2.15 468 I IB-580 Np-M i-Pr Bnzl 2.05 454 I IB-581 Chm 4-OH-Bnzl i-Bu 2.02 440 I IB-582 4-F-Bnzl 4-OH-Bnzl i-Pnt 1.96 466 I IB-583 4-F-Bnzl 4-OH-Bnzl Bnzl 1.88 486 I IB-584 Hdr-E Ph-Et Bnzl 1.75 420 I IB-585 Hdr-E Np-M i-Bu 1.80 422 I IB-586 Hdr-E 4-F-Bnzl i-Bu 1.62 390 I IB-587 i-Pnt Hdr-E 4-OH-Bnzl 1.36 402 I IB-588 Np-M Hdr-E Bnzl 1.89 456 I IB-589 Np-M Np-M 4-OH-Bnzl 2.06 568 I IB-590 Np-M 4-F-Bnzl i-Bu 2.16 486 I IB-591 Chm Hdr-E 4-OH-Bnzl 1.56 428 I IB-592 Chm 4-F-Bnzl Bnzl 2.23 476 I IB-593 Ph-Et Hdr-E Np-M 1.88 470 I IB-594 Ph-Et i-Pnt Np-M 2.24 496 I IB-595 Ph-Et Hxy Np-M 2.33 510 I IB-596 Np-M Hdr-E Ph-Et 1.94 470 I IB-597 Np-M Hxy Ph-Et 2.34 510 I IB-598 Np-M Hxy Np-M 2.36 546 I IB-599 Np-M 4-F-Bnzl i-Pnt 2.26 500 I IB-600 Chm 4-F-Bnzl i-Pnt 2.28 456 I IB-601 Bnzl Np-M 4-OH-Bnzl 1.98 518 I IB-602 Bnzl Hdr-E Np-M 1.85 456 I IB-603 Bnzl i-Pnt Np-M 2.29 482 I IB-604 Bnzl Hxy Np-M 2.29 496 I IB-605 Bnzl i-Pr Np-M 2.11 454 I IB-606 Bnzl 4-OH-Bnzl Np-M 1.96 518 I IB-607 i-Bu Hdr-E 4-OH-Bnzl 1.40 388 I IB-608 i-Bu 4-F-Bnzl Np-M 2.15 486 I IB-609 i-Bu Cbm-E i-Bu 1.59 365 I IB-610 Hdr-E Cbx-E Np-M 1.56 438 I IB-611 i-Pnt Cbx-E i-Bu 1.68 380 I IB-612 Np-M Cbx-E Bnzl 1.89 484 I IB-613 Chm Cbx-E i-Pnt 1.95 420 I

TABLE 3-20 IB-614 Chm Cbx-E Np-M 2.02 490 I IB-615 4-F-Bnzl Cbx-E 4-OH-Bnzl 1.53 468 I IB-616 Bnzl Cbx-E Np-M 1.85 484 I IB-617 Hdr-E Bnzl i-Pnt 1.79 286 I IB-618 Hdr-E Bnzl Ph-Et 1.79 420 I IB-619 Hdr-E Bnzl Bnzl 1.71 406 I IB-620 Hdr-E i-Bu Ph-Et 1.74 386 I IB-621 Hdr-E i-Bu Np-M 1.80 422 I IB-622 Hdr-E i-Bu Bnzl 1.59 372 I IB-623 Hdr-E i-Bu 4-OH-Bnzl 1.48 388 I IB-624 i-Pnt Bnzl Ph-Et 2.17 446 I IB-625 Ph-Et i-Bu 4-OH-Bnzl 1.88 448 I IB-626 Chm Bnzl i-Pnt 2.35 I IB-627 Chm Bnzl 4-OH-Bnzl 2.01 474 I IB-628 4-F-Bnzl Bnzl 4-OH-Bnzl 1.94 486 I IB-629 4-F-Bnzl i-Bu Bnzl 2.06 436 I IB-630 4-F-Bnzl i-Bu i-Bu 2.03 402 I IB-631 4-F-Bnzl i-Bu 4-OH-Bnzl 1.90 452 I IB-632 Bnzl Bnzl Ph-Et 2.12 466 I IB-633 i-Bu i-Bu Ph-Et 2.11 398 I IB-634 4-OH-Bnzl Bnzl Ph-Et 1.87 482 I IB-635 4-OH-Bnzl i-Bu Np-M 1.97 484 I IB-636 i-Pnt Cbm-E Ph-Et 1.80 427 I IB-637 Chm Cbm-E Bnzl 1.83 439 I IB-638 i-Pnt Hdr-E Bnzl 1.68 386 I IB-639 i-Pnt Hdr-E i-Bu 1.62 352 I IB-640 Ph-Et Hdr-E Bnzl 1.77 420 I IB-641 Ph-Et Hdr-E i-Bu 1.77 386 I IB-642 Ph-Et 4-F-Bnzl 4-OH-Bnzl 1.99 500 I IB-643 Np-M Hdr-E i-Bu 1.87 422 I IB-644 Np-M i-Pnt i-Bu 2.27 448 I IB-645 Np-M i-Pnt 4-OH-Bnzl 2.06 498 I IB-646 Chm Hdr-E i-Bu 1.79 378 I IB-647 Chm i-Pnt Bnzl 2.32 438 I IB-648 Chm i-Pnt 4-OH-Bnzl 2.07 454 I IB-649 4-F-Bnzl Hdr-E Bnzl 1.76 424 I IB-650 4-F-Bnzl Hdr-E i-Bu 1.70 390 I IB-651 4-F-Bnzl i-Pnt Bnzl 2.17 450 I IB-652 4-F-Bnzl i-Pnt i-Bu 2.14 416 I IB-653 4-F-Bnzl Np-M i-Bu 2.19 486 I IB-654 4-F-Bnzl Hxy Bnzl 2.24 464 I IB-655 4-F-Bnzl Hxy i-Bu 2.24 I IB-656 4-F-Bnzl Hxy 4-OH-Bnzl 2.02 480 I IB-657 Hdr-E 4-F-Bnzl i-Pnt 1.83 404 I IB-658 i-Pnt Hdr-E Ph-Et 1.79 400 I IB-659 i-Pnt Hdr-E Np-M 1.94 436 I

TABLE 3-21 IB-660 Ph-Et Hxy i-Pnt 2.39 I IB-661 Np-M Hdr-E i-Pnt 1.98 436 I IB-662 Np-M Hxy i-Pnt 2.44 I IB-663 Chm Hdr-E Ph-Et 1.89 426 I IB-664 Chm Hdr-E Np-M 1.98 462 I IB-665 Chm Hxy Ph-Et 2.50 I IB-666 Chm Hxy Np-M 2.54 I IB-667 Chm 4-F-Bnzl Ph-Et 2.31 490 I IB-668 4-F-Bnzl Hdr-E i-Pnt 1.77 404 I IB-669 4-F-Bnzl Hdr-E Ph-Et 1.78 438 I IB-670 4-F-Bnzl Hdr-E Np-M 1.87 474 I IB-671 4-F-Bnzl i-Pnt Ph-Et 2.21 464 I IB-672 4-F-Bnzl i-Pnt Np-M 2.27 500 I IB-673 4-F-Bnzl Hxy i-Pnt 2.30 I IB-674 4-F-Bnzl Hxy Ph-Et 2.31 I IB-675 4-F-Bnzl Hxy Np-M 2.37 I IB-676 Bnzl Hdr-E Bnzl 1.70 406 I IB-677 Bnzl Hdr-E i-Bu 1.66 372 I IB-678 Bnzl i-Pnt 4-OH-Bnzl 1.95 448 I IB-679 Bnzl Hxy 4-OH-Bnzl 2.02 462 I IB-680 Bnzl Hdr-E i-Pnt 1.79 386 I IB-681 Bnzl Hdr-E Ph-Et 1.76 420 I IB-682 i-Bu Hdr-E i-Bu 1.62 338 I IB-683 i-Bu i-Pnt i-Bu 2.11 364 I IB-684 i-Bu i-Pnt 4-OH-Bnzl 1.88 414 I IB-685 i-Bu Hdr-E i-Pnt 1.71 352 I IB-686 i-Bu Hdr-E Ph-Et 1.74 386 I IB-687 i-Bu Hdr-E Np-M 1.82 422 I IB-688 i-Bu i-Pnt Ph-Et 2.17 412 I IB-689 i-Bu 4-F-Bnzl i-Pnt 2.13 416 I IB-690 i-Bu 4-F-Bnzl Ph-Et 2.22 I IB-691 Ph-Et Bnzl Cbx-E 1.84 448 I IB-692 4-F-Bnzl Bnzl Cbx-E 1.79 452 I IB-693 Np-M i-Pnt Cbx-E 1.99 464 I IB-694 Cbx-E Bnzl i-Pnt 1.79 414 I IB-695 Cbx-E Bnzl i-Bu 1.64 400 I IB-696 Cbx-E i-Bu i-Pnt 1.77 380 I IB-697 Bnzl i-Pnt Cbx-E 1.84 414 I IB-698 Bnzl Bnzl Cbx-E 1.82 434 I IB-699 Bnzl i-Bu Cbx-E 1.74 400 I IB-700 i-Bu i-Pnt Cbx-E 1.81 380 I IB-701 Hdr-E Cbm-E Ph-Et 1.46 401 I IB-702 Hdr-E Cbm-E Bnzl 1.39 387 I IB-703 i-Pnt Cbm-E Np-M 1.86 463 I IB-704 i-Pnt Cbm-E Bnzl 1.71 413 I IB-705 i-Pnt Cbm-E i-Bu 1.71 379 I

TABLE 3-22 IB-706 i-Pnt Cbm-E 4-OH-Bnzl 1.38 429 I IB-707 Ph-Et Cbm-E Bnzl 1.77 447 I IB-708 Ph-Et Cbm-E i-Bu 1.77 413 I IB-709 Ph-Et Cbm-E 4-OH-Bnzl 1.55 463 I IB-710 Chm Cbm-E Ph-Et 1.91 453 I IB-711 Chm Cbm-E i-Bu 1.84 405 I IB-712 4-F-Bnzl Cbm-E Bnzl 1.76 451 I IB-713 4-F-Bnzl Cbm-E i-Bu 1.71 417 I IB-714 Hdr-E i-Pnt Bnzl 1.72 386 I IB-715 Hdr-E i-Pnt i-Bu 1.71 352 I IB-716 Hdr-E i-Pnt 4-OH-Bnzl 1.61 402 I IB-717 Hdr-E Ph-Et i-Bu 1.74 386 I IB-718 i-Pnt Np-M i-Bu 2.29 448 I IB-719 i-Pnt Np-M 4-OH-Bnzl 2.02 498 I IB-720 Ph-Et i-Pnt 4-OH-Bnzl 1.99 462 I IB-721 Np-M Ph-Et 4-OH-Bnzl 2.09 532 I IB-722 Chm Ph-Et i-Bu 2.32 438 I IB-723 Chm Np-M 4-OH-Bnzl 2.13 524 I IB-724 4-F-Bnzl i-Pnt 4-OH-Bnzl 2.00 466 I IB-725 4-F-Bnzl Ph-Et i-Bu 2.16 450 I IB-726 4-F-Bnzl Ph-Et 4-OH-Bnzl 1.96 500 I IB-727 Hdr-E i-Pnt Np-M 1.88 436 I IB-728 Np-M i-Pnt Ph-Et 2.33 496 I IB-729 Np-M Ph-Et Np-M 2.38 I IB-730 Chm i-Pnt Ph-Et 2.36 I IB-731 Chm Np-M i-Pnt 2.46 I IB-732 4-F-Bnzl Ph-Et i-Pnt 2.22 464 I IB-733 Bnzl i-Pnt Ph-Et 2.20 446 I IB-734 Bnzl Cbm-E Bnzl 1.74 433 I IB-735 i-Bu Np-M i-Bu 2.25 434 I IB-736 i-Bu i-Pnt Np-M 2.27 448 I IB-737 i-Bu Cbm-E Np-M 1.84 449 I IB-738 i-Bu Cbm-E 4-OH-Bnzl 1.40 415 I IB-739 4-OH-Bnzl i-Pnt i-Bu 1.84 414 I IB-740 4-OH-Bnzl i-Pnt Ph-Et 1.95 462 I IB-741 4-OH-Bnzl i-Pnt Np-M 2.01 498 I IB-742 4-OH-Bnzl Cbm-E Ph-Et 1.59 463 I IB-743 4-OH-Bnzl Cbm-E Np-M 1.75 499 I IB-744 Hdr-E Bnzl i-Bu 1.67 372 I IB-745 Hdr-E Bnzl 4-OH-Bnzl 1.51 422 I IB-746 Hdr-E i-Bu i-Bu 1.57 338 I IB-747 i-Pnt Bnzl Np-M 2.21 482 I IB-748 i-Pnt Bnzl i-Bu 2.10 398 I IB-749 i-Pnt Bnzl 4-OH-Bnzl 1.82 448 I IB-750 i-Pnt i-Bu Ph-Et 2.16 412 I IB-751 i-Pnt i-Bu Np-M 2.18 448 I

TABLE 3-23 IB-752 i-Pnt i-Bu Bnzl 2.06 398 I IB-753 i-Pnt i-Bu i-Bu 2.04 364 I IB-754 i-Pnt i-Bu 4-OH-Bnzl 2.34 I IB-755 Ph-Et Bnzl i-Pnt 2.22 446 I IB-756 Ph-Et Bnzl Bnzl 2.10 466 I IB-757 Ph-Et Bnzl i-Bu 2.13 432 I IB-758 Ph-Et Bnzl 4-OH-Bnzl 1.90 482 I IB-759 Ph-Et i-Bu Bnzl 2.08 432 I IB-760 Ph-Et i-Bu i-Bu 2.10 398 I IB-761 Np-M Bnzl i-Bu 2.22 468 I IB-762 Np-M i-Bu i-Bu 2.16 434 I IB-763 Np-M i-Bu 4-OH-Bnzl 1.97 484 I IB-764 Chm Bnzl Ph-Et 2.31 472 I IB-765 Chm Bnzl i-Bu 2.24 424 I IB-766 Chm i-Bu Ph-Et 2.27 438 I IB-767 Chm i-Bu Np-M 2.32 474 I IB-768 Chm i-Bu Bnzl 2.19 424 I IB-769 Chm i-Bu i-Bu 2.22 390 I IB-770 Chm i-Bu 4-OH-Bnzl 1.99 440 I IB-771 4-F-Bnzl Bnzl i-Pnt 2.18 450 I IB-772 4-F-Bnzl Bnzl Bnzl 2.10 470 I IB-773 4-F-Bnzl Bnzl i-Bu 2.12 436 I IB-774 4-F-Bnzl i-Bu Ph-Et 2.11 450 I IB-775 Ph-Et i-Pnt Bnzl 2.18 446 I IB-776 Bnzl i-Pnt Bnzl 2.13 432 I IB-777 Bnzl Bnzl Np-M 2.20 502 I IB-778 Bnzl i-Bu Ph-Et 2.14 432 I IB-779 Bnzl i-Bu 4-OH-Bnzl 1.85 434 I IB-780 i-Bu i-Pnt Bnzl 2.15 398 I IB-781 i-Bu Bnzl i-Pnt 2.19 398 I IB-782 i-Bu Bnzl Np-M 2.16 468 I IB-783 i-Bu Bnzl 4-OH-Bnzl 1.85 434 I IB-784 i-Bu i-Bu Np-M 2.19 434 I IB-785 i-Bu i-Bu 4-OH-Bnzl 1.81 400 I IB-786 4-OH-Bnzl Bnzl i-Pnt 1.90 448 I IB-787 4-OH-Bnzl Bnzl i-Bu 1.80 434 I IB-788 Ph-Et Cbm-E Np-M 1.91 497 I IB-789 Ph-Et i-Pr Np-M 2.19 468 I IB-790 Np-M Cbm-E Bnzl 1.88 483 I IB-791 i-Pnt Np-M Bnzl 2.27 483 I IB-792 Ph-Et Np-M i-Bu 2.29 482 I IB-793 Ph-Et Np-M 4-OH-Bnzl 2.09 532 I IB-794 Np-M i-Pnt Bnzl 2.29 482 I IB-795 Np-M Ph-Et Bnzl 2.32 516 I IB-796 Np-M Np-M i-Bu 2.37 518 I IB-797 Np-M 4-F-Bnzl Bnzl 2.24 520 I

TABLE 3-24 IB-798 Chm Np-M Bnzl 2.41 508 I IB-799 4-F-Bnzl Np-M Bnzl 2.25 520 I IB-800 Ph-Et Np-M i-Pnt 2.36 497 I IB-801 Ph-Et 4-F-Bnzl Np-M 2.27 534 I IB-802 Np-M i-Pnt Np-M 2.42 532 I IB-803 Np-M Np-M i-Pnt 2.41 532 I IB-804 Np-M Np-M Ph-Et 2.39 566 I IB-805 Np-M 4-F-Bnzl Ph-Et 2.28 534 I IB-806 Np-M 4-F-Bnzl Np-M 2.36 570 I IB-807 Chm Np-M Ph-Et 2.47 522 I IB-808 Chm Np-M Np-M 2.47 558 I IB-809 4-F-Bnzl Np-M Ph-Et 2.28 534 I IB-810 4-F-Bnzl Np-M Np-M 2.31 570 I IB-811 Bnzl Np-M i-Pnt 2.30 482 I IB-812 Bnzl 4-F-Bnzl Np-M 2.21 520 I IB-813 Bnzl Cbm-E Np-M 1.86 483 I IB-814 i-Bu Np-M Np-M 2.39 518 I IB-815 4-OH-Bnzl Np-M Bnzl 2.01 518 I IB-816 4-OH-Bnzl Np-M Ph-Et 2.05 532 I IB-817 Np-M Bnzl Ph-Et 2.32 516 I IB-818 Np-M Cbm-E Np-M 2.00 533 I IB-819 Chm Bnzl Np-M 2.40 508 I IB-820 Hdr-E Np-M Bnzl 1.89 456 I IB-821 i-Pnt Ph-Et 4-OH-Bnzl 1.94 462 I IB-822 Ph-Et i-Pnt i-Bu 2.13 412 I IB-823 Ph-Et Np-M Bnzl 2.33 516 I IB-824 Ph-Et Hxy i-Bu 2.35 426 I IB-825 Np-M Np-M Bnzl 2.39 552 I IB-826 Chm Ph-Et 4-OH-Bnzl 2.02 488 I IB-827 Hdr-E i-Pnt Ph-Et 1.82 400 I IB-828 Hdr-E Np-M i-Pnt 1.98 436 I IB-829 Hdr-E Np-M Ph-Et 1.99 470 I IB-830 Hdr-E Np-M Np-M 2.02 506 I IB-831 Hdr-E 4-F-Bnzl Np-M 1.90 474 I IB-832 i-Pnt Np-M Ph-Et 2.45 496 I IB-833 i-Pnt Np-M Np-M 2.45 532 I IB-834 i-Pnt 4-F-Bnzl Np-M 2.24 500 I IB-835 Chm i-Pnt Np-M 2.46 488 I IB-836 Bnzl Ph-Et 4-OH-Bnzl 1.98 482 I IB-837 Bnzl Np-M Bnzl 2.30 502 I IB-838 Bnzl Ph-Et Np-M 2.28 516 I IB-839 i-Bu Hxy Bnzl 2.24 412 I IB-840 i-Bu 4-F-Bnzl Bnzl 2.11 436 I IB-841 4-OH-Bnzl Hdr-E Np-M 1.72 472 I IB-842 4-OH-Bnzl Np-M Np-M 2.08 568 I IB-843 4-OH-Bnzl i-Bu Ph-Et 1.89 448 I

TABLE 3-25 IB-844 Ph-Et Cbx-E i-Bu 0.85 414 C IB-845 Ph-Et Cbx-E i-Pnt 0.89 428 C IB-846 4-OH-Bnzl Cbx-E i-Pnt 0.73 430 C IB-847 4-OH-Bnzl Cbx-E Bnzl 0.75 450 C IB-848 4-OH-Bnzl Cbx-E Ph-Et 0.74 C IB-849 Bnzl Cbx-E i-Bu 0.80 400 C IB-850 Bnzl Cbx-E i-Pnt 0.84 414 C IB-851 Bnzl Cbx-E Ph-Et 0.85 448 C IB-852 i-Bu Cbx-E Ph-Et 0.84 414 C IB-853 i-Bu Cbx-E 4-OH-Bnzl 0.54 416 C IB-854 i-Pnt Cbx-E Ph-Et 0.84 428 C IB-855 i-Pnt Cbx-E 4-OH-Bnzl 0.68 430 C IB-856 Chm Cbx-E Ph-Et 0.91 454 C IB-857 Chm Cbx-E 4-OH-Bnzl 0.77 456 C IB-858 i-Pnt Cbx-E Bnzl 0.80 414 C IB-859 Chm Cbx-E Bnzl 0.90 440 C IB-860 4-OH-Bnzl Cbx-E i-Bu 0.69 416 C

TABLE 3-26

Compound Retention Mass Measurement number R₁ R₂ R₃ R₄ RT (min) (M + H)⁺ condition IB-861 methyl 2-(1H-indol-3-yl)ethyl benzyl H 1.212 429 B IB-862 benzyl Np-M i-Bu H 1.29  468 B IB-863 benzyl 4-(trifluoromethyl)benzyl i-Bu H 1.298 486 B IB-864 4-Cl-Bnzl benzyl i-Bu H 1.288 452 B IB-865 3-Cl-Bnzl benzyl i-Bu H 1.293 452 B IB-866 4-methoxybenzyl benzyl i-Bu H 1.263 448 B IB-867 4-methylbenzyl benzyl i-Bu H 1.288 432 B IB-868 i-Pnt i-Bu benzyl H 1.277 398 B IB-869 i-Bu i-Bu 4-Cl-Bnzl H 1.275 418 B IB-870 i-Bu i-Pnt benzyl H 1.287 398 B IB-871 i-Bu 4-Cl-Bnzl i-Bu H 1.285 418 B IB-872 4-hydroxybenzyl benzyl i-Bu H 1.187 434 B

TABLE 3-27 IB-873 4-(dimethyl- benzyl i-Bu H 1.255 461 B amino)- benzyl IB-874 4-(tert- benzyl i-Bu H 1.345 474 B butyl)- benzyl IB-875 i-Bu benzyl i-Pnt H 1.283 398 B IB-876 i-Pnt benzyl i-Bu H 1.067 398 B IB-877 4-(trifluoro- benzyl i-Bu H 1.29 502 B methyl)- benzyl IB-878 4-ethoxy- benzyl i-Bu H 1.275 462 B benzyl IB-879 benzyl naphthalen- i-Bu H 1.282 468 B 2-ylmethyl IB-880 4-methyl- benzyl i-Bu ethyl 1.332 460 B benzyl IB-881 4-methyl- benzyl i-Bu i-Bu 1.495 488 B benzyl IB-882 4-methyl- benzyl i-Bu acetyl 1.223 474 B benzyl IB-883 4-methyl- benzyl i-Bu 3-methyl- 1.312 516 B benzyl butanoyl IB-884 4-methyl- benzyl i-Bu 2-phenyl- 1.3 550 B benzyl acetyl IB-885 4-methyl- benzyl i-Bu methoxy- 1.267 490 B benzyl carbonyl IB-886 4-methyl- benzyl i-Bu 2-methyl- 1.328 532 B benzyl propoxy- carbonyl IB-887 4-methyl- benzyl i-Bu benzyloxy- 1.347 566 B benzyl carbonyl IB-888 4-methyl- benzyl i-Bu amino- 1.173 475 B benzyl carbonyl IB-889 4-methyl- benzyl i-Bu N-benzyl- 1.288 565 B benzyl amino- carbonyl IB-890 benzyl pyridin- i-Bu H 1.11 419 B 4-ylmethyl IB-891 4-(dimethyl- 3-hydroxy- i-Bu H 1.223 477 B amino)- benzyl benzyl IB-892 4-(dimethyl- 4-hydroxy- i-Bu H 1.208 477 B amino)- benzyl benzyl IB-893 4-methoxy- benzyl benzyl H 0.98 482 C benzyl IB-894 4-methoxy- benzyl benzyl tert- 1.06 582 C benzyl butoxy- carbonyl

TABLE 3-28 IB-895 methyl benzyl benzyl tert- 0.97 476 C butoxy- carbonyl IB-896 methyl benzyl benzyl H 0.84 376 C IB-897 phenethyl benzyl 2-(tert- H 1.13 534 C butyl- dimethyl- silyloxy)- ethyl IB-898 cyclo- 4-(tert- 2-(tert- H 1.16 554 C pentyl- butoxy)- butoxy- methyl benzyl carbonyl)- ethyl IB-899 cyclo- 4-(tert- 2-(tert- methoxy- 1.04 612 C pentyl- butoxy)- butoxy- carbonyl methyl benzyl carbonyl)- ethyl IB-900 cyclo- 4- 2-carboxy- H 0.77 442 C pentyl- hydroxy- ethyl methyl benzyl IB-901 cyclo- 4- 2-carboxy- methoxy- 0.76 500 C pentyl- hydroxy- ethyl carbonyl methyl benzyl IB-902 4-nitro- 4-(tert- 2-(tert- H 1.06 607 C benzyl butoxy)- butoxy- benzyl carbonyl)- ethyl IB-903 phenethyl benzyl 2-hydroxy- H 0.85 420 C ethyl IB-904 phenethyl benzyl 2-hydroxy- acetyl 0.81 462 C ethyl IB-905 phenethyl benzyl 2-hydroxy- methoxy- 0.86 478 C ethyl carbonyl IB-906 phenethyl benzyl 2-hydroxy- ethyl 0.9 448 C ethyl IB-907 4-nitro- 4-(tert- 2-(tert- methoxy- 1.04 665 C benzyl butoxy)- butoxy- carbonyl benzyl carbonyl)- ethyl IB-908 1-naphthyl- benzyl benzyl benzyl 1.14 592 C methyl IB-909 4-amino- 4-(tert- 2-(tert- methoxy- 0.94 635 C benzyl butoxy)- butoxy- carbonyl benzyl carbonyl)- ethyl IB-910 4-(cyclo- 4-(tert- 2-(tert- methoxy- 1.05 731 C pentyl- butoxy)- butoxy- carbonyl carbonyl- benzyl carbonyl)- amino)- ethyl benzyl IB-911 4-(2-car- 4-(tert- 2-(tert- methoxy- 0.92 735 C boxyethyl- butoxy)- butoxy- carbonyl carbonyl- benzyl carbonyl)- amino)- ethyl benzyl IB-912 4-(2-car- 4-(tert- 2-(tert- methoxy- 0.9 734 C boxyethyl- butoxy)- butoxy- carbonyl carbonyl- benzyl carbonyl)- amino)- ethyl benzyl

TABLE 3-29 IB-913 4-nitro- 4-hydroxy- 2-carboxyl H 0.76 495 C benzyl benzyl ethyl IB-914 4-(cyclo- 4-hydroxy- 2-carboxyl methoxy- 0.79 619 C pentyl- benzyl ethyl carbonyl carbonyl- amino)- benzyl IB-915 4-nitro- 4-(tert- 2-(tert- tert-butoxy- 1.12 707 C benzyl butoxy)- butoxy- carbonyl benzyl carbonyl)- ethyl IB-916 4-(cyclo- 4-(tert- 2-(tert- methoxy- 1.14 717 C pentyl- butoxy)- butoxy- carbonyl methyl- benzyl carbonyl)- amino)- ethyl benzyl IB-917 4-(cyclo- 4-(tert- 2-(tert- tert- 1.14 774 C pentyl- butoxy)- butoxy- butoxy- carbonyl- benzyl carbonyl)- carbonyl amino)- ethyl benzyl IB-918 4-(cyclo- 4-(tert- 2-(tert- tert- 1.24 760 C pentyl- butoxy)- butoxy- butoxy- methyl- benzyl carbonyl)- carbonyl amino)- ethyl benzyl IB-919 4-nitro- 4-(tert- 2-(tert- formyl 0.98 635 C benzyl butoxy)- butoxy- benzyl carbonyl)- ethyl IB-920 4-(2-car- 4-hydroxy- 2-carboxyl methoxy- 0.61 622 C bamoyl- benzyl ethyl carbonyl ethyl- carbonyl- amino)- benzyl IB-921 4-(cyclo- 4-hydroxy- 2-carboxyl methoxy- 0.82 605 C pentyl- benzyl ethyl carbonyl methyl- amino)- benzyl IB-922 4-(cyclo- 4-hydroxy- 2-carboxyl H 0.79 561 C pentyl- benzyl ethyl carbonyl- amino)- benzyl IB-923 4-(cyclo- 4-hydroxy- 2-carboxyl H 0.75 547 C pentyl- benzyl ethyl methyl- amino)- benzyl

TABLE 3-30 Formula XXIB

Compound Retention Mass Measurement number R₁ R_(2A) R_(2B) R₃ R₄ RT (min) (M + H)⁺ condition IB-924 4-Me-Bnzl H Bnzl i-Bu N-isobutyl- 2.88 531  B1 aminocarbonyl IB-925 i-Bu H 4-Cl-Bnzl Ph-Et H 2.93 466  B1 IB-926 i-Bu H 3-Cl-Bnzl Ph-Et H 2.94 466  B1 IB-927 i-Bu H 4-MeO-Bnzl Ph-Et H 2.84 462  B1 IB-928 i-Bu H 4-Me-Bnzl Ph-Et H 2.93 446  B1 IB-929 i-Bu H 2-Npm Ph-Et H 2.97 482  B1 IB-930 i-Bu H Bnzl Ph-Pr H 1.36 446 B IB-931 i-Bu H 3-Cl-Bnzl Ph-Pr H 1.31 480 B IB-932 i-Bu H 3-F-Bnzl Ph-Pr H 1.35 464 B IB-933 i-Bu H 3-Me-Bnzl Ph-Pr H 1.38 460 B IB-934 i-Bu H 3-MeO-Bnzl Ph-Pr H 1.36 476 B IB-935 i-Bu H 3-Cl-Bnzl Ph-Bu H 1.33 494 B IB-936 i-Bu H 3-F-Bnzl Ph-Bu H 1.29 478 B IB-937 i-Bu H 3-Me-Bnzl Ph-Bu H 1.38 474 B IB-938 i-Bu H 3-MeO-Bnzl Ph-Bu H 1.31 491 B IB-939 i-Bu H Bnzl Ph-Bu H 1.32 461 B IB-940 i-Pnt H 3-F-Bnzl Ph-Pr H 1.31 478 B IB-941 1-Npm H pentyl Ph-Et H 1.08 496 C IB-942 1-Npm H cyclohexyl Ph-Et H 1.08 508 C IB-943 1-Npm H cyclopentyl Ph-Et H 1.06 494 C IB-944 1-Npm piperidine ^(†) Ph-Et H 1.04 494 C IB-945 1-Npm piperidine ^(†) Ph-Et H 1.00 480 C IB-946 1-Npm H Hxy 4-methylphenethyl H 1.14 524 C IB-947 1-Npm H Hxy 2-(naphthalen-2-yl)ethyl H 1.16 560 C IB-948 1-Npm H heptyl Ph-Et H 1.14 524 C IB-949 1-Npm H Hxy 4-isopropylphenethyl H 1.19 552 C IB-950 1-Npm H Hxy cyclohexylethyl H 1.19 516 C IB-951 tBuO-E H 4-fluorophenethyl 1-Npm H 1.06 544 C IB-952 H H 4-tBuO-Bnzl tBOC-E methoxycarbonyl 0.93 530 C IB-953 ** 2-phenylacetyl H 4-tBuO-Bnzl tBOC-E methoxycarbonyl  1.17, 648 C 1.20

TABLE 3-31 IB- 3- H 4-tBuO- tBOC- methoxy- 1.16, 614 C 954 methyl- Bnzl E carbonyl 1.21 ** buta- noyl IB- 2- H 4-OH- Cbx-E methoxy- 0.78, 536 C 955 phenyl- Bnzl carbonyl 0.83 ** acetyl IB- 3- H 4-OH- Cbx-E methoxy- 0.75, 502 C 956 methyl- Bnzl carbonyl 0.81 ** buta- noyl IB- i-Bu H Ph-Et Ph-Et H 2.89 446 B1 957 IB- i-Bu H 1-Npm Ph-Et H 2.97 482 B1 958 IB- Chm H tBuO-E 1-Npm H 1.10 518 C 959 IB- tBuO- H Ph-Et 1-Npm H 1.06 526 C 960 E IB- Hdr-E H 4- 1-Npm H 0.90 488.3 C 961 fluoro- phenethyl IB- 3- H 4-F-Bnzl 1-Npm H 1.04 544.4 C 962 tert- butoxy- propyl IB- tBuO- H 4-Cl-Bnzl 1-Npm H 1.07, 546.3 C 963 E 1.09 IB- Hdr-E H 4-Cl-Bnzl 1-Npm H 0.92 490.3 C 964 IB- Hdr-E H 4-Cl-Bnzl 1-Npm H 0.92 490.2 C 965 IB- 3- H 4-F-Bnzl 1-Npm H 0.87 488.3 C 966 hydroxy- propyl IB- 1-Npm H Hxy 3- H 1.14 524.4 C 967 methyl- phen- ethyl IB- 1-Npm H β- Ph-Et H 1.01 546.4 C 968 hydroxy- phenethyl IB- 1-Npm H α- Ph-Et H 1.01 560.4 C 969 hydroxy- methyl- phenethyl IB- 1-Npm H α- Ph-Et H 1.03 560.4 C 970 hydroxy- methyl- phenethyl IB- 4-Nt- H Bnzl tBOC- H 0.97 535 C 971 Bnzl E IB- 4-Nt- H Bnzl tBOC- ethoxy- 0.98 563 C 972 Bnzl E carbonyl IB- H H Bnzl tBOC- ethoxy- 0.87 472 C 973 E carbonyl IB- phenyl- H Bnzl tBOC- ethoxy- 0.14, 590 C 974 acetyl carbonyl 0.16 IB- phenyl- H Bnzl Cbx-E ethoxy- 0.91, 534 C 975 acetyl carbonyl 0.97 IB- 4- H Bnzl tBOC- ethoxy- 0.87 577 C 976 amino E carbonyl benzyl IB- 4- H Bnzl tBOC- ethoxy- 1.09 659 C 977 (cyclo- E carbonyl pentyl- methyl- amino)- benzyl IB- 4- H Bnzl Cbx-E ethoxy- 0.93 603 C 978 (cyclo- carbonyl pentyl- methyl- amino)- benzyl IB- 4- H Bnzl tBOC- ethoxy- 1.00 673 C 979 (cyclo- E carbonyl pentyl- carbonyl- amino)- benzyl IB- 3- H Bnzl tBOC- ethoxy- 1.13, 556 C 980 methyl- E carbonyl 1.16 ** butanoyl

TABLE 3-32 IB- H H Bnzl Bnzl tert- 0.93 462 C 981 butoxy- carbonyl IB- 3- H Bnzl Cbx-E ethoxy- 0.89, 500 C 982 methyl- carbonyl 0.96 ** butanoyl IB- iso- H Bnzl Cbx-E ethoxy- 0.94 502 C 983 propoxy- carbonyl carbonyl IB- phenyl- H Bnzl 3- ethoxy- 1.05, 562 C 984 acetyl ethoxy- carbonyl 1.08 ** 3-oxo- propyl IB- benzoyl H Bnzl Bnzl tert- 1.22 566 C 985 butoxy- carbonyl IB- phenyl- H Bnzl Bnzl tert- 1.23 580 C 986 acetyl butoxy- carbonyl IB- 4- H Bnzl Cbx-E ethoxy- 0.87 617 C 987 (cyclo carbonyl pentyl- carbonyl- amino)- benzyl IB- 1-Npm H 4-F-Bnzl 2-OH- H 0.89 474.3 C 988 Et IB- 2-OH- H Ph-Et 1-Npm H 0.89 470.3 C 989 Et IB- 4- H Bnzl i-Bu H 1.02 490.3 C 990 tBuO-Bnzl IB- 4- H i-Bu Bnzl H 1.03 490.4 C 991 tBuO-Bnzl IB- 2- H Bnzl 1-Npm H 1.04 512.4 C 992 OtBu-Et IB- 2-OH- H Bnzl 1-Npm H 0.87 456.3 C 993 Et IB- 4-OH- H i-Bu Bnzl H 0.85 434.3 C 994 Bnzl IB- 1-Npm H 4-F-Bnzl 2- H 1.17 588.4 C 995 OTBS-Et ^(†) Ring formed together by R_(2A) and R_(2B) ** IB-953, 954, 955, 956, 980, 982, and 984 are mixtures of cis-trans isomers. For this reason, two values are shown for the retention of LCMS.

TABLE 4-1

Compound Synthesis number R₁ R₂ R₃ R₄ method Intermediate IF-1 i-Bu Bnzl Bnzl H EX IIF-1 IF-2 i-Bu i-Bu i-Bu H IF-1 IIF-2 IF-3 i-Bu i-Bu Bnzl H IF-1 IIF-3 IF-4 Bnzl i-Bu i-Bu H IF-1 IIF-4 IF-5 i-Bu Bnzl i-Bu H IF-1 IIF-5 IF-6 Bnzl i-Bu Bnzl H IF-1 IIF-6 IF-7 Bnzl Bnzl i-Bu H IF-1 IIF-7 IF-8 Bnzl Bnzl Bnzl H IF-1 IIF-8 IF-9 i-Pnt Bnzl Bnzl H IF-1 IIF-9 IF-10 Bnzl Bnzl i-Pnt H IF-1 IIF-10 IF-11 i-Bu Bnzl Ph-Et H IF-1 IIF-11 IF-12 i-Bu Ph-Et Bnzl H IF-1 IIF-12 IF-13 i-Bu Bnzl 3-Me-Bnzl H IF-1 IIF-13 IF-14 i-Bu Bnzl 4-Me-Bnzl H IF-1 IIF-14 IF-15 i-Bu 3-Me-Bnzl Bnzl H IF-1 IIF-15 IF-16 i-Bu 4-Me-Bnzl Bnzl H IF-1 IIF-16 IF-17 i-Bu 3-Cl-Bnzl Bnzl H IF-1 IIF-17 IF-18 i-Bu 4-Cl-Bnzl Bnzl H IF-1 IIF-18 IF-19 3,4-Cl₂-Bnzl Bnzl i-Bu H IF-1 IIF-19 IF-20 Bnzl 3,4-Cl₂-Bnzl i-Bu H IF-1 IIF-20 IF-22 i-Bu 4-OH-Bnzl Bnzl H IF-40 IF-23 IF-23 i-Bu 4-(tert-butoxy)benzyl Bnzl H IF-1 IIF-23 IF-24 i-Bu Np-M Bnzl H IF-1 IIF-24 IF-25 i-Bu Hdr-E Bnzl H IF-1 IIF-25 IF-26 i-Bu Cbx-E Bnzl H EX IF-27 IF-27 i-Bu 2-(tert-butoxy)-2-oxoethyl Bnzl H IF-1 IIF-27 IF-28 i-Bu Cbm-E Bnzl H IF-1 IIF-28 IF-29 i-Bu 4-aminobutyl Bnzl H IB-29 IF-30 IF-30 i-Bu 4-((tert-butoxycarbonyl)amino)butyl Bnzl H IF-1 IIF-30 IF-31 i-Bu Chm Bnzl H IF-1 IIF-31 IF-32 i-Bu (tetrahydro-2H-pyran-2-yl)methyl Bnzl H IF-1 IIF-32 IF-33 i-Bu Bnzl 4-aminobutyl H EX IF-34

TABLE 4-2 IF-34 i-Bu Bnzl 4-((tert- H IF-1 IIF-34 butoxy- carbonyl) - amino)butyl IF-35 i-Bu Bnzl Cbx-E H IB-35 IF-73 IF-36 i-Bu Bnzl 3- H IF-1 IIF-36 methoxy- 3- oxopropyl IF-38 i-Bu Bnzl Chm H IF-1 IIF-38 IF-39 Chm Bnzl Bnzl H IF-1 IIF-39 IF-40 4-OH- Bnzl Bnzl H EX IF-41 Bnzl IF-41 4- Bnzl Bnzl H EX IIF-41 (tert- butoxy)- benzyl IF-42 Np-M Bnzl Bnzl H IF-1 IIF-42 IF-43 i-Bu Bnzl Bnzl Ac EX IF-1 IF-44 i-Bu i-Bu i-Bu Ac IF-43 IF-2 IF-45 i-Bu i-Bu Bnzl Ac IF-43 IF-3 IF-46 Bnzl i-Bu i-Bu Ac IF-43 IF-4 IF-47 i-Bu Bnzl i-Bu Ac IF-43 IF-5 IF-49 Bnzl Bnzl i-Bu Ac IF-43 IF-7 IF-50 Bnzl Bnzl Bnzl Ac IF-43 IF-8 IF-54 i-Bu Ph-Et Bnzl Ac IF-43 IF-12 IF-57 i-Bu 3-Me-Bnzl Bnzl Ac IF-43 IF-15 IF-58 i-Bu 4-Me-Bnzl Bnzl Ac IF-43 IF-16 IF-68 i-Bu Bnzl Bnzl Bz IB-68 IF-1 IF-69 i-Bu Bnzl Bnzl Et IB-69 IF-1 IF-70 i-Bu Bnzl Bnzl meth- IB-70 IF-1 oxy- carbonyl IF-71 i-Bu Bnzl Bnzl Me EX IF-1 IF-72 Bnzl Bnzl i-Bu Et IB-69 IF-7 IF-73 i-Bu Bnzl Cbx-E tBOC IB-73 IF-74 IF-74 i-Bu Bnzl 3- tBOC IB-74 IF-36 methoxy- 3- oxopropyl IF-76 3- Bnzl Bnzl H IF-1 IIF-76 (tert- butoxy)- 3- oxo- propyl IF-77 Bnzl Bnzl 4-OH-Bnzl H IF-1 IIF-77 IF-80 Np-M Bnzl Pr H IB-1 IIF-80

TABLE 4-3 Compound LCMS t_(R) Mass Elution Yield number Name of compound (min) (M + H)⁺ condition (%) IF-1 (3S*,3aS*,6S*,7R*,7aS*)-N,7- 0.99 418 B 62 dibenzyl-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-2 (3S*,3aS*,6S*,7R*,7aS*)-N,1,7- 0.93 350 B 73 triisobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide

TABLE 4-4 IF-3  (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N,1- 0.96 384 B 67 diisobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-4  (3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N,7- 0.97 384 B 82 diisobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-5  (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1,7- 0.95 384 B 73 diisobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-6  (3S*,3aS*,6S*,7R*,7aS*)-1,7-dibenzyl- 1.00 418 B 68 N-isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-7  (3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl- 0.99 418 B 64 7-isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-8  (3S*,3aS*,6S*,7R*,7aS*)-N,1,7- 1.02 452 B 69 tribenzyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-9  (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 1.01 432 B 47 1-isopentyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-10 (3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl- 1.02 432 B 60 7-isopentyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-11 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 0.99 432 B 63 isobutyl-7-phenethyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-12 (3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-7- 1.01 432 B 60 isobutyl-N-phenethyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-13 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 1.01 432 B 55 isobutyl-7-(3-methylbenzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-14 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 1.01 432 B 57 isobutyl-7-(4-methylbenzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-15 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 1.02 432 B 62 isobutyl-N-(3-methylbenzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-16 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 1.02 432 B 63 isobutyl-N-(4-methylbenzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-17 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N- 1.03 452 B 69 (3-chlorobenzyl)-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-18 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N- 1.03 452 B 68 (4-chlorobenzyl)-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-19 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 1.13 486 B 38 (3,4-dichlorobenzyl)-7-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide

TABLE 4-5 IF-20 (3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N- 1.06 486 B 37 (3,4-dichlorobenzyl)-7-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-22 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-(4- 0.71 434 A 95 hydroxybenzyl)-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-23 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 0.87 490 A 95 isobutyl-N-(4-(tert-butoxy)benzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-24 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 0.85 468 A 77 isobutyl-N-(naphthalen-1- ylmethyl)octahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-25 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N-(2- 0.65 372 A 95 hydroxyethyl)-1-isobutyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-26 3-((3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 0.66 400 A 100 isobutyloctahydro-1H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide)propanoic acid IF-27 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 0.81 456 A 100 isobutyl-N-(2-(tert-butoxy)-2- oxoethyl)octahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-28 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl- 0.67 399 A 53 N-(3-amino-3-oxopropyl)-1- isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-29 (3S*,3aS*,6S*,7R*,7aS*)-N-(4- 0.83 399 A 100 aminobutyl)-7-benzyl-1- isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-30 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1- 0.81 499 A 80 isobutyl-N-(4-((tert- butoxycarbonyl)amino)butyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-31 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-N- 0.85 424 A 22 cyclohexylmethyl-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-32 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-  0.76, 426 A 93 isobutyl-N-((tetrahydro-2H-pyran-2- 0.75 yl)methyl)octahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-33 (3S*,3aS*,6S*,7R*,7aS*)-7-(4- 0.62 399 A 100 aminobutyl)-N-benzyl-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-34 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 0.82 499 A 78 isobutyl-7-(4-((tert- butoxycarbonyl)amino)butyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-35 3-((3S*,3aS*,6S*,7R*,7aS*)-3a- 0.65 400 A 100 (benzylcarbamoyl)-1-isobutyloctahydro- 1H-3,6-methanopyrrolo[3,2-c]pyridin- 7-yl)propanoic acid IF-36 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 0.72 414 A isobutyl-7-(3-methoxy-3- oxopropyl)octahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-38 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-7- 0.86 424 A 83 (cyclohexylmethyl)-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide

TABLE 4-6 IF-39 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 0.86 458 A 62 1-cyclohexylmethyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-40 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 0.75 468 A 63 1-(4-hydroxybenzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-41 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 0.90 524 A 52 1-(4-(tert-butoxy)benzyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-42 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 0.88 502 A 65 1-(naphthalen-1-ylmethyl)octahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-43 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N,7- 1.08 460 B 51 dibenzyl-1-isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-44 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl- 1.04 392 B 82 N,1,7-triisobutyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-45 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-7- 1.05 426 B 83 benzyl-N,1-diisobutyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-46 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-1- 1.05 426 B 79 benzyl-N,7-diisobutyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-47 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N- 1.06 426 B 88 benzyl-1,7-diisobutyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-49 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-N,1- 1.08 460 B 84 dibenzyl-7-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-50 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl- 1.10 494 B 75 N,1,7-tribenzyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-54 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-1- 1.10 474 B 58 benzyl-7-isobutyl-N-phenethyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-57 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-7- 1.12 474 B 40 benzyl-1-isobutyl-N- (3-methylbenzyl)octahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-58 (3S*,3aS*,6S*,7R*,7aS*)-4-acetyl-7- 1.12 474 B 55 benzyl-1-isobutyl-N-(4- methylbenzyl)octahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-68 (3S*,3aS*,6S*,7R*,7aS*)-4-benzoyl- 1.17 522 B 51 N,7-dibenzyl-1-isobutyloctahydro- 6H-3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-69 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 1.06 446 B 57 4-ethyl-1-isobutyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-70 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 1.13 476 B 32 1-isobutyl-4- (methoxycarbonyl)octahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide

TABLE 4-7 IF-71 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl- 1.02 432 B 38 1-isobutyl-4-methyloctahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-72 (3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl- 1.06 446 B 45 4-ethyl-7-isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide IF-73 tert-butyl (3S*,3aS*,6S*,7R*,7aS*)-6- 0.84 500 A 9 (benzylcarbamoyl)-1-isobutyl-7-(2- carboxyethyl)octahydro-5H-3,6- methanopyrrolo[3,2-c]pyridine-5- carboxylate IF-74 tert-butyl (3S*,3aS*,6S*,7R*,7aS*)- 0.91 514 A 71 3a-(benzylcarbamoyl)-1-isobutyl-7- (3-methoxy-3-oxopropyl)octahydro- 4H-3,6-methanopyrrolo[3,2-b] pyridine-4-carboxylate IF-76 tert-butyl 3- 1.04 490 B 53 ((3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-6- (benzylcarbamoyl)octahydro-1H-3,6- methanopyrrolo[3,2-c]pyridin-1- yl)propanoate IF-77 (3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl- 0.93 468 B 60 7-(4-hydroxybenzyl)octahydro-6H- 3,6-methanopyrrolo[3,2-c]pyridine- 6-carboxamide IF-80 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1- 0.84 454 A 44 (naphthalen-1-ylmethyl)-7- propyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6- carboxamide

TABLE 4-8

Compound Retention Mass Measurement number R₁ R₂ R₃ RT (min) (M + H)⁺ condition IF-81 Cbm-M Np-M i-Bu 0.71 435 C IF-82 Cbm-M Np-M Bnzl 0.72 469 C IF-83 Cbm-M Np-M 4-OH-Bnzl 0.67 485 C IF-84 Cbm-M Np-M i-Pnt 0.73 449 C IF-85 Cbm-M Np-M Ph-Et 0.75 483 C IF-86 Cbm-M Ph-Et i-Bu 0.66 399 C IF-87 Cbm-M Ph-Et Bnzl 0.68 433 C IF-88 Cbm-M Ph-Et 4-OH-Bnzl 0.63 449 C IF-89 Cbm-M Ph-Et i-Pnt 0.70 413 C IF-90 Cbm-M Ph-Et Np-M 0.74 483 C IF-91 Cbm-M Np-M Np-M 0.76 519 C IF-92 Cbm-M 4-F-Bnzl i-Bu 0.65 403 C IF-93 Cbm-M 4-F-Bnzl Bnzl 0.67 437 C

TABLE 4-9 IF-94 Cbm-M 4-F-Bnzl 4-OH-Bnzl 0.62 453 C IF-95 Cbm-M 4-F-Bnzl i-Pnt 0.69 417 C IF-96 Cbm-M 4-F-Bnzl Ph-Et 0.71 451 C IF-97 Cbm-M 4-F-Bnzl Np-M 0.73 487 C IF-98 Cbm-M i-Pnt i-Bu 0.66 365 C IF-99 Cbm-M i-Pnt Bnzl 0.67 399 C IF-100 Cbm-M i-Pnt 4-OH-Bnzl 0.62 415 C IF-101 Cbm-M i-Pnt Cbx-E 0.58 381 C IF-102 Cbm-M i-Pnt Ph-Et 0.71 413 C IF-103 Cbm-M i-Pnt Np-M 0.73 449 C IF-104 Cbm-M Hxy i-Bu 0.71 379 C IF-105 Cbm-M Hxy Bnzl 0.72 413 C IF-106 Cbm-M Hxy 4-OH-Bnzl 0.67 429 C IF-107 Cbm-M Hxy Cbx-E 0.63 395 C IF-108 Cbm-M Hxy i-Pnt 0.73 393 C IF-109 Cbm-M Hxy Ph-Et 0.75 427 C IF-110 Cbm-M Hxy Np-M 0.77 463 C IF-111 Cbm-M i-Pr i-Bu 1.03 337 D IF-112 Cbm-M i-Pr Bnzl 0.58 371 C IF-113 Cbm-M i-Pr 4-OH-Bnzl 0.97 387 D IF-114 Cbm-M i-Pr Cbx-E 0.22 353 E IF-115 Cbm-M i-Pr i-Pnt 1.09 351 D IF-116 Cbm-M i-Pr Ph-Et 0.63 385 C IF-117 Cbm-M i-Pr Np-M 0.65 421 C IF-118 Cbm-M i-Bu i-Bu 0.62 351 C IF-119 Cbm-M i-Bu Bnzl 0.64 385 C IF-120 Cbm-M i-Bu 4-OH-Bnzl 0.59 401 C IF-121 Cbm-M i-Bu Cbx-E 0.93 367 D IF-122 Cbm-M i-Bu i-Pnt 0.66 365 C IF-123 Cbm-M i-Bu Ph-Et 0.69 399 C IF-124 Cbm-M i-Bu Np-M 0.71 435 C IF-125 Cbm-M Bnzl i-Bu 0.65 385 C IF-126 Cbm-M Bnzl Bnzl 0.67 419 C IF-127 Cbm-M Bnzl 4-OH-Bnzl 0.62 435 C IF-128 Cbm-M Bnzl Cbx-E 0.99 401 D IF-129 Cbm-M Bnzl i-Pnt 0.69 399 C IF-130 Cbm-M Bnzl Ph-Et 0.71 433 C IF-131 Cbm-M Bnzl Np-M 0.73 469 C IF-132 Cbm-M 4-OH-Bnzl i-Bu 0.57 401 C IF-133 Cbm-M 4-OH-Bnzl Bnzl 0.59 435 C IF-134 Cbm-M 4-OH-Bnzl Cbx-E 0.87 417 D IF-135 Cbm-M 4-OH-Bnzl i-Pnt 0.60 415 C IF-136 Cbm-M 4-OH-Bnzl Ph-Et 0.63 449 C IF-137 Cbm-M 4-OH-Bnzl Np-M 0.65 485 C IF-138 Cbm-M Cbx-E Bnzl 0.94 401 D IF-139 Cbm-M Cbx-E 4-OH-Bnzl 0.47 417 D

TABLE 4-10 IF-140 Cbm-M Cbx-E Ph-Et 1.01 415 D IF-141 Cbm-M Cbx-E Np-M 0.60 451 C IF-142 Cbm-M Cbm-E i-Bu 0.23 366 E IF-143 Cbm-M Cbm-E Bnzl 0.88 400 D IF-144 Cbm-M Cbm-E 4-OH-Bnzl 0.23 416 E IF-145 Cbm-M Cbm-E Cbx-E 0.20 382 E IF-146 Cbm-M Cbm-E i-Pnt 0.91 380 D IF-147 Cbm-M Cbm-E Ph-Et 0.89 414 D IF-148 Cbm-M Cbm-E Np-M 0.57 450 C IF-149 Cbm-M Gun-Pr i-Bu 0.83 394 D IF-150 Cbm-M Gun-Pr Bnzl 0.92 428 D IF-151 Cbm-M Gun-Pr 4-OH-Bnzl 0.34 442 ¹⁾ E IF-152 Cbm-M Gun-Pr i-Pnt 0.93 408 D IF-153 Cbm-M Gun-Pr Ph-Et 0.96 442 D IF-154 Cbm-M Gun-Pr Np-M 1.01 478 D IF-155 Cbm-M Hdr-E i-Bu 0.46 339 E IF-156 Cbm-M Hdr-E Bnzl 0.49 373 C IF-157 Cbm-M Hdr-E 4-OH-Bnzl 0.35 389 E IF-158 Cbm-M Hdr-E Cbx-E 0.20 355 E IF-159 Cbm-M Hdr-E i-Pnt 0.93 353 D IF-160 Cbm-M Hdr-E Ph-Et 0.98 387 D IF-161 Cbm-M Hdr-E Np-M 0.58 423 C IF-162 Gun-Pr Np-M i-Bu 1.25 477 D IF-163 Gun-Pr Np-M Bnzl 0.72 511 C IF-164 Gun-Pr Np-M 4-OH-Bnzl 0.69 527 C IF-165 Gun-Pr Np-M i-Pnt 1.28 491 D IF-166 Gun-Pr Np-M Ph-Et 0.75 525 C IF-167 Gun-Pr Np-M Np-M 1.31 561 D IF-168 Gun-Pr Hxy i-Pnt 0.74 435 C IF-169 Gun-Pr Hxy Ph-Et 1.30 469 D IF-170 Gun-Pr Hxy Np-M 1.33 505 D IF-171 Gun-Pr i-Pr i-Bu 1.08 379 D IF-172 Gun-Pr i-Pr 4-OH-Bnzl 1.04 429 D IF-173 Gun-Pr i-Pr i-Pnt 1.12 393 D IF-174 Gun-Pr i-Pr Ph-Et 1.15 427 D IF-175 Gun-Pr i-Pr Np-M 1.17 463 D IF-176 Gun-Pr 4-F-Bnzl i-Bu 1.17 445 D IF-177 Gun-Pr 4-F-Bnzl Bnzl 0.68 479 C IF-178 Gun-Pr 4-F-Bnzl 4-OH-Bnzl 1.13 495 D IF-179 Gun-Pr 4-F-Bnzl i-Pnt 1.21 459 D IF-180 Gun-Pr 4-F-Bnzl Ph-Et 0.71 493 C IF-181 Gun-Pr 4-F-Bnzl Np-M 0.72 529 C IF-182 i-Bu Hdr-E Cbm-M 0.63 339 G IF-183 i-Bu Ph-Et Cbm-M 3.40 399 G IF-184 i-Bu Np-M Cbm-M 3.87 435 G IF-185 i-Bu i-Bu Gun-Pr 3.15 393 G

TABLE 4-11 IF-186 i-Bu Bnzl Gun-Pr 3.42 427 G IF-187 i-Bu 4-OH-Bnzl Gun-Pr 3.09 443 G IF-188 i-Bu Hdr-E Gun-Pr 1.17 381 G IF-189 i-Bu Ph-Et Gun-Pr 3.57 441 G IF-190 i-Bu Np-M Gun-Pr 3.87 477 G IF-191 i-Bu Hxy Gun-Pr 3.79 421 G IF-192 i-Bu 4-F-Bnzl Gun-Pr 3.49 445 G IF-193 Bnzl Cbx-E Cbm-M 1.82 401 G IF-194 Bnzl Hdr-E Cbm-M 1.52 373 G IF-195 Bnzl i-Pnt Cbm-M 3.59 399 G IF-196 Bnzl Ph-Et Cbm-M 3.62 433 G IF-197 Bnzl i-Pr Cbm-M 3.02 371 G IF-198 Bnzl 4-OH-Bnzl Gun-Pr 3.54 477 G IF-199 Bnzl Hdr-E Gun-Pr 2.74 415 F IF-200 4-OH-Bnzl Ph-Et Gun-Pr 3.59 491 G IF-201 4-OH-Bnzl Np-M Gun-Pr 3.90 527 G IF-202 Cbx-E i-Pr Cbm-M 0.95 353 G IF-203 i-Pnt i-Bu Cbm-M 3.25 365 G IF-204 i-Pnt Bnzl Cbm-M 3.47 399 F IF-205 i-Pnt 4-OH-Bnzl Cbm-M 3.13 415 G IF-206 i-Pnt Ph-Et Cbm-M 2.43 413 F IF-207 i-Pnt Np-M Cbm-M 2.62 449 F IF-208 i-Pnt Hxy Cbm-M 3.97 393 G IF-209 i-Pnt i-Pr Cbm-M 2.97 351 G IF-210 i-Pnt 4-F-Bnzl Cbm-M 3.60 417 G IF-211 i-Pnt Bnzl Gun-Pr 3.60 441 G IF-212 i-Pnt Ph-Et Gun-Pr 3.79 455 G IF-213 i-Pnt Np-M Gun-Pr 2.63 491 G IF-214 i-Pnt i-Pr Gun-Pr 3.25 393 G IF-215 i-Pnt 4-F-Bnzl Gun-Pr 3.72 459 G IF-216 Ph-Et Bnzl Cbm-M 2.45 433 F IF-217 Ph-Et 4-OH-Bnzl Cbm-M 3.40 449 G IF-218 Ph-Et Cbx-E Cbm-M 2.85 415 G IF-219 Ph-Et Cbm-E Cbm-M 2.67 414 G IF-220 Ph-Et Gun-Pr Cbm-M 2.94 442 G IF-221 Ph-Et Hdr-E Cbm-M 2.75 387 G IF-222 Ph-Et i-Pnt Cbm-M 3.87 413 G IF-223 Ph-Et Np-M Cbm-M 2.75 483 F IF-224 Ph-Et 4-F-Bnzl Cbm-M 2.52 451 F IF-225 Ph-Et Hdr-E Gun-Pr 3.05 429 G IF-226 Np-M i-Bu Cbm-M 2.49 435 F IF-227 Np-M Bnzl Cbm-M 2.62 469 F IF-228 Np-M Cbm-E Cbm-M 3.27 450 G IF-229 Np-M Gun-Pr Cbm-M 3.32 478 G IF-230 Np-M Hdr-E Cbm-M 3.29 423 G IF-231 Np-M Ph-Et Cbm-M 2.65 483 F

TABLE 4-12 IF-232 Np-M Np-M Cbm-M 2.84 519 F IF-233 Np-M i-Pr Cbm-M 3.62 421 G IF-234 Np-M 4-F-Bnzl Cbm-M 2.65 487 F IF-235 Np-M i-Bu Gun-Pr 3.70 477 G IF-236 Np-M Bnzl Gun-Pr 3.88 511 G IF-237 Np-M 4-OH-Bnzl Gun-Pr 3.62 527 G IF-238 Np-M Cbm-E Gun-Pr 3.22 492 G IF-239 Np-M Hdr-E Gun-Pr 3.20 465 G IF-240 Np-M i-Pnt Gun-Pr 3.95 491 G IF-241 Np-M Ph-Et Gun-Pr 4.07 525 G IF-242 Np-M Np-M Gun-Pr 4.27 561 G IF-243 Np-M Hxy Gun-Pr 4.25 505 G IF-244 Np-M i-Pr Gun-Pr 2.38 463 F IF-245 Np-M 4-F-Bnzl Gun-Pr 3.95 529 G IF-246 Chm Bnzl Cbm-M 3.75 425 G IF-247 Chm 4-OH-Bnzl Cbm-M 3.40 441 G IF-248 Chm Cbx-E Cbm-M 2.90 407 G IF-249 Chm Cbm-E Cbm-M 2.74 406 G IF-250 Chm i-Pnt Cbm-M 2.50 405 F IF-251 Chm Ph-Et Cbm-M 2.52 439 F IF-252 Chm Np-M Cbm-M 2.69 475 F IF-253 Chm Hxy Cbm-M 4.17 419 G IF-254 Chm i-Pr Cbm-M 3.29 377 F IF-255 Chm 4-F-Bnzl Cbm-M 2.54 443 F IF-256 Chm Bnzl Gun-Pr 3.79 467 G IF-257 Chm i-Pnt Gun-Pr 3.90 447 G IF-258 Chm Ph-Et Gun-Pr 3.95 481 G IF-259 Chm Np-M Gun-Pr 4.27 517 G IF-260 Chm Hxy Gun-Pr 4.12 461 G IF-261 Chm 4-F-Bnzl Gun-Pr 3.95 485 G IF-262 4-F-Bnzl i-Bu Cbm-M 3.34 403 G IF-263 4-F-Bnzl Bnzl Cbm-M 3.57 437 G IF-264 4-F-Bnzl 4-OH-Bnzl Cbm-M 3.22 453 G IF-265 4-F-Bnzl Cbx-E Cbm-M 2.34 419 G IF-266 4-F-Bnzl Cbm-E Cbm-M 1.63 418 G IF-267 4-F-Bnzl Hdr-E Cbm-M 1.79 391 G IF-268 4-F-Bnzl i-Pnt Cbm-M 3.70 417 G IF-269 4-F-Bnzl Ph-Et Cbm-M 2.43 451 F IF-270 4-F-Bnzl Np-M Cbm-M 2.62 487 F IF-271 4-F-Bnzl Hxy Cbm-M 2.60 431 F IF-272 4-F-Bnzl i-Pr Cbm-M 3.10 389 G IF-273 4-F-Bnzl Hdr-E Gun-Pr 2.70 433 G IF-274 4-F-Bnzl i-Pr Gun-Pr 3.37 431 G IF-275 Cbx-E i-Bu Cbm-M 3.20 367 G IF-276 Cbx-E i-Pnt Cbm-M 3.54 381 G IF-277 Bnzl Bnzl Cbm-M 2.38 419 F

TABLE 4-13 IF-278 Bnzl Np-M Cbm-M 4.09 469 G IF-279 Bnzl Hxy Cbm-M 4.02 413 G IF-280 Bnzl 4-F-Bnzl Cbm-M 2.43 437 F IF-281 Bnzl Bnzl Gun-Pr 2.40 461 F IF-282 Bnzl i-Pnt Gun-Pr 2.47 441 F IF-283 Bnzl Ph-Et Gun-Pr 2.50 475 F IF-284 Bnzl Np-M Gun-Pr 2.62 511 F IF-285 Bnzl Hxy Gun-Pr 2.62 455 F IF-286 Bnzl 4-F-Bnzl Gun-Pr 2.47 479 F IF-287 Ph-Et Bnzl Gun-Pr 2.52 475 F IF-288 Ph-Et 4-OH-Bnzl Gun-Pr 2.38 491 F IF-289 Ph-Et i-Pnt Gun-Pr 2.57 455 F IF-290 Ph-Et Np-M Gun-Pr 2.72 525 F IF-291 Ph-Et Hxy Gun-Pr 2.70 469 F IF-292 Ph-Et 4-F-Bnzl Gun-Pr 2.59 493 F IF-293 4-F-Bnzl i-Bu Gun-Pr 2.34 445 F IF-294 4-F-Bnzl Bnzl Gun-Pr 2.43 479 F IF-295 4-F-Bnzl i-Pnt Gun-Pr 2.50 459 F IF-296 4-F-Bnzl Ph-Et Gun-Pr 2.50 493 F IF-297 4-F-Bnzl Np-M Gun-Pr 2.63 529 F IF-298 4-F-Bnzl Hxy Gun-Pr 2.63 473 F IF-299 i-Bu Cbm-E Cbx-E 1.03 381 H IF-300 i-Bu Cbm-E i-Pnt 2.15 379 H IF-301 i-Bu Gun-Pr i-Bu 2.13 393 H IF-302 i-Bu Gun-Pr Bnzl 2.19 427 H IF-303 i-Bu Gun-Pr 4-OH-Bnzl 1.79 443 H IF-304 i-Bu Gun-Pr i-Pnt 1.95 407 H IF-305 i-Bu Gun-Pr Ph-Et 1.98 441 H IF-306 i-Bu Gun-Pr Np-M 2.08 477 H IF-307 Bnzl Cbm-E Cbx-E 1.76 415 H IF-308 Bnzl Cbm-E i-Pnt 2.02 413 H IF-309 Bnzl Gun-Pr i-Bu 1.82 427 H IF-310 Bnzl Gun-Pr Bnzl 2.02 461 H IF-311 Bnzl Gun-Pr 4-OH-Bnzl 1.87 477 H IF-312 Bnzl Gun-Pr i-Pnt 2.05 441 H IF-313 Bnzl Gun-Pr Ph-Et 2.08 475 H IF-314 Bnzl Gun-Pr Np-M 2.14 511 H IF-315 4-OH-Bnzl Cbm-E Cbx-E 1.28 431 H IF-316 4-OH-Bnzl Cbm-E i-Pnt 1.85 429 H IF-317 4-OH-Bnzl Gun-Pr i-Bu 1.85 443 H IF-318 4-OH-Bnzl Gun-Pr Bnzl 1.91 477 H IF-319 4-OH-Bnzl Gun-Pr i-Pnt 1.89 457 H IF-320 4-OH-Bnzl Gun-Pr Ph-Et 1.96 491 H IF-321 4-OH-Bnzl Gun-Pr Np-M 2.00 527 H IF-322 Cbx-E Cbm-E i-Pnt 1.73 395 H IF-323 Gun-Pr i-Bu i-Bu 1.98 393 H

TABLE 4-14 IF-324 Gun-Pr i-Bu Bnzl 1.99 427 H IF-325 Gun-Pr i-Bu 4-OH-Bnzl 1.92 443 H IF-326 Gun-Pr i-Bu i-Pnt 2.10 407 H IF-327 Gun-Pr i-Bu Ph-Et 2.15 441 H IF-328 Gun-Pr i-Bu Np-M 2.14 477 H IF-329 Gun-Pr Bnzl i-Bu 2.06 427 H IF-330 Gun-Pr Bnzl Bnzl 2.08 461 H IF-331 Gun-Pr Bnzl 4-OH-Bnzl 1.98  47 H IF-332 Gun-Pr Bnzl i-Pnt 2.16 441 H IF-333 Gun-Pr Bnzl Ph-Et 2.19 475 H IF-334 Gun-Pr Bnzl Np-M 2.21 511 H IF-335 Gun-Pr 4-OH-Bnzl i-Bu 1.89 443 H IF-336 Gun-Pr 4-OH-Bnzl Bnzl 1.95 477 H IF-337 Gun-Pr 4-OH-Bnzl i-Pnt 1.92 457 H IF-338 Gun-Pr 4-OH-Bnzl Ph-Et 1.97 491 H IF-339 Gun-Pr 4-OH-Bnzl Np-M 2.01 527 H IF-340 Gun-Pr Cbm-E i-Bu 1.64 408 H IF-341 Gun-Pr Cbm-E Bnzl 1.72 442 H IF-342 Gun-Pr Cbm-E 4-OH-Bnzl 1.15 458 H IF-343 Gun-Pr Cbm-E i-Pnt 1.73 422 H IF-344 Gun-Pr Cbm-E Ph-Et 1.79 456 H IF-345 Gun-Pr Cbm-E Np-M 1.84 492 H IF-346 Gun-Pr Hdr-E i-Bu 1.70 381 H IF-347 Gun-Pr Hdr-E Bnzl 1.73 415 H IF-348 Gun-Pr Hdr-E 4-OH-Bnzl 1.59 431 H IF-349 Gun-Pr Hdr-E i-Pnt 1.78 395 H IF-350 Gun-Pr Hdr-E Ph-Et 1.82 429 H IF-351 Gun-Pr Hdr-E Np-M 1.84 465 H IF-352 Gun-Pr i-Pnt i-Bu 2.07 407 H IF-353 Gun-Pr i-Pnt Bnzl 2.10 441 H IF-354 Gun-Pr i-Pnt 4-OH-Bnzl 2.02 457 H IF-355 Gun-Pr i-Pnt Ph-Et 2.12 455 H IF-356 Gun-Pr i-Pnt Np-M 2.22 491 H IF-357 Gun-Pr Ph-Et i-Bu 2.09 441 H IF-358 Gun-Pr Ph-Et Bnzl 2.10 475 H IF-359 Gun-Pr Ph-Et 4-OH-Bnzl 2.02 491 H IF-360 Gun-Pr Ph-Et i-Pnt 2.18 455 H IF-361 Gun-Pr Ph-Et Np-M 2.19 525 H IF-362 Hdr-E Cbm-E Cbx-E 0.41 369 H IF-363 Hdr-E Cbm-E i-Pnt 1.71 367 H IF-364 Hdr-E Gun-Pr i-Bu 1.64 381 H IF-365 Hdr-E Gun-Pr Bnzl 1.76 415 H IF-366 Hdr-E Gun-Pr 4-OH-Bnzl 1.84 431 H IF-367 Hdr-E Gun-Pr i-Pnt 1.75 395 H IF-368 Hdr-E Gun-Pr Ph-Et 1.81 429 H IF-369 Hdr-E Gun-Pr Np-M 1.83 465 H

TABLE 4-15 IF-370 i-Pnt Cbm-E Cbx-E 1.75 395 H IF-371 i-Pnt Gun-Pr i-Bu 2.01 407 H IF-372 i-Pnt Gun-Pr Bnzl 2.05 441 H IF-373 i-Pnt Gun-Pr 4-OH-Bnzl 1.91 H IF-374 i-Pnt Gun-Pr Ph-Et 2.09 455 H IF-375 i-Pnt Gun-Pr Np-M 2.15 491 H IF-376 Ph-Et Cbm-E Cbx-E 1.85 429 H IF-377 Ph-Et Cbm-E i-Pnt 2.09 427 H IF-378 Ph-Et Gun-Pr i-Bu 2.05 441 H IF-379 Ph-Et Gun-Pr Bnzl 2.18 H IF-380 Ph-Et Gun-Pr 4-OH-Bnzl 1.94 491 H IF-381 Ph-Et Gun-Pr i-Pnt 2.11 455 H IF-382 Ph-Et Gun-Pr Np-M 2.20 525 H IF-383 Np-M Cbm-E Cbx-E 1.91 465 H IF-384 Np-M Cbm-E i-Pnt 2.17 463 H IF-385 Np-M Gun-Pr i-Bu 1.82 477 H IF-386 Np-M Gun-Pr Bnzl 2.15 511 H IF-387 Np-M Gun-Pr 4-OH-Bnzl 1.97 527 H IF-388 Np-M Gun-Pr i-Pnt 2.17 491 H IF-389 Np-M Gun-Pr Ph-Et 2.20 525 H IF-390 Np-M Gun-Pr Np-M 2.22 561 H IF-391 Chm Cbm-E Cbx-E 1.83 421 H IF-392 Chm Cbm-E i-Pnt 2.10 419 H IF-393 Chm Gun-Pr i-Bu 2.06 433 H IF-394 Chm Gun-Pr Bnzl 2.13 467 H IF-395 Chm Gun-Pr 4-OH-Bnzl 1.91 483 H IF-396 Chm Gun-Pr i-Pnt 2.13 447 H IF-397 Chm Gun-Pr Ph-Et 2.15 481 H IF-398 Chm Gun-Pr Np-M 2.22 517 H IF-399 4-F-Bnzl Cbm-E Cbx-E 1.78 433 H IF-400 4-F-Bnzl Cbm-E i-Pnt 2.06 431 H IF-401 4-F-Bnzl Gun-Pr i-Bu 2.03 445 H IF-402 4-F-Bnzl Gun-Pr Bnzl 2.10 479 H IF-403 4-F-Bnzl Gun-Pr 4-OH-Bnzl 1.90 495 H IF-404 4-F-Bnzl Gun-Pr i-Pnt 2.10 459 H IF-405 4-F-Bnzl Gun-Pr Ph-Et 2.13 493 H IF-406 4-F-Bnzl Gun-Pr Np-M 2.19 529 H IF-407 Ph-Et i-Bu i-Pnt 1.54 412 I IF-408 Np-M i-Bu i-Pnt 1.68 448 I IF-409 Chm i-Bu i-Pnt 1.55 404 I IF-410 4-F-Bnzl i-Bu i-Pnt 1.51 416 I IF-411 Bnzl i-Bu i-Pnt 1.46 398 I IF-412 i-Bu i-Bu i-Pnt 1.40 364 I IF-413 i-Pnt Cbx-E Np-M 1.41 464 I IF-414 i-Pnt Cbx-E i-Bu 1.15 380 I IF-415 Chm Cbx-E i-Pnt 1.15 420 I

TABLE 4-16 IF-416 Chm Cbx-E Np-M 1.51 490 I IF-417 4-F-Bnzl Cbx-E Np-M 1.46 502 I IF-418 i-Pnt 4-F-Bnzl Cbx-E 1.18 432 I IF-419 Chm Np-M Cbx-E 1.40 490 I IF-420 4-F-Bnzl Np-M Cbx-E 1.42 502 I IF-421 Cbx-E 4-F-Bnzl i-Bu 1.27 418 I IF-422 Cbx-E Np-M i-Pnt 1.48 464 I IF-423 Cbx-E 4-F-Bnzl Np-M 1.47 502 I IF-424 Cbx-E i-Bu Bnzl 1.20 400 I IF-425 Cbx-E 4-OH-Bnzl Np-M 1.28 500 I IF-426 Bnzl Hxy Cbx-E 1.31 428 I IF-427 i-Bu Hxy Cbx-E 1.24 394 I IF-428 i-Bu Cbx-E Np-M 1.35 450 I IF-429 i-Bu Cbx-E i-Bu 1.02 366 I IF-430 Hdr-E i-Bu i-Pnt 1.23 352 I IF-431 Ph-Et i-Bu Np-M 1.75 482 I IF-432 Np-M i-Bu Ph-Et 1.75 482 I IF-433 Np-M i-Bu Np-M 1.96 518 I IF-434 Np-M i-Bu Bnzl 1.73 468 I IF-435 Np-M Cbm-E 4-OH-Bnzl 1.17 499 I IF-436 4-F-Bnzl i-Bu Np-M 1.73 486 I IF-437 i-Pnt Ph-Et i-Bu 1.55 412 I IF-438 Ph-Et Hxy i-Bu 1.67 426 I IF-439 Chm Ph-Et 4-OH-Bnzl 1.43 488 I IF-440 4-F-Bnzl Ph-Et Np-M 1.77 534 I IF-441 Bnzl i-Bu Np-M 1.65 468 I IF-442 4-OH-Bnzl Hdr-E Np-M 1.26 472 I IF-443 4-OH-Bnzl i-Bu i-Pnt 1.25 414 I IF-444 Hdr-E Cbx-E Np-M 1.15 438 I IF-445 i-Pnt 4-OH-Bnzl Cbx-E 0.97 430 I IF-446 Chm Cbx-E i-Bu 1.25 406 I IF-447 Chm 4-OH-Bnzl Cbx-E 1.12 456 I IF-448 Np-M Hdr-E Cbx-E 1.13 438 I IF-449 Cbx-E Np-M i-Bu 1.43 450 I IF-450 Cbx-E Hxy i-Bu 1.43 394 I IF-451 Cbx-E Hdr-E Ph-Et 0.91 402 I IF-452 Cbx-E Hdr-E Np-M 1.13 438 I IF-453 Cbx-E 4-F-Bnzl Ph-Et 1.41 466 I IF-454 Cbx-E i-Bu Ph-Et 1.30 414 I IF-455 Cbx-E i-Bu 4-OH-Bnzl 1.11 416 I IF-456 Cbx-E Cbm-E Ph-Et 0.95 429 I IF-457 Cbx-E Cbm-E Np-M 1.16 465 I IF-458 Cbx-E 4-OH-Bnzl i-Pnt 1.13 430 I IF-459 Bnzl Cbx-E Np-M 1.42 484 I IF-460 i-Bu Np-M Cbx-E 1.32 450 I IF-461 4-OH-Bnzl Np-M Cbx-E 1.26 I

TABLE 4-17 IF-462 Hdr-E 4-OH-Bnzl Ph-Et 1.20 I IF-463 Hdr-E 4-OH-Bnzl Np-M 1.27 472 I IF-464 i-Pnt 4-OH-Bnzl Ph-Et 1.40 462 I IF-465 i-Pnt 4-OH-Bnzl Np-M 1.53 498 I IF-466 i-Pnt 4-OH-Bnzl Bnzl 1.37 448 I IF-467 i-Pnt 4-OH-Bnzl i-Bu 1.32 414 I IF-468 Ph-Et 4-OH-Bnzl i-Pnt 1.48 462 I IF-469 Ph-Et 4-OH-Bnzl Bnzl 1.46 482 I IF-470 Ph-Et 4-OH-Bnzl i-Bu 1.38 448 I IF-471 Np-M 4-OH-Bnzl i-Pnt 1.63 498 I IF-472 Np-M 4-OH-Bnzl Bnzl 1.58 518 I IF-473 Np-M 4-OH-Bnzl i-Bu 1.51 484 I IF-474 Chm 4-OH-Bnzl i-Pnt 1.46 454 I IF-475 Chm 4-OH-Bnzl Ph-Et 1.49 488 I IF-476 Chm 4-OH-Bnzl Np-M 1.62 524 I IF-477 Chm 4-OH-Bnzl Bnzl 1.43 474 I IF-478 Chm 4-OH-Bnzl i-Bu 1.41 440 I IF-479 4-F-Bnzl 4-OH-Bnzl i-Pnt 1.41 466 I IF-480 4-F-Bnzl 4-OH-Bnzl Np-M 1.58 536 I IF-481 4-F-Bnzl 4-OH-Bnzl Bnzl 1.38 486 I IF-482 4-F-Bnzl 4-OH-Bnzl i-Bu 1.32 452 I IF-483 i-Pnt Hdr-E Bnzl 1.23 386 I IF-484 Ph-Et Hdr-E Bnzl 1.30 420 I IF-485 Np-M Hdr-E 4-OH-Bnzl 1.17 472 I IF-486 Chm Hdr-E Bnzl 1.33 412 I IF-487 4-F-Bnzl Hdr-E Bnzl 1.24 424 I IF-488 4-F-Bnzl Hdr-E 4-OH-Bnzl 0.75 440 I IF-489 i-Pnt Hdr-E Ph-Et 1.29 400 I IF-490 4-F-Bnzl Hdr-E i-Pnt 1.30 404 I IF-491 4-F-Bnzl Hdr-E Ph-Et 1.34 438 I IF-492 Bnzl Hdr-E i-Bu 1.17 372 I IF-493 Bnzl 4-OH-Bnzl i-Pnt 1.40 448 I IF-494 Bnzl 4-OH-Bnzl Bnzl 1.37 468 I IF-495 Bnzl 4-OH-Bnzl i-Bu 1.29 434 I IF-497 i-Bu Hdr-E i-Pnt 1.12 352 I IF-498 i-Bu Hdr-E Ph-Et 1.18 386 I IF-499 i-Bu 4-OH-Bnzl i-Pnt 1.29 414 I IF-500 i-Bu 4-OH-Bnzl Np-M 1.46 484 I IF-501 i-Bu 4-OH-Bnzl i-Bu 1.22 400 I IF-502 4-OH-Bnzl Hdr-E i-Pnt 0.99 402 I IF-503 4-OH-Bnzl i-Pr i-Pnt 1.20 400 I IF-504 4-OH-Bnzl i-Pr Np-M 1.39 470 I IF-505 Np-M Bnzl 4-OH-Bnzl 1.46 518 I IF-506 4-F-Bnzl Bnzl Np-M 1.73 520 I IF-507 Hdr-E Hxy i-Bu 1.43 366 I IF-508 Hdr-E 4-F-Bnzl Bnzl 1.31 424 I

TABLE 4-18 IF-509 i-Pnt 4-F-Bnzl 4-OH-Bnzl 1.40 466 I IF-510 Ph-Et Hxy 4-OH-Bnzl 1.59 476 I IF-511 Np-M Hxy i-Bu 1.89 462 I IF-512 Np-M Hxy 4-OH-Bnzl 1.69 512 I IF-513 Chm Hxy i-Bu 1.75 418 I IF-514 Chm Hxy 4-OH-Bnzl 1.49 468 I IF-515 Hdr-E 4-F-Bnzl i-Pnt 1.42 404 I IF-516 Hdr-E 4-F-Bnzl Ph-Et 1.41 438 I IF-517 Ph-Et Hxy i-Pnt 1.83 440 I IF-518 Np-M Hdr-E Ph-Et 1.46 470 I IF-519 Np-M Hxy i-Pnt 1.98 476 I IF-520 Chm Hxy i-Pnt 1.81 432 I IF-521 Chm 4-F-Bnzl Ph-Et 1.67 490 I IF-522 4-F-Bnzl Hxy Ph-Et 1.85 478 I IF-523 i-Bu Hxy 4-OH-Bnzl 1.46 428 I IF-524 i-Bu 4-F-Bnzl 4-OH-Bnzl 1.37 452 I IF-525 i-Bu 4-F-Bnzl Ph-Et 1.63 450 I IF-526 Np-M i-Bu Cbx-E 1.39 450 I IF-527 Ph-Et i-Pnt Cbx-E 1.35 428 I IF-528 Cbx-E i-Pnt Bnzl 1.41 414 I IF-529 Cbx-E i-Pnt Ph-Et 1.46 428 I IF-530 Cbx-E i-Bu i-Pnt 1.30 380 I IF-531 Hdr-E Cbm-E Np-M 1.10 437 I IF-532 Hdr-E Cbm-E i-Bu 1.26 353 I IF-533 Hdr-E 4-OH-Bnzl i-Bu 1.47 388 I IF-534 Ph-Et 4-OH-Bnzl Np-M 1.55 532 I IF-535 Np-M Cbm-E i-Bu 1.36 449 I IF-536 Chm Cbm-E Np-M 1.51 489 I IF-537 Chm Cbm-E 4-OH-Bnzl 1.01 455 I IF-538 4-F-Bnzl Cbm-E Ph-Et 1.31 465 I IF-539 4-F-Bnzl Cbm-E Np-M 1.41 501 I IF-540 Hdr-E Ph-Et Bnzl 1.32 420 I IF-541 Hdr-E Ph-Et 4-OH-Bnzl 1.25 436 I IF-542 Hdr-E Np-M i-Bu 1.42 422 I IF-543 Hdr-E Np-M 4-OH-Bnzl 1.34 I IF-544 Hdr-E 4-F-Bnzl i-Bu 1.21 390 I IF-545 i-Pnt Ph-Et 4-OH-Bnzl 1.36 462 I IF-546 i-Pnt Hxy i-Bu 1.61 392 I IF-547 i-Pnt 4-F-Bnzl Bnzl 1.58 450 I IF-548 i-Pnt 4-F-Bnzl i-Bu 1.48 416 I IF-549 Ph-Et 4-F-Bnzl Bnzl 1.62 484 I IF-550 Ph-Et 4-F-Bnzl i-Bu 1.56 450 I IF-551 Chm Np-M i-Bu 1.75 474 I IF-552 4-F-Bnzl Np-M 4-OH-Bnzl 1.48 536 I IF-553 Hdr-E Ph-Et i-Pnt 1.37 400 I IF-554 i-Pnt Hxy Ph-Et 1.77 440 I

TABLE 4-19 IF-555 i-Pnt Hxy Np-M 1.84 476 I IF-556 Ph-Et 4-F-Bnzl i-Pnt 1.66 464 I IF-557 Chm 4-F-Bnzl i-Pnt 1.66 456 I IF-558 4-F-Bnzl Np-M i-Pnt 1.73 500 I IF-559 Bnzl Hxy Bnzl 1.70 446 I IF-560 Bnzl Hxy i-Bu 1.63 412 I IF-561 Bnzl 4-F-Bnzl Bnzl 1.55 470 I IF-562 Bnzl Hxy i-Pnt 1.67 426 I IF-563 Bnzl Hxy Ph-Et 1.74 460 I IF-564 Bnzl Cbm-E Ph-Et 1.31 447 I IF-565 Bnzl 4-OH-Bnzl Ph-Et 1.45 482 I IF-566 Bnzl 4-OH-Bnzl Np-M 1.53 518 I IF-567 i-Bu Ph-Et 4-OH-Bnzl 1.33 448 I IF-568 i-Bu Np-M 4-OH-Bnzl 1.42 484 I IF-569 i-Bu Hxy i-Bu 1.53 378 I IF-570 i-Bu Np-M i-Pnt 1.61 448 I IF-571 i-Bu Hxy i-Pnt 1.61 392 I IF-572 i-Bu Hxy Ph-Et 1.66 426 I IF-573 i-Bu Hxy Np-M 1.83 462 I IF-574 i-Bu 4-F-Bnzl Np-M 1.67 486 I IF-575 i-Bu Cbm-E Ph-Et 1.19 413 I IF-576 i-Bu 4-OH-Bnzl Ph-Et 1.31 448 I IF-577 4-OH-Bnzl Ph-Et Bnzl 1.44 482 I IF-578 4-OH-Bnzl Np-M i-Bu 1.47 484 I IF-579 4-OH-Bnzl Hdr-E Ph-Et 1.59 436 I IF-580 4-OH-Bnzl Ph-Et Np-M 1.61 532 I IF-581 Np-M 4-OH-Bnzl Ph-Et 1.64 532 I IF-582 Np-M 4-OH-Bnzl Np-M 1.80 568 I IF-583 i-Pnt Hxy 4-OH-Bnzl 1.50 442 I IF-584 4-F-Bnzl i-Pnt Bnzl 1.65 450 I IF-585 4-F-Bnzl i-Pnt i-Bu 1.57 416 I IF-586 4-F-Bnzl Ph-Et Bnzl 1.69 484 I IF-587 4-F-Bnzl Hxy Bnzl 1.79 464 I IF-588 Chm 4-F-Bnzl Np-M 1.79 526 I IF-589 4-F-Bnzl i-Pnt Np-M 1.82 500 I IF-590 4-OH-Bnzl Ph-Et i-Bu 1.40 448 I IF-591 i-Pnt Bnzl Cbx-E 1.23 414 I IF-592 Ph-Et Bnzl Cbx-E 1.31 448 I IF-593 Np-M i-Pnt Cbx-E 1.51 464 I IF-594 Cbx-E i-Bu Np-M 1.43 450 I IF-595 Bnzl Bnzl Cbx-E 1.19 434 I IF-596 Np-M i-Pr Np-M 1.81 504 I IF-597 i-Pnt Hdr-E i-Bu 1.13 352 I IF-598 i-Pnt Hdr-E 4-OH-Bnzl 0.61 402 I IF-599 i-Pnt Hxy Bnzl 1.67 426 I IF-600 Ph-Et Hdr-E i-Bu 1.23 386 I

TABLE 4-20 IF-601 Ph-Et Hdr-E 4-OH-Bnzl 1.01 436 I IF-602 Ph-Et Hxy Bnzl 1.75 460 I IF-603 Np-M Hdr-E Bnzl 1.49 456 I IF-604 Np-M Hdr-E i-Bu 1.35 422 I IF-605 Np-M Hxy Bnzl 1.92 496 I IF-606 Chm Hdr-E i-Bu 1.23 378 I IF-607 Chm Hdr-E 4-OH-Bnzl 0.99 428 I IF-608 Chm 4-F-Bnzl Bnzl 1.61 476 I IF-609 4-F-Bnzl Hdr-E i-Bu 1.17 390 I IF-610 Hdr-E Ph-Et Np-M 1.48 470 I IF-611 i-Pnt Hdr-E Np-M 1.45 436 I IF-612 Ph-Et Hdr-E Np-M 1.44 470 I IF-613 Np-M Hdr-E i-Pnt 1.43 436 I IF-614 Np-M Hdr-E Np-M 1.59 506 I IF-615 Np-M Hxy Ph-Et 1.96 510 I IF-616 Np-M Hxy Np-M 2.10 546 I IF-617 Chm Hdr-E i-Pnt 1.35 392 I IF-618 Chm Hdr-E Ph-Et 1.39 426 I IF-619 Chm Hdr-E Np-M 1.46 462 I IF-620 4-F-Bnzl Hdr-E Np-M 1.43 474 I IF-621 Bnzl Hdr-E Bnzl 1.22 406 I IF-622 Bnzl Hdr-E 4-OH-Bnzl 0.75 422 I IF-623 Bnzl Hdr-E Ph-Et 1.31 420 I IF-624 Bnzl Hdr-E Np-M 1.42 456 I IF-625 i-Bu Hdr-E Np-M 1.33 422 I IF-627 Hdr-E Bnzl i-Pnt 1.34 386 I IF-628 Hdr-E Bnzl Bnzl 1.30 406 I IF-629 Hdr-E Bnzl i-Bu 1.25 372 I IF-630 Hdr-E Bnzl 4-OH-Bnzl 1.22 422 I IF-631 Hdr-E i-Bu i-Bu 1.15 338 I IF-632 i-Pnt Bnzl Ph-Et 1.62 446 I IF-634 i-Pnt Bnzl 4-OH-Bnzl 1.31 448 I IF-635 i-Pnt i-Bu Ph-Et 1.54 412 I IF-636 i-Pnt i-Bu i-Bu 1.42 364 I IF-637 i-Pnt i-Bu 4-OH-Bnzl 1.30 414 I IF-638 Ph-Et Bnzl i-Pnt 1.66 446 I IF-639 Ph-Et Bnzl i-Bu 1.56 432 I IF-640 Ph-Et Bnzl 4-OH-Bnzl 1.40 482 I IF-641 Ph-Et i-Bu Bnzl 1.58 432 I IF-642 Np-M Bnzl i-Bu 1.73 468 I IF-643 Chm Bnzl Ph-Et 1.66 472 I IF-644 Chm Bnzl i-Bu 1.59 424 I IF-645 Chm Bnzl 4-OH-Bnzl 1.34 474 I IF-646 Chm i-Bu Np-M 1.76 474 I IF-647 Chm i-Bu 4-OH-Bnzl 1.35 440 I IF-648 4-F-Bnzl Bnzl Ph-Et 1.68 484 I

TABLE 4-21 IF-649 4-F-Bnzl Bnzl Bnzl 1.60 470 I IF-650 4-F-Bnzl Bnzl i-Bu 1.57 436 I IF-651 4-F-Bnzl Bnzl 4-OH-Bnzl 1.32 486 I IF-652 4-F-Bnzl i-Bu Ph-Et 1.59 450 I IF-653 4-F-Bnzl i-Bu Bnzl 1.52 436 I IF-654 4-F-Bnzl i-Bu i-Bu 1.48 402 I IF-655 4-F-Bnzl i-Bu 4-OH-Bnzl 1.29 452 I IF-656 Hdr-E i-Pnt Bnzl 1.36 386 I IF-657 Ph-Et i-Pnt i-Bu 1.62 412 I IF-658 Chm i-Pnt Bnzl 1.65 438 I IF-659 Chm i-Pnt i-Bu 2.29 404 I IF-660 Hdr-E i-Pnt Np-M 1.53 436 I IF-661 Np-M i-Pnt Ph-Et 1.91 496 I IF-662 Chm i-Pnt Ph-Et 1.72 452 I IF-663 Chm i-Pnt Np-M 1.83 488 I IF-664 4-F-Bnzl i-Pnt Ph-Et 1.68 464 I IF-665 Bnzl i-Pnt Bnzl 1.61 432 I IF-666 Bnzl i-Pnt 4-OH-Bnzl 1.36 448 I IF-667 Bnzl i-Pnt Ph-Et 1.65 446 I IF-670 Bnzl i-Bu Ph-Et 1.54 432 I IF-671 i-Bu i-Pnt i-Bu 1.44 364 I IF-672 i-Bu i-Pnt 4-OH-Bnzl 1.30 414 I IF-673 i-Bu i-Pnt Ph-Et 1.56 412 I IF-674 i-Bu i-Pnt Np-M 1.71 448 I IF-675 i-Bu Bnzl i-Pnt 1.53 398 I IF-678 i-Bu Bnzl 4-OH-Bnzl 1.23 434 I IF-679 i-Bu i-Bu Ph-Et 1.48 398 I IF-680 i-Bu i-Bu Np-M 1.59 434 I IF-683 i-Bu i-Bu 4-OH-Bnzl 1.23 400 I IF-684 4-OH-Bnzl i-Pnt Np-M 1.62 498 I IF-686 i-Pnt Cbm-E Ph-Et 1.28 427 I IF-687 Np-M i-Pnt 4-OH-Bnzl 1.56 498 I IF-688 Chm 4-F-Bnzl i-Bu 1.56 442 I IF-689 4-F-Bnzl Hxy 4-OH-Bnzl 1.47 480 I IF-690 Ph-Et Hdr-E i-Pnt 1.30 400 I IF-691 Bnzl i-Pnt i-Bu 1.54 398 I IF-692 Bnzl Hxy 4-OH-Bnzl 1.45 462 I IF-693 Cbx-E Bnzl Bnzl 1.30 434 I IF-694 Cbx-E Bnzl i-Bu 1.24 400 I IF-695 Bnzl i-Pnt Cbx-E 1.26 414 I IF-696 i-Pnt Cbm-E Np-M 1.46 463 I IF-697 i-Pnt Cbm-E Bnzl 1.28 413 I IF-698 Ph-Et Cbm-E Bnzl 1.36 447 I IF-699 Ph-Et Cbm-E i-Bu 1.24 413 I IF-700 Chm Cbm-E Ph-Et 1.43 453 I IF-701 Chm Cbm-E Bnzl 1.36 439 I

TABLE 4-22 IF-702 4-F-Bnzl Cbm-E Bnzl 1.27 451 I IF-703 4-F-Bnzl Cbm-E i-Bu 1.23 417 I IF-704 Hdr-E Ph-Et i-Bu 1.31 386 I IF-705 i-Pnt Np-M i-Bu 1.69 448 I IF-706 i-Pnt Np-M 4-OH-Bnzl 1.50 498 I IF-707 Ph-Et i-Pnt 4-OH-Bnzl 1.47 462 I IF-708 Np-M Ph-Et 4-OH-Bnzl 1.57 532 I IF-709 Chm i-Pnt 4-OH-Bnzl 1.40 454 I IF-710 Chm Ph-Et Bnzl 1.72 472 I IF-711 Chm Ph-Et i-Bu 1.69 438 I IF-712 Chm Np-M 4-OH-Bnzl 1.58 524 I IF-713 4-F-Bnzl i-Pnt 4-OH-Bnzl 1.38 466 I IF-714 4-F-Bnzl Ph-Et i-Bu 1.62 450 I IF-715 4-F-Bnzl Ph-Et 4-OH-Bnzl 1.42 500 I IF-716 4-F-Bnzl Np-M i-Bu 1.71 486 I IF-717 Chm Ph-Et i-Pnt 1.76 452 I IF-718 Chm Ph-Et Np-M 1.94 522 I IF-719 Chm Np-M i-Pnt 1.81 488 I IF-720 4-F-Bnzl Ph-Et i-Pnt 1.68 464 I IF-721 Bnzl Ph-Et i-Bu 1.58 432 I IF-722 Bnzl Ph-Et 4-OH-Bnzl 1.41 482 I IF-723 Bnzl Ph-Et i-Pnt 1.68 446 I IF-724 Bnzl Cbm-E Bnzl 1.24 433 I IF-725 i-Bu Ph-Et i-Bu 1.51 398 I IF-726 i-Bu Np-M i-Bu 1.62 434 I IF-727 i-Bu Ph-Et i-Pnt 1.62 412 I IF-728 i-Bu Cbm-E Np-M 1.37 449 I IF-730 4-OH-Bnzl Np-M i-Pnt 1.62 I IF-731 4-OH-Bnzl Cbm-E Np-M 1.29 499 I IF-732 i-Pnt Bnzl Np-M 1.72 482 I IF-733 i-Pnt Bnzl i-Bu 1.49 398 I IF-734 i-Pnt i-Bu Np-M 1.66 448 I IF-735 i-Pnt i-Bu Bnzl 1.50 398 I IF-736 Ph-Et Bnzl Np-M 1.76 516 I IF-737 Ph-Et Bnzl Bnzl 1.61 466 I IF-738 Ph-Et i-Bu i-Bu 1.49 398 I IF-739 Np-M i-Bu i-Bu 1.66 434 I IF-740 Chm Bnzl i-Pnt 1.69 438 I IF-742 Chm i-Bu i-Bu 1.49 390 I IF-743 4-F-Bnzl Bnzl i-Pnt 1.64 450 I IF-744 Ph-Et i-Pnt Bnzl 1.65 446 I IF-746 Bnzl Bnzl Ph-Et 1.58 466 I IF-747 Bnzl Bnzl Np-M 1.72 502 I IF-751 Bnzl i-Bu 4-OH-Bnzl 1.26 434 I IF-752 i-Bu i-Pnt Bnzl 1.50 398 I IF-753 i-Bu Bnzl Np-M 1.64 468 I

TABLE 4-23 IF-755 4-OH-Bnzl Bnzl i-Pnt 1.42 448 I IF-756 Ph-Et Cbm-E Np-M 1.48 497 I IF-757 Ph-Et i-Pr Np-M 1.65 468 I IF-758 Hdr-E Np-M Bnzl 1.46 456 I IF-759 i-Pnt Np-M Bnzl 1.72 482 I IF-760 Ph-Et Np-M i-Bu 1.71 482 I IF-761 Ph-Et Np-M 4-OH-Bnzl 1.57 532 I IF-762 Np-M i-Pnt Bnzl 1.86 482 I IF-763 Np-M Np-M i-Bu 1.95 518 I IF-764 Chm Np-M Bnzl 1.77 508 I IF-765 4-F-Bnzl Np-M Bnzl 1.76 520 I IF-766 Ph-Et Np-M i-Pnt 1.74 497 I IF-767 Np-M Np-M i-Pnt 1.96 532 I IF-768 Np-M 4-F-Bnzl Np-M 2.03 570 I IF-769 Chm Np-M Ph-Et 1.85 522 I IF-770 Chm Np-M Np-M 1.95 558 I IF-771 4-F-Bnzl Np-M Ph-Et 1.80 534 I IF-772 4-F-Bnzl Np-M Np-M 1.95 570 I IF-773 Bnzl Np-M i-Bu 1.67 468 I IF-774 Bnzl Np-M i-Pnt 1.73 482 I IF-775 Bnzl 4-F-Bnzl Np-M 1.75 520 I IF-776 Bnzl Cbm-E Np-M 1.42 483 I IF-777 i-Bu Np-M Ph-Et 1.71 482 I IF-778 i-Bu Np-M Np-M 1.81 518 I IF-779 4-OH-Bnzl Np-M Np-M 1.71 568 I IF-780 Hdr-E i-Bu Ph-Et 1.34 386 I IF-781 Hdr-E i-Bu 4-OH-Bnzl 1.12 388 I IF-782 Ph-Et i-Bu 4-OH-Bnzl 1.44 I IF-783 Ph-Et Cbm-E 4-OH-Bnzl 1.03 463 I IF-784 Np-M Bnzl i-Pnt 1.84 482 I IF-785 Np-M Bnzl Ph-Et 1.88 516 I IF-786 Np-M Bnzl Np-M 2.03 552 I IF-787 Np-M i-Bu 4-OH-Bnzl 1.40 484 I IF-788 Np-M Cbm-E Np-M 1.65 533 I IF-789 Np-M i-Pr Ph-Et 1.69 468 I IF-790 Np-M i-Pr Bnzl 1.67 454 I IF-791 Chm Bnzl Np-M 1.80 508 I IF-792 Hdr-E i-Pnt i-Bu 1.30 352 I IF-793 Ph-Et Np-M Bnzl 1.80 516 I IF-794 Np-M Np-M Bnzl 2.05 552 I IF-795 Np-M 4-F-Bnzl Bnzl 1.89 520 I IF-796 Hdr-E i-Pnt Ph-Et 1.44 400 I IF-797 Hdr-E Np-M i-Pnt 1.50 436 I IF-798 Hdr-E Np-M Ph-Et 1.50 470 I IF-799 i-Pnt Np-M Ph-Et 1.78 496 I IF-800 i-Pnt 4-F-Bnzl Ph-Et 1.63 464 I

TABLE 4-24 IF-801 i-Pnt 4-F-Bnzl Np-M 1.71 500 I IF-802 Ph-Et i-Pnt Np-M 1.77 496 I IF-803 Ph-Et Np-M Np-M 1.93 566 I IF-804 Ph-Et 4-F-Bnzl Np-M 1.84 534 I IF-805 Bnzl Np-M Bnzl 1.72 502 I IF-806 Bnzl Np-M 4-OH-Bnzl 1.45 518 I IF-807 Bnzl 4-F-Bnzl i-Bu 1.55 436 I IF-808 Bnzl 4-F-Bnzl 4-OH-Bnzl 1.39 486 I IF-809 Bnzl i-Pnt Np-M 1.79 482 I IF-810 Bnzl Np-M Ph-Et 1.81 516 I IF-811 Bnzl 4-F-Bnzl i-Pnt 1.60 450 I IF-812 Bnzl i-Pr Np-M 1.54 454 I IF-814 i-Bu Hxy Bnzl 1.62 412 I IF-815 i-Bu 4-F-Bnzl Bnzl 1.52 436 I IF-816 4-OH-Bnzl i-Pnt Ph-Et 1.51 462 I IF-817 4-OH-Bnzl Bnzl Ph-Et 1.43 482 I IF-818 4-OH-Bnzl Bnzl i-Bu 1.32 434 I IF-819 4-OH-Bnzl i-Bu i-Bu 1.25 400 I IF-820 i-Pnt Cbx-E Bnzl 0.70 414 C IF-821 Ph-Et Cbx-E i-Pnt 0.73 428 C IF-822 Chm Cbx-E Bnzl 0.72 440 C IF-823 4-OH-Bnzl Cbx-E i-Pnt 0.61 430 C IF-824 4-OH-Bnzl Cbx-E Ph-Et 0.65 464 C IF-825 Bnzl Cbx-E i-Bu 0.67 400 C IF-826 Bnzl Cbx-E i-Pnt 0.70 414 C IF-827 Bnzl Cbx-E Ph-Et 0.71 448 C IF-828 i-Bu Cbx-E Ph-Et 0.67 414 C IF-829 i-Bu Cbx-E 4-OH-Bnzl 0.70 416 C IF-830 i-Pnt Cbx-E Ph-Et 0.72 428 C IF-831 i-Pnt Cbx-E 4-OH-Bnzl 0.59 430 C IF-832 Chm Cbx-E Ph-Et 0.74 454 C IF-833 Chm Cbx-E 4-OH-Bnzl 0.62 456 C IF-835 Ph-Et Cbx-E i-Bu 0.69 414 C IF-836 4-OH-Bnzl Cbx-E i-Bu 0.58 416 C ¹⁾ (M-H)⁻

TABLE 4-25

Compound Retention Mass Measurement number R₁ R₂ R₃ R₄ RT (min) (M + H)⁺ condition IF-837 Bnzl Np-M i-Bu H 1.127 468 B IF-838 Bnzl 4-(trifluoromethyl)benzyl i-Bu H 1.14 486 B

TABLE 4-26 IF-839 4-Cl-Bnzl Bnzl i-Bu H 1.13 452 B IF-840 3-Cl-Bnzl Bnzl i-Bu H 1.14 452 B IF-841 4-methoxybenzyl Bnzl i-Bu H 1.072 448 B IF-842 4-methylbenzyl Bnzl i-Bu H 1.097 432 B IF-843 i-Pnt i-Bu Bnzl H 1.278 398 B IF-844 i-Bu i-Bu 4-Cl-Bnzl H 1.275 418 B IF-845 i-Bu i-Pnt Bnzl H 1.082 398 B IF-846 i-Bu 4-Cl-Bnzl i-Bu H 1.085 418 B IF-847 4-hydroxybenzyl Bnzl i-Bu H 1.187 434 B IF-848 4-(dimethylamino)benzyl Bnzl i-Bu H 1.097 461 B IF-849 4-(tert-butyl)benzyl Bnzl i-Bu H 1.175 474 B IF-850 i-Bu Bnzl i-Pnt H 1.075 398 B IF-851 i-Pnt Bnzl i-Bu H 1.29 398 B IF-852 4-(trifluoromethyl)benzyl Bnzl i-Bu H 1.18 502 B IF-853 4-ethoxybenzyl Bnzl i-Bu H 1.112 462 B IF-854 Bnzl naphthalen-2-ylmethyl i-Bu H 1.142 468 B IF-855 4-methylbenzyl Bnzl i-Bu ethyl 1.172 460 B IF-856 4-methylbenzyl Bnzl i-Bu i-Bu 1.303 488 B IF-857 4-methylbenzyl Bnzl i-Bu acetyl 1.187 474 B IF-858 4-methylbenzyl Bnzl i-Bu 3-methylbutanoyl 1.247 516 B IF-859 4-methylbenzyl Bnzl i-Bu 2-phenylacetyl 1.253 550 B IF-860 4-methylbenzyl Bnzl i-Bu methoxycarbonyl 1.23 490 B IF-861 4-methylbenzyl Bnzl i-Bu 2-methylpropoxycarbonyl 1.292 532 B IF-862 4-methylbenzyl Bnzl i-Bu benzyloxycarbonyl 1.297 566 B IF-863 4-methylbenzyl Bnzl i-Bu aminocarbonyl 1.157 475 B

TABLE 4-27 IF-864 4-methylbenzyl Bnzl i-Bu N-benzylaminocarbonyl 1.252 565 B IF-865 Bnzl pyridin-4-ylmethyl i-Bu H 1.11 419 B IF-866 4-(dimethylamino)benzyl 3-hydroxybenzyl i-Bu H 1.223 477 B IF-867 4-(dimethylamino)benzyl 4-hydroxybenzyl i-Bu H 1.208 477 B IF-868 2-hydroxyethyl 4-fluorobenzyl Np-M H 0.76 474 C IF-869 4-methoxybenzyl Bnzl Bnzl H 0.83 482 C IF-870 4-methoxybenzyl Bnzl Bnzl tert-butoxycarbonyl 1.01 582 C IF-871 ethyl Bnzl Bnzl tert-butoxycarbonyl 0.94 490 C IF-872 phenethyl Bnzl 2-(tert-butyldimethylsilyloxy) H 0.95 534 C ethyl IF-873 cyclopentylmethyl 4-(tert-butoxy)benzyl 2-(tert-butoxycarbonyl)ethyl H 0.93 554 C IF-874 4-nitrobenzyl 4-(tert-butoxy) 2-(tert-butoxycarbonyl)ethyl H 0.97 607 C benzyl IF-875 phenethyl Bnzl 2-hydroxyethyl H 0.72 420 C IF-876 cyclopentylmethyl 4-(tert-butoxy)benzyl 2-(tert-butoxycarbonyl)ethyl methoxycarbonyl 1.03 612 C IF-877 cyclopentylmethyl 4-hydroxybenzyl 2-carboxyethyl methoxycarbonyl 0.71 500 C IF-878 cyclopentylmethyl 4-hydroxybenzyl 2-carboxyethyl H 0.64 442 C IF-879 phenethyl Bnzl 2-hydroxyethyl methoxycarbonyl 0.8 478 C IF-880 4-aminobenzyl 4-(tert-butoxy)benzyl 2-(tert-butoxycarbonyl)ethyl formyl 0.89 605 C IF-881 4-(cyclopentylcarbonylamino) 4-(tert-butoxy)benzyl 2-(tert-butoxycarbonyl)ethyl formyl 1 701 C benzyl IF-882 4-(cyclopentylmethylamino) 4-(tert-butoxy)benzyl 2-(tert-butoxycarbonyl)ethyl formyl 1.07 687 C benzyl

TABLE 4-28 IF- 4-(cyclopentylmethylamino) 4- 2- H 0.81 561 C 883 benzyl hydroxybenzyl methoxycarbonylethyl IF- 4-(cyclopentylmethylamino) 4- 2- H 0.75 547 C 884 benzyl hydroxybenzyl carboxylethyl

TABLE 4-29 Formula XXIF

Compound Retention Mass Measurement number R₁ R_(2A) R_(2B) R₃ R₄ RT (min) (M + H)⁺ condition IF-885 i-Bu H 4-Cl-Bnzl Ph-Et H 1.99 466  B1 IF-886 i-Bu H 3-Cl-Bnzl Ph-Et H 1.98 466  B1 IF-887 i-Bu H 4-MeO-Bnzl Ph-Et H 1.75 462  B1 IF-888 i-Bu H 4-Me-Bnzl Ph-Et H 1.92 446  B1 IF-889 i-Bu H 2-Npm Ph-Et H 2.07 482  B1 IF-890 i-Bu H Bnzl Ph-Pr H 1.89 446 B IF-891 i-Bu H 3-Cl-Bnzl Ph-Pr H 1.16 480 B IF-892 i-Bu H 3-F-Bnzl Ph-Pr H 1.14 464 B IF-893 i-Bu H 3-Me-Bnzl Ph-Pr H 1.13 460 B IF-894 i-Bu H 3-MeO-Bnzl Ph-Pr H 1.10 476 B IF-895 i-Bu H 3-Cl-Bnzl Ph-Bu H 1.16 494 B IF-896 i-Bu H 3-F-Bnzl Ph-Bu H 1.12 478 B IF-897 i-Bu H 3-Me-Bnzl Ph-Bu H 1.16 474 B IF-898 i-Bu H 3-MeO-Bnzl Ph-Bu H 1.12 491 B IF-899 i-Bu H Bnzl Ph-Bu H 1.13 460 B IF-900 i-Pnt H 3-F-Bnzl Ph-Pr H 1.14 478 B IF-901 1-Npm H pentyl Ph-Et H 0.92 496 C IF-902 1-Npm H cyclohexyl Ph-Et H 0.92 508 C IF-903 1-Npm H cyclopentyl Ph-Et H 0.90 494 C IF-904 1-Npm H Hxy 4-methylphenethyl H 0.99 524 C IF-905 1-Npm H Hxy 2-(naphthalen-2-yl)ethyl H 1.02 560 C IF-906 1-Npm H heptyl Ph-Et H 1.00 524 C IF-907 1-Npm H Hxy 4-isopropylphenethyl H 1.05 552 C IF-908 1-Npm H Hxy cyclohexylethyl H 1.03 516 C

TABLE 4-30 IF-909 i-Bu H Ph-Et Ph-Et H 1.87 444 B1 IF-910 Chm H tBuO-E 1-Npm H 0.87 518 C IF-911 tBuO-E H Ph-Et 1-Npm H 0.88 526 C IF-912 Ph-Et H Hxy 1-Npm H 0.95 510 C IF-913 tBuO-E H 4-fluorophenethyl 1-Npm H 0.89 544.4 C IF-914 Hdr-E H 4-fluorophenethyl 1-Npm H 0.77 488.3 C IF-915 3-tert-butoxypropyl H 4-F-Bnzl 1-Npm H 0.89 544.4 C IF-916 tBuO-E H 4-Cl-Bnzl 1-Npm H 0.9 546.3 C IF-917 3-hydroxypropyl H 4-F-Bnzl 1-Npm H 0.76 488.3 C IF-918 Hdr-E H 4-Cl-Bnzl 1-Npm H 0.78 490.3 C IF-919 1-Npm H Hxy 3-methylphenethyl H 0.99 524.4 C IF-920 1-Npm H β-hydroxyphenethyl Ph-Et H 0.84 546.4 C IF-921 1-Npm H α-hydroxymethylphenethyl Ph-Et H 0.88 560.4 C IF-922 1-Npm H α-hydroxymethylphenethyl Ph-Et H 0.85 560.4 C IF-923 4-Nt-Bnzl H Bnzl tBOC-E H 0.86 535 C IF-924 4-Nt-Bnzl H Bnzl tBOC-E ethoxycarbonyl 0.94 607 C IF-925 1-Npm H 4-F-Bnzl 2-OH-Et H 0.73 474.3 C IF-926 4-tBuO-Bnzl H Bnzl i-Bu H 0.91 490.4 C IF-927 4-tBuO-Bnzl H i-Bu Bnzl H 0.88 490.4 C IF-928 2-OtBu-Et H Bnzl 1-Npm H 0.85 512.4 C IF-929 2-OH-Et H Bnzl 1-Npm H 0.74 456.3 C IF-930 4-OH-Bnzl H i-Bu Bnzl H 0.73 434.3 C IF-931 1-Npm H 4-F-Bnzl 2-OTBS-Et H 1.01 588.4 C

Example 2: Assay Method for Anti-Rabies Virus Activity

Each tested compound prepared as a 10 mM with DMSO was first diluted to 100 μM or 40 μM with 10% fetal bovine serum-supplemented Eagle's minimal essential medium (hereinafter, medium), and further diluted with the medium to the final concentration of interest. Fifty microlitter of the diluted medium was added dropwise to each well of a 96-well plate. Furthermore, 50 μL of medium comprising 4×10² infectious units of the recombinant rabies virus 1088 strain expressing Gaussia Luciferase (GLuc) (1088/GLuc) and 4×10⁴ Neuro-2a cells were added to each well. The plate was shaken for 30 seconds with a multiple microplate mixer NS-4P (AS ONE Corporation) and then cultured for 3 days at 37° C. in the presence of 5% CO₂. After incubation, 25 μL of coelenterazine, which is a substrate of the luciferase, was added dropwise to each well of the plate, and the plate was immediately loaded into a luminescent plate reader LuMate (Awareness Technology) and shaken for 10 seconds. The relative light unit (RLU) was then measured.

The synthesized compounds were tested. It was found that the compounds described in Table 5 exhibited the higher anti-rabies virus activity compared to T-705 (generic name: Favipiravir) (IC₅₀=30 μM), which is examined as an anti-rabies antiviral drug.

The compounds are classified as A if IC_(H) is 5 μM or less, B if greater than 5 μM and less than or equal to 10 μM, and C if greater than 10 μM and less than 30 μM. The ‘na’ indicates not applicable.

TABLE 5-1 Compound IC₅₀ number Name of compound (μM) IB-3  (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-N,1- 19.6 diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-4  (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7- 19.2 diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-5  (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1,7- 18.2 diisobutyloctahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-9  (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-1- 17.0 isopentyloctahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-12 (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-7-isobutyl-N- 15.5 phenethyloctahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-13 (3S*,3aS*,6R*,7R*,7aS*)-N-benzyl-1-isobutyl-7-(3- 14.3 methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IB-15 (3S*,3aS*,6R*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3- 15.9 methylbenzyl)octahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide

TABLE 5-2 IF-1  (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-1- 12.6 isobutyloctahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-6  (3S*,3aS*,6S*,7R*,7aS*)-1,7-dibenzyl-N- 16.3 isobutyloctahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-7  (3S*,3aS*,6S*,7R*,7aS*)-N,1-dibenzyl-7- 8.5 isobutyloctahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-9  (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-1- 15.6 isopentyloctahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-11 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-isobutyl-7- 17.5 phenethyloctahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-13 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-isobutyl-7-(3- 13.1 methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-14 (3S*,3aS*,6S*,7R*,7aS*)-N-benzyl-1-isobutyl-7-(4- 14.1 methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-15 (3S*,3aS*,6S*,7R*,7aS*)-7-benzyl-1-isobutyl-N-(3- 17.1 methylbenzyl)octahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IF-20 (3S*,3aS*,6S*,7R*,7aS*)-1-benzyl-N-(3,4- 11.6 dichlorobenzyl)-7-isobutyloctahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6-carboxamide IF-69 (3S*,3aS*,6S*,7R*,7aS*)-N,7-dibenzyl-4-ethyl-1- 16.5 isobutyloctahydro-6H-3,6-methanopyrrolo[3,2- c]pyridine-6-carboxamide IIB-4  (3S*,3aS*,6R*,7R*,7aS*)-1-benzyl-N,7-dilsobutyl- 8.9 1,2,3,6,7,7a-hexahydro-3aH-3,6-methanopyrrolo[3,2- b]pyridine-3a-carboxamide IIF-16 (3S*,3aR*,6S*,7R*,7aR*)-7-benzyl-1-isobutyl-N-(4- 28.7 methylbenzyl)-1,2,3,3a,7,7a-hexahydro-6H-3,6- methanopyrrolo[3,2-c]pyridine-6-carboxamide

TABLE 5-3 Table. Anti-rabies activity of compound of formula IB Compound Anti-rabies number R₁ R₂ R₃ R4 activity IB-3  i-Bu i-Bu Bnzl H C IB-4  Bnzl i-Bu i-Bu H C IB-5  i-Bu Bnzl i-Bu H C IB-9  i-Pnt Bnzl Bnzl H C IB-12 i-Bu phenethyl Bnzl H C IB-13 i-Bu Bnzl 3-methylbenzyl H C IB-15 i-Bu 3-methylbenzyl Bnzl H C IB-42 Np-M Bnzl Bnzl H C IB-81 carbamoylmethyl 1-naphthylmethyl i-Bu H C IB-82 carbamoylmethyl 1-naphthylmethyl Bnzl H C IB-83 carbamoylmethyl 1-naphthylmethyl 4-hydroxybenzyl H C IB-84 carbamoylmethyl 1-naphthylmethyl i-Pnt H C IB-86 carbamoylmethyl 2-phenylethyl i-Bu H C IB-87 carbamoylmethyl 2-phenylethyl Bnzl H A IB-89 carbamoylmethyl 2-phenylethyl i-Pnt H A (A: IC₅₀ ≤ 5 μM,B: 5 μM < IC₅₀ ≤ 10 μM,C: 10 μM < IC₅₀ < 30 μM)

TABLE 5-4 IB-90 carbamoylmethyl 1-naphthylmethyl 1-naphthylmethyl H A IB-92 carbamoylmethyl 4-fluorobenzyl Bnzl H C IB-95 carbamoylmethyl 4-fluorobenzyl 2-phenylethyl H A IB-96 carbamoylmethyl 4-fluorobenzyl 1-naphthylmethyl H C IB-97 carbamoylmethyl 2-phenylethyl 1-naphthylmethyl H A IB-102 carbamoylmethyl i-Pnt 2phenylethyl- H A IB-103 carbamoylmethyl i-Pnt 1-naphthylmethyl H C IB-105 carbamoylmethyl hexyl Bnzl H C IB-108 carbamoylmethyl hexyl i-Pnt H C IB-109 carbamoylmethyl hexyl 2-phenylethyl H C IB-110 carbamoylmethyl hexyl 1-naphthylmethyl H A IB-130 carbamoylmethyl Bnzl 2-phenylethyl H C IB-164 3-guanidinopropyl 1-naphthylmethyl i-Bu H A IB-174 3-guanidinopropyl hexyl 2-phenylethyl H C IB-176 3-guanidinopropyl isopropyl i-Bu H C IB-179 3-guanidinopropyl isopropyl 2-phenylethyl H C IB-182 3-guanidinopropyl 4-fluorobenzyl Bnzl H C IB-187 i-Bu i-Bu 3-guanidinopropyl H C IB-192 i-Bu i-Pnt 3-guanidinopropyl H A IB-198 Bnzl i-Bu 3-guanidinopropyl H C IB-203 4-hydroxybenzyl i-Bu 3-guanidinopropyl H C IB-207 4-hydroxybenzyl 4-fluorobenzyl 3-guanidinopropyl H C IB-247 Bnzl phenethyl 3-guanidinopropyl H C IB-249 Bnzl hexyl 3-guanidinopropyl H C IB-250 Bnzl 4-fluorobenzyl 3-guanidinopropyl H C IB-256 phenethyl hexyl 3-guanidinopropyl H C IB-260 4-fluorobenzyl Bnzl 3-guanidinopropyl H C IB-262 4-fluorobenzyl phenethyl 3-guanidinopropyl H C IB-274 Bnzl 3-amino-3-oxopropyl i-Pnt H C

TABLE 5-5 IB-276 Bnzl 3- Bnzl H C guanidinopropyl IB-279 Bnzl 3- phenethyl H C guanidinopropyl IB-280 Bnzl 3- Np-M H C guanidinopropyl IB-300 3- Bnzl Np-M H C guanidinopropyl IB-327 3- phenethyl Np-M H C guanidinopropyl IB-342 phenethyl 3-amino-3- i-Pnt H C oxopropyl IB-344 phenethyl 3- Bnzl H C guanidinopropyl IB-346 phenethyl 3- i-Pnt H C guanidinopropyl IB-347 phenethyl 3- Np-M H C guanidinopropyl IB-349 Np-M 3-amino-3- i-Pnt H A oxopropyl IB-350 Np-M 3- i-Bu H C guanidinopropyl IB-351 Np-M 3- Bnzl H C guanidinopropyl IB-353 Np-M 3- i-Pnt H A guanidinopropyl IB-354 Np-M 3- phenethyl H A guanidinopropyl IB-357 cyclohexylmethyl 3-amino-3- i-Pnt H C oxopropyl IB-361 cyclohexylmethyl 3- i-Pnt H C guanidinopropyl IB-362 cyclohexylmethyl 3- phenethyl H A guanidinopropyl IB-365 4- 3-amino-3- i-Pnt H C fluorobenzyl oxopropyl IB-369 4- 3- i-Pnt H C fluorobenzyl guanidinopropyl IB-372 2- i-Bu i-Pnt H C hydroxyethyl IB-378 i-Bu i-Bu i-Pnt H A IB-381 i-Pnt 2- Np-M H C carboxyethyl IB-384 4- 2- Np-M H C fluorobenzyl carboxyethyl IB-386 i-Pnt 4- 2- H C fluorobenzyl carboxyethyl IB-389 cyclohexylmethyl Np-M 2- H C carboxyethyl

TABLE 5-6 IB-390 4- Np-M 2- H C fluorobenzyl carboxyethyl IB-392 2- Np-M i-Bu H C carboxyethyl IB-394 2- 4- Bnzl H C carboxyethyl fluorobenzyl IB-398 2- Np-M i-Pnt H C carboxyethyl IB-399 2- 4- i-Pnt H C carboxyethyl fluorobenzyl IB-402 2- 4- i-Pnt H C carboxyethyl hydroxybenzyl IB-410 4- 2- Np-M H C hydroxybenzyl carboxyethyl IB-417 Np-M 4- Np-M H C hydroxybenzyl IB-425 2- Np-M 2- H C hydroxyethyl carboxyethyl IB-426 i-Pnt Np-M hydroxymethyl H A IB-430 2- i-Bu phenethyl H A carboxyethyl IB-431 2- i-Bu hydroxymethyl H C carboxyethyl IB-449 phenethyl 4- i-Bu H C hydroxybenzyl IB-458 4- 4- i-Bu H C fluorobenzyl hydroxybenzyl IB-459 Np-M 2- 4- H C hydroxyethyl hydroxybenzyl IB-461 phenethyl 2- i-Pnt H C hydroxyethyl IB-464 Bnzl 4- i-Bu H A hydroxybenzyl IB-465 i-Bu 4- i-Pnt H C hydroxybenzyl IB-470 2- 4- Np-M H C hydroxyethyl hydroxybenzyl IB-476 2- hexyl Bnzl H A hydroxyethyl IB-477 2- hexyl i-Bu H A hydroxyethyl IB-478 2- hexyl 4- H C hydroxyethyl hydroxybenzyl IB-479 2- 4- Bnzl H C hydroxyethyl fluorobenzyl IB-481 i-Pnt 4- 4- H A fluorobenzyl hydroxybenzyl IB-484 cyclohexylmethyl phenethyl Bnzl H A IB-490 2- hexyl i-Pnt H A hydroxyethyl IB-492 2- 4- phenethyl H A hydroxyethyl fluorobenzyl

TABLE 5-7 IB-495 i-Bu phenethyl i-Bu H A IB-498 i-Bu 4- 4- H A fluorobenzyl hydroxybenzyl IB-499 4- 4- i-Bu H A hydroxybenzyl fluorobenzyl IB-501 4- isopropyl i-Pnt H A hydroxybenzyl IB-502 4- isopropyl Np-M H A hydroxybenzyl IB-505 i-Pnt Bnzl 2- H C carboxyethyl IB-508 phenethyl i-Bu 2- H C carboxyethyl IB-510 cyclohexylmethyl i-Bu 2- H C carboxyethyl IB-515 2- 4- phenethyl H C carboxyethyl hydroxybenzyl IB-516 2- 4- Np-M H C carboxyethyl hydroxybenzyl IB-520 Np-M 3-amino-3- i-Bu H A oxopropyl IB-521 Np-M 3-amino-3- 4- H C oxopropyl hydroxybenzyl IB-522 cyclohexylmethyl 3-amino-3- Np-M H C oxopropyl IB-525 4- 3-amino-3- Np-M H C fluorobenzyl oxopropyl IB-527 2- Np-M 4- H C hydroxyethyl hydroxybenzyl IB-531 2- phenethyl i-Pnt H C hydroxyethyl IB-535 Bnzl 3-amino-3- phenethyl H C oxopropyl IB-536 i-Bu phenethyl 4- H C hydroxybenzyl IB-539 i-Bu 3-amino-3- phenethyl H C oxopropyl IB-540 4- phenethyl i-Bu H C hydroxybenzyl IB-541 4- Np-M i-Bu H A hydroxybenzyl IB-544 4- phenethyl i-Pnt H C hydroxybenzyl IB-549 2- 4- 4- H C hydroxyethyl fluorobenzyl hydroxybenzyl IB-551 i-Pnt hexyl i-Bu H A IB-553 i-Pnt 4- i-Bu H A fluorobenzyl IB-562 Bnzl hexyl Bnzl H C IB-568 Bnzl 4- phenethyl H C fluorobenzyl IB-574 4- i-Pnt Bnzl H C hydroxybenzyl

TABLE 5-8 IB-575 2- i-Bu Np-M H C carboxyethyl IB-576 i-Pnt 4- phenethyl H C hydroxybenzyl IB-577 i-Pnt 4- Bnzl H C hydroxybenzyl IB-581 cyclohexylmethyl 4- i-Bu H C hydroxybenzyl IB-582 4- 4- i-Pnt H C fluorobenzyl hydroxybenzyl IB-583 4- 4- Bnzl H C fluorobenzyl hydroxybenzyl IB-585 2- Np-M i-Bu H C hydroxyethyl IB-588 Np-M 2- Bnzl H A hydroxyethyl IB-593 phenethyl 2- Np-M H C hydroxyethyl IB-602 Bnzl 2- Np-M H C hydroxyethyl IB-610 2- 2- Np-M H C hydroxyethyl carboxyethyl IB-611 i-Pnt 2- i-Bu H C carboxyethyl IB-613 cyclohexylmethyl 2- i-Pnt H C carboxyethyl IB-614 cyclohexylmetyl 2- Np-M H C carboxyethyl IB-616 Bnzl 2- Np-M H C carboxyethyl IB-618 2- Bnzl phenethyl H A hydroxyethyl IB-619 2- Bnzl Bnzl H C hydroxyethyl IB-621 2- i-Bu Np-M H A hydroxyethyl IB-625 phenethyl i-Bu 4- H C hydroxybenzyl IB-630 4- i-Bu i-Bu H A fluorobenzyl IB-631 4- i-Bu 4- H C fluorobenzyl hydroxybenzyl IB-633 i-Bu i-Bu phenethyl H A IB-636 i-Pnt 3-amino-3- phenethyl H C oxopropyl IB-637 cyclohexylmethyl 3-amino-3- Bnzl H A oxopropyl IB-640 phenethyl 2- Bnzl H A hydroxyethyl IB-641 phenethyl 2- i-Bu H C hydroxyethyl

TABLE 5-9 IB-642 phenethyl 4- 4- H A fluorobenzyl hydroxybenzyl IB-643 Np-M 2- i-Bu H C hydroxyethyl IB-646 cyclohexylmethyl 2- i-Bu H C hydroxyethyl IB-648 cyclohexylmethyl i-Pnt 4- H C hydroxybenzyl IB-649 4- 2- Bnzl H C fluorobenzyl hydroxyethyl IB-650 4- 2- i-Bu H C fluorobenzyl hydroxyethyl IB-656 4- hexyl 4- H A fluorobenzyl hydroxybenzyl IB-657 2- 4- i-Pnt H C hydroxyethyl fluorobenzyl IB-658 i-Pnt 2- phenethyl H C hydroxyethyl IB-659 i-Pnt 2- Np-M H A hydroxyethyl IB-663 cyclohexylmethyl 2- phenethyl H A hydroxyethyl IB-668 4- 2- i-Pnt H A fluorobenzyl hydroxyethyl IB-669 4- 2- phenethyl H C fluorobenzyl hydroxyethyl IB-676 Bnzl 2- Bnzl H C hydroxyethyl IB-678 Bnzl i-Pnt 4- H A hydroxybenzyl IB-680 Bnzl 2- i-Pnt H C hydroxyethyl IB-681 Bnzl 2- phenethyl H C hydroxyethyl IB-684 i-Bu i-Pnt 4- H C hydroxybenzyl IB-687 i-Bu 2- Np-M H C hydroxyethyl IB-688 i-Bu i-Pnt phenethyl H A IB-694 2- Bnzl i-Pnt H C carboxyethyl IB-703 i-Pnt 3-amino-3- Np-M H A oxopropyl IB-707 phenethyl 3-amino-3- Bnzl H A oxopropyl IB-708 phenethyl 3-amino-3- i-Bu H A oxopropyl IB-710 cyclohexylmethyl 3-amino-3- phenethyl H A oxopropyl

TABLE 5-10 IB-712 4- 3-amino-3- Bnzl H A fluorobenzyl oxopropyl IB-714 2- i-Pnt Bnzl H A hydroxyethyl IB-725 4- phenethyl i-Bu H A fluorobenzyl IB-727 2- i-Pnt Np-M H A hydroxyethyl IB-729 Np-M phenethyl Np-M H A IB-734 Bnzl 3-amino-3- Bnzl H C oxopropyl IB-737 i-Bu 3-amino-3- Np-M H C oxopropyl IB-739 4- i-Pnt i-Bu H C hydroxybenzyl IB-743 4- 3-amino-3- Np-M H A hydroxybenzyl oxopropyl IB-749 i-Pnt Bnzl 4- H C hydroxybenzyl IB-753 i-Pnt i-Bu i-Bu H A IB-757 phenethyl Bnzl i-Bu H A IB-759 phenethyl i-Bu Bnzl H A IB-760 phenethyl i-Bu i-Bu H A IB-762 Np-M i-Bu i-Bu H A IB-763 Np-M i-Bu 4- H C hydroxybenzyl IB-770 cyclohexylmethyl i-Bu 4- H C hydroxybenzyl IB-772 4- Bnzl Bnzl H A fluorobenzyl IB-773 4- Bnzl i-Bu H A fluorobenzyl IB-774 4- i-Bu phenethyl H A fluorobenzyl IB-777 Bnzl Bnzl Np-M H A IB-780 i-Bu i-Pnt Bnzl H A IB-783 i-Bu Bnzl 4- H C hydroxybenzyl IB-786 4- Bnzl i-Pnt H C hydroxybenzyl IB-787 4- Bnzl i-Bu H C hydroxybenzyl IB-804 Np-M Np-M phenethyl H A IB-813 Bnzl 3-amino-3- Np-M H A oxopropyl IB-831 2- 4- Np-M H A hydroxyethyl fluorobenzyl IB-864 4-C1-Bnzl Bnzl i-Bu H B IB-865 3-C1-Bnzl Bnzl i-Bu H B IB-866 4- Bnzl i-Bu H B methoxybenzyl

TABLE 5-11 IB-867 4- Bnzl i-Bu H B methylbenzyl IB-870 i-Bu i-Pnt Bnzl H C IB-871 i-Bu 4-Cl-Bnzl i-Bu H C IB-873 4- Bnzl i-Bu H B (dimethylamino)- benzyl IB-874 4-(tert- Bnzl i-Bu H B butyl)benzyl IB-875 i-Bu Bnzl i-Pnt H C IB-876 i-Pnt Bnzl i-Bu H C IB-877 4- Bnzl i-Bu H B (trifluoromethyl)- benzyl IB-878 4- Bnzl i-Bu H C ethoxybenzyl IB-879 Bnzl naphthalen- i-Bu H A 2-ylmethyl IB-880 4- Bnzl i-Bu ethyl A methylbenzyl IB-881 4- Bnzl i-Bu i-Bu A methylbenzyl IB-883 4- Bnzl i-Bu 3- A methylbenzyl methylbutanoyl IB-884 4- Bnzl i-Bu 2- A methylbenzyl phenylacetyl IB-885 4- Bnzl i-Bu methoxy- B methylbenzyl carbonyl IB-886 4- Bnzl i-Bu 2- B methylbenzyl methylpropoxy- carbonyl IB-887 4- Bnzl i-Bu benzyloxy- B methylbenzyl carbonyl IB-888 4- Bnzl i-Bu aminocarbonyl C methylbenzyl IB-889 4- Bnzl i-Bu N- B methylbenzyl benzylamino- carbonyl IB-891 4- 3- i-Bu H C (dimethylamino)- hydroxybenzyl benzyl IB-892 4- 4- i-Bu H C (dimethylamino)- hydroxybenzyl benzyl

TABLE 5-12 Anti-rabies activity of compounds of formula XXIB Compound Anti-rabies number R₁ R_(2A) R_(2B) R₃ R₄ activity IB-924 4-Me- H Bnzl i-Bu N-isobutylamino- na Bnzl carbonyl IB-925 i-Bu H 4-Cl-Bnzl Ph-Et H A IB-926 i-Bu H 3-Cl-Bnzl Ph-Et H A IB-927 i-Bu H 4-MeO-Bnzl Ph-Et H A IB-928 i-Bu H 4-Me-Bnzl Ph-Et H A IB-929 i-Bu H 2-Npm Ph-Et H A IB-930 i-Bu H Bnzl Ph-Pr H A IB-931 i-Bu H 3-Cl-Bnzl Ph-Pr H A IB-932 i-Bu H 3-F-Bnzl Ph-Pr H A IB-933 i-Bu H 3-Me-Bnzl Ph-Pr H A IB-934 i-Bu H 3-MeO-Bnzl Ph-Pr H A IB-935 i-Bu H 3-Cl-Bnzl Ph-Bu H A IB-936 i-Bu H 3-F-Bnzl Ph-Bu H A IB-937 i-Bu H 3-Me-Bnzl Ph-Bu H A IB-938 i-Bu H 3-MeO-Bnzl Ph-Bu H A IB-939 i-Bu H Bnzl Ph-Bu H A IB-940 i-Pnt H 3-F-Bnzl Ph-Pr H A IB-957 i-Bu H Ph-Et Ph-Et H A IB-958 i-Bu H 1-Npm Ph-Et H A

TABLE 5-13 Table. Anti-rabies activity of compounds of formula IF Compound Anti-rabies number R₁ R₂ R₃ R₄ activity IF-1  i-Bu Bnzl Bnzl H C IF-6  Bnzl i-Bu Bnzl H C IF-7  Bnzl Bnzl i-Bu H B IF-9  i-Pnt Bnzl Bnzl H C IF-11 i-Bu Bnzl phenethyl H C IF-13 i-Bu Bnzl 3-methylbenzyl H C IF-14 i-Bu Bnzl 4-methylbenzyl H C (A: IC₅₀ ≤ 5 μM,B: 5 μM < IC₅₀ ≤ 10 μM,C: 10 μM < IC₅₀ < 30 μM)

TABLE 5-14 IF-15  i-Bu 3- Bnzl H C methylbenzyl IF-20  Bnzl 3,4- i-Bu H C dichlorobenzyl IF-38  i-Bu Bnzl cyclohexylmethyl H C IF-42  Np-M Bnzl Bnzl H C IF-69  i-Bu Bnzl Bnzl ethyl C IF-81  2-amino-2- Np-M i-Bu H C oxoethyl IF-82  2-amino-2- Np-M Bnzl H C oxoethyl IF-84  2-amino-2- Np-M i-Pnt H C oxoethyl IF-85  2-amino-2- Np-M phenethyl H C oxoethyl IF-90  2-amino-2- phenethyl Np-M H C oxoethyl IF-91  2-amino-2- Np-M Np-M H A oxoethyl IF-95  2-amino-2- 4- i-Pnt H C oxoethyl fluorobenzyl IF-97  2-amino-2- 4- Np-M H C oxoethyl fluorobenzyl IF-109 2-amino-2- hexyl phenethyl H C oxoethyl IF-110 2-amino-2- hexyl Np-M H A oxoethyl IF-137 2-amino-2- 4- Np-M H A oxoethyl hydroxybenzyl IF-214 i-Pnt isopropyl 3- H C guanidinopropyl IF-219 phenethyl 3-amino- 2-amino-2- H C 3-oxopropyl oxoethyl IF-223 phenethyl Np-M 2-amino-2- H C oxoethyl IF-226 Np-M i-Bu 2-amino-2- H C oxoethyl IF-230 Np-M 2- 2-amino-2- H C hydroxyethyl oxoethyl IF-235 Np-M i-Bu 3- H C guanidinopropyl IF-236 Np-M Bnzl 3- H C guanidinopropyl IF-239 Np-M 2- 3- H C hydroxyethyl guanidinopropyl IF-243 Np-M hexyl 3- H A guanidinopropyl IF-244 Np-M isopropyl 3- H A guanidinopropyl

TABLE 5-15 IF-245 Np-M 4- 3- H A fluoro- guanidinopropyl benzyl IF-246 cyclohexyl- Bnzl 2-amino-2- H C methyl oxoethyl IF-247 cyclohexyl- 4- 2-amino-2- H C methyl hydroxy- oxoethyl benzyl IF-251 cyclohexyl- phenethyl 2-amino-2- H C methyl oxoethyl IF-260 cyclohexyl- hexyl 3- H C methyl guanidinopropyl IF-262 4- i-Bu 2-amino-2- H A fluorobenzyl oxoethyl IF-269 4- phenethyl 2-amino-2- H C fluorobenzyl oxoethyl IF-274 4- isopropyl 3- H C fluorobenzyl guanidinopropyl IF-284 Bnzl Np-M 3- H C guanidinopropyl IF-285 Bnzl hexyl 3- H C guanidinopropyl IF-297 4- Np-M 3- H C fluorobenzyl guanidinopropyl IF-298 4- hexyl 3- H C fluorobenzyl guanidinopropyl IF-300 i-Bu 3- i-Pnt H C amino- 3- oxopropyl IF-356 3- i-Pnt Np-M H C guanidino- propyl IF-359 3- phenethyl 4-hydroxybenzyl H C guanidino- propyl IF-384 Np-M 3- i-Pnt H C amino- 3- oxopropyl IF-386 Np-M 3- Bnzl H C guanidino- propyl IF-389 Np-M 3- phenethyl H A guanidino- propyl IF-390 Np-M 3- Np-M H C guanidino- propyl IF-411 Bnzl i-Bu i-Pnt H A IF-412 i-Bu i-Bu i-Pnt H A IF-413 i-Pnt 2- Np-M H C carboxy- ethyl IF-416 cyclohexyl- 2- Np-M H C methyl carboxy- ethyl IF-417 4- 2- Np-M H C fluorobenzyl carboxy- ethyl IF-419 cyclohexyl- Np-M 2-carboxyethyl H C methyl IF-422 2- Np-M i-Pnt H C carboxyethyl IF-428 i-Bu 2- Np-M H C carboxy- ethyl IF-435 Np-M 3- 4-hydroxybenzyl H A amino- 3- oxopropyl IF-437 i-Pnt phenethyl i-Bu H C

TABLE 5-16 IF-439 cyclohexyl- phenethyl 4-hydroxybenzyl H A methyl IF-444 2- 2- Np-M H C hydroxyethyl carboxy- ethyl IF-445 i-Pnt 4- 2-carboxyethyl H C hydroxy- benzyl IF-447 cyclohexyl- 4- 2-carboxyethyl H C methyl hydroxy- benzyl IF-452 2- 2- Np-M H C carboxyethyl hydroxy- ethyl IF-454 2- i-Bu phenethyl H C carboxyethyl IF-455 2- i-Bu 4-hydroxybenzyl H C carboxyethyl IF-458 2- 4- i-Pnt H C carboxyethyl hydroxy- benzyl IF-464 i-Pnt 4- phenethyl H C hydroxy- benzyl IF-465 i-Pnt 4- Np-M H C hydroxy- benzyl IF-466 i-Pnt 4- Bnzl H C hydroxy- benzyl IF-468 phenethyl 4- i-Pnt H C hydroxy- benzyl IF-469 phenethyl 4- Bnzl H C hydroxy- benzyl IF-470 phenethyl 4- i-Bu H C hydroxy- benzyl IF-472 Np-M 4- Bnzl H A hydroxy- benzyl IF-473 Np-M 4- i-Bu H A hydroxy- benzyl IF-474 cyclohexyl- 4- i-Pnt H A methyl hydroxy- benzyl IF-475 cyclohexyl- 4- phenethyl H C methyl hydroxy- benzyl IF-477 cyclohexyl- 4- Bnzl H A methyl hydroxy- benzyl IF-478 cyclohexyl- 4- i-Bu H A methyl hydroxy- benzyl IF-479 4- 4- i-Pnt H A fluorobenzyl hydroxy- benzyl IF-481 4- 4- Bnzl H C fluorobenzyl hydroxy- benzyl IF-482 4- 4- i-Bu H C fluorobenzyl hydroxy- benzyl IF-486 cyclohexyl- 2- Bnzl H C methyl hydroxy- ethyl

TABLE 5-17 IF-490 4- 2- i-Pnt H C fluorobenzyl hydroxyethyl IF-493 Bnzl 4- i-Pnt H A hydroxybenzyl IF-494 Bnzl 4- Bnzl H C hydroxybenzyl IF-500 i-Bu 4- Np-M H C hydroxybenzyl IF-503 4- isopropyl i-Pnt H A hydroxybenzyl IF-504 4- isopropyl Np-M H C hydroxybenzyl IF-505 Np-M Bnzl 4-hydroxybenzyl H A IF-508 2- 4- Bnzl H C hydroxyethyl fluorobenzyl IF-514 cyclohexyl- hexyl 4-hydroxybenzyl H A methyl IF-516 2- 4- phenethyl H A hydroxyethyl fluorobenzyl IF-525 i-Bu 4- phenethyl H C fluorobenzyl IF-536 cyclohexyl- 3-amino- Np-M H A methyl 3- oxopropyl IF-539 4- 3-amino- Np-M H A fluorobenzyl 3- oxopropyl IF-542 2- Np-M i-Bu H A hydroxyethyl IF-543 2- Np-M 4-hydroxybenzyl H C hydroxyethyl IF-545 i-Pnt phenethyl 4-hydroxybenzyl H C IF-546 i-Pnt hexyl i-Bu H C IF-547 i-Pnt 4- Bnzl H A fluorobenzyl IF-548 i-Pnt 4- i-Bu H C fluorobenzyl IF-560 Bnzl hexyl i-Bu H A IF-561 Bnzl 4- Bnzl H A fluorobenzyl IF-565 Bnzl 4- phenethyl H A hydroxybenzyl IF-567 i-Bu phenethyl 4-hydroxybenzyl H C IF-568 i-Bu Np-M 4-hydroxybenzyl H A IF-569 i-Bu hexyl i-Bu H C IF-576 i-Bu 4- phenethyl H C hydroxybenzyl IF-578 4- Np-M i-Bu H A hydroxybenzyl IF-580 4- phenethyl Np-M H C hydroxybenzyl

TABLE 5-18 IF-583 i-Pnt hexyl 4-hydroxybenzyl H A IF-584 4- i-Pnt Bnzl H A fluorobenzyl IF-585 4- i-Pnt i-Bu H A fluorobenzyl IF-586 4- phenethyl Bnzl H C fluorobenzyl IF-596 Np-M isopropyl Np-M H C IF-599 i-Pnt hexyl Bnzl H C IF-602 phenethyl hexyl Bnzl H C IF-603 Np-M 2- Bnzl H C hydroxy- ethyl IF-604 Np-M 2- i-Bu H C hydroxy- ethyl IF-606 cyclohexyl- 2- i-Bu H C methyl hydroxy- ethyl IF-610 2- phenethyl Np-M H C hydroxyethyl IF-611 i-Pnt 2- Np-M H C hydroxy- ethyl IF-612 phenethyl 2- Np-M H C hydroxy- ethyl IF-613 Np-M 2- i-Pnt H C hydroxy- ethyl IF-614 Np-M 2- Np-M H C hydroxy- ethyl IF-619 cyclohexyl- 2- Np-M H C methyl hydroxy- ethyl IF-620 4- 2- Np-M H A fluorobenzyl hydroxy- ethyl IF-624 Bnzl 2- Np-M H C hydroxy- ethyl IF-635 i-Pnt i-Bu phenethyl H C IF-639 phenethyl Bnzl i-Bu H A IF-640 phenethyl Bnzl 4-hydroxybenzyl H C IF-641 phenethyl i-Bu Bnzl H A IF-644 cyclohexyl- Bnzl i-Bu H A methyl IF-645 cyclohexyl- Bnzl 4-hydroxybenzyl H C methyl IF-646 cyclohexyl- i-Bu Np-M H A methyl IF-649 4- Bnzl Bnzl H A fluorobenzyl IF-650 4- Bnzl i-Bu H A fluorobenzyl IF-652 4- i-Bu phenethyl H A fluorobenzyl IF-653 4- i-Bu Bnzl H C fluorobenzyl IF-654 4- i-Bu i-Bu H A fluorobenzyl

TABLE 5-19 IF-656 2- i-Pnt Bnzl H C hydroxyethyl IF-657 phenethyl i-Pnt i-Bu H A IF-658 cyclohexyl- i-Pnt Bnzl H A methyl IF-659 cyclohexyl- i-Pnt i-Bu H C methyl IF-660 2- i-Pnt Np-M H C hydroxyethyl IF-665 Bnzl i-Pnt Bnzl H A IF-670 Bnzl i-Bu phenethyl H A IF-673 i-Bu i-Pnt phenethyl H A IF-674 i-Bu i-Pnt Np-M H C IF-675 i-Bu Bnzl i-Pnt H A IF-679 i-Bu i-Bu phenethyl H A IF-680 i-Bu i-Bu Np-M H C IF-684 4- i-Pnt Np-M H C hydroxybenzyl IF-691 benzyl i-Pnt i-Bu H C IF-692 Bnzl hexyl 4-hydroxybenzyl H A IF-699 phenethyl 3- i-Bu H C amino- 3- oxopropyl IF-705 i-Pnt Np-M i-Bu H A IF-706 i-Pnt Np-M 4-hydroxybenzyl H A IF-707 phenethyl i-Pnt 4-hydroxybenzyl H A IF-708 Np-M phenethyl 4-hydroxybenzyl H A IF-709 cyclohexyl- i-Pnt 4-hydroxybenzyl H C methyl IF-710 cyclohexyl- phenethyl Bnzl H A methyl IF-711 cyclohexyl- phenethyl i-Bu H C methyl IF-714 4- phenethyl i-Bu H A fluorobenzyl IF-715 4- phenethyl 4-hydroxybenzyl H A fluorobenzyl IF-717 cyclohexyl- phenethyl i-Pnt H A methyl IF-718 cyclohexyl- phenethyl Np-M H A methyl IF-721 Bnzl phenethyl i-Bu H A IF-722 Bnzl phenethyl 4-hydroxybenzyl H A IF-723 Bnzl phenethyl i-Pnt H C IF-725 i-Bu phenethyl i-Bu H C IF-726 i-Bu Np-M i-Bu H C IF-727 i-Bu phenethyl i-Pnt H A IF-730 4- Np-M i-Pnt H C hydroxybenzyl

TABLE 5-20 IF-733 i-Pnt Bnzl i-Bu H A IF-734 i-Pnt i-Bu Np-M H A IF-735 i-Pnt i-Bu Bnzl H C IF-738 phenethyl i-Bu i-Bu H C IF-739 Np-M i-Bu i-Bu H A IF-740 cyclohexyl- Bnzl i-Pnt H C methyl IF-742 cyclohexyl- i-Bu i-Bu H C methyl IF-743 4- Bnzl i-Pnt H C fluorobenzyl IF-744 phenethyl i-Pnt Bnzl H A IF-753 i-Bu Bnzl Np-M H C IF-758 2- Np-M Bnzl H A hydroxyethyl IF-778 i-Bu Np-M Np-M H A IF-779 4- Np-M Np-M H C hydroxybenzyl IF-789 Np-M isopropyl phenethyl H C IF-805 Bnzl Np-M Bnzl H C IF-807 Bnzl 4- i-Bu H A fluorobenzyl IF-815 i-Bu 4- Bnzl H A fluorobenzyl IF-830 i-Pnt 2- phenethyl H C carboxy- ethyl IF-837 Bnzl Np-M i-Bu H B IF-838 Bnzl 4- i-Bu H C (trifluoro- methyl)- benzyl IF-839 4-Cl-Bnzl Bnzl i-Bu H B IF-840 3-Cl-Bnzl Bnzl i-Bu H B IF-841 4- Bnzl i-Bu H B methoxybenzyl IF-842 4- Bnzl i-Bu H A methylbenzyl IF-845 i-Bu i-Pnt Bnzl H C IF-846 i-Bu 4-Cl- i-Bu H C Bnzl IF-848 4- Bnzl i-Bu H B (dimethylamino)- benzyl IF-849 4-(tert- Bnzl i-Bu H B butyl)benzyl IF-850 i-Bu Bnzl i-Pnt H B IF-851 i-Pnt Bnzl i-Bu H C IF-852 4- Bnzl i-Bu H B (trifluoro- methyl)benzyl

TABLE 5-21 IF-853 4- Bnzl i-Bu H B ethoxybenzyl IF-854 Bnzl naphthalen- i-Bu H B 2- ylmethyl IF-855 4- Bnzl i-Bu ethyl B methylbenzyl IF-856 4- Bnzl i-Bu i-Bu A methylbenzyl IF-859 4- Bnzl i-Bu 2- B methylbenzyl phenylacetyl IF-860 4- Bnzl i-Bu methoxy- C methylbenzyl carbonyl IF-861 4- Bnzl i-Bu 2- B methylbenzyl methyl- propoxy- carbonyl IF-862 4- Bnzl i-Bu benzyloxy- B methylbenzyl carbonyl IF-864 4- Bnzl i-Bu N- C methylbenzyl benzyl- amino- carbonyl IF-866 4- 3- i-Bu H C (dimethyl- hydroxy- amino)benzyl benzyl IF-867 4- 4- i-Bu H C (dimethyl- hydroxy- amino)benzyl benzyl

TABLE 5-22 Anti-rabies activity of compounds of formula XXIF Compound Anti-rabies number R₁ R_(2A) R_(2B) R₃ R₄ activity IF-885 i-Bu H 4-Cl-Bnzl Ph-Et H A IF-886 i-Bu H 3-Cl-Bnzl Ph-Et H A IF-887 i-Bu H 4-MeO-Bnzl Ph-Et H A IF-888 i-Bu H 4-Me-Bnzl Ph-Et H A IF-889 i-Bu H 2-Npm Ph-Et H A IF-890 i-Bu H Bnzl Ph-Pr H B IF-891 i-Bu H 3-Cl-Bnzl Ph-Pr H A IF-892 i-Bu H 3-F-Bnzl Ph-Pr H A IF-893 i-Bu H 3-Me-Bnzl Ph-Pr H B IF-894 i-Bu H 3-MeO-Bnzl Ph-Pr H A IF-895 i-Bu H 3-Cl-Bnzl Ph-Bu H A IF-896 i-Bu H 3-F-Bnzl Ph-Bu H A IF-897 i-Bu H 3-Me-Bnzl Ph-Bu H A IF-898 i-Bu H 3-MeO-Bnzl Ph-Bu H B IF-899 i-Bu H Bnzl Ph-Bu H B IF-900 i-Pnt H 3-F-Bnzl Ph-Pr H A IF-909 i-Bu H Ph-Et Ph-Et H A

TABLE 5-23 Anti-rabies activity of compounds of formula IIB (A: IC₅₀ ≤ 5 μM, B: 5 μM < IC₅₀ ≤ 10 μM, C: 10 μM < IC₅₀ < 30 μM) Anti- Compound rabies number R₁ R₂ R₃ activity IIB-4 Bnzl i-Bu i-Bu B IIB-83 4-Cl-Bnzl Bnzl i-Bu A IIB-84 3-Cl-Bnzl Bnzl i-Bu A IIB-85 4-methoxybenzyl Bnzl i-Bu B IIB-86 4-methylbenzyl Bnzl i-Bu B IIB-94 4-(dimethylamino)benzyl Bnzl i-Bu B IIB-95 4-(tert-butyl)benzyl Bnzl i-Bu B IIB-96 4-(trifluoromethoxy)benzyl Bnzl i-Bu B IIB-97 4-ethoxybenzyl Bnzl i-Bu C IIB-101 4-hydroxybenzyl Bnzl i-Pnt B IIB-102 Bnzl naphthalen-2- i-Bu A ylmethyl IIB-103 i-Pnt 4-Cl-Bnzl i-Bu B IIB-104 i-Pnt 4-fluorobenzyl i-Bu B

TABLE 5-24 Anti-rabies activity of compounds of formula XXIIB Anti- Compound rabies number R₁ R_(2A) R_(2B) R₃ activity IIF-325 i-Pnt H 3-Cl-Bnzl Bnzl A IIF-328 i-Pnt H 4-Me-Bnzl Bnzl A IIF-329 i-Pnt H 4-MeO-Bnzl Bnzl A IIB-329 Me H quinolin-8-ylethyl Bnzl A IIB-330 Me H quinolin-5-ylethyl Bnzl A IIB-331 i-Bu H 4-Cl-Bnzl Ph-Et A IIB-332 i-Bu H 3-Cl-Bnzl Ph-Et A IIB-333 i-Bu H 4-MeO-Bnzl Ph-Et A IIB-334 i-Bu H 4-Me-Bnzl Ph-Et A IIB-335 i-Bu H 2-Npm Ph-Et A IIB-336 i-Bu H Bnzl Ph-Pr A IIB-337 i-Bu H 3-Cl-Bnzl Ph-Pr A IIB-338 i-Bu H 3-F-Bnzl Ph-Pr A IIB-339 Cpm H 4-OH-Bnzl 2-Cbx-Et na IIB-340 i-Bu H 3-Me-Bnzl Ph-Pr A IIB-341 i-Bu H 3-MeO-Bnzl Ph-Pr A IIB-342 i-Bu H 3-Cl-Bnzl Ph-Bu B IIB-343 i-Bu H 3-F-Bnzl Ph-Bu A IIB-344 i-Bu H 3-Me-Bnzl Ph-Bu A IIB-345 i-Bu H 3-MeO-Bnzl Ph-Bu A IIB-346 i-Bu H Bnzl Ph-Bu A IIB-347 i-Pnt H 3-F-Bnzl Ph-Pr A IIF-327 i-Pnt H 4-F-Bnzl Bnzl A IIF-370 i-Pnt H Ph-Et Bnzl A IIF-371 i-Pnt H 1-Npm Bnzl A IIB-374 i-Bu H 4-F-Bnzl Ph-Et A IIB-375 i-Bu H Ph-Et Ph-Et A IIB-376 i-Bu H 1-Npm Ph-Et A IIB-378 4-F-Bnzl H 1-Npm i-Bu A

TABLE 5-25 Anti-rabies activity of compounds of formula IIF (A: IC₅₀ ≤ 5 μM, B: 5 μM < IC₅₀ ≤ 10 μM, C: 10 μM < IC₅₀ < 30 μM) Anti- Compound rabies number R₁ R₂ R₃ activity IIF-16 i-Bu 4-Me-Bnzl Bnzl C IIF-83 4-Cl-Bnzl Bnzl i-Bu A IIF-84 3-Cl-Bnzl Bnzl i-Bu B IIF-85 4-methoxybenzyl Bnzl i-Bu B IIF-86 4-methylbenzyl Bnzl i-Bu A IIF-94 4-(dimethylamino)benzyl Bnzl i-Bu B IIF-95 4-(tert-butyl)benzyl Bnzl i-Bu A IIF-96 4-(trifluoromethoxy)benzyl Bnzl i-Bu B IIF-97 4-ethoxybenzyl Bnzl i-Bu C IIF-101 4-hydroxybenzyl Bnzl i-Pnt B IIF-102 Bnzl naphthalen-2- i-Bu A ylmethyl IIF-103 i-Pnt 4-Cl-Bnzl i-Bu B IIF-104 i-Pnt 4-fluorobenzyl i-Bu B

TABLE 5-26 Anti-rabies activity of compounds of formula XXIIF Compound Anti-rabies number R₁ R_(2A) R_(2B) R₃ activity IIF-325 i-Pnt H 3-Cl-Bnzl Bnzl A IIF-326 i-Pnt H 4-Cl-Bnzl Bnzl A IIF-327 i-Pnt H 4-F-Bnzl Bnzl A IIF-328 i-Pnt H 4-Me-Bnzl Bnzl A IIF-329 i-Pnt H 4-MeO-Bnzl Bnzl A IIF-330 i-Bu H 4-Cl-Bnzl Ph-Et A IIF-331 i-Bu H 3-Cl-Bnzl Ph-Et A IIF-332 i-Bu H 4-MeO-Bnzl Ph-Et A IIF-333 i-Bu H 4-Me-Bnzl Ph-Et A IIF-334 i-Bu H 2-Npm Ph-Et A IIF-335 i-Bu H Bnzl Ph-Pr A IIF-336 i-Bu H 3-Cl-Bnzl Ph-Pr A IIF-337 i-Bu H 3-F-Bnzl Ph-Pr A IIF-338 Cpm H 4-OH-Bnzl 2-Cbx-Et na IIF-339 i-Bu H 3-Me-Bnzl Ph-Pr A IIF-340 i-Bu H 3-MeO-Bnzl Ph-Pr A IIF-341 i-Bu H 3-Cl-Bnzl Ph-Bu A IIF-342 i-Bu H 3-F-Bnzl Ph-Bu A IIF-343 i-Bu H 3-Me-Bnzl Ph-Bu A IIF-344 i-Bu H 3-MeO-Bnzl Ph-Bu A IIF-345 i-Bu H Bnzl Ph-Bu A IIF-346 i-Pnt H 3-F-Bnzl Ph-Pr A IIF-370 i-Pnt H Ph-Et Bnzl A IIF-371 i-Pnt H 1-Npm Bnzl A IIF-372 i-Bu H 4-F-Bnzl Ph-Et A IIF-373 i-Bu H Ph-Et Ph-Et A IIF-374 i-Bu H 1-Npm Ph-Et A IIF-376 4-F-Bnzl H 1-Npm i-Bu A

Example 3: Efficacy in a Mouse Model of Rabies

In this example, it was tested whether the compound of the present disclosure is effective in a rabies mouse model.

(Materials and Methods)

Recombinant rabies virus 1088 strain expressing Red Firefly Luciferase (RFLuc) (1088/RFLuc) was generated by replacing the E2Cr gene of the recombinant virus 1088/E2Cr with the RFLuc gene (Isomura M, Yamada K, Noguchi K, Nishizono A. Near-infrared fluorescent protein iRFP720 is optimal for in vivo fluorescence imaging of rabies virus infection. J Gen Virol. 2017, 98(11): 2689-2698. doi: 10.1099/jgv.0.000950.). Hairless mice (Hos: HR-1, 6-week old, female; Hoshino Laboratory Animals) were inoculated with 1×10⁵ infectious units of 1088/RFLuc intramuscularly into the right hindlimb and administered the test compound intraperitoneally for 6 days (Day 0 to Day 6), beginning 1 hour after inoculation. Actually, 0.5 mL of the solution (2% DMSO, 2% Solutol HS 15, and penicillin/streptomycin-added Dulbecco's phosphate buffered saline, available from Nacalai tesque, Sigma-Aldrich, etc.) supplemented with/without the compound (25 mg/kgBW) was administered twice daily with a 6-hour interval between doses. The inoculated mice were monitored for clinical signs and weighed everyday. The viral dynamics in the treated mice were observed longitudinally using in vivo imaging as follows; mice were administered D-Luciferin solution (150 mg/kgBW; Wako Pure Chemical Industry) intraperitoneally and then imaged (exposure time of 2 minutes and electron-multiplying gain of 300) with the Lumazone imaging system (Nippon Roper) under 2% isoflurane inhalation anesthesia after 15 minutes of substrate injection. The obtained images (16-bit TIFF) were processed and analysed using the ImageJ software. The compounds listed in Table 5 that were evaluated in Example 2 were tested as the test compounds.

(Results)

On days 6 and 8 after virus inoculation, the viral dynamics and the effect of the test compounds were observed in the mice, where the virus-driven luciferase luminescence served as an indicator. It was observed that the viral propagation and dissemination in the brain and spinal cord were significantly suppressed in three of four infected mice that were given the test compound at 50 mg/kgBW/day for 6 days (Days 0 to 5) compared to the solvent administered group, indicating that the antiviral effect of the test compounds on rabies virus was also confirmed in the infected mouse model. In other words, the compounds listed in Table 5 that were evaluated in Example 2 were confirmed to attain a significant therapeutic/prophylactic effect. For the nucleic acid analog drug favipiravir (product name: Avigan tablet/Toyama Chemical), which was confirmed to be effective on rabies virus, a significant prophylactic effect was confirmed in ddY mice given in a dose of 300 mg/kgBW/day, but not 100 mg/kgBW/day, for 7 days immediately after viral inoculation (Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 2016, 213(8): 1253-1261.doi:10.1093/infdis/jiv586.). Therefore, the present compound can be provided as a novel and highly effective rabies therapeutic agent that has a different mechanism of action from favipiravir.

Example 4: Anti-Cancer Cell Activity Evaluation Method

The minimum inhibitory concentration (MIC) with respect to cells was evaluated for compounds in Example 2 with which cell death of the host, i.e., mouse neuroblastoma cell strain Neuro-2A, was observed.

Each tested compound prepared as a 10 mM with DMSO was first diluted to 100 μM or 40 μM with 10% fetal bovine serum-supplemented medium, and further diluted with the medium to the final concentration of interest. Fifty microlitter of the diluted medium was added dropwise to each well of a 96-well plate. Furthermore, 50 μL of medium comprising 4×10² infectious units of 1088/GLuc and 4×10⁴ Neuro-2a cells were added to each well. The plate was shaken for 30 seconds with the microplate mixer NS-4P and then cultured for 3 days at 37° C. in the presence of 5% CO₂. After incubation, 25 μL of coelenterazine was added dropwise to each well of the plate, and the plate was immediately loaded into the luminescent plate reader LuMate and shaken for 10 seconds. The relative light unit (RLU) was then measured, and entries in which a cell death caused due to virus infection were excluded.

The following tables show the results of evaluating the compounds. Some compounds were evaluated as a mixture as shown in the following tables. The compounds are classified as a if the minimum inhibitory concentration (MIC) is 10 μM or less, b if greater than 10 μM and less than or equal to 20 μM, and c if greater than 20 μM and less than or equal to 40 μM. The ‘na’ indicates not applicable.

TABLE 6-1 Anti-cancer cell activity of compounds of formula XXIB Compound Anti-cancer number R₁ R_(2A) R_(2B) R₃ R₄ cell activity IB-924 4-Me- H Bnzl i-Bu N-isobutyl- na Bnzl aminocarbonyl IB-925 i-Bu H 4-Cl-Bnzl Ph-Et H c IB-926 i-Bu H 3-Cl-Bnzl Ph-Et H b IB-927 i-Bu H 4-MeO-Bnzl Ph-Et H c IB-928 i-Bu H 4-Me-Bnzl Ph-Et H c IB-929 i-Bu H 2-Npm Ph-Et H b IB-930 i-Bu H Bnzl Ph-Pr H c IB-931 i-Bu H 3-Cl-Bnzl Ph-Pr H c IB-932 i-Bu H 3-F-Bnzl Ph-Pr H c IB-933 i-Bu H 3-Me-Bnzl Ph-Pr H b IB-934 i-Bu H 3-MeO-Bnzl Ph-Pr H b IB-935 i-Bu H 3-Cl-Bnzl Ph-Bu H c IB-936 i-Bu H 3-F-Bnzl Ph-Bu H b IB-937 i-Bu H 3-Me-Bnzl Ph-Bu H c IB-938 i-Bu H 3-MeO-Bnzl Ph-Bu H c IB-939 i-Bu H Bnzl Ph-Bu H c IB-940 i-Pnt H 3-F-Bnzl Ph-Pr H c IB-957 i-Bu H Ph-Et Ph-Et H c IB-958 i-Bu H 1-Npm Ph-Et H b (a: MIC ≤ 10 μM, b: 10 μM < MIC ≤ 20 μM, c: 20 μM < MIC ≤ 40 μM)

TABLE 6-2 Anti-cancer cell activity of compounds of formula XXIF Compound Anti-cancer number R₁ R_(2A) R_(2B) R₃ R₄ cell activity IF-885 i-Bu H 4-Cl-Bnzl Ph-Et H c IF-886 i-Bu H 3-Cl-Bnzl Ph-Et H c IF-887 i-Bu H 4-MeO-Bnzl Ph-Et H c IF-888 i-Bu H 4-Me-Bnzl Ph-Et H na IF-889 i-Bu H 2-Npm Ph-Et H b IF-890 i-Bu H Bnzl Ph-Pr H c IF-891 i-Bu H 3-Cl-Bnzl Ph-Pr H b IF-892 i-Bu H 3-F-Bnzl Ph-Pr H c IF-893 i-Bu H 3-Me-Bnzl Ph-Pr H c IF-894 i-Bu H 3-MeO-Bnzl Ph-Pr H c IF-895 i-Bu H 3-Cl-Bnzl Ph-Bu H b IF-896 i-Bu H 3-F-Bnzl Ph-Bu H b IF-897 i-Bu H 3-Me-Bnzl Ph-Bu H b IF-898 i-Bu H 3-MeO-Bnzl Ph-Bu H c IF-899 i-Bu H Bnzl Ph-Bu H c IF-900 i-Pnt H 3-F-Bnzl Ph-Pr H c IF-909 i-Bu H Ph-Et Ph-Et H na

TABLE 6-3 Anti-cancer cell activity of compounds of formula XXIIB and formula XXIIF Compound Anti-cancer number R₁ R_(2A) R_(2B) R₃ cell activity Mixture of i-Pnt H 3-Cl-Bnzl Bnzl c IIB-326 and IIF-325 Mixture of i-Pnt H 4-Me-Bnzl Bnzl c IIB-327 and IIF-328 Mixture of i-Pnt H 4-MeO-Bnzl Bnzl na IIB-328 and IIF-329 IIB-329 Me H quinolin-8- Bnzl na ylethyl IIB-330 Me H quinolin-5- Bnzl na ylethyl IIB-331 i-Bu H 4-Cl-Bnzl Ph-Et c IIB-332 i-Bu H 3-Cl-Bnzl Ph-Et b IIB-333 i-Bu H 4-MeO-Bnzl Ph-Et na IIB-334 i-Bu H 4-Me-Bnzl Ph-Et c IIB-335 i-Bu H 2-Npm Ph-Et c IIB-336 i-Bu H Bnzl Ph-Pr c IIB-337 i-Bu H 3-Cl-Bnzl Ph-Pr c IIB-338 i-Bu H 3-F-Bnzl Ph-Pr c IIB-339 Cpm H 4-OH-Bnzl 2-Cbx-Et na IIB-340 i-Bu H 3-Me-Bnzl Ph-Pr c IIB-341 i-Bu H 3-MeO-Bnzl Ph-Pr c IIB-342 i-Bu H 3-Cl-Bnzl Ph-Bu b IIB-343 i-Bu H 3-F-Bnzl Ph-Bu c IIB-344 i-Bu H 3-Me-Bnzl Ph-Bu b IIB-345 i-Bu H 3-MeO-Bnzl Ph-Bu c IIB-346 i-Bu H Bnzl Ph-Bu b IIB-347 i-Pnt H 3-F-Bnzl Ph-Pr c Mixture of i-Pnt H 4-F-Bnzl Bnzl b IIB-371 and IIF-327 Mixture of i-Pnt H Ph-Et Bnzl na IIB-372 and IIF-370 Mixture of i-Pnt H 1-Npm Bnzl c IIB-373 and IIF-371 IIB-374 i-Bu H 4-F-Bnzl Ph-Et c IIB-375 i-Bu H Ph-Et Ph-Et na IIB-376 i-Bu H 1-Npm Ph-Et c IIB-378 4-F-Bnzl H 1-Npm i-Bu b

TABLE 6-4 (continuation) Compound Anti-cancer number R₁ R_(2A) R_(2B) R₃ cell activity IIF-326 i-Pnt H 4-Cl-Bnzl Bnzl b IIF-330 i-Bu H 4-Cl-Bnzl Ph-Et c IIF-331 i-Bu H 3-Cl-Bnzl Ph-Et c IIF-332 i-Bu H 4-MeO-Bnzl Ph-Et na IIF-333 i-Bu H 4-Me-Bnzl Ph-Et c IIF-334 i-Bu H 2-Npm Ph-Et c IIF-335 i-Bu H Bnzl Ph-Pr na IIF-336 i-Bu H 3-Cl-Bnzl Ph-Pr c IIF-337 i-Bu H 3-F-Bnzl Ph-Pr b IIF-338 Cpm H 4-OH-Bnzl 2-Cbx-Et na IIF-339 i-Bu H 3-Me-Bnzl Ph-Pr c IIF-340 i-Bu H 3-MeO-Bnzl Ph-Pr na IIF-341 i-Bu H 3-Cl-Bnzl Ph-Bu b IIF-342 i-Bu H 3-F-Bnzl Ph-Bu c IIF-343 i-Bu H 3-Me-Bnzl Ph-Bu c IIF-344 i-Bu H 3-MeO-Bnzl Ph-Bu c IIF-345 i-Bu H Bnzl Ph-Bu c IIF-346 i-Pnt H 3-F-Bnzl Ph-Pr c IIF-372 i-Bu H 4-F-Bnzl Ph-Et c IIF-373 i-Bu H Ph-Et Ph-Et c IIF-374 i-Bu H 1-Npm Ph-Et c IIF-376 4-F-Bnzl H 1-Npm i-Bu c

[Note]

As disclosed above, the present disclosure is exemplified by the use of its preferred embodiments. However, it is understood that the scope of the present disclosure should be interpreted based solely on the Claims. It is also understood that any patent, any patent application, and any other references cited herein should be incorporated herein by reference in the same manner as the contents are specifically described herein. The present application is a continuation-in-part application that claims priority to Japanese Patent Application No. 2018-153227 filed on Aug. 16, 2018 and International Publication No. PCT/JP2019/032032 filed on Aug. 15, 2019 with the Japan Patent Office. The entire content thereof is incorporated herein by reference.

INDUSTRIAL APPLICABILITY

The present disclosure is useful in the field of rabies and cancer treatment and prophylaxis. 

1. A compound represented by formula XXIF:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein R₁, R₃, and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, R_(2A) and R_(2B) are each independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.
 2. A compound represented by formula XXIB:

or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein, R₁, R₃, and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, R_(2A) and R_(2B) are each independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted.
 3. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R₁, R₃, and R₄ are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R_(2A) and R_(2B), and the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.
 4. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R₁, R₃, and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, R_(2A) and R_(2B) are each independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted-, or (2) wherein (2) wherein R₁, R₃, and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁, R₃, and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, R_(2A) and R_(2B) are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R_(2A) and R_(2B) together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.
 5. (canceled)
 6. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R₁ and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III; or (2) wherein R₁ and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, carbamoyl, or optionally alkylcarbamoyl, wherein the croups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III; or (3) wherein R₁ and R₄ are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro, formyl, substituted carbonyl, or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted, carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₁ and R₄ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV; or (4) wherein R₁ and R₄ are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy, formyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, arylcarbonyl, carbamoyl, alkylcarbamoyl, or arylalkylcarbamoyl, wherein the substituted aminos each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV. 7-9. (canceled)
 10. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy, wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₃ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV; or (2) wherein R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consist of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy, or (3) wherein R₃ is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.
 11. (canceled)
 12. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, (1) wherein R_(2A) and R_(2B) are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, or substituted cycloalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI; or (2) wherein R_(2A) and R_(2B) are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy, heteroarylalkyl, alkoxycarbonyl-substituted heteroarylalkyl, or cycloalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI, or (3) wherein R_(2A) is hydrogen, R_(2B) is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl haloalkyl, alkoxy, and hydroxy, or cycloalkyl.
 13. (canceled)
 14. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim wherein R₁ is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV. 15.-16. (canceled)
 17. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 1, wherein R₄ is hydrogen, alkyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, carbamoyl, or arylalkylcarbamoyl. 18.-40. (canceled)
 41. A method for the prophylaxis or treatment of rabies, comprising administering a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
 42. A method for the prophylaxis or treatment of cancer, comprising administering a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
 43. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R₁, R₃, and R₄ are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I, and the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and carbonyl of R_(2A) and R_(2B), and the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group I.
 44. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R₁, R₃, and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, R_(2A) and R_(2B) are each independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted carbonyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are each independently and optionally substituted, or (2) wherein R₁, R₃, and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁, R₃, and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, R_(2A) and R_(2B) are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted heteroaryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R_(2A) and R_(2B) are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle or heteroaryl ring, wherein the non-aryl heterocycle and the heteroaryl ring are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group II.
 45. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R₁ and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted cycloalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted heterocycloalkylcarbonyl, optionally substituted heterocycloalkyloxycarbonyl, carbamoyl, optionally substituted alkylcarbamoyl, optionally substituted alkoxycarbamoyl, optionally substituted arylcarbamoyl, optionally substituted heteroarylcarbamoyl, optionally substituted cycloalkylcarbamoyl, or optionally substituted heterocycloalkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or (2) wherein R₁ and R₄ are each independently, hydrogen, optionally substituted alkyl, optionally substituted arylalkyl, formyl, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted arylcarbonyl, optionally substituted aryloxycarbonyl, carbamoyl, or optionally substituted alkylcarbamoyl, wherein the groups of R₁ and R₄ are optionally substituted with one to the maximum substitutable number of the same or different substituents selected from substituent group III, or (3) wherein R₁ and R₄ are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, substituted oxy, substituted carbonyl, cycloalkyl, and substituted cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, substituted oxy, amino, substituted amino, and nitro, formyl, substituted carbonyl, or substituted oxycarbonyl, wherein the substituted amino, substituted oxy, substituted alkyl, substituted carbonyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₁ and R₄ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or (4) wherein R₁ and R₄ are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, and cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, substituted amino, nitro, and hydroxy, formyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, carbamoyl, alkylcarbamoyl, or arylalkylcarbamoyl, wherein the substituted aminos each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV.
 46. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amino, substituted amino, carboxy, substituted oxycarbonyl, carbamoyl, substituted aminocarbonyl, hydroxy, substituted oxy, cycloalkyl, and substituted cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carboxy, substituted oxycarbonyl, hydroxy, and substituted oxy, wherein the substituted amino, substituted oxy, substituted oxycarbonyl, substituted aminocarbonyl, substituted alkyl, substituted cycloalkyl, substituted carbonyl, and substituted oxycarbonyl in R₃ each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or (2) wherein R₃ is hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, trialkylsilyloxy, amino, alkoxycarbonylamino, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, alkoxycarbonyl, and hydroxy, or (3) wherein R₃ is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of alkyl and hydroxy.
 47. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, (1) wherein R_(2A) and R_(2B) are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of formyl, substituted carbonyl, hydroxy, substituted oxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, substituted alkyl, hydroxy, and substituted oxy, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, or substituted cycloalkyl, wherein the substituted carbonyl, substituted oxy, substituted amino, substituted cycloalkyl, substituted heterocycloalkyl, substituted heteroarylalkyl, and substituted alkyl in R_(2A) and R_(2B) each independently have one to the maximum substitutable number of the same or different substituents selected from substituent group IV, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI, or (2) wherein R_(2A) and R_(2B) are each independently, hydrogen, alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, alkoxy, alkoxycarbonyl, carbamoyl, carboxy, hydroxy, amino, alkoxycarbonylamino, cycloalkyl, and heterocycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy, heteroarylalkyl, alkoxycarbonyl-substituted heteroarylalkyl, or cycloalkyl, or R_(2A) and R_(2B), together with the nitrogen atom to which they are attached, form a 5- to 6-membered non-aryl heterocycle, wherein the non-aryl heterocycle is optionally substituted with one or up to the maximum substitutable number of the same or different substituents selected from substituent group VI, or (3) wherein R_(2A) is hydrogen, R_(2B) is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl, arylalkyl, arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, and hydroxy, or cycloalkyl.
 48. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, wherein R₁ is alkyl, alkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of amidinoamino, carbamoyl, carboxy, hydroxy, and cycloalkyl, arylalkyl, or arylalkyl substituted with one to the maximum substitutable number of the same or different substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, substituted amino, and hydroxy, wherein the substituted amino has one to the maximum substitutable number of the same or different substituents selected from substituent group IV.
 49. The compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to claim 2, wherein R₄ is hydrogen, alkyl, alkylcarbonyl, arylalkylcarbonyl, arylalkyloxycarbonyl, alkoxycarbonyl, carbamoyl, or arylalkylcarbamoyl.
 50. A method for the prophylaxis or treatment of rabies, comprising administering a therapeutically effective amount of the compound according to claim 2, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
 51. A method for the prophylaxis or treatment of cancer, comprising administering a therapeutically effective amount of the compound according to claim 2 or a pharmaceutically acceptable salt thereof, to a subject in need thereof. 